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Abstract 
Background 
Dengue, leptospirosis and rickettsial infections are the most common non-malaria 
causes of acute undifferentiated febrile illness in Southeast Asia. Current diagnostic tests 
are inadequate for clinical use. 
Methods 
 We conducted a two year prospective fever study in three outpatient clinics on the 
Thailand-Myanmar border, recruiting patients aged at least five years with acute 
undifferentiated febrile illness. The study was divided into two parts: non-malaria and 
malaria patients. Specimens were tested to determine the causes of fever and to evaluate 
the clinical diagnostic accuracy of the tests for early diagnosis of dengue, leptospirosis and 
rickettsial infections.  
Results 
A total of 1,029 febrile patients were recruited: 908 non-malaria and 121 malaria 
patients. A laboratory confirmed diagnosis was made in 34.5% of non-malaria patients, of 
which 15.9% were dengue, 6.0% leptospirosis, 6.0% murine typhus, and 3.2% scrub 
typhus. Co-infection was found in 1.7% with mostly leptospirosis and scrub typhus (1.5%). 
In malaria patients, co-infection was found in 8.3% in most cases with scrub typhus 
(7.4%). 
An immunochromatographic test (ICT) (Non-structural protein 1 [NS1] and 
Immunoglobulin M [IgM]/Immunoglobulin G [IgG] detection) and real-time reverse 
transcriptase polymerase chain reaction (rRT-PCR) were evaluated for dengue diagnosis 
using acute plasma specimens. Sensitivities of the ICT and rRT-PCR were 86.1% (95% 
confidence interval [CI] 79.4-91.3) and 97.2% (95% CI 93.0-99.2), and specificities were 
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94.9% (95% CI 93.0-96.4) and 99.1% (95% CI 98.1-99.7), respectively compared against 
IgM/IgG enzyme-linked immunosorbent assay (ELISA). Combining rRT-PCR with ICT 
improved the sensitivity of the diagnostic process to 98.6% (95% CI 95.1-99.8). 
The IgM ICT and 47kDa quantitative real-time PCR (qPCR) for scrub typhus and 
17kDa qPCR for murine typhus were evaluated using acute plasma specimens for the IgM 
ICT and acute buffy coat specimens for the qPCRs. Sensitivities of the IgM ICT, 47kDa 
qPCR and 17kDa qPCR were 27.3% (95% CI 15.0-42.8), 22.7% (95% CI 11.5-37.8) and 
31.5% (95% CI 19.5-45.6) respectively. Specificities of the IgM ICT, 47kDa qPCR and 
17kDa qPCR were 93.5% (95% CI 91.5-95.1), 99.6% (95% CI 98.9-99.9) and 99.7% (95% 
CI 99.0-100), respectively compared to IgM ELISA/indirect immunofluorescence assay 
(IFA). 
A 16S rRNA qPCR was validated and implemented for leptospirosis diagnosis. The 
analytical performance was good, it was found to be 100% specific and had a limit of 
detection of one copy per microliter (µl) of DNA template. 
Sub-microscopic malaria infection detected using 18S rRNA qPCR was found in 
17.5% of non-malaria patients. The geometric mean of parasitaemia was very low (281.1 
parasites/µl [95% CI 172.5-458.2]). It was unlikely to be the cause of fever at this low 
level. 
C-reactive protein (CRP) result was able to distinguish between dengue virus 
infection (9.0 milligrams per litre (mg/l) (Interquartile range [IQR] 7.9-18.0)) and bacterial 
infections (106.5 mg/l [IQR 40.8-166.5] for leptospirosis, 55.2 mg/l [IQR 40.7-114.0] for 
scrub typhus and 24.7 mg/l [IQR 15.0-48.6] for murine typhus, P<0.0001 for all). 
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Conclusion 
 The new generation ICT that included NS1 antigen detection was clinically useful 
and appropriate to implement in the field for early diagnosis of acute dengue infection. The 
rRT-PCR for dengue could replace the gold standard serology for early diagnosis using a 
single specimen. The IgM ICT, 47kDa and 17kDa qPCRs were inadequate for diagnosis of 
scrub typhus and murine typhus due to low clinical diagnostic sensitivity. For leptospirosis 
16S rRNA qPCR, the excellent analytical performance warrants further investigation on its 
clinical usefulness. The CRP was found to be a useful tool to clinicians for determining 
whether a patient had a viral or bacterial infection. Early diagnosis of scrub typhus, murine 
typhus, and leptospirosis remains challenging. Development and clinical evaluation of 
improved diagnostic tests is urgently needed. 
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1 Background and Introduction 
1.1 Common causes of acute undifferentiated febrile illness in a rural Southeast 
Asian setting 
Acute undifferentiated febrile illness (AUFI) is the most common clinical 
presentation to health care services in developing countries and is a major public health 
problem, especially in rural areas where infrastructure, clinical laboratory facilities and 
sanitary conditions remain poor [1]. AUFI describes an acute and short duration of febrile 
illness accompanied by non-specific symptoms and signs, unlike fever of unknown origin 
(FUO) also known as pyrexia of unknown origin (PUO), which describes prolonged 
undiagnosed fevers. The definition of AUFI may be distinguished from FUO by fever 
duration, progression of illness and underlying causes [2, 3]. 
The causes of fever include a wide variety of infectious and non-infectious diseases 
such as neoplastic diseases, collagen vascular diseases and numerous miscellaneous 
diseases, however the majority are caused by infections [3]. The term AUFI has different 
implications depending on local epidemiology, and often refers to self-limiting viral 
syndrome or flu-like illness in developed countries. In most developing countries, malaria 
and other non-malarial infections such as dengue, leptospirosis and rickettsial infections 
present as AUFI [2, 4]. The actual aetiologies of AUFI are generally overlooked and 
patients are empirically treated to cover the potential diagnoses based on clinical 
presentations. Knowledge of local patterns or epidemiology of diseases is crucial for 
treatment decision-making. The accurate incidence and prevalence of infectious diseases 
are largely unknown, with estimates based on individual reports and dependent on the 
interest of local health care providers. There is increasing evidence that most cases of 
febrile illness in malaria endemic areas are not actually caused by malaria [5]. Data from 
previous fever studies have confirmed that dengue, leptospirosis, rickettsial infections 
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(especially scrub typhus and murine typhus), typhoid, chikungunya and Japanese 
encephalitis (JE) are common causes of non-malaria AUFI in Southeast Asia (SE Asia) 
including rural areas [6-12]. Many common causes of febrile illness in the tropics have no 
specific symptoms and signs, with headache, fever and chills being common features [6, 
11], making diagnosis in the field difficult, with the exception of malaria, which is easily 
detectable by microscopy or rapid diagnostic tests [13, 14]. Rapid diagnostic tools are not 
available for most non-malaria causes of AUFI and those that are available often have poor 
accuracy and are relatively expensive [15]. Serological diagnostic tools are the standard 
method for confirmation of these infections, but they require paired acute and convalescent 
phase specimens, which often are not temporally useful for patient management. New 
molecular diagnostic tools require an investment in technology, infrastructure and training 
that is unfeasible in many rural areas. Hence, very few clinical diagnoses are confirmed by 
laboratory investigation. 
1.1.1 Acute undifferentiated febrile illness in SE Asia 
The PubMed search term (acute [All Fields] AND undifferentiated [All Fields] 
AND ("fever" [MeSH Terms] OR "fever" [All Fields])) OR (acute [All Fields] AND 
undifferentiated [All Fields] AND ("fever" [MeSH Terms] OR "fever" [All Fields] OR 
"febrile" [All Fields]) AND illness [All Fields]) AND rural [All Fields] AND ("asia, 
southeastern" [MeSH Terms] OR ("asia" [All Fields] AND "southeastern" [All Fields]) OR 
"southeastern asia" [All Fields] OR ("southeast" [All Fields] AND "asia" [All Fields]) OR 
"southeast asia" [All Fields]), in combination with the limiting term for articles published 
in English, was used to identify relevant studies. 
There have been 13 published studies of AUFI conducted in SE Asia including five 
from Thailand [6, 7, 10, 11, 16], two from Laos [12, 17], three from Cambodia [18-20], 
one from Vietnam [8], one from Malaysia [21] and one multi-centre study that included 
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Thailand, Vietnam, Indonesia, Malaysia and Philippines [22]. No studies are available 
from Myanmar. The causes of AUFI from these studies are summarised in Table 1.1 
focussing on dengue, leptospirosis, rickettsial infection and malaria. 
These studies were conducted from 1975 to 2011 and included hospital and 
community based health centres, selecting patients aged from 1-87 years old, and from 
rural and urban areas. These studies diagnosed a range of different infectious diseases 
according to laboratory capacity and suspected causes of AUFI. No study used exactly the 
same laboratory testing as any of the other studies, which makes comparisons difficult. 
Nevertheless, the results suggested that dengue, leptospirosis, rickettsial infections and 
malaria account for a significant proportion of AUFI cases in these countries. The 
proportion of co-infection was variably reported as 0.6-22.8% of cases. Malaria is often co-
infected with other pathogens with the highest rate reported when the study included 
malaria patients diagnosed by nested-polymerase chain reaction (nested-PCR) [18].  
In 1984, a study of febrile illness in rural Malaysia reported that scrub typhus was 
the most frequent diagnosis observed in 19.3% of febrile illness, especially among palm oil 
labourers, followed by typhoid and paratyphoid fever (7.4%), and flavivirus infection 
(7.0%). Leptospirosis was found in 6.8% and malaria accounted for 6.2% [21]. In Vietnam, 
dengue was found to be a major cause of AUFI, responsible for one-third of febrile illness 
presenting to primary health services [8]. In Laos, the common causes of non-malaria fever 
were dengue (8.0%), scrub typhus (7.0%), JE (6.0%), leptospirosis (6.0%), and 
bacteraemia (2.0%) [12]. This is in line with another study from Laos in patients with 
jaundice and hepatitis who had fever. After excluding hepatitis virus infection, dengue was 
the most common cause (21.6%), followed by rickettsial infection (8.0%), and 
leptospirosis (7.9%). Septicaemia accounted for 8.2% of the patients with fever [17].  
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Table 1.1 Studies of acute undifferentiated febrile illness (AUFI) from SE Asia (focus on dengue, leptospirosis, rickettsial infection and 
malaria). 
1st author 
Country 
Location (position 
in country) 
Year of 
study 
Inclusion criteria Total patients 
analysed [n] 
and age range 
Laboratory 
diagnosis  
n (%) 
Dengue 
n (%) 
Leptospirosis 
n (%) 
Rickettsiosis 
n (%) 
Malaria 
n (%) 
Co-
infection 
n (%) 
Capeding 
Multicentre [22] 
5 SE Asia countriesa Jun-10 to 
 Jul-11 
T1 ≥38°C for ≥2d 289 
2-14y 
165 (57.0)b 33 (11.4) 3 (1.0%)c 17 (5.9) Not tested Not 
reported 
Chheng  
Cambodia [19] 
Siem Reap (NW) Oct-09 to 
Oct-10 
T1 ≥38°C <48hr 1,225 
<16y 
575 (46.9) 198 
(16.2) 
17 (1.4) 134 (10.9) 24 (2.0) 131/575 
(22.8)d 
Mueller  
Cambodia [18] 
Soun Kouma, Ou 
Chra (W), Snoul (E) 
Jan-08 to  
Dec-10 
T2 >38°C 
History fever <8d 
1,193  
7-49y 
874 (73.3)e 75 (6.3) 112 (9.4) 49 (4.1) 676 
(56.7)e 
146 (12.2) 
Mayxay  
Laos [12] 
Luang Namtha 
(NW), Salavan (S) 
May-08 to  
Dec-10 
T2 ≥38°C 
History fever ≤8d 
1,938  
5-49y 
799 (41.0) 156/1927 
(8.0) 
109/1934 (6.0) 141/1938 
(7.3) 
22/1936 
(1.0) 
101/1938 
(5.0) 
Watthanaworawit  
Thailand [16]  
Tak (NW) Apr-08 to  
Aug-08 
T3 ≥38°C 
History fever <7d 
162 
15-63y 
98 (60.5) 72 (44.4) 6 (3.7) 16 (9.9) Excluded 1 (0.6) 
Kasper 
Cambodia [20] 
9 health care clinics 
(SC) 
Dec-06 to 
Dec-09 
T2 >38°C for 
≥24hr and <10d 
9,997 
≥2y 
Not defined 
(38.0) 
883/9,975 
(8.9) 
2,076/9,975 
(20.8)f 
- g (32.0) 716/9,954 
(7.2) 
94 (1.0)h 
McGready 
Thailand [10] 
Tak (NW) May-04 to  
Jan-06 
T2 >37.5°C 
Pregnant 
203 
Not defined 
138 (65.4)i 20 (9.5)i 5 (2.4)i 26 (12.3)i 51 (24.2)i 8 (3.9) 
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Table 1.1 Studies of acute undifferentiated febrile illness (AUFI) from SE Asia (focus on dengue, leptospirosis, rickettsial infection and 
malaria) (continued). 
1st author 
Country 
Location 
(position in 
country) 
Year of 
study 
Inclusion criteria Total patients 
analysed [n] 
and age range 
Laboratory 
diagnosis  
n (%) 
Dengue 
n (%) 
Leptospirosis 
n (%) 
Rickettsiosis 
n (%) 
Malaria 
n (%) 
Co-
infection 
n (%) 
Syhavong 
Laos [17] 
 
Vientiane (S) May-01 
to  
May-04 
Jaundice/↑AST/ALT 
 
392 
0.4-83y 
130/392 (33.2) 
excluding 
Hepatitis A 
30/139 
(21.6) 
24/303 (7.9) 24/301 (8.0) 0/68 (0) 44/392 
(11.2) 
Phuong 
Vietnam [8] 
Binh Thuan (S) Apr-01 to  
Mar-02 
T1 ≥38°C and  
history fever <14d 
697 
4-82y 
234 (33.6) 45 (6.5)j 
234 (33.6) 
9 (1.3)j Not reported Excluded  Not 
reported 
Suttinont 
Thailand [7] 
5 centres  
(NE, S, C)k 
Jul-01 to  
Jun-02 
History fever <15d 845 
15-87y 
577 (68.3) 64 (7.6)l 312 (36.9) 206 (24.4) Excluded 112 (13.2) 
Ellis 
Thailand [11] 
Sangkhlaburi 
(W) 
Jun-99 to 
Mar-02 
T3 ≥38°C or 
history fever <48hr 
613 
20-87y 
294 (48.0) 9 (1.5) 107 (17.5) 36 (5.9) 155 
(25.3) 
34 (5.5) 
Leelarasamee 
Thailand [6] 
10 community 
based hospitals 
(N, NE, C, E, S) 
1991-
1993 
T4 >38.3°C in <24hr 
and History fever 3-
14d 
1,137  
>2y 
471 (38.7) 
 
70 (5.7) 14 (1.1) 156 (12.8) Excluded 65 (5.4) 
Brown 
Malaysia [21] 
Mentekab (C) 1975-
1979 
Not reported 1,629 
Not defined 
1,025 (62.9) 114 (7.0)m 110 (6.8) 327 (20.1) 101 (6.2) 14 (0.9) 
Remark: ALT=Alanine aminotransferase, AST=Aspartate aminotransferase, °C=Degree celsius, d=Days, hr=Hours, n=number, position in country: 
(C=Central, E=East, N=North, S=South, W=West), T=Temperature (1Axillary, 2Tympanic, 3Not specified, 4Oral), y=Years 
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aIndonesia, Malaysia, Philippines, Thailand, Vietnam; bIgM positive for at least one of dengue, chikungunya, hepatitis A, influenza A, leptospirosis, 
rickettsia, and S. typhi; cDetected, but not confirmed; dNumber of co-infections in microbiologically positive episodes; ePolymerase chain reaction (PCR) 
based diagnosis of malaria; fSerologically identified by IgM Enzyme-linked immunosorbent assay (ELISA), but not confirmed by Microscopic 
agglutination test (MAT); gScrub typhus, typhus group and spotted fever group IgG tested positive on convalescent specimen 133/1,906 (7.0%), 261/1,946 
(13.4%), and 146/1,263 (11.6%), respectively, and then confirmed on paired specimens 35/133 (26.3%), 56/261 (21.5%), and 21/146 (14.4%), 
respectively; hActive co-infection by a combination of PCR, blood culture, and/or malaria smear; iNumber of diagnoses (n=211) in pregnant woman 
(n=203) with fever was shown; jPresumptive diagnosis; kNakhon Rachasima, Loei, Bureeum (NE), Chumphon (S), Ratchaburi (C); lObvious dengue cases 
were excluded; mFlavivirus. 
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In Cambodia, the biggest study and the first systemic assessment of the aetiologies 
of AUFI was conducted between 2006 and 2009 in the south central part of the country. 
Influenza viruses were reported as the most frequent pathogens (19.9%), followed by 
dengue (8.9%), malaria (7.2%) and bacterial infection (6.3%) [20]. A subsequent 
prospective study of AUFI in rural Cambodia showed that malaria was the most frequent 
cause (56.7%). Leptospirosis was the second most common observed in 9.4%, followed by 
dengue (6.3%), and rickettsiosis (4.1%) [18]. Another prospective study in hospitalised 
children in Northwest Cambodia reported dengue (16.2%), scrub typhus (7.8%), and JE 
(5.8%) as the most common causes of AUFI in this population. Invasive bacterial infection 
accounted for 6.3% of the febrile episodes with Salmonella enterica serovar Typhi 
responsible for the majority of infections (1.8% of febrile episodes) [19]. There were 
similar findings from a multi-centre study which reported that chikungunya, typhoid, and 
dengue were the most common identified causes of children with AUFI in SE Asia [22]. 
The rates of dengue, leptospirosis and rickettsial illness are not directly comparable 
between studies (Table 1.1). Firstly, the enrolment of patients to these studies was highly 
inconsistent. Temperature was measured by different methods: four studies used tympanic 
[10, 12, 18, 20], three studies used axillary [8, 19, 22] and one study used oral temperature 
[6]. There were three studies that did not specify how temperature measurement was done 
for inclusion although a cut-off point for fever was defined [11, 16, 17]. One further study 
did not require a measured temperature for inclusion only specifying days of fever [7] and 
in the study from Malaysia patients were reported to be febrile but no cut-off point or 
temperature measurement method was reported [21]. Secondly, history of fever was 
similarly variably defined from less than 24 hours to less than 15 days of fever or not 
described at all. Thirdly, the age, sex and pregnancy status of enrolled patients varied. 
Finally, different laboratory methods and diagnostic algorithms were used for confirmation 
of diseases. 
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1.1.2 Acute undifferentiated febrile illness in Thailand 
In Thailand, the terminology of acute pyrexia of unknown origin (acute PUO) is 
used in the reporting system. It is one of the communicable diseases that must be reported 
to the Bureau of Epidemiology, Department of Disease Control, Ministry of Public Health. 
It was suggested that the term acute PUO in the Thai reporting system should be changed 
to acute undifferentiated febrile illness (AUFI) due to the fact that it does not conform with 
the definition of classical PUO [3, 6].  In this thesis, the term AUFI will be used instead of 
acute PUO. 
Based on Thai surveillance data there were around 200,000-500,000 cases of AUFI 
reported each year between 2003 and 2014, with an annual morbidity rate ranging from 
294.38 to 807.00 per 100,000 population. The number of cases and morbidity rate were 
highest in 2013 (Figure 1.1). During the same period of time, the trend in the number of 
deaths and mortality rate was opposite to that for the number of cases and morbidity 
incidence rate. The number of deaths was highest in 2003 and has declined since then, with 
the mortality rate now below 0.05 per 100,000 population (Figure 1.2). However, these 
numbers are likely to be unreliable as they are based on clinical diagnosis alone, and rarely 
confirmed by the laboratory. It is also difficult to obtain an accurate estimate of mortality 
when convalescent sera for laboratory confirmed diagnosis are not available from most 
fatal cases. 
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Figure 1.1 Number of cases and morbidity rate of AUFI reported in Thailand 
between 2003 and 2014. 
 
Figure 1.2 Number of deaths and mortality rate of AUFI reported in Thailand 
between 2003 and 2014. 
Source for Figures 1.1 and 1.2: Centre of Epidemiological Information, Bureau of 
Epidemiology, Department of Disease Control, Ministry of Public Health, Thailand, 
http://www.boe.moph.go.th/boedb/surdata/disease.php?dcontent=old&ds=18.  
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When a country has a strong malaria control program, such as Thailand where 
patients can access a rapid and accurate diagnosis of malaria, physicians are often faced 
with the problem of AUFI. The more malaria is brought under control the more the relative 
frequency of AUFI patients becomes apparent [23]. This is one likely explanation for 
Thailand recognising AUFI as a significant problem and conducting some of the earliest 
AUFI studies more than 20 years ago. Figure 1.3 maps the locations of study sites of AUFI 
in Thailand. 
The first was an epidemiological study (Leelarasamee et al., 2004) conducted in 10 
community-based hospitals that represented each part of Thailand (North, Northeast, 
Central, East and South) [6]. The specific location of the study sites was not mentioned, 
hence they are not in Figure 1.3. Hospitals enrolled patients over a one year period 
between 1991-1993 and inclusion criteria were outpatient presentation of patients aged 
over two years with a 3-14 day duration of fever and an oral temperature over 38.3°C, with 
no obvious single organ involvement or infectious disease that could be diagnosed by 
physical examination, as well as negative or non-conclusive results of complete blood 
count, thick film for malaria (i.e. malaria patients were excluded from this study), 
urinalysis and chest x-ray. This study showed that the most common causes of AUFI were 
rickettsial infections, influenza, and dengue fever, with scrub typhus found in 7.5%, 
followed by influenza (6.0%), dengue fever (5.7%), murine typhus (5.3%), enteric fever 
(1.9%), chikungunya infection (1.1%), leptospirosis (1.1%) and melioidosis (0.9%). 
Primary bacteraemia was found in 3.2% by blood culture with Escherichia coli, 
streptococci, salmonella, Enterobacter spp., and Staphylococcus aureus being the five 
most common pathogens. Co-infection (two or more pathogens identified) was found in 
5.4% of the patients. The majority of patients (61.3%) remained undiagnosed. 
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Figure 1.3 A map showing the locations of study sites of AUFI in Thailand [7, 10, 11, 16]. 
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The second published study (Ellis et al., 2006) was conducted from June 1999 to 
March 2002 in the rural area of the west border of Thailand in Sangkhlaburi district, 
Kanchanaburi province on the border with Myanmar (Figure 1.3), which is home to a 
variety of ethnic groups including Thai, Karen, Mon, and Burman [11]. In this study, the 
inclusion criteria were adult inpatients and outpatients presenting with a temperature 
≥38°C or history of fever over the previous 48 hours (and patients with fever longer than 
48 hours as long as the cause of fever was not yet established). Malaria patients were 
included in the study and this was found to be the most common cause (25.3%), followed 
by leptospirosis (17.5%), rickettsial infections (5.9%; with 3.3% spotted fever group 
(SFG), 1.5% murine typhus and 1.1% scrub typhus), dengue fever (1.5%), and several 
cases of JE, AIDS, typhoid, and pulmonary tuberculosis (PTB). This was in contrast with 
the study of Leelarasamee et al., 2004 where rickettsial infection, mostly scrub typhus, was 
the major cause whereas the major rickettsiosis observed in this study was SFG, which has 
been rarely reported in Thailand. Co-infections were common (5.5%), particularly for 
malaria and leptospirosis. No specific diagnosis was confirmed in 52% of the patients.  
The third study (Suttinont et al., 2006) also included adult patients from five 
different hospitals including three in the Northeast (Maharat Nakhon Rachasima Hospital 
in Nakhon Rachasima province, Loei Hospital in Loei province, and Banmai Chaiyapod 
Hospital in Bureeum province), one in the South (Chumphon Hospital in Chumphon 
province), and one in the centre of the country (Ratchaburi Hospital in Ratchaburi 
province) (Figure 1.3), recruited over a one year period between July 2001 and June 2002 
[7]. Patients presenting with acute fever of less than 15 days duration and without an 
obvious focus of infection were included and those with malaria or clinically obvious 
dengue virus infection were excluded. From this study, leptospirosis was the major cause 
(36.9%) of adult AUFI and scrub typhus (19.9%) was the second most common disease 
found, followed by viral infection including dengue and influenza (10.7%), murine typhus 
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(2.8%), Rickettsia helvetica (1.3%), Q fever (1.0%), and other bacterial infections (1.2%). 
Thirteen percent of the patients had co-infections. The most common was co-infection with 
leptospirosis and scrub typhus (3.9%), followed by scrub typhus and influenza co-infection 
(3.4%). The causes of AUFI remained unknown in almost one third of cases. 
The fourth published study (McGready et al., 2010) was from the rural area of Tak 
province on the Thailand-Myanmar border, more than 500km north west of Bangkok, and 
was specifically conducted in pregnant women. The study included refugee and migrant 
women of Karen and Burman ethnic groups living and working on both sides of the border 
[10]. This study was conducted from May 2004 to January 2006 at Shoklo Malaria 
Research Unit (SMRU) clinics located in Mae La (MLA) refugee camp, and at three sites 
for migrants named after their village locations in Thailand: Wang Pha (WPA), Mun Ru 
Chai (MRC) and Mawker Thai (MKT). The inclusion criteria for this study were 
pregnancy, regardless of gestation, agreed to hospitalisation and a confirmed temperature 
of >37.5°C.  The exclusion criterion was enrolment in a Plasmodium falciparum malaria 
study that was being conducted concurrently. This resulted in the study being biased 
towards including febrile cases of Plasmodium vivax malaria. Despite this malaria was the 
leading cause (24.2%) of fever, followed by pyelonephritis (19.4%), rickettsial infection 
(12.3%), dengue (9.5%), acute respiratory infection (8.1%), and leptospirosis (2.4%). 
Several cases of other causes were observed including enteric fever, suspected 
chorioamnionitis, endometritis, chicken pox, cholecystitis, gastroenteritis, pyelolithiasis 
and asymptomatic urinary tract infection. Co-infection was found in 3.9% of the patients, 
mainly malaria and rickettsia. Causes of AUFI remained unknown in 19.0% (40/211), 
however, if malaria was excluded the proportion of unknown causes increased to 25.0% 
(40/160). 
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The final study was a pilot study (Watthanaworawit et al., 2011) conducted prior to 
the work described in this thesis and excluded patients with malaria [16]. This study was 
conducted from April to August 2008 at two of the SMRU clinics: MLA and MKT (Figure 
1.3). The inclusion criteria were adults (defined as those aged ≥15 years) with a 
temperature of ≥38°C and of less than seven days duration. The study did use clinical 
symptoms or physical signs consistent with dengue, leptospirosis, or rickettsiosis 
(abnormal bleeding, eye redness, headache, myalgia or rash) as an inclusion criterion and 
excluded those who had a clear alternative diagnosis such as malaria, urinary tract 
infection (UTI) or pneumonia. Unsurprisingly, dengue was the main pathogen detected 
(44.4%), followed by murine typhus (5.6%), scrub typhus (4.3%), leptospirosis (3.7%), 
and typhoid (2.5%). Co-infection was found in only one case (acute secondary dengue 
infection and typhoid), and 39.5% remained undiagnosed. 
1.1.3 Acute undifferentiated febrile illness and mortality 
As most AUFI never receives a confirmed laboratory diagnosis, it is difficult to 
obtain good estimates of mortality. While there are many case reports available these are 
inherently biased. In addition, studies of AUFI are limited in terms of sample size and 
resources. Resource limitations reduce the number of laboratory tests that can be 
performed to determine aetiology and patients who die usually do not have convalescent 
sera available, resulting in reduced ability to confirm a diagnosis. In the 13 studies in Table 
1.1, six did not report on mortality [7, 8, 16, 18, 20, 22]. Mortality data were reported in 
seven studies: four hospital-based studies (recruited in the inpatient department [IPD]) [10, 
17, 19, 21], one community-based study (recruited in the outpatient department [OPD]) 
[6], and two studies recruiting patients in both the OPD and IPD [11, 12]. 
In both studies from Laos mortality was reported [12, 17]. In the most recent study 
(Mayxay et al., 2013) that recruited inpatients and outpatients (n=1,938), there were six 
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inpatient deaths giving an overall case fatality rate of 0.7% (6/857). Causes of death 
included one from each of the following: melioidosis, Staphylococcus aureus bacteraemia, 
JE, dengue, no diagnosis and one not detailed [12]. The other study from Laos (Syhavong 
et al., 2010) recruited patients who were admitted to hospital with a focus on aetiology in 
patients with jaundice and/or raised aspartate aminotransferase/alanine aminotransferase 
(AST/ALT). The report included significantly more deaths: 13 died in hospital amongst 
389 patients with discharge results, equivalent to an overall case fatality rate of 3.3%. 
Amongst these deaths the aetiology included hepatitis C virus (2), hepatitis A virus (1), 
hepatitis B virus (1), leptospirosis (1), scrub typhus (1) and unknown (7) [17]. 
Mortality was reported in a paediatric hospital-based study from Cambodia. Sixty 
nine of 1,225 children died or were discharged to die at home (overall case fatality rate 
5.6%). The diagnoses included 19 invasive bacterial infections, 19 patients with clinical 
pneumonia, 11 patients with viral infection, and seven patients with other primary clinical 
diagnoses such as clinical diarrhoea or UTI. The source of fever was unknown in 13 
patients [19]. 
Three studies from Thailand, including two from the Thailand-Myanmar border, 
reported mortality; one community-based study [6], one hospital-based study [10], and one 
study recruiting patients in both IPD and OPD [11]. The study of Leelarasamee and 
colleagues reported 13 deaths amongst 1,137 patients recruited in OPD (case fatality rate 
of 1.1%) and most of these were secondary to nosocomial infections following admission 
for the underlying disease. The aetiology assigned was one case with dengue, influenza 
and murine typhus, two with Staphylococcus aureus bacteraemia and 10 were unknown 
[6]. In the pregnancy study, of 203 pregnant women who agreed to hospitalisation and 
were enrolled, one died (overall case fatality rate 0.5%) and no diagnosis was available for 
her [10]. In West Thailand, eight of 613 patients died, giving an overall case fatality rate of 
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1.3%; including two typhoid, one leptospirosis, two end-stage HIV infection, two with no 
specified diagnosis, and one hepatitis death but with no specific aetiology assigned [11].  
Finally, in Malaysia, there were eight confirmed deaths in the 1,629 patients but the 
fate of 47 who left the hospital against medical advice was not available. Hence, the 
overall case fatality rate was 0.5% (eight of 1,582) [21], although the mortality rates are 
likely to have been underestimated. There were two patients who died of typhoid, two of 
septicaemia and one each of pulmonary tuberculosis, melioidosis, scrub typhus and 
unknown cause. 
From these 13 studies reporting on 20,320 patients with AUFI in SE Asia, there 
were 118 deaths reported from 7 studies [6, 10-12, 17, 19, 21], or an overall case fatality 
rate of 2.0% (118 of 6,006; 95% confidence interval [CI] 1.6-2.3). The case fatality rates 
for hospital-based studies, community-based studies and the study that included patients 
from IPD and OPD were approximately 2.7% (91/3,399; 95% CI 2.2-3.3), 1.1% (13/1,137; 
95% CI 0.6-1.9), and 1.0% (14/1,470; 95% CI 0.5-1.6), respectively. Aetiology of death 
was ascertained for approximately three-quarters of the cases: 70.3% (83/118). 
1.1.4 Acute undifferentiated febrile illness and clinical features 
Headache, fever and chills are common clinical features of most infectious causes 
of AUFI. In the Cambodian AUFI study of almost 10,000 outpatients, it was observed that 
the most common clinical features were headache (69.5%), cough (57.5%), chills (48.1%), 
malaise (46.8%) and sore throat (46.6%) [20]. In the Lao study of patients aged 5-49 years, 
few clinical features were useful to predict the aetiology of non-malaria fever. Briefly, it 
was observed that platelet count of less than 100,000/µl was associated with dengue; 
female gender and hepatomegaly with scrub typhus; and age less than 15 years, vomiting, 
cough and c-reactive protein (CRP) more than 5mg/l were associated with leptospirosis 
[12]. In adults in Thailand, patients with confirmed dengue had lower white cell counts 
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(4.8 vs 7.2 x103/cubic millimetre (mm3), P<0.0001) and platelets (147 vs. 162 x103/mm3) 
than patients with non-dengue infection [16], while clinical symptoms did not differ 
significantly between the two groups. In Vietnam 48.9% (22/45) of clinically diagnosed 
dengue cases were serologically confirmed. In the same study 32.5% (212/652) of patients 
not diagnosed as dengue were positive by serology, indicating a very poor agreement 
between clinical and serological diagnosis [8]. In pregnant women with AUFI in Thailand, 
physician predicted diagnosis (excluding malaria) was poor: 22.4% (4/18) of dengue, 
19.0% (4/21) of rickettsial infections and 16.7% (1/5) of leptospirosis cases were 
confirmed by laboratory testing [10]. In Laos hospitalised patients with jaundice or raised 
AST/ALT, those with leptospirosis and typhus had higher total bilirubin:AST ratio and 
total bilirubin:ALT ratio than patients with dengue, septicaemia or viral hepatitis (A, B, C, 
and E) [17]. In West Thailand, a regression analysis of 107 cases of leptospirosis and 36 
cases of rickettsiosis did not reveal any differential clinical features [11]. 
1.1.5 Acute undifferentiated febrile illness and diagnostics 
The difficulty of diagnosing these infections clinically is compounded by a lack of 
diagnostic test availability in the disease endemic areas. Hence, very few clinical diagnoses 
are confirmed by laboratory investigation. In the 13 studies described above, different 
laboratory tests were used to establish a diagnosis and sometimes further testing was 
required for confirmation. To comprehend the breadth of testing for AUFI, the dengue, 
leptospirosis and rickettsial diagnostics and the use of non-specific markers testing 
(complete blood count (CBC) and CRP) are summarised in Table 1.2. Most studies used 
serological tests to confirm diagnosis of these infections. Culture of organisms was rare: 
only one study from Malaysia did cell culture for flaviviruses [21], three studies performed 
culture for leptospirosis [7, 10, 12] and three for rickettsiosis [10, 12, 21]. Only one study 
used rapid diagnostic tests for dengue, leptospirosis and scrub typhus in the field with 
subsequent confirmation by serology and non-structural protein 1 (NS1) antigen detection 
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for dengue, culture and serology for leptospirosis, and culture, serology and PCR for scrub 
typhus [10]. In a study from Cambodia, PCR and nucleotide sequencing of all PCR 
products were used to improve specificity to define the causes of these infections [18]. 
Blood culture was commonly performed for other bacterial infections and CBC was also 
common for routine clinical investigation. CRP testing was used in only two recent studies 
from Laos [12] and Cambodia [18]. Amongst the 13 studies, only the recent study from 
Laos [12] had diagnostic and confirmation tests of diseases which covered the detection 
windows of antigen, antibody and organism/nucleic acid and this study also conducted the 
greatest number of tests of all the studies. 
Data from Table 1.2 contains the range of diagnostic tests used in different studies. 
This table does not illustrate the true complexity of the diagnostic methods used: serology 
test kits were purchased from different manufacturers; some studies followed 
manufacturer’s instructions while others used in-house methods; quantitative cut-offs for 
positivity were not consistent between studies in part due to different background 
endemicity; and diagnostic algorithms were study dependent. For example, in the study of 
Capeding et al. [22], the Platelia Dengue NS1 Ag kit (Bio-Rad, USA), Dengue Virus IgM 
Capture DxSelect ELISA kit and Dengue Virus IgG Capture DxSelect ELISA kit (Focus 
Diagnostics, USA) were used to define dengue infection status. The Leptospirosis Indirect 
Haemagglutination (IHA) test (Focus Diagnostics, USA) was used to detect leptospirosis. 
The Rickettsia Indirect Immunofluorescence assay (IFA) IgG/IgM (Focus Diagnostics, 
USA) was used for Rickettsia. These tests were used according to the manufacturer’s 
instructions. In another study from Mayxay et al. [12], a combination of four different 
ELISA kits was used for the detection of dengue and JE (Panbio, Brisband, Australia): one 
for the detection and differentiation of IgM against dengue and JE (Japanese encephalitis-
Dengue IgM Combo), one for detection of high level of anti-dengue IgG in acute 
secondary infection (Dengue IgG Capture), one for low level of anti-dengue IgG (Dengue 
 51 
IgG indirect ELISA) and one for detection of NS1 (Dengue Early ELISA). This 
combination was performed according to the manufacturer’s instructions. The microscopic 
agglutination test (MAT) was used for confirmation of leptospirosis using a cut-off titre of 
≥1:400 or four-fold rise in paired sera to define positives. IFA was used for detection of 
IgG or IgM antibodies against Orientia tsutsugamushi and Rickettsia typhi. A positive 
result was defined as ≥1:400 titre of IgM or IgG. The author noted that it was uncertain 
whether the cut-off titre used in the study was correct for the situation in Laos. Another 
example is that even using the same technique for laboratory tests, there are some 
differences in detailed procedure such as in the study of Leelarasamee et al.[6], 
leptospirosis was diagnosed using MAT test which included only Leptospira bataviae as 
representative serogroup and the cut-off titre was 1:100 or more, whereas a panel of 
reference strains from 24 serogroups of Leptospira and the cut-off titre of at least 1:400 or 
four fold increase in paired specimens were used in the study of Suttinont et al. (leptospire 
culture was also performed) [7]. 
Despite a large number of studies using serological methods and culture of 
organisms for these infections, the tests were used for confirmation rather than rapid 
diagnosis for patient care.  This is mainly because serology traditionally requires paired 
acute and convalescent specimens. Culture takes a long time and needs sophisticated 
laboratory facilities and technicians. Molecular methods such as PCR have been used for 
acute diagnosis of infection as well as rapid diagnostic tests (RDT) to assist patient 
management. However, in the rural areas where the diseases are endemic, even these 
diagnostic tests are not routinely available. 
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Table 1.2 Laboratory diagnostics of acute undifferentiated febrile illness (AUFI) used in the studies from mainland SE Asia. 
Dengue Leptospirosis Rickettsia Malaria 
1st author 
S NS1 RDT PCR Cu S RDT PCR Cu S RDT PCR Smear RDT PCR 
Blood 
culture 
CBC CRP 
Capeding [22]   - - -  - - -  - - - - - -  - 
Chheng [19]   - -  - -  -  -   - -   - 
Mueller [18] - - -  - - -  - - -      -  
Mayxay [12]   -    -    -        
Watthanaworawit [16]    -  -  - - -  - - - - -   - 
Kasper [20]  - -  -  - - -  -   - -  - - 
McGready [10]    -    -      - -   - 
Syhavong [17]   - - -  - - -  - -  - -   - 
Phuong [8]  - - - - - - - - - - -  - - - - - 
Suttinont [7]  - - -   - - -  - - - - -   - 
Ellis [11]  - -  -  - - -  - -  - - -  - 
Leelarasamee [6]  - - - -  - - -  - -  - -   - 
Brown [21]  1,2 - - - -  - -   - -  - -   - 
tested, -=not tested or not mentioned; Cu=culture, CBC=complete blood count, CRP=c-reactive protein, RDT=rapid diagnostic test, S=serology 
1Flavivirus; 2Culture 
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1.2 Dengue 
1.2.1 The dengue virus 
 Dengue is caused by a small single stranded RNA (ssRNA) virus, belonging to the 
genus Flavivirus, in the Family Flaviviridae. The genome of the dengue virus has a single 
copy of positive-sense ssRNA of approximately 11 kilobases (kb) in length that encodes a 
single large polyprotein that is subsequently cleaved into ten structural and non-structural 
proteins [NS]: three structural proteins (nucleocapsid or core protein [C], precursor of 
membrane [prM] (membrane [M]), and envelope [E]) and seven non-structural proteins 
(NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). The order of proteins encoded in the 
long, single, open reading frame is 5’-C-prM(M)-E-NS1-NS2A-NS2B-NS3-NS4A-NS4B-
NS5-3’. The virion is spherical, 40-50 nanometres (nm) in diameter, with a 
lipopolysaccharide envelope. The E structural protein plays a key role in several important 
functions of dengue viruses including receptor binding, haemagglutination of erythrocytes, 
and induction of neutralising antibodies and protective immune response. The E protein 
has the sites for viral attachment to, and transport through, host cell plasma membranes, 
and contains epitopes specific for serotype, dengue complex and group. Core protein is 
responsible for encapsidation of viral RNA genome into nucleocapsid that forms the core 
of a mature virion. M protein is important in the formation and maturation of the virion.  
NS1 plays a significant role in viral RNA replication. In addition to the E protein, NS1 is 
the only other viral protein that appears to play a role in protective immunity. NS3 is 
associated with a role in protease activity and a nucleotide triphosphatase (NTPase) or 
helicase activity, while NS5 has a role as the viral RNA polymerase in viral RNA 
replication [24-26]. 
 There are four genetically closely related dengue virus serotypes (DENV) referred 
to DENV-1, DENV-2, DENV-3 and DENV-4. These are immunologically distinct, 
 54 
however there is antigenic cross-reactivity of DENV1-4 antigens as each serotype shares 
approximately 65% of the genome, which is also similar in other flaviviruses including JE 
and West Nile virus [24]. Genetic variation within each serotype has been described, 
resulting in distinct clusters called genotypes (or subtypes) [27]. Genotypes have been 
identified in numerous phylogenetic studies of dengue virus serotypes based on partial or 
complete sequencing of different genes (e.g. E genes), gene junctions (C, prM/E, NS3) or 
complete genomes. The most recent review in 2011, by Chen and Vasilakis, identified 
genotypes of DENV1-4 based on complete E gene sequences. The analysis confirmed 
previously identified genotypes and also provided greater resolution for presence of new 
genotypes. The result has shown that DENV-1 and DENV-3 have five genotypes, DENV-2 
has six genotypes and DENV-4 has four genotypes [28].  
 In October 2013, discovery of the new dengue virus serotype, DENV-5 was 
announced. The virus was isolated from a 37-year-old farmer admitted in a hospital in 
Sarawak state of Malaysia in 2007. It was initially thought to be the sylvatic DENV-4 
which circulates among non-human primates and Aedes nivalis mosquitoes in the forest of 
SE Asia, however after full sequencing it was observed that the virus was phylogenetically 
distinct from the previous sylvatic DENV-4 and had some similarity with DENV-2. This 
was the only one case admitted to the hospital during the outbreak in Sarawak in 2007, no 
other cases of DENV-5 have been reported so far [29]. 
1.2.2 Epidemiology of dengue 
1.2.2.1 Transmission 
All four dengue virus serotypes are sustained in two transmission cycles: sylvatic 
and human cycles. The sylvatic cycle takes place in sylvan environments mainly in SE 
Asia and West Africa. The cycle is transmitted among arboreal canopy-dwelling Aedes 
spp. and non-human primates that appear to be the only amplification and reservoir hosts. 
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Ae. furcifer is one of the principal vectors in Africa and is primarily a canopy-dwelling 
enzootic mosquito, however they are known to move to the ground for feeding on humans. 
Similarly, in Asia the Ae. (Finlaya) niveus s.l. complex are a group of principal vectors that 
are known to feed on humans. This feeding behaviour can facilitate the movement of 
sylvatic strains of dengue virus from the forest to the peri-domestic environment [28]. The 
vectors in rural areas of Africa and SE Asia are often at high densities and dengue virus is 
known to transfer between non-human primates and humans. Almost all human infections 
are caused by dengue virus strains that circulate in domestic and peri-domestic 
environments where humans are the only amplification and reservoir hosts. 
Different species of Aedes mosquitoes are responsible for transmitting dengue virus 
infections from person to person. The female Ae. aegypti remains the most efficient of the 
mosquito vectors mainly because of its domestic nature and the fact that it bites humans 
during the day. It frequently bites several times and feeds on multiple hosts during a single 
gonotrophic cycle [30]. Transmission to humans could occur immediately if the mosquito 
is disturbed during feeding from an infected host and then changes hosts or after an 8-10 
day incubation period during which the virus multiplies in the salivary glands of the 
mosquito. Mosquitoes remain infective for life, which is usually around 30-45 days. 
Transovarial transmission (when the female passes the virus to her offspring) has also been 
reported, but the epidemiological importance of this has not been established [24, 31]. 
Ae. albopictus, Ae. polynesiensis and several species of Ae.scutelaris complex are 
also all able to transmit the dengue virus. The global distribution of only the two main 
vectors, Ae. aegypti and Ae. albopictus, puts nearly a third of the global human population 
at risk of infection [28, 31].  
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1.2.2.2 Global distribution and incidence 
 Dengue is the most important arbovirus infection in humans with a large global 
burden and is endemic between 30 degrees north latitude (°N) and 40 degrees south 
latitude (°S) (which includes all tropical and subtropical zones) wherever the 
environmental conditions permit dengue virus transmission by Aedes mosquitoes (Figure 
1.4). This includes more than 100 countries in SE Asia, the Americas, the West Pacific, 
Africa and the East Mediterranean regions [32, 33]. There are an estimated 50-100 million 
dengue infections each year, resulting in 500,000 severe dengue cases and around 20,000 
deaths, and approximately 2.5 billion people at risk living in dengue endemic countries. Its 
incidence has increased 30-fold in the past five decades [33-36]. Almost 95% of cases are 
children aged less than 15 years old, although there is an increase in the average age of 
patients with dengue infection [31, 37]. Unfortunately limited laboratory confirmation of 
dengue cases, low levels of reporting and inadequate surveillance worldwide means that 
the true distribution and public health burden are poorly described [36]. However, one of 
the most recent estimates of global dengue risk was created from a formal modelling 
framework paired with detailed longitudinal information from dengue cohort studies and 
population surfaces to infer the public health burden of dengue in 2010 [38]. The model 
developed by Bhatt and colleagues concluded that there is an estimated 390 million dengue 
infections per year, of which 96 million present as symptomatic infections, which is three 
fold higher than the figure estimated by the World Health Organization (WHO) [33]. 
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Figure 1.4 Global Dengue Risk 
Reproduced with permission from Simmons, C.P., Farrar, J.J., Nguyen v, V., and Wills, B., 
Dengue. N Engl J Med, 2012. 366(15): p. 1423-32, Copyright Massachusetts Medical 
Society [32]. 
Nearly three quarters of the global population who are exposed to dengue live in 
the Asia Pacific region. Of these, 1.3 billion people are at risk living in ten endemic 
countries in SE Asia [36] and dengue is a leading cause of hospitalisation and death among 
children in the region [39]. SE Asia has regular dengue epidemics on 3–5 year cycles [40]. 
Vietnam, Thailand and the Philippines reported the highest number of dengue cases among 
Asian countries. The Philippines reported the first dengue haemorrhagic fever (DHF) 
outbreak in 1953/1954, followed by a second outbreak in 1956. Thailand reported an 
outbreak in Bangkok in 1958. Since then the epidemic cycles in SE Asia have continued 
and become larger in magnitude [41, 42]. The incidence and spread of dengue fever have 
been increasingly reported in nine countries within the SE Asia region between 1985-2005 
and have continued to increase in recent years. By 2009, almost all member countries in 
the region reported dengue outbreaks [43]. The case fatality rates reported approximately 
1% for the region, but India, Indonesia and Myanmar where the outbreaks were far from 
urban areas, reported 3-5% case fatality rates [33].  
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1.2.2.3 Dengue in Thailand 
Thailand is one of the hyperendemic countries (all four virus serotypes circulating) 
in SE Asia with data showing that 87% of cases are secondary infections (infected for the 
second or more time either with the same or different dengue virus serotype) and only 13% 
are primary infections (infected with the dengue virus for the first time) [41, 42]. Disease 
incidence and deaths remained highest in young children aged ≤15 years. Dengue is 
seasonal and peaks during the rainy season, the number of cases peak between May and 
September, although it varies slightly between regions [44]. There is no clear pattern of 
infecting serotype with regard to severity, although DENV-2 and DENV-3 appear to be 
associated with more severe symptoms than the other dengue serotypes accompanied by 
secondary infection. It is more likely to be a suggestive trend rather than strong evidence. 
The disease severity varies for individual dengue virus serotypes, year of observations or 
studies which may be caused by other factors and in particular the sequence of different 
serotypes in primary and secondary infections [45-47]. 
The most recent data, up until 2014, comes from the Centre of Epidemiological 
Information, Bureau of Epidemiology, Department of Disease Control, Ministry of Public 
Health, Thailand. There were around 40,000-150,000 dengue cases (total dengue including 
dengue fever [DF], dengue haemorrhagic fever [DHF] and dengue shock syndrome [DSS]) 
reported each year between 2003 and 2014, with the morbidity rate ranging from 62.59 to 
241.03 per 100,000 population. The number of dengue cases and morbidity rate peaked in 
2010 and 2013 with the latter reporting the highest number of cases and morbidity rate 
(Figure 1.5). The trend in the number of deaths and mortality rate was similar to that for 
the number of cases and morbidity rate which varied during the period and peaked in 2010 
and 2013. However, the mortality rate remained below 0.25 per 100,000 population even 
during the highest morbidity rate years (Figure 1.6) [48]. 
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Figure 1.5 Number of cases and morbidity rate of dengue reported in Thailand 
between 2003 and 2014. 
 
Figure 1.6 Number of deaths and mortality rate of dengue reported in Thailand 
between 2003 and 2014. 
Note: Data from total dengue cases including DF, DHF and DSS (National Disease 
Surveillance, report 506 code: 66, 26, and 27, respectively). 
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Source for Figure 1.6 and 1.7: Centre of Epidemiological Information, Bureau of 
Epidemiology, Department of Disease Control, Ministry of Public Health, Thailand, 
http://www.boe.moph.go.th/boedb/surdata/disease.php?dcontent=old&ds=262766. 
1.2.3 Clinical features 
Dengue virus infection is responsible for a wide clinical spectrum of disease. 
Infections can cause mild acute undifferentiated febrile illness to severe disease 
characterised by haemorrhage and shock. All four virus serotypes (DENV1-4) share nearly 
identical symptoms in humans and can cause dengue fever and dengue haemorrhagic fever. 
Primary infection by a specific serotype induces lifelong protective immunity against the 
infecting serotype. A cross-protective immunity to a different serotype has been observed 
within 2-3 months of the primary infection, however there is no long-term cross-protective 
immunity [33]. Several risk factors are associated with dengue severity, including host 
factors, viral factors, and differences in dengue cross-reactive antibodies. The major risk 
factor for development of severe dengue is secondary infection with a different serotype 
from the first infection. Primary infection in infants born from dengue-immune mothers are 
at higher risk for severe infection than those born from non-immune mothers [34]. These 
are explained by antibody-dependent enhancement (ADE) where a dengue virus serotype 
uses pre-existing anti-dengue virus antibodies produced in the primary infection to 
facilitate entry of a different dengue virus serotype via macrophage Fc receptors [49, 50]. 
The immune system is tricked because the four virus serotypes have very similar surface 
antigens. The antibodies bind to surface antigen but do not inactivate the virus, resulting in 
an increased number of infected cells and a rise in viraemia. The host produces and 
releases cytokines and other mediators that cause an increase in vascular permeability in 
endothelial cells, resulting in plasma leakage. Young children are at higher risk of severe 
dengue as they may be less able to compensate for vascular leakage than adults and are 
subsequently at higher risk of dengue shock [33, 51].  
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In SE Asia, patients with dengue virus infection usually present with an acute 
undifferentiated febrile illness. The symptoms and signs are non-specific, and it is rarely 
possible to differentiate from antibiotic-treatable causes of fever, such as leptospirosis, 
typhoid and rickettsial infections [6-8, 52]. According to the WHO guideline 1997, dengue 
virus infections were classified into three categories: undifferentiated fever, DF and DHF, 
and DHF was further classified into four severity grades. The presence of 
thrombocytopenia with concurrent haemoconcentration differentiates grades I and II DHF 
from DF. DHF grade III and IV are defined as DSS [53]. Cases of DHF fulfil all of the 
following four clinical criteria: (1) fever or history of acute fever lasting 2-7 days; (2) 
haemorrhagic tendencies evidenced by at least one of the following: a positive tourniquet 
test; petechiae, ecchymoses or purpura; bleeding from the mucosa, gastrointestinal tract, 
injection sites or other locations; haematemesis or melaena; (3) thrombocytopenia 
(≤100,000 platelets/µl); and (4) evidence of plasma leakage due to increased capillary 
permeability by either haemoconcentration (increase in haematocrit (Hct) ≥20% from 
average for the same age, sex and population, or decrease by ≥20% of baseline after 
intravenous fluid treatment), pleural or abdominal effusion or hypoproteinaemia. The only 
haemorrhagic manifestation in grade I DHF is a positive tourniquet test. In grade II, there 
is spontaneous bleeding, usually in the skin and other sites. Rapid, weak pulse and narrow 
pulse pressure of <20 (millimetre of mercury) mmHg, hypotension for age, cold, clammy 
skin and restlessness is considered grade III. Profound shock with undetectable blood 
pressure or pulse is considered grade IV. This classification continues to be widely used, 
despite the fact that there have been increasing concerns regarding the difficulties and 
complexity to use this classification system [53, 54]. The recent revision of WHO 
guideline 2009 classified patients as having either dengue (with/without warning signs) or 
severe dengue [32, 33]. Briefly, patients who live in or travel to dengue endemic areas, and 
present with a combination of fever and two of the following conditions are considered as 
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having dengue: nausea, rash, aches and pains, positive tourniquet test, leukopenia or any 
warning signs which requires strict observation and medical intervention (abdominal pain 
or tenderness; persistent vomiting; clinical fluid accumulation; mucosal bleed; lethargy; 
restlessness; liver enlargement >2 centimetres (cm); increase in Hct concurrent with rapid 
decrease in platelet count). Patients who have any of the following criteria are considered 
as having severe dengue: severe plasma leakage leading to shock or fluid accumulation 
with respiratory distress, or both; severe haemorrhage; and severe organ impairment (liver: 
AST or ALT ≥1,000 International Unit per litre (IU/L); central nervous system (CNS): 
impaired consciousness; heart: cardiomyopathy or other unusual manifestations). 
After an incubation period of 3-7 days following an infective bite, the disease 
begins abruptly and follows three clinical phases: febrile phase, critical phase, and 
recovery phase (Figure 1.7).  
 
Figure 1.7 The course of dengue illness 
Reproduced with permission from World Health Organization, Dengue guideline for 
diagnosis, treatment, prevention and control, new edition, 2009 [33]. 
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Febrile phase 
Patients typically develop a sudden onset of high fever (≥38.5°C) which is often 
accompanied by headache, generalised body ache, myalgia, arthralgia and vomiting, 
sometimes with a transient macular rash. Other symptoms, including sore throat, nausea, 
anorexia and vomiting, are common. Mild haemorrhagic manifestations can occur such as 
petechiae and bruising, particularly at venepuncture sites, and mucosal membrane bleeding 
(e.g. nose and gums) may be seen. A positive tourniquet test in this phase increases the 
possibility of dengue. The test is performed by inflating a blood pressure cuff to a midway 
between the systolic and diastolic pressure on the upper arm for 5 minutes and a presence 
of 20 or more petechiae per 2.5 square centimetres (cm2) are considered positive. The liver 
can be enlarged and tender after a few days of fever. This acute febrile phase usually lasts 
2-7 days and the fever can be as high as 40°C, after which most patients recover without 
complications. Laboratory findings include mild to moderate thrombocytopenia, 
leukopenia often with a moderate increase of hepatic aminotransferase levels. The white 
blood cell (WBC) count reaches its lowest point shortly before the temperature and platelet 
count drops. This marks the end of the febrile phase and beginning of the critical phase. 
Predicting which patients will progress to develop severe dengue is not possible and 
patients should be observed for warning signs [32, 33]. 
Critical phase 
The beginning of the critical phase is around the time of defervescence, when the 
temperature drops to ≤37.5-38°C and remains below this level, usually on days 3-7 of 
illness. An increase in capillary permeability may occur at the same time with increasing 
haematocrit levels. The critical phase usually lasts 24-48 hours. It is crucial during the 
transition from the febrile phase to the critical phase for clinicians to be aware of warning 
signs for onset of vascular leakage. These signs include rapid decrease in platelet count and 
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a high or increase in Hct level, persistent vomiting, pleural effusion and ascites, increase in 
severe abdominal pain, tender hepatomegaly, lethargy or restlessness, and haemorrhagic 
manifestations. Shock occurs when a critical volume of plasma is lost due to leakage. 
Prolonged shock is associated with hypotension and major bleeding results in organ 
impairment and disseminated intravascular coagulation. In some instances, unusual 
manifestations including severe organ impairment such as liver failure, myocarditis, 
encephalopathy and/or severe bleeding may present without plasma leakage or shock. 
Patients who improve after defervescence are considered to have non-severe 
dengue. Those who progress to the critical phase of plasma leakage without defervescence 
will develop warning signs and are categorised as dengue with warning signs. This group 
will usually recover with early intravenous rehydration, however, some cases be more 
serious and progress to develop severe dengue. Proper fluid resuscitation is required to 
prevent severe shock in patients with warning signs. If untreated, mortality can be as high 
as 20%, whereas appropriate case management and intravenous rehydration can reduce 
mortality to less than 1% [32, 33]. 
Recovery phase 
Dengue-related vascular permeability is short-lived. After 24-48 hours, the critical 
phase is followed by the recovery phase where extravascular compartment fluid is 
gradually reabsorbed reverting to a normal level after approximately 48-72 hours. 
Continuing intravenous fluid or excessive fluid therapy at this stage results in a significant 
risk of fluid overload. Patients’ symptoms are generally improved after the critical phase. 
Some patients may have a rash described as “isles of white in the sea of red”, that appears 
during recovery phase. Adults may have profound fatigue or even depression for several 
weeks after recovery. The Hct stabilises or decreases due to the dilutional effect of 
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reabsorbed fluid. The WBC count usually starts to increase soon after defervescence 
whereas platelet count recovery typically occurs later [32, 33]. 
1.2.4 Laboratory diagnosis 
Differentiating dengue virus infection from other infections using simple clinical 
and laboratory criteria in the disease endemic areas can be helpful where further tests are 
not available. The most common features of dengue infection are associated with 
haemorrhagic manifestations, particularly gum bleeding, low platelet and white blood cell 
count [55, 56]. However, these are not specific, and accurate clinical diagnosis is difficult 
due to a wide range of clinical presentations. Laboratory confirmation of dengue virus 
infection is therefore required for clinical management, surveillance and research to 
document the burden of this disease so that health planning and prevention can be applied. 
Rapid diagnostics are required for management of the acutely unwell patients.  
Diagnostic methodologies include virus isolation, detection of viral nucleic acid, 
antigens and antibodies specific to the dengue virus or a combination of these tests. The 
timing of specimen collection and infection status, whether the infection is primary or 
secondary are critical for test choice (Figure 1.8).  
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Figure 1.8 Detection opportunities for laboratory diagnostic methodologies of 
dengue.  
NS1 denotes non-structural protein 1 
Adapted with permission from World Health Organization, Dengue guideline for 
diagnosis, treatment, prevention and control, new edition, 2009 [33]. 
During the acute phase of disease, dengue virus and its components (RNA or 
antigen (NS1)) can be detected in whole blood, plasma, serum, and infected tissues from 0-
7 days after onset of fever and correlate with fever duration. Virus isolation, nucleic acid or 
antigen detection methods are not routinely performed by clinical laboratories. Serological 
tests such as Enzyme-linked immunosorbent assay (ELISA) are more commonly used and 
seroconversion of immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies is 
the standard for serological confirmation of dengue infection [33]. In primary infection, 
IgM antibody is detected typically five or more days after onset of fever. IgM level peaks 
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about two weeks after onset of symptoms and lasts for 2-3 months, whereas IgG antibody 
is detected later with low titre from 8-10 days after onset of fever. It can be detectable for 
several months or probably even for life. In secondary infection, IgM antibody appears 
earlier or in the same time frame as primary infection but titres are usually lower than 
those obtained in primary infection and can be undetectable in some cases. IgG antibody 
appears rapidly with high titres soon after onset of fever and persists for 10 months to life 
[33, 34, 57]. Highly accurate laboratory diagnostic tests usually require more complicated 
techniques and skilled personnel while rapid point-of-care diagnostic tests have lower 
accuracy. Virus isolation and nucleic acid detection are more specific than serological 
tests, but are also expensive and labour-intensive. Figure 1.9 shows a comparison between 
the accessibility of the diagnostic tests and the confidence in the results of the test. 
 
Figure 1.9 Comparison of diagnostic tests according to their accessibility and 
confidence. 
Reproduced with permission from World Health Organization, Dengue guideline for 
diagnosis, treatment, prevention and control, new edition, 2009 [33]. 
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1.2.4.1 Isolation of dengue virus 
Virus culture is the definitive diagnostic test, since it is highly specific, and remains 
the gold standard for detection of dengue virus infection, in spite of the fact that it usually 
requires several days to weeks to complete. There have been four methods of viral 
isolation used for dengue viruses: inoculation of diagnostic specimens intrathoracically 
into adult mosquitoes (Ae. aegypti, Ae. albopictus, and Toxorhynchites splendens), 
intracerebrally into newborn mice, into mammalian cell cultures (using Vero, LLCMK2, 
and BHK21 cell lines), and into mosquito cell cultures (using C6/36 or AP61 cell lines 
from Ae. albopictus or Aedes pseudoscutellaris, respectively) [58].  
Mosquito inoculation is the most sensitive method, but the least used, as it needs 
insectaries to produce large numbers of mosquitoes for inoculation and isolation 
precautions to avoid the release of infected mosquitoes. Mosquito cell culture is the most 
widely used method of dengue virus isolation for routine diagnosis where laboratory 
facility is available. Mammalian cell cultures may be used but are less efficient. Mouse 
brain inoculation is expensive, slow, and has low sensitivity therefore it is not routinely 
used and is no longer recommended for viral isolation. Optimal specimens for virus 
isolation should be collected during viraemia, usually before five days of illness. 
Specimens can be whole blood, plasma, serum or tissues collected from fatal cases (i.e. 
liver, lung, spleen, lymph nodes, thymus, bone marrow and other tissues). Prior to culture, 
specimens should be kept at 4-8°C for up to 24 hours or kept frozen at -70°C or liquid 
nitrogen for long-term storage [33, 57, 58]. 
Jarman et al., has reported that the virus isolation rate was 62.5% when using direct 
C6/36 cell culture. Specimens that were negative for direct C6/36 isolation were inoculated 
into T. splendens followed by C6/36 cell culture and this increased the isolation rate up to 
79.4%. The virus isolation positivity rate of the four serotypes ranged between 71.5-84.2%. 
The rate was higher in patients with primary infection than those with secondary infection 
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(91.0 and 77.6%, respectively). Moreover, specimens collected early in the course of 
illness had a higher positivity rate: 85.3% when collected before or at day four of illness 
and 65.4% when collected later than day four. This study suggested that the factors that 
might influence overall performance of virus isolation included higher viraemia, lower 
level of anti-dengue IgM and IgG, days of fever (≤4 days), primary infection, high body 
temperature (≥38°C) with a final clinical diagnosis of dengue, and infecting serotype 
(DENV-4) [59]. 
Other advantages beside diagnosis are that virus isolates can be kept and 
characterised for further studies such as genome sequencing, virus-antibody interactions, 
and infectivity measures. Isolation followed by an immunofluorescence assay (IFA) for 
confirmation generally takes 1-2 weeks and is possible only if the specimen is properly 
stored [33]. Laboratory equipment is expensive and culture requires experienced 
technicians to develop and maintain cell cultures. Hence, this method is not widely 
available in most developing countries and not widely used in routine diagnostic 
laboratories. 
1.2.4.2 Antigen detection 
NS1 is a highly conserved glycoprotein produced by all flaviviruses and is the 
major diagnostic marker for dengue virus infection. NS1 is produced from dengue-virus 
infected cells as soluble monomers that dimerised in the lumen of endoplasmic reticulum 
and is subsequently transported to the cell surface where the protein remains membrane-
associated or is secreted into extracellular milieu as a soluble hexamer [60]. NS1 can be 
detectable in the bloodstream from the first day after onset of illness up to day nine, when 
the clinical phase of disease is over. Alcon et al. reported that NS1 levels in primary 
infection ranged from 0.04 to 2 micrograms per millilitre (µg/ml) in acute phase serum 
specimens (day 0-7) and 0.04µg/ml in a convalescent phase specimen (day 8 and later). In 
secondary infection, levels ranged from 0.01 to 2µg/ml in acute phase serum specimens 
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and NS1 was not detectable in convalescent phase serum specimens [61]. A study, limited 
to DENV-1, reported that NS1 can persist until 18 days after onset of illness with a peak at 
days 6-10, however this study was limited to the small number of specimens tested after 10 
days of fever and only one specimen was positive on day 18. The authors did not indicate 
the status of infection whether primary or secondary infection [62]. The NS1 level in 
plasma has been found to correlate with viraemia titre and disease severity [63].  
Many studies have investigated the utility of rapid immunochromatographic tests 
(ICT) and ELISAs, targeting NS1 as a diagnostic tool during acute phase of infection [64-
66]. The ICT format has several advantages compared to the ELISA format such as being 
simple to perform, and results being available within minutes. The most recent meta-
analysis of NS1 was reported in 2014 [67], analysing 18 studies including ELISA and ICT 
formats. The pooled sensitivity and specificity of the ELISA format (analysed from 14 
studies) were 67.0% (95% CI 59.0-74.0) and 99.0% (95% CI 97.0-99.0), respectively. For 
the ICT format, the pooled sensitivity and specificity (analysed from nine studies) were 
71.0% (95% CI 61.0-79.0) and 99.0% (95% CI 98.0-100), respectively. NS1 tests have 
been applied to serotype specific identification assays. The highest accuracy for serotyping 
was obtained from 2/6 analysed studies, 82.4 and 80.5%, using Dengue NS1 Ag STRIP kit. 
The kit was shown to be the best test for confirmation and serotype identification among 
the tests used in the analysis [67]. The complementarity with antibodies is the most 
important aspect of the NS1 detectability, since the positivity of viraemia and virus RNA 
detections are normally concomitant with the NS1 positivity. In an attempt to improve the 
sensitivity of the assay, combined NS1-based capture and IgM assays have been evaluated 
in three studies. Using these assays the pooled sensitivity increased to 83.0% (95% CI 
68.0-92.0), however the specificity decreased to 86.0% (95% CI 79.9-01.0) [67]. This is 
possibly due to false positive IgM results as a positive IgM on a single specimen cannot 
not confirm acute dengue infection. 
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In summary, NS1 antigen detection has shown generally very high specificity for 
confirmation of dengue infection, however some manufacturers’ tests are not as specific as 
they should be. The sensitivity varies depending on primary or secondary infection, days of 
fever, the NS1 kit/test format, and which gold standard comparators are used. Whole 
blood, plasma and serum are commonly used for NS1 antigen detection assays. Urine 
specimens may be useful when serum cannot be collected and in limited resource settings, 
however the positivity rate was low, ranging from 13.0-43.0%, in one study [68]. Other 
specimen types, such as tissue sections, can be used to detect dengue antigens by 
immunohistochemistry [57]. 
1.2.4.3 Antibody-based diagnosis 
Antibody-based serological diagnostic methods play a significant role and have 
been widely used for the diagnosis of dengue infection. The haemagglutination inhibition 
(HI) test was the standard method due to its high sensitivity, relatively ease, and because it 
can differentiate between primary and secondary infections. However, the lack of 
specificity, requirement for paired samples and the fact that it is unable to identify 
infecting serotype are limitations of this method [58]. The complement fixation (CF) test is 
not commonly used for routine diagnosis, although it is very specific in primary infection 
and can detect the infecting serotype. It is difficult to perform [25, 58]. The plaque 
reduction neutralisation test (PRNT) is used to quantify the titre of neutralizing antibodies 
that inhibit dengue virus infection. PRNT is not routinely used for dengue diagnosis as it is 
time consuming, labour intensive and low throughput, although it remains widely used for 
immunity studies [51] and dengue vaccinology [69].  
ELISAs have been widely used and are considered to be the most useful tests due to 
their technical feasibility and high sensitivity. Innis and colleagues have evaluated the IgM 
and IgG antibody-based ELISA to replace the HI test as the gold standard serological test 
[70]. This study showed that the sensitivity of the IgM antibody ELISA was 78.0% (95% 
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CI 75.0-81.0) when evaluated using acute serum specimens and 97.0% (95% CI 96.0-
98.0%) using paired serum specimens as compared to the HI test. Primary and secondary 
infection could be classified using the ratio of anti-dengue IgM to IgG antibody ELISA 
unit. The IgM and IgG antibody ELISA has been widely used as gold standard serology for 
dengue infection instead of the HI test [71]. There are commercially available test kits for 
semi-quantitative detection of IgM and IgG antibodies [72, 73]. The sensitivity and 
specificity of the IgM antibody ELISA ranged from 61.5-99.0% and 79.9-100%, 
respectively. 
Most of the dengue serodiagnostic assays require paired specimens to confirm 
infection, which results in delayed diagnosis of acute dengue infection and are not usually 
helpful for patient management. Attempts to find sensitive and specific tests for 
confirmation of infection from single acute specimens in patients with acute dengue 
infection have focused on evaluation and comparison of ELISA test kits as well as rapid 
diagnostic tests which potentially could be used in the field [71, 73-75]. The use of salivary 
(Immunoglobulin A) IgA antibody ELISA for early dengue detection has been reported 
recently. This may be useful in dengue endemic areas where the majority of cases are 
secondary infection when sensitivity was 100% in the first three days of fever with 97.0% 
specificity. However, the sensitivity was low in primary infection (36.0%) [76]. 
The IgM antibody-based ICTs have been evaluated for use as rapid diagnostic tests 
for dengue virus infection [71]. Early RDTs for dengue IgM antibody detection had low 
sensitivity, ranging from 6.4-65.3%, with specificities ranging from 69.1-100% in one 
comparison [71]. Newer RDTs, such as the Standard Diagnostics (SD) IgM, have been 
demonstrated to have improved sensitivity (79.2%) and specificity (89.4%) [77]. Addition 
of NS1 antigen detection has been shown to improve the sensitivity (92.9%) [77]. 
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The addition of NS1 antigen detection to the combination of antibody-based 
detection ICT improved the detection accuracy of the test and extends the possible window 
to detect early acute specimens [77-79].  
The limitation of these antibody-based techniques is cross-reactivity between all 
four serotypes of dengue virus and other flaviviruses [58] and therefore testing on paired 
specimens is still considered the most reliable serodiagnostic test for dengue [56]. 
1.2.4.4 Molecular-based diagnosis 
Many molecular techniques for dengue viral RNA detection have been published. 
Reverse transcriptase polymerase chain reaction (RT-PCR), nested-RT PCR and real-time 
RT-PCR (rRT-PCR) have been developed for rapid detection and typing of dengue 
infection (group and serotype specific) from clinical specimens [80-86]. Among these PCR 
assays, a nested-RT PCR developed by Lanciotti et al. [80], single tube multiplex RT-PCR 
by Harris et al. [81], and one-step SYBR Green I-based rRT-PCR by Shu et al. [86] are 
well known and well validated. PCR was found to be useful in the early phase of dengue 
infection, being more sensitive than virus isolation, able to confirm the diagnosis and able 
to identify the infecting serotype from clinical specimens [87]. A prospective study 
evaluating diagnostic tests for detection of acute dengue infection on single acute 
specimens demonstrated the usefulness of rRT-PCR for rapid and early detection, with 
high sensitivity and specificity (88.9 and 95.6%, respectively) [16].  
Recently, several isothermal-based molecular techniques have been developed to 
overcome the limitations of PCRs. These techniques do not require an expensive 
thermocycler, just a water bath or heat block is sufficient. They are quick and easy to 
perform compared to RT-PCR. One of the techniques, transcription-mediated amplification 
(TMA), was shown to be highly sensitive: it could detect dengue RNA in approximately 
89.0% of acute phase clinical specimens. This technique was 10 to 100 times more 
sensitive as compared to rRT-PCR [88]. Another isothermal-based molecular tool, real-
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time reverse transcription-loop-mediated isothermal amplification (RT-LAMP), has been 
developed for rapid detection and differentiation of dengue virus serotype. RT-LAMP 
reactions are performed at 60°C for more than 30 minutes. The results are interpreted by 
either visualised turbidity or quantitative fluorescence detection using SYBR Green. 
Several studies reported the usefulness of this technique as simple and potentially highly 
feasible in clinical settings [89, 90]. The most recent technique, recombinase polymerase 
amplification assay (RPA) has been developed for rapid diagnosis of dengue infection and 
is proposed to be simpler than the RT-LAMP. This technique is performed at 39-42°C for 
less than 30 minutes and is performed using a portable fluorescence-reading device [91]. 
Only one pair of primer is required, rather than three pairs for RT-LAMP [90], in which 
multiplexing the target is possible. A study evaluating this assay in two field sites: 
Kedougou (Senegal) and Bangkok (Thailand), showed high diagnostic accuracy of the test. 
The sensitivity and specificity were 98.0 and 100% for Senegal, and 72.0 and 100% for 
Thailand, respectively [91].  
A study by De Paula et al., that investigated different specimen types for dengue 
viral detection by RT-PCR, showed that serum is the best clinical sample for RT-PCR 
amplification [92]. In contrast, in a study from Thailand that compared the results of RT-
PCR with the use of whole blood and plasma or serum revealed that RNA extracted from 
whole blood followed by RT-PCR resulted in higher detection rate than the use of plasma 
or serum (74.0 and 52.0%, respectively). Moreover, RT-PCR was able to detect viral RNA 
up until day nine of illness when using whole blood, whereas the use of plasma/serum 
allowed the detection of viral RNA until day seven [93].  
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1.3 Leptospirosis 
1.3.1 The Leptospira 
 Leptospires are thin spirochaetes, corkscrew-shaped bacteria, which differ from 
other spirochaetes by the presence of end hooks (Figure 1.10). The organism is 
approximately 0.25 x 6-25 micrometres (µm) in size, hooked at one or both ends, highly 
motile, and is an obligate aerobe. They are catalase and oxidase positive. Spirochetes share 
features of both Gram-positive and Gram-negative bacteria [94]. Similar to other 
spirochaetes, leptospires have a typical double membrane structure, in which the 
cytoplasmic membrane is closely associated with the peptidoglycan cell wall as in Gram-
positive bacteria. They also have an outer membrane in which the lipopolysaccharide 
(LPS) composition is similar to that of Gram-negative bacteria. However, it appears to be 
fluid and labile and has relatively low endotoxic activity, which is different from the outer 
membrane of Gram-negative bacteria [95, 96]. Since the organism stains poorly and is too 
thin to be visible by conventional light microscopy, dark-field or phase-contrast 
microscopy of wet preparations is required for direct visualisation of leptospires [94]. 
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Figure 1.10 High-resolution scanning electron micrograph of Leptospira interrogans 
serovar copenhageni showing characteristic hooked ends. 
Reprinted from Bharti, A.R., Nally, J.E., Ricaldi, J.N., Matthias, M.A., Diaz, M.M., 
Lovett, M.A., Levett, P.N., Gilman, R.H., Willig, M.R., Gotuzzo, E., and Vinetz, J.M., 
Leptospirosis: a zoonotic disease of global importance. Lancet Infect Dis, 2003. 3(12): p. 
757-71 with permission from Elsevier [94]. 
Leptospires belong to the genus Leptospira, family Leptospiraceae, order 
Spirochaetales [96]. Leptospira is divided into several species and subspecies, called 
serogroups and serovars. Serogroups comprise antigenically related serovars, usually 
associated with a natural host [97]. The classification of Leptospira has undergone many 
changes over time. Traditionally, the genus Leptospira was divided into two serological 
species, Leptospira interrogans and Leptospira biflexa. The former comprises all 
pathogenic strains and the latter contains the saprophytic strains. Both species have been 
divided serologically into numerous serovars using the cross-agglutination absorption test 
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(CAAT) [97, 98]. More than 200 serovars of L. interrogans, categorized into 24 
serogroups, and more than 60 serovars of L. biflexa have been recognized [98]. The 
currently used genetically-based classification system indicates that at least 20 species can 
be identified by deoxyribonucleic acid (DNA) hybridization analysis [97]. Phylogenetic 
analysis of the 16S ribosomal ribonucleic acid (rRNA) gene sequence divides Leptospira 
species into three groups based on the pathogenicity status: pathogenic, saprophytic, and 
intermediate species with unknown pathogenicity [97, 99]. The current schematic 
classification of the organism (Figure 1.11) includes eight pathogenic, seven non-
pathogenic, and five intermediate Leptospira species [97, 99, 100]. 
 
Figure 1.11  Classification of Leptospira [97, 99, 100]. 
The serological and genetic based identification and classification systems are 
particularly complicated and poorly correlated: for example, serovars of the same 
serogroup may be distributed among different species, and pathogenic and non-pathogenic 
serovars appear within the same species [97, 98]. Moreover, the retention of the L. 
interrogans and L. biflexa as specific names in the genomic classification leads to 
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confusion in the nomenclature of Leptospires. The recommendation currently used 
suggests species name followed by the term ‘ serovar’ and serovar name with initial capital 
letter and non-italic, for example Leptospira interrogans serovar Autumnalis [101].  
A great deal of work in the last decade has led to publications on the whole genome 
sequence of two pathogenic strains (L. interrogans and L. borgpetersenii) and one non-
pathogenic strain, the saprophyte L. biflexa [102-105]. The genome sizes of Leptospira 
spp. are approximately 3.9-4.6 megabases (mb) located on two circular chromosomes. A 
complete genome sequence of a representative virulent serovar type strain (Lai) of L. 
interrogans serogroup Icterohaemorragiae consists of a 4.33 mb large chromosome and a 
359 kb small chromosome, with total of 7,768 predicted genes [102]. The much larger size 
of the leptospiral genome compared to other spirochaetes such as Treponema sp. has been 
suggested as one explanation for the ability of Leptospira to live in several different 
environments and hosts [102, 103]. 
1.3.2 Epidemiology of leptospirosis 
1.3.2.1 Transmission 
 Leptospirosis is an infectious disease caused by pathogenic leptospires that are 
transmitted to humans by either direct or indirect contact with the urine of an infected 
animal. Many domestic animals including dogs, pigs, and rodents are important sources of 
human infection as they are the major natural reservoirs and carriers [98]. Humans are 
mostly a dead-end host and are infected by direct contact with infected soil or water. 
Occupational exposure is important. Farmers, fish workers, miners, veterinarians, military 
personnel or sewer workers who work in dirty areas and have contact with infected 
animals or exposure to water or soil contaminated by infected animal urine or body fluids 
are at high risk of infection. Similarly, people living in poor housing with lack of adequate 
sanitation are also at risk of exposure to leptospires in both rural and urban slum 
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communities. In addition, people involved in outdoor freshwater leisure activities are also 
at risk. Besides regional environmental and occupational exposure, international travel to 
disease endemic areas is also a risk factor for disease acquisition [106, 107].  
Leptospires are naturally sustained by chronic infection or persistent colonisation of 
the renal tubules of maintenance hosts after primary infection. The hosts or carriers can 
remain asymptomatic and can excrete leptospires in their urine for long periods of time or 
even for their entire lives. Organisms are usually transferred from animal to animal by 
direct contact. Leptospires survive in moist and warm soil, stagnant water at neutral or 
alkaline pH, favouring survival in tropical environments [94]. Human to human 
transmission occurs only very rarely and has never been proven to be an important source 
of transmission [94, 108]. 
1.3.2.2 Global distribution and incidence 
Leptospirosis is one of the most widespread zoonoses in the world, present in both 
tropical and temperate zones.  The incidence of human infection is significantly higher in 
the tropics than in the temperate regions mainly because leptospires can survive longer in 
warm and humid conditions. The disease occurs in both industrialised and developing 
countries, however endemicity in low-income countries is traditionally strongly associated 
with local environment conditions and occupational exposure as humans are accidentally 
infected through contact with contaminated water [94, 98]. More recently, leptospirosis has 
been highlighted as an emerging zoonotic bacterial infection in part because of infection 
related mortality following natural disasters in dense urban populations as reported after 
Typhoon Ondoy in the Philippines in 2009 [109]. It is of major importance not only in 
human public health but also in animal production worldwide.  
The true global incidence of leptospirosis is largely unknown, and is likely to be 
underestimated for a number of reasons, including the lack of awareness amongst 
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healthcare workers, meaning the disease is under-recognised, as well as inadequate 
diagnostic tools and the difficulties of confirming the diagnosis [110].  In addition, to 
complicate matters, many infections in endemic settings are asymptomatic or subclinical 
[94] and there is a lack of notification systems, or notification is not mandatory, in the vast 
majority of countries [107]. To address these problems the WHO set up a group known as 
the Leptospirosis Burden Epidemiology Reference Group (LERG), which aims to assess 
the global burden of human leptospirosis. The second meeting of LERG from 2010 
generated a systematic literature review that estimated the median global annual incidence 
of endemic (excluding outbreak cases) and epidemic human leptospirosis as five and 14 
per 100,000 population, respectively [111]. The incidence of endemic human leptospirosis 
varied by region, with median (range) incidences per 100,000 population from highest to 
lowest of: Africa 95.5 (62.8-160.2), West Pacific 66.4 (1.1-975.0), America 12.5 (0.1-
306.2), SE Asia 4.8 (0.3-7.3) and Europe 0.5 (0.1-15.8). This is in reasonable agreement 
with previous incidence estimates from 2003. Disease incidence of more than 100 per 
100,000 may occur during outbreaks and in high-exposure risk groups [108]. The 
geographical distribution of leptospirosis is shown in Figure 1.12 [112]. The annual 
incidence of human leptospirosis data derived from official data from 1996 onwards for 
certain countries, including the 28 countries with the highest incidence are listed in Figure 
1.13 [112]. 
 81 
 
Figure 1.12 Global annual incidence of human leptospirosis. 
Colours reflect incidence, in declining order: red, pink, green, yellow. Gold reflects areas 
with probable, but not estimated, high incidence. White reflects absence of data. 
Reprinted from Pappas, G., Papadimitriou, P., Siozopoulou, V., Christou, L., and Akritidis, 
N., The globalization of leptospirosis: worldwide incidence trends. Int J Infect Dis, 2008. 
12(4): p. 351-7 with permission from Elsevier [112]. 
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Figure 1.13 Annual incidence of leptospirosis worldwide. 
Reprinted from Pappas, G., Papadimitriou, P., Siozopoulou, V., Christou, L., and Akritidis, 
N., The globalization of leptospirosis: worldwide incidence trends. Int J Infect Dis, 2008. 
12(4): p. 351-7 with permission from Elsevier [112]. 
1.3.2.3 Leptospirosis in Thailand 
In Thailand, leptospirosis is endemic with the number of cases reported ranging 
from 100-400 cases per year in the decades prior to 1996. The number of cases suddenly 
increased to over 2,000 cases per year in 1997 and reached 6,000 cases in 1999. A 
remarkable change occurred in the year 2000 with more than 14,000 cases [113]. This peak 
was followed by a gradual decline to below 3,000 cases in 2005. After that, the number of 
cases has stabilised at around 2,000-5,000 cases per year (Figure 1.14). The number of 
deaths and mortality rate per 100,000 population is shown in Figure 1.15. Most cases 
throughout this period were reported from Northeast Thailand. As previously highlighted 
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mortality data is unreliable due to the routine surveillance system used. A study of flood 
data from 2010-2012 examined the temporal and spatial patterns of leptospirosis, its 
association with flooding and animal census data in Thailand. The results showed a spatial 
association of leptospirosis with location in Northeast Thailand but no significant 
association with flooding. The high incidence of the disease in the Northeast region was 
explained by agriculture and animal farming activities in the region [114]. 
The number of leptospirosis cases reported in Thailand by the Bureau of 
Epidemiology, Department of Disease control, Ministry of Public Health demonstrated the 
seasonal variation in disease occurrence, with most cases occurring during the rainy 
season, July to October [113]. This is in line with the finding of a study from patients with 
clinically suspected leptospirosis in nine provinces, representing all regions of Thailand. 
The study could confirm the diagnosis in 20% of cases and most cases presented in the 
rainy season [115]. 
 
Figure 1.14 Number of cases and morbidity rate of leptospirosis reported in 
Thailand between 2003 and 2014. 
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Figure 1.15 Number of deaths and mortality rate of leptospirosis reported in 
Thailand between 2003 and 2014. 
Source for Figure 1.14 and Figure 1.15: Centre of Epidemiological Information, Bureau of 
Epidemiology, Department of Disease Control, Ministry of Public Health, Thailand, 
http://www.boe.moph.go.th/boedb/surdata/disease.php?dcontent=old&ds=43. 
1.3.3 Clinical features 
 The clinical features of leptospirosis are highly variable ranging from a mild, 
influenza-like illness or self-limited febrile illness to a life threatening illness. While the 
illness develops, a broad spectrum of organ systems may be involved, reflecting the 
systemic nature of infection. Clinical diagnosis is difficult due to the variation and non-
specific clinical manifestations. It is often confused with other diseases such as influenza, 
scrub typhus and dengue fever [107, 108]. 
Leptospira enters the human body via cuts or abrasions of the skin through mucous 
membranes with an incubation period of 5-14 days (range of 2-30 days) [108]. In 1967, 
Turner described the clinical presentation of leptospiral infection as having two 
overlapping phases, the acute or septicaemic phase and the immune phase [116]. Since 
then, the clinical presentation of the disease has been generally described as a biphasic 
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pattern with an initial acute or septicaemic phase. This is characterised by leptospiraemia 
which usually lasts for approximately seven days. Patients typically present with a sudden 
onset of febrile illness. The fever then subsides for few days before the immune phase 
begins. The immune phase is characterised by the production of antibody against 
Leptospira and excretion of leptospires in the urine (Figure 1.16) [98]. Most of the 
complications of leptospirosis are associated with localisation of leptospires within the 
tissues during the immune phase, starting the second week of illness. Fever can be biphasic 
and may reoccur in this phase [94, 98]. In addition to the biphasic pattern of fever, the 
clinical presentation of leptospirosis is also classified into two forms, based on the severity 
of clinical symptoms: anicteric and icteric leptospirosis [98]. 
Anicteric leptospirosis is the milder form of the disease. The vast majority of 
people infected with leptospires may be asymptomatic or have very mild symptoms with a 
self-limiting infection and do not seek medical care. Several serological studies in endemic 
areas have revealed evidence of subclinical infection. A population-based case-control 
study in Seychelles, the country with the highest incidence globally, reported that 37% and 
9% of controls had past or current subclinical infection, respectively [117]. A smaller 
proportion of patients present with an acute febrile illness with other symptoms including 
chills, headache, myalgia, tiredness, abdominal pain, conjunctival suffusion, nausea, 
vomiting, diarrhoea, and less commonly, a skin rash [94, 98, 107]. These anicteric 
symptoms usually last for approximately a week and their resolution corresponds with the 
appearance of antibodies. The fever may be biphasic and may reoccur after a remission of 
a few days (Figure 1.16). The mortality is almost zero in anicteric leptospirosis. Few 
patients present with severe complications. Aseptic meningitis may be found in less than a 
quarter of cases and pulmonary haemorrhage may complicate the course of illness and lead 
to mortality [98]. 
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Figure 1.16 Biphasic nature of leptospirosis and relevant investigations at different 
stages of disease.  
Note: Specimens 1 and 2 for serology are acute phase specimens, 3 is a convalescent phase 
specimen which may facilitate detection of a delayed immune response, and 4 and 5 are 
follow-up specimens which can provide epidemiology information, such as the 
presumptive infecting serogroup. 
Reproduced from Levett, P.N., Leptospirosis. Clin Microbiol Rev, 2001. 14(2): p. 296-326 
with permission from American Society for Microbiology [98]. 
 
Icteric leptospirosis is a severe form of the disease. The clinical course of the icteric 
form often progresses very rapidly. This severe form occurs in between 5-10% of all 
patients with leptospirosis. Severe cases frequently present late in the course of their 
illness, which contributes to the high mortality rate (range between 5-15%) [98]. Severe 
leptospirosis is characterised by multiple organ dysfunction including liver, kidneys, lungs, 
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and brain [107]. Jaundice presents in this form of the disease. The combination of jaundice, 
renal failure and haemorrhage is known as Weil’s disease, the most severe form of this 
disease. The syndrome can develop after the acute phase as the second biphasic phase, or 
the two phases may be not obviously distinguished and present as a single, progressive 
illness [94, 107]. 
1.3.4 Laboratory diagnosis of leptospirosis 
 The diagnosis of leptospirosis based on clinical presentation is difficult and 
inaccurate because of its broad spectrum and non-specific clinical features. Laboratory 
diagnosis is important for confirmation of disease status. Laboratory diagnosis may be 
achieved by the detection of the organisms or their components in clinical specimens i.e. 
isolation of leptospires in culture, detection of nucleic acid or detection of specific 
antibodies.  
1.3.4.1 Microscopic examination 
Dark-field microscopy (DFM) has been used to directly examine body fluids such 
as blood, cerebrospinal fluid (CSF), urine and dialysate fluid, but the test lacks both 
sensitivity and specificity. A study from India showed 60% sensitivity and 61% specificity 
when using DFM alone compared with IgM ELISA and clinical diagnosis [118]. Diagnosis 
of clinical specimens using this method has demonstrated that both false positive and false 
negative diagnoses can be easily made even in experienced hands [119]. 
1.3.4.2 Isolation and identification of Leptospira 
Leptospiraemia occurs during the first stage of illness, beginning before the 
symptom onset and usually declines by the end of the first week of acute illness [98].  
During this phase, the leptospires can be isolated from blood and CSF [94]. Urine culture 
could be performed from the beginning of the second week of symptom onset although the 
duration of urinary excretion varies, but may be several weeks (Figure 1.16) [94]. 
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Definitive diagnosis could be made by the culture and isolation of Leptospira using the 
recommended Ellinghausen, McCullough, Johnson, and Harris (EMJH) medium [120]. A 
study from Thailand has reported that whole blood and deposit from spun plasma are the 
optimal specimens to use for culture [120]. However, isolation of leptospires by culture is 
rarely used as a diagnostic test in clinical settings because it is complicated, time 
consuming, labour intensive and has low sensitivity. Culture should be maintained for at 
least 12 weeks and requires weekly examination by the DFM before a negative result can 
be reported [115, 120]. A new solid medium, named Leptospira Vanaporn Wuthiekanun 
(LVW) agar, facilitates more rapid growth and enables isolation of a single colony and 
simple antimicrobial susceptibility testing of Leptospira spp.: clear minimum inhibitory 
concentrations (MICs) can be read within seven days after inoculation [121]. However, the 
LVW agar has never been evaluated as a diagnostic test and has not been used for primary 
diagnosis. 
Leptospire isolates are identified either by serological or molecular methods. 
Traditional methods relied on CAAT, which only a small number of laboratories perform. 
Monoclonal antibodies are available for many serovars but not all. More recently, 
molecular methods for identification and typing of leptospires have been developed and 
studied extensively. The methods include PCR and digestion of chromosomal DNA by 
restriction endonucleases (PCR-REA), nested-PCR restriction fragment length 
polymorphism (PCR-RFLP), real-time PCR, pulse field gel electrophoresis (PFGE), loop-
mediated isothermal amplification (LAMP), sequencing and many PCR-based methods 
[122-126]. Sequence-based identification of Leptospira is increasingly becoming standard. 
PFGE has been shown to identify most serovars. It is more complementary to rather than 
replacement of the serological methods. Whole genome sequencing will likely become the 
reference laboratory standard in the near future. Strain subtyping for epidemiological 
purposes can be performed by simple methods such as RFLP. However, this method has 
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poor reproducibility between laboratories. More recently sequence-based methods such as 
multiple locus sequence typing (MLST) have been developed (based on PCR technique 
and DNA sequencing) and applied to characterize different gene targets. This method has 
advantages over other typing methods. It is simple to standardise on an automated DNA 
sequencer and reproducible within and between laboratories. This method can be used for 
molecular epidemiological and evolutionary studies as well as population genetics [127, 
128]. 
1.3.4.3 Serology-based diagnosis 
In most cases, leptospirosis is diagnosed by serological methods because of limited 
capacity for culture and molecular diagnosis. IgM antibody is detectable in the blood at 
approximately 5-7 days and peaks at 2-3 weeks after onset of illness (Figure 1.16) [107]. 
An acute blood specimen for serology should be taken as soon as possible at presentation 
of the patient and a convalescent specimen should be taken at least a week later. An 
increased IgM antibody titre in the convalescent specimen compared with the acute 
specimen suggests acute or current infection. Serological methods can be divided into 
those in which the titre of antibody can be quantified such as MAT, IFA and ELISA, and 
those which can give only qualitative results (positive or negative) such as ICT and latex 
agglutination test (LA). In addition, serological diagnostic tests can also be classified into 
two main categories: serovar-specific (i.e. MAT) and non-serovar-specific tests (i.e. 
ELISA, IFA, ICT, LA) [107]. 
The use of agglutination tests was described soon after the first isolation of the 
organism when only a few serovars were recognised [98]. The “gold standard” reference 
method for confirmatory serological diagnosis of leptospirosis is the MAT, in which sera 
from patients are reacted with a suspension of live antigens from a panel of leptospiral 
serovars [108, 119]. However, this method requires the laboratory to maintain panels of 
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live leptospires, of which there are more than 250 serovars, based on a culture method 
which is time consuming and requires technical expertise. Repeated weekly subculture is 
also a hazard to laboratory workers [98]. MAT interpretation is complicated by a high 
degree of cross-reaction between different serogroups particularly in acute phase 
specimens. It is insensitive during the acute phase of illness, since antibody levels usually 
are not detectable before the first few days after infection. Like other serological methods, 
paired specimens are required to confidently confirm diagnosis. The cut-off titre is 
uncertain, depending on the background level of exposure in the population and 
seroprevalence, hence different cut-offs and interpretations are applied in different 
geographical localities [98, 129-132]. It is important to include a range of antigens used 
that represent all serogroups and locally common serovars, since the MAT is serogroup 
specific but not accurate to detect infecting serovar [107]. A recent study in Thailand 
evaluated MAT accuracy and indicated that this assay is a poor predictor of infecting 
serovar. Culture of infecting isolates and CAAT remain the technique of choice during 
epidemiologic studies in this setting [133].  
Due to the limited ability to detect early stage of illness and complexity of the 
MAT, other serodiagnostic methods have been developed. Complement fixation (CF) was 
widely used, but the assay was not standardized and has been replaced by ELISA. There 
are many applications and modifications of ELISA as well as other serological tests 
including IgM ELISA assays [134], IgM dipstick assays [135], IgM Immunoblots [130], 
IgM dot-ELISA dipstick tests [136], IHA [137], LA [138], and lateral flow rapid tests 
[139]. These tests are simple, rapid, allow detection during acute phase of the disease and 
results can be obtained quickly enough for patient management. However, the overall 
conclusion of studies of these serological diagnostic tests is that the diagnostic accuracy in 
a clinical setting in endemic areas is poor and the tests are relatively expensive, especially 
in the rural areas of developing countries. ELISA tests are less specific than MAT since 
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they are based on genus-specific antigens which do not give an indication of the infecting 
serovars and these results require confirmation by MAT [108, 140]. Other serodiagnostic 
methods, including IFA [136, 141], radioimmunoassay (RIA) [142], 
counterimmunoelectrophoresis (CIE) [143, 144], and thin-layer immunoassay (TIA) [145], 
have been developed but are not widely used. The rapid bedside RDTs are inaccurate for 
early diagnosis of acute leptospirosis infection [110, 139, 146]. 
1.3.4.4 Molecular-based diagnosis 
Leptospiral DNA has been amplified from various clinical specimen types such as 
serum, urine, CSF and a number of post-mortem organ specimens [107]. Many quantitative 
real-time PCR (qPCR) using TaqMan probe-based assays have been developed to detect 
leptospiral DNA and quantify the bacterial load in clinical and environmental specimens. 
Assays developed for diagnostic use can be considered in two main categories, targeting 
either housekeeping gene such as rrs, gyrB, or secY, or pathogen specific genes such as 
lipL32, lig or lfbl [107]. A 16S rRNA gene qPCR has been developed and shown to be 
specific and able to discriminate pathogenic from non-pathogenic strains. The limit of 
detection of leptospires was as few as two cells in serum and 10 cells in urine [147]. A 
more recent qPCR assay was developed targeting the LipL32 gene, which is present only in 
pathogenic strains. The lower limit of detection was 20 genomic equivalents (GE)/reaction. 
This study suggested that whole blood and plasma were better specimens compared to 
serum when testing spiked specimens [148]. These two assays, 16S rRNA and LipL32 
qPCRs have subsequently been evaluated in a clinical setting to use as a tool for early 
detection [149, 150]. The clinical sensitivity and specificity compared against positive 
culture and/or MAT using acute whole blood specimen were 56.0% (95% CI 47.0-64.0) 
and 90.0% (95% CI 83.0-94.0) for the 16S rRNA assay, and 43.0% (95% CI 34.0-52.0) and 
93.0% (95% CI 88.0-97.0) for the LipL32 assay, respectively. In addition, both assays 
showed high sensitivity in subgroup of culture positive patients with 95.0% (95% CI 83.0-
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99.0) and 87.0% (95% CI 73.0-96.0) for 16S rRNA and LipL32 assays, respectively. Early 
diagnosis of leptospirosis using qPCR is possible particularly when culture is not available 
[149]. LAMP is an inexpensive alternative method for rapid DNA detection. A LipL41 
LAMP was the first assay of this method for the detection of leptospires with a limit of 
detection of 100 GE/reaction [151]. Subsequently, a 16S rRNA LAMP was developed to 
detect pathogenic and intermediate leptospires. The limit of detection was 10 GE/reaction 
[125]. Clinical evaluation of the LipL41 LAMP was also done in this study, using acute 
blood specimen compared to positive culture and/or MAT. The sensitivity and specificity 
of the 16S rRNA LAMP assay were 43.6% (95% CI 35.0-52.5) and 83.5% (95% CI 76.0-
89.3), respectively, and for LipL41 LAMP were 37.6% (95% CI 29.3-46.4) and 90.2% 
(95% CI 83.9-94.7), respectively. Similar to the qPCR assay, the sensitivity of the 16S 
rRNA LAMP assay was high in patients with positive culture (84.6% [95% CI 69.5-94.1]). 
The 16S rRNA qPCR and LAMP assays could detect around half of the patients with 
leptospirosis, but the clinical utility of LAMP assay was reduced by low specificity. 
Further evaluation of these assays in a clinical setting is still needed [125]. A limitation of 
PCR- or LAMP-based diagnostic assays is the current inability to identify the infecting 
serovar. Although this is not significant for individual patient management, it has great 
value for both epidemiological and public health aspects of disease management. However, 
whole genome sequencing has recently been applied to clinical specimens and it is possible 
that direct serovar identification may be possible in the future. 
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1.4 Rickettsial diseases 
1.4.1 The Rickettsia and Orientia 
Rickettsial diseases are zoonoses and are among the oldest known vector-borne 
diseases, caused by a variety of obligate intracellular Gram-negative bacteria of the order 
Rickettsiales and are vectored by arthropods and trematodes [152]. The bacteria in the 
order Rickettsiales have long been described as short, Gram-negative rods that retain basic 
fuchsin when stained by the Gimenez’s method [153] and are strictly associated with 
eukaryotic cells. Historically, the order Rickettsiales included the families Rickettsiaceae, 
Bartonellaceae and Anaplasmataceae [154]. However, the classification and taxonomy of 
Rickettsiales has undergone major reorganisation in the past decades. Traditionally, 
members of the order Rickettsiales were classified based on morphological, antigenic, and 
metabolic characteristics. The classification has been continually modified as more data 
have become available, particularly the new identification techniques based on molecular 
methods and phylogenetic studies, especially 16S rRNA gene sequence analyses. For 
example, members of the family Bartonellaceae (including Bartonella quintana, causative 
agent of trench fever), although highly fastidious, are cultivable on enriched 
bacteriological culture media and phylogenetically lie in the alpha 2 subgroup of the 
Proteobacteria, unlike other Rickettsia species that are in the alpha subgroup. These 16S 
rRNA sequences resulted in removal of the family Bartonellaceae from the order 
Rickettsiales [155]. Furthermore, Coxiella burnetii, causative agent of Q fever, has also 
been removed from the Rickettsiales because its 16S rRNA sequence was more similar to 
members of the gamma subgroup of the Proteobacteria [155]. Hence, they were removed 
from this order which currently comprises two families: Anaplasmataceae and 
Rickettsiaece [156]. The order Rickettsiales includes bacterial members of the genera 
Anaplasma, Ehrlichia, Neorickettsia, Orientia, Rickettsia and Wolbachia [157]. The 
diseases caused by these organisms are commonly classified into three main groups 
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including rickettsioses caused by bacteria of the genus Rickettsia; scrub typhus caused by 
the genus Orientia, both from family Rickettsiaceae; and ehrlichioses and anaplasmoses 
caused by bacterial members of the family Anaplasmataceae [158].  
Rickettsiae are obligate intracellular Gram-negative bacteria that can be visualised 
by Gimenez and Giemsa stains, but not Gram stain. Cell size ranges from 0.3x0.8µm to 
0.5x2.0µm [159]. Currently, the genus Rickettsia contains at least 27 recognised species 
and several dozens of uncharacterised strains [160]. Rickettsia philipii, Rickettsia 
monacensis and Rickettsia hoogstraalii were recognised in addition to the 25 validated 
species that previously reported since 2009 [157]. The members of the genus Rickettsia are 
classified into (1) spotted fever group (SFG) rickettsiae that included the largest number of 
species (more than 20 different species); (2) typhus group (TG) rickettsiae that contains 
Rickettsia prowazekii and Rickettsia typhi; (3) the Rickettsia bellii group and (4) the 
Rickettsia canadensis group. The R. bellii and R. canadensis have not so far been reported 
to cause human infection [152]. Table 1.3 summarises the characteristics of validated 
Rickettsia species. The scrub typhus group (STG) of Orientiae currently includes Orientia 
tsutsugamushi, Orientia chuto and potentially other Orientia and Orientia-like spp. [161-
163]. 
The genome sizes of Rickettsiales are small as a result of reductive evolution and 
consist of a single circular chromosome. The genome sequences of more than ten species 
within Rickettsiales are available and the sizes range from 0.8 to 2.1mb [164]. There are 
some bacteria that have highly stable genome without virtually repeats or mobile elements 
such as R. prowazekii (genome size 1.1mb) [165], whereas others have an extraordinarily 
high proportion of repeats and conjugative elements such as O. tsutsugamushi (genome 
size 2.1mb), its repeat density is 200-fold higher than that of R. prowazekii [166]. 
Currently, there are 45 strains within Rickettsia spp. that have genome sequences available. 
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These sequences reveal wide variations in size and genome content. The genome sizes 
vary from 1.11 to 2.1mb for R. typhi and R. prowazekii, and a Rickettsia endosymbiont of 
Ixodes scapularis, respectively [160]. 
This thesis focuses on the family Rickettsiaceae, including Rickettsia typhi and O. 
tsutsugamushi, as they are currently considered the major rickettsial infections in Thailand 
[7, 167]. R. typhi is small (0.4x1.3µm). It is the causative agent of murine typhus, also 
known as endemic typhus or flea-borne typhus [168]. O. tsutsugamushi was formerly 
known as Rickettsia tsutsugamushi. The name Orientia is from Orient, the area where this 
organism is widely distributed [161]. The Orientia is an obligate intracellular Gram- 
negative bacterium that propagates in host cell cytoplasm by binary fission. The cell size is 
approximately 0.5-0.8µm in diameter and 1.2-3.0µm long, which is slightly larger than that 
of R. prowazekii (the causative agent of epidemic typhus), R. typhi (the agent of murine 
typhus) and Rickettsia rickettsii (the agent of Rocky Mountain spotted fever, RMSF) [169]. 
O. tsutsugamushi has various antigenic variations. Hence, many different antigenic types 
of strains exist including the three major types that are well known, Gilliam, Karp and 
Kato. Other antigenic types such as Shimokoshi, Kawasaki, Kuroki and others have also 
been described [161]. The distribution of the strains is dependent on the geographical area. 
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Table 1.3 Characteristics of validated Rickettsia species. 
Species Type strain Vector Geographical distribution Pathogenic role 
R. aeschlimannii MC16 Hy. marginatum, R. appendiculatus, Ha. punctata France, Morocco Unnamed spotted fever 
R. africae ESF-5 Am. hebraeum, Am. variegatum, R. appendiculatus Sub-Saharan Africa, Reunion 
Island, West Indies 
African tick-bite fever 
R. akari MK Al. sanguineus USA Rickettsialpox 
R. asiatica IO-1 I. ricinus Japan Unknown 
R. australis Phillips I. holocyclus, I. tasmani, I. cornuatus Australia Queensland tick typhus 
R. bellii 369L42–1 D. variabilis, D. occidentalis, D. albopictus, Ha. lepopalustris, 
Am. cooperi, Ornithodoros concanensis, Argas cooleyi 
USA, Brazil Unknown 
R. canadensis 2678 Ha. Leporispalustris USA Unknown 
R. conorii subsp.conorii Malish 7 R. sanguineus, Ha. Leachii Mediterranean area, Africa Mediterranean spotted fever 
R. conorii subsp. Indica ITTR R. sanguineus, B. microplus, Ha. leachii India Indian tick typhus 
R. conorii subsp. caspia A-167 R. sanguineus, R. pumilio Chad, Kosovo, Russia Astrakhan fever 
R. conorii subsp. israelensis ISTTCDC1 R. sanguineus Israel Israeli spotted fever 
R. felis URRWXCal2 Ctenocaphalides felis, Ar. erinacei Worldwide Flea spotted fever 
R. heilongjiangensis 54 D. silvarum China, Russia, Thailand Far Eastern rickettsiosis 
R. helvetica C9P9 I. ricinus, I. ovatus, I. persulcatus, I. monospinosus Europe, Japan Suspected agent of a rickettsiosis 
R. honei RB Ap. Hydrosauri, Am. cajennense, I. granulatus Australia Flinders Island spotted fever 
R. japonica YH D. taiwanensis, Ha. flava I. ovatus, H. longicornis Japan Oriental or Japanese spotted fever 
R. massiliae Mtu1 R. sanguineus, R. turanicus, R. mulsamae, R. lunulatus, R. 
sulcatus 
France Unnamed rickettsiosis 
R. montanensis M/5–6 D. variabilis, D. andersoni USA Unknown 
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Table 1.3 Characteristics of validated Rickettsia species (continued) 
Species Type strain Vector Geographical distribution Pathogenic role 
R. parkeri Maculatum20 Am. maculatum, Am. triste, Am. americanum USA Unnamed rickettsiosis 
R. peacockii Skalkaho D. andersoni USA Unknown 
R. prowazekii Breinl Pediculus humanus humanus Africa, Russia, South America Epidemic typhus 
R. raoultii Khabarovsk R. pumilio, D. nttalli, D. marginatus, D. Silvarum, D. 
reticulates 
France, Russia TIBOLA or DEBONEL 
R. rhipicephali 3–7-6 D. occidentalis, R. sanguineus Africa, Europe, USA Unknown 
R. rickettsii Sheila Smith Am. aureolatum, Am. cajennense, D. andersoni, D. variabilis, 
R. sanguineus 
Brazil, Mexico, Panama, USA Rocky mountain spotted fever 
R. sibirica subsp. Sibirica 246 D. nuttalli, D. silvarum, D. marginatus, D. auratus, D. 
sinicus, D. pictus, Ha. concinna, Ha. yeni, Ha. Wellingtoni 
China, Russia Siberian or North Asian tick 
typhus 
R. sibirica subsp. 
Mongolitimonae 
HA-91 Hy. asiaticum, Hy. Truncatum Algeria, China, France, Greece, 
South Africa 
Lymphangitis-associated 
rickettsiosis 
R. slovaca 13-B D. marginatus, D. reticulates Europe, Russia TIBOLA or DEBONEL 
R. tamurae AT-1 Am. Testudinarium Japan Unknown 
R. typhi Wilmington X. cheopis, C. felis, L. segnis Worldwide Murine typhus 
Al.=Allodermanyssus; Am.=Amblyomma, Ap.=Aponomma; Ar.=Archeopsylla; B.=Boophilus; D.=Dermacentor; Ha.=Haemaphysalis; Hy.=Hyalomma; I.=Ixodes; L.=Leptopsylla; 
R.=Rhipicephalus; X.=Xenopsylla 
DEBONEL=Dermacentor-borne necrosis and lymphadenopathy; TIBOLA=Tick-borne lymphadenopathy 
This table is reproduced with permission from Fournier, P.E. and Raoult, D., Current knowledge on phylogeny and taxonomy of Rickettsia spp. Ann N Y 
Acad Sci, 2009. 1166: p. 1-11. Copyright John Wiley and Sons [157]. 
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1.4.2 Epidemiology of Rickettsia and Orientia 
1.4.2.1 Transmission 
The epidemiology of human diseases caused by rickettsial infections is closely 
related to their vectors, natural hosts and their geographic distribution as shown in Table 
1.3. The organisms are associated with arthropods including ticks, mites, fleas, lice, and 
mosquitoes, which may act as vectors or reservoirs [160]. The SFG rickettsiae are 
transmitted mainly by Ixodidae (hard ticks), but also transmitted by Argasidae (soft ticks; 
i.e. Rickettsia hoogstraalii), fleas (R. felis) and mites (R. akari). The TG rickettsiae are 
transmitted by human body lice (R. prowazekii) and fleas (R. typhi).  
Murine typhus is transmitted by fleas, in which the main vector is rat fleas 
(Xenopsylla cheopis), and the main reservoirs are rodents, mainly Rattus norvegicus and 
Rattus rattus. However, many other rodents, as well as wild and domestic animals, 
including cats, are also hosts. The transmission occurs by contact with flea feces that are 
contaminated with R. typhi during or after blood feeding, either by inhalation, conjunctival 
contamination or disrupted skin or by flea bites [160]. In the majority of cases, 
transmission is associated with areas that have a large number of rats around. Fleas are also 
the vectors of other rickettsiae such as R. felis, mainly cat flea (Ctenocephalides felis). 
Arthropods can acquire the organisms by vertical transmission or by co-feeding, occurring 
when several arthropods feed next to one another on the same host. These may complicate 
the transmission and epidemiology of rickettsiae [160]. 
Scrub typhus is transmitted by the bite of the infected larval stage of the 
trombiculid mite, called chigger. Its primary vector is Leptotrombidium deliensis, but 
several other species are also implicated [170]. Humans are accidental dead-end hosts that 
become infected when residing in areas that have infected chiggers: person-to-person 
transmission has never been reported. Infection is mainly associated with active rice field 
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activities, but many cases are acquired during other outdoor activities, for example logging 
and military operations. O. tsutsugamushi is maintained in mites by highly efficient 
transovarial transmission (from females to their offspring via eggs). The transmission of O. 
tsutsugamushi appears to be dependent on seasonal activities between chiggers and 
humans, during the seasons of high and stable temperature and humidity [167]. A study 
from Thailand confirmed this seasonal variation, by demonstrating that most patients were 
diagnosed with scrub typhus during the end of the rainy season and the beginning of 
winter, whereas murine typhus was evenly diagnosed in all seasons [170]. 
1.4.2.2 Global distribution and incidence 
 Geographical distribution of Rickettsia and Orientia largely depends on the 
arthropod vectors and reservoirs, since most of these vectors prefer specific optimal 
environmental conditions and hosts [167]. The global distribution of Rickettsia and 
Orientia are shown in Figure 1.17 and Figure 1.18. Murine typhus is an urban disease. It 
has a worldwide distribution, whereas scrub typhus occurs mainly in rural areas and is 
endemic in the Asia Pacific region. Scrub typhus and murine typhus are the most common 
rickettsial causes of acute undifferentiated fever and are widely endemic in Asia, but a 
number of SFG rickettsia have also been recognized in Asia including R. felis [7, 156, 170-
174] and R. honei [175]. Twelve cases of R. felis infection have been reported in Asia; 
three from Thailand [171, 176], three from Republic of Korea [177], three from Sri Lanka 
[178], one from Laos [172], one from Taiwan [179] and one from Israel [180].  
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Figure 1.17 Worldwide distribution of Rickettsia. World map detailing the presence 
of selected rickettsial species (as indicated by symbols) by continent/country. 
Reproduced from Luce-Fedrow, A., Mullins, K., Kostik, A.P., St John, H.K., Jiang, J., and 
Richards, A.L., Strategies for detecting rickettsiae and diagnosing rickettsial diseases. 
Future Microbiol, 2015. 10(4): p. 537-64 with permission from Future Medicine Ltd [152]. 
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Figure 1.18 Distribution of Orientia. World map detailing the presence of selected 
Orientiae (as indicated by symbols) by continent/country. 
Reproduced from Luce-Fedrow, A., Mullins, K., Kostik, A.P., St John, H.K., Jiang, J., and 
Richards, A.L., Strategies for detecting rickettsiae and diagnosing rickettsial diseases. 
Future Microbiol, 2015. 10(4): p. 537-64 with permission from Future Medicine Ltd [152]. 
1.4.2.3 Scrub typhus and murine typhus in Thailand 
There is an estimated one billion people at risk and one million cases of scrub 
typhus occurring worldwide each year [167]. Scrub typhus and murine typhus are 
widespread in Thailand. Although, the data on incidence of murine typhus is scarce there 
are individual reports from studies indicating that murine typhus is circulating [170].  
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In Thailand, less than 100 scrub typhus cases were reported per year before 1983, 
750-900 cases per year were reported between 1988 and 1991, and 3,000-5,000 cases per 
year have been reported since 2001 [170]. The most up to date data for scrub typhus from 
the Centre of Epidemiological Information, Bureau of Epidemiology, Department of 
Disease Control, Ministry of Public Health, Thailand is up until 2014. There were 
approximately 4,000-11,000 scrub typhus cases reported each year between 2003 and 
2014, with morbidity rates ranging from 5.98 to 17.09 per 100,000 population. The number 
of scrub typhus cases and morbidity rate have been increasing in recent years and peaked 
in 2013 (Figure 1.19). The number of deaths and mortality rate varied over the same period 
but remained below 10 cases a year with a maximum mortality rate of 0.02/100,000 
population in 2012 (Figure 1.20). For reasons discussed previously, the scrub typhus 
mortality rate is unreliable due to the routine surveillance system approach.  
 
Figure 1.19 Number of cases and morbidity rate of scrub typhus reported in 
Thailand between 2003-2014. 
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Figure 1.20 Number of deaths and mortality rate of scrub typhus reported in 
Thailand between 2003-2014. 
Source for Figure 1.19 and Figure 1.20: Centre of Epidemiological Information, Bureau of 
Epidemiology, Department of Disease Control, Ministry of Public Health, Thailand, 
http://www.boe.moph.go.th/boedb/surdata/disease.php?dcontent=old&ds=44.  
There are no summary statistical data available for murine typhus from the national disease 
surveillance report from the Bureau of Epidemiology, Thailand. 
1.4.3 Clinical features of scrub typhus and murine typhus 
 Rickettsial infections are difficult to diagnose even by experienced health care 
providers. The early symptoms and signs of these infections are notoriously non-specific. 
Diagnosis of scrub typhus and murine typhus based on clinical presentations is difficult as 
clinical symptoms and signs of these diseases overlap with those of other acute febrile 
illnesses such as other rickettsial infections, leptospirosis and dengue [7].  
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Scrub typhus 
 Scrub typhus is an acute febrile illness. Its clinical manifestations range from a 
mild and self-limiting illness to a more severe, and sometimes fatal, disease. The general 
course and prognosis of the disease vary according to the characteristics of the endemic 
strain. The classical clinical manifestation of scrub typhus usually consists of, but is not 
limited to, eschar, regional and generalised lymphadenopathy, and maculopapular rash 
[167, 181]. After infection, clinical symptoms appear after an incubation period of 5-20 
days [181]. Fever in scrub typhus rises abruptly and peaks in days 3-4 of the disease. The 
fever can persist for more than three weeks in untreated patients [181]. The primary 
clinical presentations are eschar (often not present) and regional lymphadenopathy 
followed by fever, headache, myalgia, generalised lymphadenopathy, cough, 
gastrointestinal symptoms, transient hearing loss and rash [182]. Complications may 
develop after the first week of illness. Meningoencephalitis, pulmonary involvement, acute 
renal failure, and disseminated intravascular coagulation, may manifest in severe cases 
[167, 181].  
The chigger bite site can appear on any part of the body, however it often localised 
in the areas that are difficult to examine, such as the genital region or under the armpit. The 
bite sites are usually painless and not recognised by the patients. This site may later 
develop into an eschar. It begins as small papule and enlarges with a central black necrosis 
resembling the mark of a cigarette burn [167]. A single eschar is usually found, although 
more than one infected chigger can attack a patient resulting in multiple eschars [183, 
184]. A prospective study from Korea reported a differential distribution of eschars in 
males and females among 176 scrub typhus patients. An eschar was present in 92% of the 
patients, including one patient with three eschars. The presence of eschar was more 
common on the front of the body rather than on the back for both genders. For males, the 
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most common site was the area within 30 centimetres below the umbilicus, whereas the 
front chest above the umbilicus was the most common in females [184].  
The eschar can be seen early in the course of disease: they are usually formed by 
the time that fever appears and can be a useful clinical diagnostic clue, although their 
presence is widely variable ranging from 7-97% [182, 185, 186]. In some cases, an 
atypical eschar can be found in warm and damp areas such as the axilla or perineum, in 
which the necrotic eschar is not formed but instead, an ulcer with a shallow, purulent base 
surrounded by a clear, erythematous band may be formed. The eschar may be easily 
overlooked and misdiagnosed in these cases [184].  
A transient maculopapular rash may appear at the end of the first week of illness, 
and last a few days to a week. The rash is often difficult to observe and usually 
predominates on the trunk and may appear on the face, palms and soles in rare cases [181]. 
Murine typhus 
Murine typhus is a mild disease with non-specific symptom and signs. Although 
clinical features of murine typhus are generally mild or self-limited without complications 
in most cases, some patients develop septic shock, acute respiratory failure and multi-
organ failure leading to death [187]. After an incubation period of 7-14 days, the most 
common clinical presentations include fever, headache, rash and arthralgia. Fever in 
murine typhus can last 3-7 days. Although rash is considered a common hallmark of 
rickettsial disease, it is neither always seen at presentation nor in all patients. The presence 
of rash in patients with murine typhus is widely variable ranging from 20-80% [168]. A 
study of scrub typhus and murine typhus from North Vietnam reported rash was more 
likely to be found in patients with murine typhus, whereas eschar was more significantly 
associated in patients with scrub typhus, and rarely seen in patients with murine typhus 
[188].  
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The rash may appear around one week after onset of fever and lasts for 1-4 days. It 
may be non-pruritic, macular, or maculopapular, usually occurs on the trunk and then 
spreads peripherally, sparing palms and soles [168]. Other clinical presentations have also 
been reported such as nausea, vomiting, abdominal pain, diarrhoea, jaundice, and cough. 
These various non-specific symptoms can lead to misdiagnosis at presentation. The clinical 
signs may last for 7-14 days in untreated patients [167]. 
1.4.4 Laboratory diagnosis 
 Clinical manifestations of rickettsial infections are widely variable and non-
specific, thus clinical diagnosis at the time of presentation is difficult. Laboratory diagnosis 
is useful for confirmation of these infections. Understanding the time course of infection is 
crucial in diagnosing the disease. 
During inoculation, the number of rickettsiae is too low to be detected in blood and 
humans do not develop disease at this stage. In scrub typhus and several SFG rickettsioses, 
eschar may develop at the inoculation site within a few days. At this stage, eschar can be 
used as a clinical specimen for laboratory diagnosis as the number of rickettsiae is 
multiplied and can be detected by culture, molecular methods or immunohistochemistry 
staining [189]. Figure 1.21 demonstrates detection and time course of rickettsial infections.  
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Figure 1.21 Detection and time course of rickettsial infections. 
Ag= antigen, dark blue bar= fever, Inoc= inoculation, light blue bar= rash, red bar= eschar 
Reproduced from Richards, A.L., Worldwide detection and identification of new and old 
rickettsiae and rickettsial diseases. FEMS Immunol Med Microbiol, 2012. 64(1): p. 107-
10 with permission from Oxford University Press [189]. 
Blood specimens can be collected for the diagnosis when patient presents with 
fever and other clinical symptoms and signs. Duration of rickettsaemia varies by the 
organisms and by the use of antibiotics. Rash appears approximately 3-5 days after disease 
onset and lasts for approximately 5-8 days. Biopsy of a rash area can be used to detect 
rickettsiae. Culture of rickettsiae, antigen or DNA detection can be performed prior to 
disease onset, in the case of eschar presenting. However, it is more likely to be performed 
at the time of disease onset. Detection of IgM and IgG antibodies against rickettisiae in 
serum or plasma by serology methods are frequently used. In initial infection, IgM 
antibody generally appears by eight days after disease onset and increases rapidly, while 
IgG antibody does not appear until 12 days after disease onset and increases more slowly. 
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In re-infection, IgG antibody initially appears by six days, while IgM antibody is variably 
detectable [190]. The IgM and IgG antibody persist for months to years, respectively. The 
acute specimen should be collected as early in the course of disease as possible and the 
convalescent specimen should be collected at least 14 days after. Paired acute and 
convalescent specimens should be used to confidently confirm the diagnosis and a 
seroconversion or a fourfold rise in titre indicates a current infection [189, 191]. A single 
acute specimen can be used in settings where an optimal cut-off titre is already determined 
[192]. 
1.4.4.1 Staining and culture of Rickettsiae 
 Stains are not commonly used in term of diagnostics since they lack sensitivity and 
specificity, however the stains such as Giemsa, Gimenez, and acridine orange are still used 
in the research laboratory to monitor the presence of rickettsiae in cell culture [152]. 
Like other bacteria, isolation of the organisms is the most definitive method for 
diagnosis. However, culture of Rickettsia and Orientia is difficult as they are obligate 
intracellular bacteria that require a living host to grow. Isolation of these organisms has 
been performed using embryonated hen’s eggs, Vero (African green monkey kidney) cells 
and L929 (mouse fibroblast) cells [193, 194]. Isolation can be performed from blood and 
skin biopsy. Shell vial cell culture assay remains the best tool for isolation of intracellular 
bacteria [193]. However, the sensitivity of culture is low. Recent analysis using Bayesian 
latent class models (LCMs) showed that blood culture for O. tsutsugamushi had sensitivity 
of 24.4% (95% CI 12.2-41.3) [195]. Moreover, culture is insensitive when antibiotic 
treatment has been given and specimens for culture should be inoculated as soon as 
possible to increase the sensitivity. The incubation time for culture positivity can be as 
long as 27 days (range 16-37) [194] and containment in biosafety level 3 laboratory 
facilities is required. Therefore, current methods of isolation are not appropriate for routine 
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diagnosis [196]. However, the culture method is essential for drug sensitivity testing, 
molecular epidemiology studies and for providing a source material for other diagnostic 
test evaluations. 
1.4.4.2 Serology-based diagnosis 
Similar to dengue and leptospirosis, serological tests are the most widely used 
diagnostic tools for rickettsial infections. Many serology-based diagnostic tests have been 
developed and have encountered the same issues found in the other diseases regarding the 
interpretation and diagnostic accuracy of the tests.  
 The Weil-Felix agglutination test is based on the detection of antibodies to various 
Proteus species that contain antigens which cross-react to antigens from Rickettsia spp. 
Proteus vulgaris strain OX-2 antigen cross-reacts with SFG rickettsiae except for RMSF. 
P. vulgaris strain OX-19 antigen cross-reacts with TG rickettsiae and RMSF, and Proteus 
mirabilis Kingsbury strain antigen (OX-K) cross-reacts with O. tsutsugamushi [197]. The 
test is easy to perform and inexpensive, and has long been widely used for diagnosis of 
rickettsial diseases. However, it has been replaced by other serological diagnostic assays 
because of lack of sensitivity and specificity [197-201].  
The IFA and indirect immunoperoxidase test (IIP) have been widely used as 
reference serological methods to confirm the diagnosis using acute and convalescent sera. 
However, the tests are time consuming, require a fluorescence microscope (IFA) and 
experienced laboratory technicians. Cross-reactivity, variation of sensitivity and specificity 
depending on species and cut-off level determined by each laboratory remain problematic 
[159, 191, 196]. Within the same laboratory, the reading of the assays are inherently 
subjective if performed by different operators as showed in a study comparing inter- and 
intra-operation variability in reading the IFA for diagnosis of scrub typhus and murine 
typhus. The inter-operator variability was significantly related to the experience of the 
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operator in reading the tests [202]. Recent analysis using Bayesian LCMs to determine the 
optimal cut-off titre for IgM IFA in diagnosis of scrub typhus was assessed. The result 
demonstrated that the optimal cut-off titres of ≥1:3,200 in an acute specimen or of a ≥4-
fold rise to ≥1:3,200 in a convalescent specimen provided the highest diagnostic accuracy 
(81.6% sensitivity and 100% specificity) [192]. However, further evaluation using this cut-
off in other settings is required. 
ELISAs have been developed to overcome the cross-reactivity amongst members 
of the genus Rickettsia by using blocking binding of monoclonal species-specific epitopes 
[203] or recombinant protein antigens [204, 205]. Evaluation studies of IgM capture 
ELISA using recombinant protein have revealed good performance and it may be able to 
replace IFA in a diagnostic laboratory, especially in rural areas where the complicated 
techniques are usually not available [204, 206]. Nevertheless, in disease endemic areas, 
these serodiagnostic assays require paired specimens to detect a rising titre of IgG in 
secondary infections [205]. This results in delayed diagnosis and therefore may not help 
patient management. A recent study evaluated an IgM antibody-based ELISA for acute 
diagnosis of scrub typhus and proposed to use it as an alternative reference test to the IgM 
antibody-based IFA. With the optimal cut-off optical density (OD) of 1.474 at a specimen 
dilution of 1:400, this IgM ELISA had high sensitivity and specificity using paired 
specimens (85.7% (95% credible interval [CrI] 77.4-86.7) sensitivity and 98.1% (CrI 97.2-
100) specificity) [207].  
Other antibody-based point-of-care tests have been developed for rapid diagnosis 
of scrub typhus and murine typhus, including ICT and immunoblot assays. In a study from 
Laos, IgM antibody-based ICT for scrub typhus and immunoblot assay for murine typhus 
were assessed on acute serum specimens. The sensitivity of the scrub typhus ICT was low, 
23.8% (95% CI 15.9-33.3) when compared against a four-fold rising IgM IFA titre, and 
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39.1% (95% CI 34.1-44.2) when compared against an acute specimen IgM IFA titre of 
≥1:400. However, the specificity was high for both comparisons, 86.2% (95% CI 84.1-
88.6) and 99.5% (95% CI 98.7-99.9), respectively. For the murine typhus immunoblot 
assay, similarly, the test had low sensitivity but high specificity. The sensitivity was 61.2% 
(95% CI 53.7-68.3) when compared to a four-fold rising IgM IFA titre, and 54.6% (95% 
CI 49.1-60.0) when compared to an acute specimen IgM IFA titre of ≥1:400. The 
specificity was 86.5% (95% CI 84.1-88.8) and 94.1% (95% CI 92.0-95.7), respectively 
[208]. The antibody-based rapid tests generally have good specificity but poor sensitivity, 
therefore the usefulness of this test in clinical settings for acute diagnosis is limited. The 
use of total antibody-based rapid tests in disease endemic areas is a drawback rather than 
useful to the clinicians to differentiate acute infection from past infection. In such areas, 
patients are likely to have had previous infections, resulting in detection of the persistent 
IgG antibody responses and the test may have an inevitably low specificity [209]. 
1.4.4.3 Molecular-based diagnosis 
In recent years, molecular assays have been developed and evaluated as rapid 
diagnostic tools for acute rickettsial infection. PCR assays have been developed for 
detection of Ricksettsial species and O. tsutsugamushi from blood and skin biopsy 
specimens and can detect the presence of organisms 4-8 days prior to the development of 
antibodies that are needed for serological testing [210]. Eschar and swabbed lesions or rash 
biopsies contain the highest number of organisms and are the specimen of choice. The 
sensitivity of PCR, to detect O. tsutsugamushi, can be as high as ~90% when using buffy 
coat or eschar specimens [211, 212]. However, using buffy coat specimen, PCR can be 
affected by antibiotic treatment, with sensitivity decreasing to 60.5% within three days 
after treatment and to 10.0% after four days of treatment [211]. Using eschar specimens, 
PCR remains positive for O. tsutsugamushi after treatment with antibiotics [212, 213].  
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1.4.4.3.1 Conventional PCR 
Nested-PCR for detection of nucleic acid from acute blood specimens based on a 
gene encoding the 56kDa outer membrane protein (56kDa) has proven useful for early 
diagnosis of scrub typhus [214]. A prospective study from Korea proved the usefulness of 
this nested-PCR targeting 56kDa (slightly modified from Furuya et al., 1993 [214]) from 
buffy coat as a rapid and reliable test for confirming the diagnosis of the disease with 
82.2% sensitivity and 100% specificity [215]. In addition, another study of the clinical 
usefulness of eschar PCR (56kDa) for diagnosis of scrub typhus was reported with high 
sensitivity and specificity (86.0% and 100%, respectively) [212]. However, in Northeast 
Thailand, it has been shown that this 56kDa PCR had a high specificity (99.2%) but a low 
sensitivity (29%). The low sensitivity may be explained by the sequence variability in the 
region of primer annealing as O. tsutsugamushi shows a high degree of genetic 
polymorphism [216].  
1.4.4.3.2 Real-time PCR 
A 16S rRNA gene SYBR Green-based real-time PCR assay was developed and 
evaluated for clinical diagnostic accuracy in a study of scrub typhus in Thailand. The assay 
had 44.8% sensitivity and 99.7% specificity compared against paired serology by IFA. 
This was considered insufficient to diagnose scrub typhus in this endemic setting [216].  
 Several specific and sensitive qPCR assays were established to enable 
quantification of bacterial loads in clinical specimens. They were able to detect <10 copies 
of purified target DNA [210, 217-220], however in clinical specimens the assays may not 
be as sensitive. Detection of the 16S rRNA gene by qPCR was reported to determine the O. 
tsutsugamushi loads in patients with scrub typhus. The analytical performance was high 
with 100% specificity and the limit of detection was 0.04 copies/µl but the clinical 
diagnostic accuracy was not determined [221]. A qPCR targeting a 47kDa outer membrane 
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protein gene highly specific for O. tsutsugamushi was developed and the assay was able to 
detect the DNA target at between 3-10 copies/reaction. The assay was tested in animal 
models during the development phase and was able to detect 3-21 copies/µl of monkey 
blood [210]. A study from Thailand evaluating this 47kDa qPCR assay to detect O. 
tsutsugamushi in patients with scrub typhus reported that the assay correctly detected 
10/10 patients who were culture positive and could detect 7/17 patients who were culture 
negative. The O. tsutsugamushi loads ranged from 1,076 to 28,812 copies/µl of blood 
[222]. This assay will require further evaluation in clinical specimens. A qPCR assay 
targeting a 17kDa antigen gene (Rickettsia-specific) was developed to detect Rickettsia 
spp. in ticks. The limit of detection was found to be three copies/reaction [217, 223]. 
Another qPCR assay targeting the outer membrane protein B gene (ompB) was established 
for the detection of R. typhi in fleas. The detection limit was three copies/µl [218]. The 
47kDa, 17kDa and ompB gene targets are widely used for research purposes and applied 
for different PCR formats [224-226]. However, there are not many published data on 
validation of the assays in patient specimens or clinical diagnosis evaluation in qPCR 
format. This warrants further investigation on the usefulness of these assays for diagnosis 
in a clinical setting. 
A highly sensitive real-time PCR assay was developed for detection and 
quantification of O. tsutsugamushi, based on the groEL gene, which encodes the 60kDa 
heat shock protein, from contemporary Thai strains. This gene presented as a 
representative target for molecular diagnostics and had a high degree of conservation 
across strains. The detection values ranged from 2-31,668 copies/µl when tested using 
buffy coat specimens [219].  
In order to improve molecular diagnostic assays, and to be less time consuming, a 
SYBR Green-based multiplex real-time PCR targeting 47kDa, citrate synthase (gltA) and 
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ompB genes was established to identify and differentiate STG, TG and SFG rickettsiae, but 
the clinical diagnostic utility of the assay with patient samples has not been described yet 
[220]. A TaqMan probe-based multiplex real-time PCR assay targeting 47kDa, groEL, and 
human interferon beta (IFN-β gene) genes was developed and evaluated to improve early 
diagnosis of scrub typhus. The assay had high sensitivity (86.5%, 95% CI 74.2-94.4) and 
specificity (100%, 95% CI 97.3-100) compared to a four-fold rise in IgM/IgG IFA titre 
[225]. However, these molecular methods might not be available in most areas where the 
diseases are endemic.  
1.4.4.3.3 Isothermal amplification 
A simple, rapid and sensitive method for detection of scrub typhus using loop-
isothermal DNA amplification (LAMP) targeting the groEL gene has been described with 
sensitivity comparable with conventional nested-PCR (56kDa gene) [227]. The diagnostic 
accuracy of the LAMP assay in a clinical setting was evaluated in a prospective study in 
Thailand. The sensitivity of the LAMP was 53.0% (95% CI 39.0-66.0) and the specificity 
was 94.0% (95% CI 88.0-98.0). The results showed that diagnostic accuracy was similar to 
real-time and nested-PCR but better than IgM ICT (47.0% [95% CI 34.0-61.0] sensitivity 
and 95.0% [95% CI 89.0-98.0] specificity) in early detection. This can be considered as a 
valid molecular method for early detection of scrub typhus. Results from this study also 
suggested that combining the LAMP with IgM ICT improved the diagnostic sensitivity 
(67.0% (95% CI 53.0-79.0) with a specificity of 91.0% (95% CI 83.0-95.0) [228]. 
Following this finding, an evaluation of the commercial antibody-based ICTs demonstrated 
overall improved diagnostic performances when used in combination with LAMP showing 
the potentially utility of them as point-of-care tests [229]. A study from Laos used a LAMP 
assay targeting ompB gene for detection of R. typhi and evaluated its clinical performance 
characteristics. The clinical sensitivity of the assay during development phase 
(retrospective known clinical specimens) was 48.0% (95% CI 32.5-62.7) and the 
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specificity was 100% (95% CI 100-100). In a prospective evaluation phase, the specificity 
remained high with 98.5% (95% CI 97.0-100) but the sensitivity was even lower with 
33.0% (95% CI 9.2-56.8). The low sensitivity of the LAMP assay was mainly due to the 
low R. typhi loads in clinical specimens as determined by qPCR (210 copies/ml of blood) 
[230]. 
A rapid molecular-based diagnostic test, RPA, using a lateral flow test (RPA-nfo) 
and real-time fluorescent detection (RPA-exo) has recently been developed targeting the 
47kDa gene of O. tsutsugamushi or 17kDa gene of R. typhi for early diagnosis of acute 
scrub typhus and murine typhus infections. Similar to LAMP but simpler, the optimal 
reaction temperature was 37°C, using only one pair of primer for a reaction and the 
reaction could be completed within 30 minutes. The RPA assay detection level was 
comparable to that of quantitative PCR method. The assay is simple and rapid with 
promising high sensitivity and specificity. The results of this development warrants its 
further evaluation in clinical settings [231].  
As described above, many PCR assays have been developed and evaluated in 
different clinical settings. The analytical accuracy of PCR assays is usually very high. The 
clinical diagnostic specificity is also generally very high, but the clinical diagnostic 
sensitivity in endemic settings needs to be improved. The development of PCR assays is 
still in progress and further evaluation in different clinical settings, especially in the 
endemic areas, is required. 
1.5 Bacteraemia in outpatients 
Bacteraemia is the presence of live bacteria in the bloodstream. Like other AUFI, 
the clinical presentations are non-specific. The most common clinical presentation of 
bacteraemia is fever. Blood culture is often performed to investigate general causes of 
bacteraemia. There is little data on community-acquired bacteraemia in febrile patients in 
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SE Asia [232]. Bacteraemia is relatively uncommon in patients who are not sufficiently 
unwell to require hospital admission, especially adults [233]. In the USA, the prevalence of 
bacteraemia could be as low as 1.8% (24/1,350) of non-admitted adult patients [234]. Most 
literature on bacteraemia in outpatients relates to young children under the age of five 
years. The prevalence of bacteraemia is generally low and it is rarely found in paediatric 
outpatients with AUFI, although some may have bacteraemia with Salmonella Typhi or 
Streptococcus pneumoniae [235, 236].  
1.6 Sub-microscopic malaria 
In SE Asia, transmission of malaria is low, unstable and seasonal. Most malaria 
infections are symptomatic and are detected by malaria smear or RDTs [13, 237]. 
However, in such low transmission areas (i.e. parasite prevalence by microscopy is <10%), 
the proportion of sub-microscopic infections is high (70-80%) compared to the areas of 
high transmission intensity (~20% when parasite prevalence by microscopy is ≥75%) 
[238].  
Thick and thin blood film microscopic examination is the gold standard diagnostic 
test for detection of malaria parasitaemia, however it requires skilled and experienced 
technicians to obtain an accurate detection. The limit of detection could be as low as 5-10 
parasites/µl of blood in experienced hands, although accuracy is not reliable at a very low 
parasitaemia <5-10 parasites/µl of blood in routine clinical diagnosis [239]. A systematic 
review using Bayesian LCMs to analyse the accuracy of malaria diagnostic tests revealed 
that the sensitivity and specificity of the microscopy in symptomatic patients with 
Plasmodium falciparum ranges between 89.5-96.2% and 97.2-99.7%, respectively in 
endemic areas [240]. For Plasmodium non-falciparum, the sensitivity and specificity 
ranges between 90.1-98.4% and 95.8-99.8%, respectively [240].  
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Simple, sensitive and specific antigen-based RDT that detect P. falciparum 
histidine-rich protein II (HRP-II), pan-malaria or species specific (Plasmodium) lactate 
dehydrogenase (pLDH), or aldolase antigens are widely used [13]. The limit of detection is 
around 100 parasites/µl of blood [240]. These RDT formats are useful in clinical settings 
where microscopy is not available or there is a lack of a trained microscopist. pLDH and 
aldolase antigen are rapidly cleared after effective treatment, but HRP-II antigen may 
persist for longer than a month [239]. This limits the use of HRP-II-based RDT in high 
transmission areas [13]. The HRP-II-based RDTs are as good as the routine clinical 
microscopy for P. falciparum in endemic areas, but microscopy remains more reliable for 
detection of non-falciparum malaria [239, 240]. 
Sub-microscopic malaria infection is identified using PCR technique. PCR is not 
used in routine diagnosis of malaria infection. It is used for research purposes such as 
epidemiology studies of malaria in low transmission settings. PCR has been developed for 
malaria detection based on several target genes such as 18S rRNA [241-245], tRNA [246], 
and mitochondrial genes [247]. Of these 18S rRNA is most commonly used. Finger-prick 
capillary blood specimens (≤5µl), blood spot (~30µl), or small volume blood specimens 
(100-200µl) have been normally used for PCR assays [245-248]. The sensitivity of the 
PCR assays is limited by the specimen volume. A qPCR assay targeting 18S rRNA gene 
was developed and assessed using large volume blood specimen (1ml). The assay was able 
to detect malarial DNA as low as 22 parasites/ml of blood (95% CI 21.8-74.9) [249]. This 
assay is currently used to detect Plasmodium species and quantify their parasitaemia for 
active screening of asymptomatic subjects in malaria elimination strategies.  
 
  118 
1.7 Study rationale and objectives 
1.7.1 Rationale for the study 
 AUFI is a common clinical presentation in tropical countries and infections 
presenting this way still remain a major public health problem, especially in rural areas 
which lack good infrastructure, clinical laboratory facilities and have poor sanitary 
conditions [1]. Many common causes of febrile illness in the tropics have no specific 
symptoms and signs, making diagnosis in the clinic difficult [11]. It is rarely possible to 
establish a definitive diagnosis clinically in patients with AUFI and they are difficult to 
diagnose in clinic based laboratories that often have limited resources, and thus, under-
reported. Accurate and rapid diagnostic tests are usually not available in disease endemic 
areas. Therefore, very few clinical diagnoses of these infections are confirmed by 
laboratory investigation. However, dengue, leptospirosis and rickettsial infection 
(especially scrub typhus and murine typhus) are likely to be common causes of AUFI 
among the population living along the Thailand-Myanmar border where this study took 
place and have been shown, in clinical studies, to be common in rural SE Asia generally 
[6, 7, 11].  
 Dengue is the most widespread mosquito-borne viral disease. It is estimated by 
WHO that 50-100 million dengue infections occur annually worldwide, with a 30-fold 
increase incidence over the past five decades [35]. Increasing incidence and spread of 
dengue fever have been reported in nine countries within the SE Asia region between 
1985-2005 and has continued to increase in recent years [43]. In addition, the most recent 
estimate of global risk shows that there are around 390 million dengue infections (96 
million symptomatic) globally per year, which is over three times higher than the figure 
estimated by the WHO [38].  
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 Rickettsial infections are the second most frequently reported non-malaria causes 
of fever in SE Asia [250] and are a significant risk among refugee populations, especially 
those living along the Thailand-Myanmar border [171, 251], Scrub typhus and murine 
typhus are the most common rickettsial causes of AUFI and are widely endemic in Asia, 
with an estimated one million cases of scrub typhus occurring each year [167, 172].  
The incidence of leptospirosis is estimated to be approximately 10-100 per 100,000 
in the humid tropics. The disease incidence may be more than 100 per 100,000 during 
outbreaks and in high-exposure risk groups [108]. 
The gold standard tests for these infections rely on paired serology which is time 
consuming and results in delayed diagnosis confirmation. Field deployment of accurate 
rapid tests would facilitate the timely diagnosis of these diseases [2, 15]. 
While malaria has decreased globally, non-malaria causes of fever have become 
apparent and remain a major cause of AUFI in SE Asia [250]. This is in line with the data 
reported by the six clinics of the Shoklo Malaria Research Unit (SMRU) located along the 
Thailand-Myanmar border. While malaria cases have been decreasing steadily, non-
malaria fever cases of unknown diagnosis have remained consistently high over the period 
October 2007 to September 2014 (Figure 1.22 and Figure 1.23). 
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Figure 1.22 Proportion of febrile patients with malaria presenting to SMRU clinics 
between October 2007 and September 2014. 
Note: Data for Oct 2007-Sep 2008 from Thay Ka Ya was not available. 
 
 
Figure 1.23 Proportion of febrile patients with unknown diagnosis presenting to 
SMRU clinics between October 2007 and September 2014. 
Note: Data from Mae La, and for Oct 2007-Sep 2009 from Thay Ka Ya were not available. 
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This present study represented a relatively new avenue of investigation for SMRU, 
and built on the study of causes of fever in pregnancy conducted between 2004-2006. This 
work found that malaria was the most common cause of fever (55.5%, 227/409). However, 
dengue, leptospirosis, scrub typhus and murine typhus were also common in a sub-cohort 
of detailed fever investigations and follow-up (47.3%, 96/203). In addition, co-infections 
were reported in 3.9% (8/203) of cases, of which malaria and rickettsia co-infection was 
the majority [10]. Improved field-based diagnostic tools are urgently required for dengue, 
leptospirosis and rickettsial infections, especially in non-malaria febrile patients. A recent 
prospective study evaluating tests for more rapid diagnosis of dengue in the SMRU clinic 
population found that a combination of rRT-PCR or NS1 Antigen detection plus IgM 
antibody detection was required for accurate confirmation of infection [16]. 
Improved understanding of the incidence of these infections in the SMRU clinic 
population would assist the development of treatment algorithms and patient management 
for fever cases, which would have relevance for the wider rural tropical population. 
1.7.2 Research question 
 What are the optimal testing strategies for diagnosis of the common causes of 
AUFI in a rural SE Asia clinic? 
1.7.3 Hypotheses to be tested 
 The main hypothesis of this study is that current diagnostic tests, usually based on 
paired serology, for common non-malaria causes of fever (dengue, leptospirosis, and 
rickettsial infections) in SE Asia are inadequate for clinical use and lead to under-diagnosis 
of these infections. The diagnostic accuracy and the clinical value of using rapid tests 
needs to be determined to diagnose causes of fever in a rural SE Asian clinical setting. The 
plan was to answer the following questions: 
  122 
1. What are the causes of AUFI in patients presenting with fever where a definitive 
diagnosis cannot be given in the field (excluding malaria)? 
2. How can we best diagnose these diseases in the field with a clinically useful 
turnaround time? 
a. Can new generation rapid tests for dengue and rickettsial infections be used 
to reliably determine the cause of infection in patients with AUFI in rural 
SE Asia? 
b. Can new molecular diagnostic assays replace current serological methods as 
gold standard tests for confirmation of these infections? 
1.7.4 Aims and objectives 
 The principal objective of the study is to determine optimal testing strategies for 
dengue, leptospirosis, and rickettsial infections (scrub typhus and murine typhus). 
Additional objectives were to: 
1. Determine the diagnostic accuracy and clinical value of using new generation rapid 
diagnostic tests and molecular diagnostic assays to diagnose causes of fever in a 
rural SE Asian clinical setting. 
2. Assess inter-operator variation for the interpretation of the ICT results. 
3. Evaluate the molecular diagnostic assays as alternatives to the ICT, and as possible 
replacement for the current serological methods as gold standard test for the 
confirmation of acute dengue and scrub typhus infections. 
4.  Estimate the occurrence of common causes of AUFI, including dengue, 
leptospirosis, rickettsial infections (focus on scrub typhus and murine typhus), and 
other invasive bacterial infections in the SMRU clinic population. 
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5. Improve the understanding of these infections in the population to assist the 
development of the treatment algorithms and patient management of non-malaria 
fever cases. 
6. Assess the impact of dual infection with malaria: 
a. Quantify and detect sub-microscopic malaria infections in febrile patients 
b. Assess the impact of malaria infection on the performance characteristics of 
the diagnostic tests under evaluation. 
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2 Materials and Methods 
2.1 Study sites 
2.1.1 Location 
Shoklo Malaria Research Unit (SMRU) is a field station of the Faculty of Tropical 
Medicine, Mahidol University, Bangkok, Thailand and is part of the Mahidol-Oxford 
Tropical Medicine Research Unit (MORU). SMRU is located in Mae Sot, approximately 
500km from Bangkok in Tak province in the Northwest Thailand, and runs five main 
clinics on the Thailand-Myanmar (Burma) border (Figure 2.1). It has been providing 
medical support and conducting research in this area since 1986 (http://www.shoklo-
unit.com/).  
 Wang Pha, approximately 30km north of Mae Sot, and Mawker Thai, 
approximately 60km south of Mae Sot, are two of the largest clinics which provide 
healthcare for the migrant population from Myanmar living and working along the border.  
Mae La temporary shelter (Mae La) is the largest camp for refugees from 
Myanmar, housed in an area of 4km2. It is located in hills adjoining the Myanmar border, 
approximately 70km north of Mae Sot. 
Patients were recruited from SMRU migrant clinics at Wang Pha and Mawker Thai 
and from the clinic at Mae La refugee camp. 
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Figure 2.1 Map of SMRU clinics (Mae La, Wang Pha, Mawker Thai, Mun Ru 
Chai, and Mae Kon Ken).  
Note: Thay Ka Ya is an extension of Wang Pha clinic and is not included on the map.  
Map courtesy of Daniel Parker. 
2.1.2 Population 
Migrants 
The true number of the migrant population living along the Thailand-Myanmar 
border is unclear. In 2011, it was estimated that there were 154,000-190,000 migrants, both 
registered and unregistered, living in Tak province and 30,000-45,000 villagers in 
Myanmar living within the SMRU catchment areas [252]. The estimated size of the 
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migrant population served by the SMRU clinics was 46,175-97,010 migrants between 
October 2007 and September 2014 (http://www.shoklo-unit.com/). 
Refugees 
Refugees from Myanmar have been arriving in Thailand since 1984. Mae La is the 
largest of the nine refugee camps along the Thailand-Myanmar border. In February 2011, 
the registered refugee population in Mae La camp was 25,093 people, accounting for 
32.5% of all registered Myanmar refugees in Thailand. The majority of the Myanmar 
refugee population in Thailand are from the Karen ethnic group (>75%) (figure from 
http://www.tbbc.org). The number of registered refugees is thought to be a large 
underestimation of the true camp population, which has been recently estimated at 
>42,000.  
2.2 Study design 
The work contained in this thesis was divided into two parts and both parts were 
conducted in parallel (Figure 2.2). This prospective fever diagnostic study (FDS) was run 
in three outpatient clinics (OPD) at Mae La, Wang Pha, and Mawker Thai, recruiting 
patients aged at least five years with undifferentiated febrile illness. Patients less than five 
years old were not included due to blood volume requirements of the study. 
PART I. (Non-malaria) 
 Patients presenting to the clinics with non-malaria fever (see section 2.4) were 
recruited into the main part, PART I, of the study (Figure 2.2). Prospective evaluations of 
various new diagnostic methodologies were performed to determine the aetiology of 
common non-malaria infections, describe the clinical features of patients presenting with 
these infections, relate their clinical status to the test performance, and also set up a bio-
bank of well-characterised clinical specimens for future diagnostic test evaluations. The 
study sites were in known malaria endemic areas, and recent research has showed that 
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asymptomatic/sub-microscopic malaria infection, detected by an ultra-sensitive qPCR 
assay, acts as a Plasmodium spp. reservoir [249, 253]. The ultra-sensitive qPCR assay was 
performed in the present study to detect sub-microscopic malaria infection. The impact of 
sub-microscopic malaria infection on the performance of the non-malaria diagnostic tests 
under evaluation was investigated. 
PART II. (Malaria) 
Patients presenting with fever and malaria according to microscopy or rapid 
diagnostic test (RDT) were recruited into PART II of the study (Figure 2.2). The non-
malaria diagnostic tests under evaluation were performed in patients with malaria as well 
as in non-malaria to detect dual infections. There were insufficient patients in this group to 
evaluate the impact of microscopic/RDT confirmed malaria infection on the performance 
of the non-malaria tests. 
 
Figure 2.2 Study flow chart. 
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2.3 Study size 
PART I. 
Patients with non-malaria undifferentiated fever were recruited at all sites and 
recruitment numbers were closely monitored to ensure that the recruitment was even 
throughout the year. Three local data sets were used to estimate an appropriate sample size. 
The studies of Ellis et al. [11], Suttinont et al. [7], and the SMRU pilot data 
(Watthanaworawit et al. [254]) are summarised below (Table 2.1). 
Table 2.1 Summary of the three fever studies using similar methodology and 
conducted in Thailand.  
Patient numbers Ellis et al. Suttinont et al. Watthanaworawit et al. 
Total patients [n] 613 adults 845 adults 162 adults 
Dengue [n (%)] 9 (1.5%) 64 (7.6%) 72 (44.4%) 
Leptospirosis [n (%)] 107 (17.5%) 312 (36.9%) 6 (3.7%) 
Rickettsial infection [n (%)] 36 (5.9%) 206 (24.4%) 16 (9.9%) 
 
From these data, it was estimated that we might diagnose the following numbers of 
cases in 1,000 participants: 
1. Dengue:   15-440 cases 
2. Leptospirosis:  40-370 cases 
3. Rickettsial infection: 60-240 cases 
 The diagnostic accuracy of the tests was estimated with the following precision 
(95% confidence intervals) based on the number of true positive (sensitivity) or true 
negative (specificity) cases as defined by the reference test result [255] (Table 2.2). For 
example, 100 confirmed cases (true positive) as defined by the reference test would have to 
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be recruited, if the sensitivity of the new test was estimated to be 90% with the 95% 
confidence interval of ±5.9%. If the prevalence of disease in the study population was 
10%, then there would be 10 confirmed cases per 100 patients seen at the clinic. Therefore, 
1,000 patients would need to be recruited to obtain 100 confirmed cases. 
Table 2.2 Estimated diagnostic accuracy of the tests [255]. 
Number of 
cases required* 
Estimated test sensitivity or specificity (95% CI)* 
50% 70% 90% 
50 ± 13.9% ± 12.7% ± 8.3% 
100 ± 9.8% ± 9.0% ± 5.9% 
200 ± 6.9% ± 6.4% ± 4.2% 
300 ± 5.7% ± 5.2% ± 3.4% 
400 ± 4.9% ± 4.5% ± 2.9% 
*As defined by the reference test result. 
PART II. 
Data on the expected frequency of dual infections is scarce: Ellis and colleagues 
reported dengue, leptospirosis, or rickettsial co-infections in 17% (26/155) of malaria cases 
[11]. Therefore, it was estimated that in order to detect 20 (95% CI 11-25) patients with 
dual infection, 120 patients with microscopically or rapid diagnostic test confirmed malaria 
(Plasmodium falciparum, Plasmodium vivax, or mixed infection) should be recruited. 
Every week, the first eligible malaria patient was recruited at each of the three study sites, 
resulting in recruitment of 120 patients over approximately 40 weeks. This pilot data will 
be used to inform the design of a larger study on dual infections. 
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2.4 Patient recruitment 
Inclusion criteria 
For PART I, any patient aged at least five years presenting to the clinic with a fever 
of at least 38°C of up to seven days duration and negative for malaria according to malaria 
smear or RDT were eligible. For PART II, patients aged at least five years presenting with 
the above criteria but with microscopically or RDT confirmed malaria infection were 
eligible (Figure 2.2). 
Exclusion criteria 
Pregnancy, currently taking antimicrobials or had taken antimicrobials in the last 
seven days prior to presentation, or unable to give informed consent (assent for paediatric 
patients) were exclusion criteria for both parts. A positive malaria smear or RDT and 
patients with a clear clinical diagnosis (except clinically suspected dengue, leptospirosis, 
rickettsial infection, or typhoid), for example; measles, chickenpox, pneumonia [256], 
skin/soft tissue infection (e.g. cellulitis), urinary tract infection and respiratory tract 
infection were excluded from PART I.  Patients with a clear secondary clinical diagnosis 
as above were also excluded from PART II (Figure 2.2). 
2.5 Malaria screening tests 
 Microscopy (smear) and/or RDT were performed for malaria diagnosis at SMRU 
outpatient clinics as part of routine malaria screening. Microscopic examination was 
performed by trained microscopists. At MLA clinic, only the smear was performed. For 
WPA and MKT clinics, the smear was performed on a quality control (QC) week (one 
week per month, also called “smear week”). The RDT was routinely performed on a non-
smear week by trained clinical staff. Additional smears were performed to confirm malaria 
infections when requested by a clinician/medic. 
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2.5.1 Microscopy (smear) 
 According to the SMRU standard operating procedure (SOP, T2), thick and thin 
films were prepared on the same slide per specimen. A blood smear one centimetre in 
diameter containing two to three drops from finger prick was used for the thick film and 
one drop for the thin film. The slide was then placed onto a homemade hot plate to dry. 
Then, the blood films were fixed using methanol (BDH Prolabo VWR, Fontenay-sous-
Bois, France). After that, the slide was stained using 10% Giemsa staining solution (BDH 
Prolabo VWR, Fontenay-sous-Bois, France) for 20 minutes. Finally, the slide was washed 
with clean water and placed on a rack to dry. The slide was examined under a microscope 
(Olympus, Tokyo, Japan) at a magnification of x1000. The results were recorded as 
negative or positive with Plasmodium species, stages and parasitaemia. Trophozoites were 
counted on the thick film against 500 white blood cells if there were <500/500 WBC or on 
the thin film if there were ≥500/500 WBC. On the thin film, the trophozoites were counted 
against 1,000 red blood cells (RBC). Schizonts and gametocytes were counted on the thick 
film against 500 WBC. 
2.5.2 Immunochromatographic (ICT) rapid diagnostic test (RDT) 
SD BIOLINE Malaria Antigen P.f/Pan POCT (Standard diagnostics, Inc., 
Gyeonggi-do, Republic of Korea) was used in the clinics. The test was designed to detect 
malaria infection in human blood and to differentiate between P. falciparum infection 
through detection of HRP-II antigen and infection from other Plasmodium species (Pan) 
through detection of pLDH antigen. Briefly, 5µl of capillary blood from a finger prick was 
added into the round sample well, followed by all of the assay diluent from the diluent 
ampoule into the square well of test device. The test was incubated at room temperature for 
a minimum of 15 minutes (up to 30 minutes) and results were interpreted no later than 30 
minutes. The test has three lines: “C” (control), “Pan” (Plasmodium species; P. vivax, P. 
malariae and P. ovale), and “P.f” (P. falciparum) lines. An unclear background and/or an 
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absence of the control line indicated an invalid result. According to the SMRU SOP (RT5), 
a positive “Pan” line was recorded as positive for P. vivax. Although this test is reported to 
be accurate, like any diagnostic test false results may occur; for example if the test is not 
performed correctly or due to interfering substances. Rheumatoid factor-contained in 
specimens and infection with Schistosoma mekongi have been shown to cause false 
positive results. It should also be noted that HRP-II antigen may persist for longer than a 
month following acute infection, limiting usage in high transmission areas [257]. 
2.6 Clinical data and specimen collection 
Patients were sampled at the acute febrile illness visit and at a follow-up visit (day 
10-14). A case report form (CRF, see Appendix 1) was completed by a clinician or medic 
trained to provide medical assistance at SMRU clinics, to record clinical symptoms and 
signs relating to the illness. 
The acute specimens were collected at the time of initial clinical assessment. For 
adult patients (≥18 years old), a total of 16ml of blood was collected. This included 6ml 
venous blood in a sterile Ethylenediaminetetraacetic acid (EDTA) tube (BD Vacutainer; 
Becton Dickinson, Franklin Lakes, NJ, USA) for CBC, CRP level, pathogen specific 
PCRs, and RDTs; 5ml venous blood (for serum) in a sterile plain tube (Teklab, Country 
Durham, UK) for serology; and 5ml of blood (BacT/ALERT FA bottle, BioMérieux, 
Durham, NC, USA) for bacterial culture. The blood was taken prior to antibiotic treatment. 
For paediatric patients (5-17 years old), a total of 8ml of blood was collected. This 
included 3ml venous blood in a sterile EDTA tube (BD Vacutainer) for CBC, CRP, 
pathogen specific PCRs and RDTs; 3ml venous blood (for serum) in sterile plain tube 
(Teklab) for serology; and 2ml of blood (BacT/ALERT PF bottle) for bacterial culture 
taken prior to antibiotic treatment (Figure 2.2). 
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Patients were reviewed at a study-specific 10-14 day follow-up visit and a repeat 
5ml (patients aged ≥18 years) or 3ml (patients aged 5-17 years old) venous blood specimen 
was collected into a sterile plain tube for serology. 
Specimens were transported to the SMRU Mae Sot laboratories on a daily basis in 
a cool box for EDTA blood and serum, or ambient temperature for blood culture. 
 After clinical review, the patient was treated according to the suspected clinical 
diagnosis following standard clinical algorithms in operation in SMRU clinics. 
Additionally, patients with malaria (PART II) were treated according to the SMRU malaria 
guideline (http://www.shoklo-unit.com/resources). Severely unwell patients were admitted 
to the clinic inpatient department for treatment. 
2.7 Specimen processing and storage 
Specimens were allocated a specimen number on arrival at SMRU Mae Sot 
laboratories. A unique ID was given to each specimen aliquot and entered into databases 
(SMRU Microbiology database for blood culture and SMRU Haematology database for 
EDTA blood (CBC and CRP), both Microsoft Access (Microsoft, Redmond, WA, USA). 
Freezerworks sample management software was used for EDTA blood and serum 
specimen storage (Dataworks Development, Mountlake, WA, USA). 
Aliquot storage 
Prior to separation all EDTA blood and serum specimens were stored in a 
refrigerator or cool box. The blood specimens from adults and children were divided as 
shown in Figure 2.3 and Figure 2.4. All aliquots (whole blood, plasma, buffy coat, packed 
red cell and serum) were stored at -80°C until further processing. The aliquot of plasma for 
dengue rapid diagnostic test was tested immediately or was stored in a refrigerator prior to 
testing, no later than three days following collection. 
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Figure 2.3 EDTA blood and serum specimen processing for adult patients. 
 
Figure 2.4 EDTA blood and serum specimen processing for child patients. 
  135 
2.8 Ethical considerations 
Written informed consent/assent was obtained from all patients, or their legal 
guardian if aged less than 18 years, prior to enrolment in the study following the scheme 
outlined in Table 2.3. Consent was obtained by the medic, nurse or doctor assessing the 
patient at the initial clinic visit. The study consent/assent and patient information sheet 
were translated into Karen and Burmese languages. For patients who were unable to read 
or write, the forms were read out and explained by a doctor, medic or nurse who spoke the 
same language as the patient or his/her guardian. A thumbprint was used to confirm and a 
witness signed the consent form. The study was reviewed by the Tak Province Community 
Ethics Advisory Board (TCAB-01-11), and was approved by the Ethics Committee of the 
Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand (MUTM 2011-008-
01) and Oxford Tropical Research Ethics Committee, University of Oxford, Oxford, UK 
(OXTREC 42-10). 
Table 2.3 Informed consent and assent form scheme. 
Age Informed Consent Form Assent Form 
Less than 7 years Parent signs ICF for permission - 
7 to 12 years Parent signs ICF for permission Child signs Assent Form 
13 to 17 years Parent and child sign the same ICF - 
18 years and over (Adult) Adult signs ICF - 
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2.9 Laboratory methods 
All specimens were processed in SMRU Mae Sot laboratories and/or sent to the 
relevant reference laboratories [i.e. MORU and Armed Forces Research Institute of 
Medical Science (AFRIMS)] for specialist serological assays. SMRU SOPs were followed 
for processing of all specimens. 
2.9.1 Dengue 
2.9.1.1 Enzyme Immuno Assay (EIA) or Enzyme-Linked Immunosorbent Assay 
(ELISA) 
Paired serum specimens were sent to AFRIMS for ELISA testing for detection of 
antibodies to dengue and JE, IgM/IgG antibodies [70, 258]. The interpretation algorithm of 
dengue virus and JE virus infection using in-house AFRIMS ELISA is shown in Appendix 
2. An acute dengue infection was defined as the presence of anti-dengue IgM of 40 EIA 
units or more in an acute specimen with the anti-dengue IgM unit being greater than the 
anti-JE IgM unit. Acute primary and secondary dengue infections were defined when the 
ratio of anti-dengue IgM to anti-dengue IgG were more than or equal to 1.8 or less than 
1.8, respectively. If the anti-dengue IgM was less than 40 units in acute specimens, an 
increase in anti-dengue IgG between acute- and convalescent-phase specimens to an 
absolute value of more than 100 units was used to define acute secondary dengue infection. 
If there were rising anti-dengue or anti-JE IgG of more than 100 units, but the anti-dengue 
IgM units were less than the anti-JE IgM units in the convalescent specimen, then acute 
secondary flavivirus infection was defined. Specimens were considered negative for acute 
infection if specific antibodies were absent in paired sera specimens collected at least 5-7 
days apart as defined in Appendix 2. The EIA units were calculated from binding index 
(BI) multiplied by 100. The BI was calculated from average OD of specimen minus OD of 
negative control divided by OD of weak positive control minus OD of negative control.  
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2.9.1.2 Immunochromatographic (ICT) rapid diagnostic test (RDT) 
Acute plasma specimens were prospectively tested as part of routine clinical 
microbiology laboratory processes at SMRU, using the SD BIOLINE Dengue Duo RDT 
(Standard diagnostics, Inc.). The test was designed to detect both NS1 antigen and 
IgM/IgG antibodies to dengue virus in human serum, plasma or whole blood. Briefly, three 
drops (~100µl) of plasma were added into the sample well marked “S” for the NS1 antigen 
test. For the IgM/IgG antibody test, 10µl of plasma were added into the sample well 
marked “S”, followed by four drops of diluent into the assay diluent well. The test was 
incubated at room temperature and the results were interpreted at 15 minutes. The NS1 
antigen test has two lines (control line “C” and test line “T”) whereas the IgM/IgG 
antibody test has three lines (control line “C”, IgM line “M”, and IgG line “G”). An 
absence of control line “C” indicates an invalid result. The test was read by three 
independent readers who were on duty in the microbiology laboratory. The readers did not 
confer while reading the test and the results were blinded (each reader did not see the 
results of the other readers). Subsequently, the consensus result (i.e. 2/3 readers with the 
same interpretation) was used for final interpretation. 
2.9.1.3 Dengue group specific one step SYBR Green based real-time RT-PCR (rRT-
PCR) assay 
Nucleic acid extraction 
Acute plasma specimens were processed in batches. Nucleic acid was extracted 
from plasma specimens using an automated nucleic acid extractor, MagCore HF16 (RBC 
Bioscience, New Taipei City, Taiwan) with MagCore Viral Nucleic Acid Extraction Kits, 
cartridge code 202 (RBC Bioscience). In summary, 10µl of carrier RNA (1mg/ml) and 
20µl of Proteinase K (10mg/ml) were added into 1.5ml sample tubes (provided by kit), 
followed by 200µl of plasma. The tubes were then placed into the MagCore/T-rack, and 
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the cartridge code 202 programme was run on the MagCore HF16, with a 60µl elution 
volume selected. Extracts were processed immediately or stored at 2-8°C prior to testing 
within 24 hours or at -80°C for longer storage. 
rRT-PCR amplification 
A one-step SYBR Green based rRT-PCR assay (Dengue group specific) targeting 
the core protein gene was performed using the original primer sequences from Shu et al. 
[259], and the modification from Watthanaworawit et al. [16]. The assay was performed 
using the SuperScript III Platinum SYBR Green One-Step qRT-PCR systems (Invitrogen, 
Carlsbad, CA, USA). Amplification was carried out using the ABI 7500 FAST real-time 
PCR system (Applied Biosystems, Foster City, CA, USA). The primer set was designed 
for universal detection of dengue viruses. It does not provide the specific serotype (DENV-
1 to 4) of the virus [259] (Table 2.4). 
Briefly, each 25µl reaction mix contained 10µl of extracted RNA, 1µl of each 
primer (10µM each) (Sigma-Aldrich, Saint Louis, MO, USA), 12.5µl of 2X SYBR Green 
reaction mix (containing 0.4mM of each deoxynucleotide triphosphate (dNTP) and 6mM 
magnesium sulfate (MgSO4)) and 0.5µl of SuperScript III RT/Platinum Taq mix (including 
RNaseOUT ribonuclease inhibitor). The reaction mix and Taq were supplied in the 
SuperScript III Platinum SYBR Green One-Step qRT-PCR kit (Invitrogen). The 
amplification conditions consisted of reverse transcription at 50°C for 30 minutes, Taq 
inhibitor inactivation at 95°C for 5 minutes, followed by 45 cycles of 95°C for 10 seconds, 
54°C for 30 seconds and 72°C for 30 seconds, and hold at 95°C for 1 minute. Melting 
curve analysis was used to confirm the specific amplicons, starting from 55°C to 95°C 
with 1%/step increment (continuous detection).  
An internal control, a human ribonuclease P (RNaseP) rRT-PCR, was used to 
detect the presence of inhibitors in the specimens [260]. The primer and probe sequences 
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are shown in Table 2.4. Each 25µl reaction mix comprised 5µl of extract, 0.5µl of each 
primer and probe (10µM each) (Sigma-Aldrich), 12.5µl of 2X reaction mix containing 
0.4mM of each dNTP and 6mM MgSO4 (supplied with the SuperScript III Platinum One-
Step qRT-PCR kit, Invitrogen), 0.5µl of SuperScript III RT/Platinum Taq mix (supplied 
with the kit, Invitrogen) and 5.5µl of nuclease-free water, using the same amplification 
conditions as dengue group specific rRT-PCR assay as described above. No template 
control (NTC), negative extraction control (NEG) and positive control were included in 
each PCR run. 
Table 2.4 Primer and probe sequences for Dengue group specific and RNaseP 
rRT-PCR. 
Name Sequences (5’è3’) 
DN_F [259] CAATATGCTGAAACGCGNGAGAAA 
DN_R [259] CCCCATCTNNYCANNATYCCTGCTGT 
RNaseP_F [260] AGATTTGGACCTGCGAGCG 
RNaseP_R [260] GAGCGGCTGTCTCCACAAGT 
RNaseP_P [260] FAM-TTCTGACCTGAAGGCTCTGCGCG-BHQ1 
F=forward primer, P=probe, and R=reverse primer; BHQ1=Black Hole Quencher1 as the 
quencher, and FAM=6-carboxy-fluorescein as the fluorescent reporter dye  
Interpretation 
Dengue group specific assay 
The positive control as well as unknown positive specimens should cross the 
threshold (14,000) with a cycle threshold (Ct) value lower than the Ct value of negative 
controls and unknown negative specimens. The Ct value of the positive control was around 
20 (5µl/reaction was applied and equivalent to 16.7 plaque forming unit (PFU)/reaction of 
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DENV1-3 and 166.7 PFU/reaction of DENV-4). Specimens were considered positive 
when the melting temperature was between 80.0°C and 83.3°C. All specimens melting 
below, or having no associated peak to these temperatures were considered negative. There 
was always some fluorescent signal for negative controls and negative specimens. This 
was either non-specific or primer-dimer-related. The fluorescence of these specimens 
usually started to decrease before they reached the plateau and their melting temperature 
was below 80.0°C (usually around 70°C). If unknown specimens had a Ct value similar to 
NTC or NEG but their fluorescence curve reached the plateau, melting curves were 
checked for a peak around 80.0°C and 83.3°C, in which case they were positive. In cases 
of doubt, the PCR product of the specimen was separated by agarose gel electrophoresis to 
check for a 170 base pairs (bp) band corresponding to dengue virus.  
Dengue virus control strains were obtained from AFRIMS, consisting of DENV-1 
(Hawaii strain), DENV-2 (New Guinea C strain), DENV-3 (H87 strain), and DENV-4 
(814669 strain). A DENV1-4 mixture was used for positive control. Nuclease-free water 
and plasma extract from a healthy donor were used as NTC and NEG, respectively.  
RNaseP (internal control) assay 
 All clinical specimens should exhibit RNaseP reaction curves that cross the 
threshold (20,000) line at or before a Ct value of 35, indicating the presence of the human 
RNaseP gene. Failure to detect RNaseP in any of the clinical specimens indicated improper 
extraction of nucleic acid from clinical materials resulting in loss of nucleic acid or carry-
over of PCR inhibitor from clinical specimens, improper assay setup and execution, or 
reagent or equipment malfunction. If a specimen was RNaseP negative, then nucleic acid 
extraction and PCR were repeated. If all of the specimens were RNaseP negative 
(including positive control), PCR failure was suspected and the assay was repeated. Plasma 
extract from a healthy donor, nuclease-free water and its extract were used as positive 
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control, NTC and NEG, respectively. A false positive result in NTC or NEG indicated 
contamination in the process. If NTC was positive, the PCR run was repeated. If NEG was 
positive, the extraction and PCR run were repeated. 
2.9.1.4 Nested-RT PCR for dengue virus serotyping assay 
All RNA extracts that were positive by the dengue group specific one step SYBR 
Green based rRT-PCR assay (section 2.9.1.3) underwent nested-RT PCR for dengue virus 
serotyping [80], modified by AFRIMS, Bangkok, Thailand [74]. The AFRIMS protocol 
was introduced and optimised at the SMRU laboratory for this study. Amplification was 
performed using a GeneAmp PCR System 9700 (Applied Biosystems).  The 50µl reaction 
mixture for the RT-PCR step contained 5µl of extracted RNA, 0.25µl of AmpliTaq DNA 
polymerase (5 Unit [U]/µl) (Gene Systems, Rockville, MD, USA), 5µl of 10X PCR buffer 
II (supplied with AmpliTaq DNA polymerase, Gene Systems), 3µl of 25mM magnesium 
chloride (MgCl2) (supplied with AmpliTaq DNA polymerase, Gene Systems), 1µl of 
GeneAmp 10mM dNTPs mixed with deoxythymidine triphosphate (dTTP) (Applied 
Biosystems), 1.25µl of each primer (D1, and D2; 10 pico moles (pmol)/µl each, Table 2.5) 
(Sigma-Aldrich), 0.25µl of 1M dithiothreitol (DTT) (Sigma-Aldrich), 0.1µl of Avian 
Myeloblastosis Virus reverse transcriptase (AMV-RT) (10U/µl) (Promega, Madison, WI, 
USA), and 32.9µl of nuclease-free water. The amplification conditions consisted of reverse 
transcription at 42°C for 60 minutes, followed by 35 cycles of 94°C for 30 seconds, 55°C 
for 1 minute and 72°C for 2 minutes, then hold at 4-10°C. The amplified RT-PCR product 
was diluted to 1:50 dilution to use in the nested-PCR step. The 50µl reaction mixture of the 
nested-PCR step contained 5µl of 1:50 diluted RT-PCR product, 5µl of 10X PCR buffer II 
(supplied with AmpliTaq DNA polymerase, Gene Systems), 5µl of 25mM MgCl2 
(supplied with AmpliTaq DNA polymerase, Gene Systems), 1µl of GeneAmp 10mM 
dNTPs mixed with dTTP (Applied Biosystems), 1.25µl of each primer (D1, TS1, TS2, 
TS3, and TS4; 10pmol/µl each, Table 2.5) (Sigma-Aldrich), 0.25µl of AmpliTaq DNA 
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polymerase (5U/µl) (Gene Systems), and 27.5µl of nuclease-free water. The amplification 
conditions consisted of 25 cycles of 94°C for 30 seconds, 53°C for 1 minute, 72°C for 2 
minutes, and then hold at 4-10°C. Positive and negative controls were included in each 
PCR run. PCR products were analysed using 1.8% (w/v) agarose gel electrophoresis, run at 
100 volts for 1 hour and 45 minutes. The products were visualised and image acquisition 
was captured by a molecular imager Gel Doc XR+ System (BioRad, Hercules, CA, USA) 
together with the Quantity One 1-D analysis software (BioRad). 
Interpretation 
A positive RT-PCR result was identified by the detection of a DNA band of 511bp. 
The result was considered negative when no band of 511bp was observed.  A specimen 
containing DENV-1, 2, 3, 4 was identified by the detection of a DNA band of 482, 119, 
290, or 392bp, respectively. Nuclease-free water and the same set of positive controls from 
dengue group specific one step SYBR Green based rRT-PCR assay (section 2.9.1.3) were 
used as negative and positive controls, respectively. Assays were valid only if the positive 
and negative controls had appropriate results. 
Table 2.5 Primer sequences for dengue virus serotyping nested-RT PCR assay. 
Name* Sequences (5’è3’) 
D1  TCAATATGCTGAAACGCGCGAGAAACCG 
D2  TTGCACCAACAGTCAATGTCTTCAGGTTC 
TS1  CGTCTCAGTGATCCGGGGG 
TS2  CGCCACAAGGGCCATGAACAG 
TS3  TAACATCATCATGAGACAGAGC 
TS4  CTCTGTTGTCTTAAACAAGAGA 
*Primer sequences from Lanciotti et al. [80]. 
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2.9.2 Leptospirosis 
2.9.2.1 16S rRNA (Leptospira spp.) quantitative real-time PCR (qPCR) assay 
Nucleic acid extraction 
Extraction was performed using the MagCore HF16 (RBC Bioscience) as described 
above (section 2.9.1.3). Bacterial DNA was extracted from acute plasma specimens in 
batches, using the MagCore Genomic DNA Whole Blood Kit, cartridge code 102 (RBC 
Bioscience). Briefly, 20µl of Proteinase K (10mg/ml) were added into 1.5ml sample tubes 
(provided by kit), followed by 200µl of plasma. The tubes were then placed into the 
machine, and the cartridge code 102 programme was run, with a 100µl elution volume 
selected. Extracts were processed immediately or stored at 2-8°C prior to testing within 24 
hours or at -80°C for longer storage. 
qPCR amplification 
The 16S rRNA qPCR assay was performed using Platinum Taq DNA polymerase 
kit (Invitrogen) and the amplification was carried out using the ABI 7500 FAST real-time 
PCR system (Applied Biosystems). The primers and probe were based on Smythe et al. 
and Slack et al. [147, 150] (Table 2.6). The assay was modified from Thaipadungpanit et 
al. [149]. A total reaction mixture of 20µl included 5µl of extracted DNA, 2µl of 10X 
buffer (supplied with Taq DNA polymerase, Invitrogen), 0.5µl of forward primer (10µM) 
(Sigma-Aldrich), 1µl of reverse primer (10µM) (Sigma-Aldrich), 0.2µl of probe (5µM) 
(Sigma-Aldrich), 1µl of dNTPs (5mM) (Roche, Basel, Switzerland), 1.7µl of MgCl2 
(50mM) (supplied with Taq DNA polymerase, Invitrogen), 0.25µl of Taq DNA 
polymerase (0.5U/reaction) (Invitrogen), and 8.35µl of nuclease-free water. A 10-fold 
serial dilution of linearised plasmid DNA from L. interrogans starting from 10,000 to 0.1 
copies/µl (six points) was used in duplicates for standard control. Nuclease-free water and 
plasma extract from a healthy donor were used for NTC and NEG, respectively. 
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Amplification was performed in the fast mode of the ABI 7500 FAST real-time PCR 
system (Applied Biosystems), consisting of 98°C for 20 seconds, followed by 45 cycles of 
95°C for 3 seconds and 58°C for 30 seconds. The human RNaseP PCR was used as an 
internal control (Table 2.4) [260]. The PCR reaction mix (both concentration and volume) 
and amplification condition were exactly the same as those of the 16S rRNA qPCR as 
described above. Plasma extract from healthy donor, nuclease-free water and its extract 
were used as positive control, NTC and NEG, respectively and they were included in each 
PCR run. 
Table 2.6 Primer and probe sequences for 16S rRNA (Leptospira spp.) qPCR 
assay. 
Name Sequences (5’è3’) 
Lepto_F [147] CCCGCGTCCGATTAG 
Lepto_R [147] TCCATTGTGGCCGRACAC 
Lepto_P [147, 150] FAM-CTCACCAAGGCGACGATCGGTAGC-BHQ1 
F=forward primer, P=probe, and R=reverse primer; BHQ1=Black Hole Quencher1 as the 
quencher, and FAM=6-carboxy-fluorescein as the fluorescent reporter dye  
Interpretation 
16S rRNA (Leptospira spp.) assay 
All specimens were considered positive when they had amplification curves above 
a fixed threshold (10,000) and a Ct value of ≤40. The standard control at 1 copy/µl was 
expected to give a Ct value of 36 and the standard control of 1-10,000 copies/µl should 
have amplified in duplicate (if not, the run was repeated). Non-amplification of the 0.1 
copies/µl control was deemed acceptable [149]. An accurate quantification was determined 
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using the control data points between 1-10,000 copies/µl (five points). Runs were valid 
only if the standard and negative controls had appropriate results. 
RNaseP (internal control) assay 
Amplification curves that cross a fixed threshold line at 10,000 should be obtained 
from all clinical specimens. A PCR run was valid when the positive control had an 
expected Ct value of 35 and no Ct value for the negative controls. Any failure to obtain an 
appropriate result resulted in an action being taken as described above (section 2.9.1.3). 
16S rRNA (L. interrogans) plasmid DNA preparation 
Insertion of fresh PCR product into vector 
Plasmid DNA control was prepared using pCR8/GW/TOPO TA cloning kit 
(Invitrogen). Amplified PCR product of the 16S rRNA gene (L. interrogans) was inserted 
into the TOPO vector. A total volume of 6µl of the cloning reaction consisted of 3µl of 
fresh PCR product, 1µl of salt solution, 1µl of water and 1µl of the TOPO vector. The 
reaction was mixed gently and was incubated for five minutes at room temperature. Then, 
the reaction tube was placed on ice for two minutes to stop ligation. After this step, the 
cloning reaction was used for the transformation step.  
Transformation 
 The inserted cloning vector was used to transform competent Escherichia coli 
(supplied with the cloning kit, Invitrogen) using a chemical transformation technique. A 
2µl volume of the inserted cloning vector from the previous step was added into a vial of 
competent E. coli. The reaction was mixed gently and was incubated on ice for 10 minutes. 
After that, the cells were heat-shocked for 30 seconds at 42°C without shaking. The tube 
was immediately transferred to ice for 2-3 minutes. Then, 250µl of room temperature 
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S.O.C. medium (supplied with the cloning kit, Invitrogen) was added into the 
transformation tube. The tube was capped tightly and was shaken horizontally (200rpm) at 
37°C for one hour in the Thermo-Shaker TS-100C (Biosan, Riga, Latvia). After this step, 
transformants were checked by streaking 10µl and 20µl of the transformation reaction onto 
prewarmed Luria-Bertani (LB) selective agar plates containing 100µg/ml spectinomycin. 
The plates were incubated over night at 37°C in an aerobic incubator. 
Analysing transformants 
Several hundred colonies should be produced on the LB selective plate for an 
efficient cloning reaction. The transformation efficiency should be ≥105 colony forming 
unit (CFU)/µg. The 16S rRNA (Leptospira spp.) qPCR was performed to confirm the 
presence and correct orientation of the insert, using a single colony on the LB selective 
plate. The colony was added directly to the qPCR reaction. Once confirmation of the insert 
was obtained, stocks of transformant E. coli were prepared. A single colony was inoculated 
onto a LB selective plate and incubated at 37°C overnight. The clone was checked by the 
16S rRNA qPCR again before storage. The transformant E. coli was transferred to skim-
milk tryptone glucose glycerol (STGG) storage medium and stored at -80°C for long term 
storage. Another single colony was inoculated onto a LB selective plate and incubated at 
37°C overnight for plasmid extraction. Circular plasmid DNA was extracted using the 
QIAprep Spin Miniprep kit (Qiagen, Hilden, Germany), following the manufacturer’s 
instructions. 
Linearisation of plasmid DNA 
The circular plasmid DNA was linearised using EcoRI restriction enzyme. A total 
volume of 100µl of restriction reaction consisted of 10µl of 10X React3 buffer, 5µl of 
EcoRI (10U/µl), 50µl of circular plasmid DNA and 35µl of water. The reaction was 
incubated at 37°C for two hours, followed by the heat-inactivation step at 80°C for 20 
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minutes. After this step, the quantity of linearised plasmid DNA was measured using the 
Qubit Fluorometer (Invitrogen). The linearised plasmid DNA was stored at -80°C for long 
term storage. 
2.9.3 Rickettsial infections 
2.9.3.1 Enzyme-linked Immunosorbent Assay (ELISA) 
All rickettsial work on acute and convalescent serum specimens was performed at 
the Serology laboratory, Microbiology Department, MORU, Bangkok. Specimens were 
screened by ELISA for detection of scrub typhus [207, 261] and murine typhus IgM 
antibodies [262]. U-bottom 96 well microtitre plates (Sterilin, Newport, UK) were coated 
with 100µl/well of O. tsutsugamushi antigen (1:1,000 dilution for Karp and Kato strains, 
and 1:1,500 dilution for Gilliam strain) or R. typhi antigen (1:3,000 dilution) in phosphate-
buffered saline (PBS) (Oxoid, Hampshire, UK). 100µl/well of PBS with no antigen were 
added for blank plates. The plates were covered with a plastic wrap and stored at 4°C for 
two days. After this time, the coated plates were washed three times with wash buffer 
(0.1% Tween 20 in PBS), then the plates were blocked with 200µl/well of blocking buffer 
(5% skim milk in wash buffer) for one hour, and finally rinsed with wash buffer three 
times. All specimens were tested in duplicate. Serum specimens were diluted 1:100 in 
blocking buffer, 100µl/well, in microtitre plates with and without antigen (blank) and 
incubated for one hour at room temperature. The plates were washed four times with wash 
buffer, and then 100µl/well of anti-human IgM horseradish peroxidase (HRP) conjugate 
(1:10,000 dilution) (Invitrogen) was added before incubation for one hour at room 
temperature. Following this, the plates underwent four washes with wash buffer and then 
100µl/well of tetramethylbenzidine (TMB) substrate (Invitrogen) was added and the plates 
incubated for 10 minutes at room temperature in the dark. After 10 minutes, 100µl/well of 
stop solution (1M HCl) (Merck, Kenilworth, NJ, USA) was added to the plates. The plates 
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were then read at a wavelength of 450nm (subtracted a reference OD value read at 630nm) 
using a Multiskan EX microplate reader (ThermoFisher Scientific, Waltham, MA, USA). 
Positive and negative controls were included in each plate. Serum specimens that were 
positive by IgM IFA (≥1:25,600 titre) for scrub typhus or murine typhus were used as 
positive controls for scrub typhus or murine typhus assay, respectively. The ODs from the 
wells without antigen were used to subtract background absorbance. All patient specimens 
that had an OD of at least a 1.4-fold increment or a high static OD between acute and 
convalescent specimens, or were positive by PCR (described in section 2.9.3.4) on the 
acute specimen, were selected for further IFA testing. 
2.9.3.2 Indirect Immunofluorescence Assay (IFA) 
The IFA assay was used to determine IgM antibody titre against O. tsutsugamushi 
antigen (Karp, Kato, and Gilliam strains) and R. typhi antigen (Wilmington strain) [208, 
263]. This assay was performed on all specimens that were suggestive of scrub typhus or 
murine typhus infection by ELISA and PCR results as described in section 2.9.3.1 and 
2.9.3.4. Slides for the scrub typhus and murine typhus IFA assays were obtained from the 
Australian Rickettsial Reference Laboratory (ARRL; Geelong, Victoria, Australia). Serum 
specimens were serially diluted two-fold from 1:100 to 1:25,600 in PBS (Oxoid) buffer 
containing 2% (w/v) skim milk powder (Becton Dickinson). Paired acute and convalescent 
serum specimens from the same patient were performed on the same slide side-by-side. 
Positive and negative controls were included for each patient. 2µl of diluted sera was 
dropped on each well of the slide, incubated at 37°C for 30 minutes in a humid chamber, 
and washed four times (five minutes each time) in PBS. Following this, the slide was dried 
and then 2µl of diluted fluorescein isothiocyanate (FITC) anti-human IgM conjugate [anti-
human IgM FITC conjugate (Invitrogen) diluted in 2% PBS-skim milk powder diluent 
containing 0.005% (w/v) Evans blue counterstain] was added on to each well of the slide, 
incubated at 37°C for 30 minutes in a humid chamber, and washed four times (five minutes 
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each time) in PBS. Fluorescence mounting medium (Dako, Glostrup, Denmark) was 
dropped onto the slide and a cover slip added. Slides were examined by epifluorescence 
microscopy (BX60; Olympus, Tokyo, Japan) at a magnification of x400 by two readers. 
The binding endpoint titre was determined as the highest titre that showed fluorescence. If 
the discrepancy in titre between two readers was greater than two-fold, a third reader result 
was obtained. The highest titre from the two readers with closest agreement was then used 
as the binding endpoint titre.  
Patients were considered to have evidence of acute infection when a ≥four-fold 
increase in titre or seroconversion between acute and convalescent specimens or a static 
titre of ≥1:25,600 was observed. 
2.9.3.3 Immunochromatographic (ICT) rapid diagnostic test (RDT) 
Acute plasma specimens were tested using SD BIOLINE Scrub typhus IgM ICT 
test for the detection of IgM antibody against O. tsutsugamushi (Boryong strain) [229]. 
The test was obtained from Standard diagnostics, Inc., Kyonggi-do, Korea and is currently 
not commercially available. Briefly, 10µl of plasma was added into the sample well, 
followed by three drops of assay diluent, and then the test was incubated at room 
temperature and the result was interpreted as positive or negative at 15 minutes. The test 
has two lines, a control line “C” and a test line “T”. An absence of “C” line indicates an 
invalid result. The tests were read by three independent readers who were on duty in the 
routine clinical microbiology laboratory at SMRU. The readers did not confer while 
reading the test and the results were blinded (each reader did not see the results of the other 
readers). Subsequently, the consensus result (i.e. 2/3 readers with the same interpretation) 
was used for final interpretation. 
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2.9.3.4 Quantitative real-time PCR (qPCR) 
The extraction method and qPCR assays for detection of rickettsia were modified 
from the original papers by Paris and Castonguay-Vanier and described in the Lao Oxford 
Mahosot Wellcome Trust Research Unit (LOMWRU) 2010 SOPs [210, 217, 218, 223]. 
The assays were then introduced and optimised at SMRU laboratory as described below 
(section 2.9.3.4.1 - 2.9.3.4.3). 
Nucleic acid extraction 
Buffy coats from acute blood specimens were analysed in batches. Bacterial DNA 
was extracted from buffy coat using the QiaAmp DNA Blood Mini kit (Qiagen) following 
the manufacturer’s instructions [264]. The lysis incubation time at 56°C was increased 
from 10 minutes to one hour and elution volume was decreased to 100µl to obtain a higher 
DNA concentration. Briefly, 20µl of protease was added into 1.5ml microcentrifuge tube 
(Axygen, Corning, NY, USA), followed by 200µl of buffy coat and 200µl of buffer AL, 
then the mixture was vortexed for 15 seconds using vortex-genie 2 (Scientific Industries, 
Bohemia, NY, USA). The tube was incubated at 56°C for one hour. Following this, the 
tube was briefly centrifuged using Biofuge PICO (Heraeus, Hanau, Germany) to remove 
any drops inside of the tube lid, and then 200µl of absolute ethanol (VWR, Arlington 
Heights, IL, USA) was added and mixed by vortexing for 15 seconds. The mixture from 
the previous step was transferred to a spin column, and was centrifuged at 8,000rpm for 
one minute. After that, the column was placed into a new collection tube and the filtrate 
was discarded in 1% Virkon (DuPont, Suffolk, UK) container for disinfection. 500µl of 
buffer AW1 was added into the column and the column was centrifuged at 8,000rpm for 
one minute. The column was placed into a new collection tube and the filtrate was 
discarded. After this step, 500µl of buffer AW2 was added into the spin column and the 
column was centrifuged at full speed (13,000rpm) for three minutes. The filtrate was 
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discarded and the spin column was put back into the collection tube, and was centrifuged 
at full speed for one minute. Following this, the spin column was placed into a new 1.5ml 
microcentrifuge tube (Axygen) and 50µl of buffer AE was added into the spin column. The 
column was centrifuged at 8,000rpm for one minute after incubation for five minutes at 
room temperature. Then, the step of adding 50µl of buffer AE into the spin column, 
incubation for five minutes and centrifugation at 8,000rpm for one minute were repeated. 
The eluted DNA was then mixed by pipetting 10 times and then was split in two tubes of 
equal volume. Extracts were processed immediately or stored at 2-8°C prior to testing 
within 24 hours or at -80°C for longer storage. 
2.9.3.4.1 47kDa qPCR assay (O. tsutsugamushi-specific) 
The 47kDa assay was performed using the Platinum Quantitative PCR SuperMix-
UDG kit (Invitrogen), and the amplification was carried out using the ABI 7500 FAST 
real-time PCR system (Applied Biosystems). This assay was used to detect the presence of 
O. tsutsugamushi DNA. Primers and probe were based on Jiang et al. [210] (Table 2.7). 
The sequences were based on the 47kDa outer membrane protein gene of the Karp, Kato, 
Gilliam, Boryong and TH1817 strains of O. tsutsugamushi. Each 25µl of reaction mix 
contained 1µl of extracted DNA, 15µl of Platinum Quantitative PCR SuperMix-UDG 
(Invitrogen), 0.25µl of each primer (OtsuFP630 and OtsuRP747; 10µM each) (Sigma-
Aldrich), 0.5µl of probe (OtsuPR665; 10µM) (Sigma-Aldrich), and 8µl of Nuclease-free 
water. A 10-fold serial dilution of linearised plasmid DNA (47kDa gene from O. 
tsutsugamushi strain UT76) from 1 to 1,000 copies/µl (four points) was used in duplicate 
for standard controls and nuclease-free water was used for negative control. The 
amplification condition comprised 50°C for 2 minutes, 95°C for 2 minutes, followed by 45 
cycles of 95°C for 15 seconds, and 60°C for 30 seconds. Standard and negative controls 
were included in each PCR run. The human RNaseP PCR was used as an internal control 
(only tested on the first 327 buffy coat specimens; primer and probe sequences are shown 
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in Table 2.4), using the same amplification condition as 47kDa assay as above, but the 
concentration of the PCR mix was slightly different: each 25µl of reaction mix contained 
1µl of extracted DNA, 15µl of Platinum Quantitative PCR SuperMix-UDG (Invitrogen), 
0.25µl of each primer (40µM each) (Sigma-Aldrich), 0.5µl of probe (10µM) (Sigma-
Aldrich), and 8µl of nuclease-free water. Nuclease-free water and buffy coat extract from a 
healthy donor were used as negative and positive controls. 
Interpretation 
47kDa qPCR assay 
The standard controls were added in duplicates (1, 10, 100, 1,000 copies/µl). The 
standard at 10, 100, and 1,000 copies/µl had to be amplified for at least one replicate for 
each dilution. If not, the run was repeated. The 1 copy/µl standard might not be amplified 
and this was acceptable as 3-10 copies/µl could be detected in the original paper [210]. 
There had to be no amplification in the negative control. All specimens were considered 
positive when they had amplification above the fixed threshold (25,000). The 
quantification was calculated from 10-1,000 copies/µl of standard controls (three points). 
For any specimens that were positive at less than 10 copies/µl, quantification was not 
reported. All positive specimens were repeated and analysed for an accurate quantification 
using the data point between 10-100,000 copies/µl of standard controls (five points). The 
standard control of 10-100,000 copies/µl had to be amplified in duplicate (if not, the run 
was repeated). Any specimens that were positive less than 10 copies/µl were considered 
positive, but lower than the level of accurate quantification. Hence, the quantity was not 
reported. 
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RNaseP (internal control) assay 
Amplification curves that cross a fixed threshold line at 50,000 should be obtained 
from all clinical specimens. A PCR run was valid when the positive control had an 
expected Ct value of 23 and no Ct value for the negative controls. Any failure to obtain an 
appropriate result resulted in action being taken as described above (section 2.9.1.3). 
This internal control assay was performed only on the first 327 specimens and only 
once for each specimen when testing a set of rickettsial PCRs including 47kDa, 17kDa and 
ompB assays, since the same DNA extracts were used for these assays and all of the 327 
specimens showed very consistent positive Ct values. 
Table 2.7 Primer and probe sequences for 47kDa, 17kDa and ompB qPCR assays. 
Name Sequences (5’è3’) 
OtsuFP630 [210] AACTGATTTTATTCAAACTAATGCTGCT 
OtsuRP747 [210] TATGCCTGAGTAAGATACRTGAATRGAATT 
OtsuPR665 [210] FAM-TGGGTAGCTTTGGTGGACCGATGTTTAATCT-
TAMRA 
R17K128F2 [217, 223] GGGCGGTATGAAYAAACAAG 
R17K238R [217, 223] CCTACACCTACTCCVACAAG 
R17K202TaqP [217, 223] FAM-CCGAATTGAGAACCAAGTAATGC-TAMRA 
Rt557F [218] TGGTATTACTGCTCAACAAGCT 
Rt678R [218] CAGTAAAGTCTATTGATCCTACACC 
Rt640BP [218] FAM-CGCGATCGTTAATAGCAGCACCAGCATTATCG 
CG-BHQ1 
BHQ1=Black Hole Quencher1 as the quencher, FAM=6-carboxy-fluorescein as the 
fluorescent reporter dye, and TAMRA=6-carboxytetramethylrhodamine as the quencher  
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2.9.3.4.2 17kDa qPCR assay (Rickettsia-specific) 
The 17kDa qPCR assay was performed using the Platinum Quantitative PCR 
SuperMix-UDG kit (Invitrogen) and amplification was carried out using the ABI 7500 
FAST real-time PCR system (Applied Biosystems). The 17kDa assay was used to detect 
bacterial species from the Rickettsia genus. Primer and probe sequences were based on 
Wright et al., and Jiang et al. [217, 223] (Table 2.7). Each 25µl of reaction mix contained 
1µl of extracted DNA, 15µl of Platinum Quantitative PCR SuperMix-UDG (Invitrogen), 
1µl of each primer (R17K128F2 and R17K238R; 10µM each) (Sigma-Aldrich) and probe 
(R17K202TaqP; 10µM) (Sigma-Aldrich), and 6µl of nuclease-free water. A 10-fold serial 
dilution of linearised plasmid DNA (17kDa gene from R.typhi strain Wilmington) from 1 
to 1,000 copies/µl (four points) was used in duplicates for standard controls and nuclease-
free water was used as negative control. The amplification conditions consisted of 50°C for 
2 minutes, 95°C for 2 minutes, followed by 45 cycles of 95°C for 15 seconds, and 60°C for 
30 seconds (same as 47kDa assay). Standard and negative controls were included in each 
PCR run.  
Interpretation 
The interpretation was the same as 47kDa assay described above (section 2.9.3.4.1) 
with a fixed threshold at 30,000 for 17kDa assay. All positive specimens from this assay 
were tested further by a specific R. typhi ompB assay. 
2.9.3.4.3 ompB (R. typhi) qPCR assay 
All positive specimens by 17kDa qPCR assay were assessed with the ompB qPCR 
assay. This assay was used to detect the unique sequence in the outer membrane protein B 
gene (ompB) of R. typhi. The primer and probe sequences were based on Henry et al. 
[218]. The reporter and quencher dyes of the probe were changed from 
Tetrachlorofluorescein (TET) and 4-(dimethylaminoazo) benzene-4-carboxylic acid 
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(DABCYL) to 6-carboxy-fluorescein (FAM) and Black Hole Quencher1 (BHQ1), 
respectively (Table 2.7). This assay was performed using the Platinum Quantitative PCR 
SuperMix-UDG kit (Invitrogen) and the amplification was carried out using the ABI 7500 
FAST real-time PCR system (Applied Biosystems). Each 25µl of reaction mix contained 
1µl of extracted DNA, 15µl of Platinum Quantitative PCR SuperMix-UDG (Invitrogen), 
1µl of each primer (Rt557F and Rt678R; 10µM each) (Sigma-Aldrich) and probe 
(Rt640BP; 10µM) (Sigma-Aldrich), and 6µl of nuclease-free water. A 10-fold serial 
dilution of linearised plasmid DNA (ompB gene from R.typhi strain Wilmington) from 1 to 
1,000 copies/µl (four points) was used in duplicates for standard controls and nuclease-free 
water was used for negative control. The amplification conditions consisted of 50°C for 2 
minutes, 94°C for 2 minutes, followed by 45 cycles of 94°C for 15 seconds, and 60°C for 
30 seconds. Standard and negative controls were included in each PCR run.  
Interpretation 
The interpretation was the same as 47kDa assay described above (section 2.9.3.4.1) 
with a fixed threshold at 30,000 for ompB assay. The 1 copy/µl standard might not be 
amplified: Henry et al. could detect 3 copies/µl or more [218].  
47kDa, 17kDa and ompB plasmid DNA preparation 
Circular plasmid DNA controls were obtained from MORU, consisting of 47kDa 
gene (O. tsutsugamushi strain UT76), 17kDa gene (R.typhi strain Wilmington) and ompB 
gene (R.typhi strain Wilmington) inserted in pGEM-T Easy vector (Promega, Madison, 
WI, USA). Linearisation of plasmid DNA was performed in the molecular suite at SMRU 
laboratory, using appropriate restriction enzymes. The 47kDa plasmid was linearised using 
SalI-HF. The 17kDa and ompB plasmids were linearised using SpeI-HF. A total volume of 
30µl of linearised reaction for 47kDa plasmid contained 3µl of 10X NEBuffer 4, 2µl of 
SalI-HF, 4µl of circular plasmid DNA (250-300ng/µl), and 21µl of distilled water. For the 
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17kDa and ompB plasmids, a total volume of 30µl of linearised reaction contained 3µl of 
10X NEBuffer 4, 3µl of 10X BSA, 2µl of SpeI-HF, 4µl of circular plasmid DNA (250-
300ng/µl), and 18µl of distilled water. The reactions were then incubated at 37°C for two 
hours, followed by the heat inactivation step at 80°C for 20 minutes. After this step, 2µl of 
each linearised plasmid DNA was checked for the complete cut by performing a 1% 
agarose gel electrophoresis. Then, the linearised plasmids were purified using QIAquick 
PCR purification kit (Qiagen), followed the manufacturer’s instructions. The quantity of 
lineared plasmid DNA was measured using the Qubit Fluorometer (Invitrogen). The 
linearised plasmid DNA was stored at -80°C for long term storage. 
2.9.4 Bacterial infection 
2.9.4.1 Blood culture 
The SMRU microbiology laboratory routinely participates in the Thailand National 
External Quality Assurance Scheme (Thailand NEQAS) in clinical microbiology from the 
Department of Medical Science (DMSc); unit code MI 1637. All blood culture specimens 
were processed using BacT/Alert FA culture bottles or BacT/Alert PF culture bottles with 
the BacT/ALERT Microbial Detection System (BioMérieux) for qualitative detection of 
aerobic and facultative anaerobic microorganisms. This was performed through the routine 
process of the SMRU microbiology laboratory following the Blood Culture SOP (MBL-2-
B). Blood culture bottles were incubated for five days before being declared negative. If a 
positive growth signal was detected, a Gram stain was performed and the relevant method 
for bacterial identification was followed, using standardised SOPs. The results were sent to 
physicians for patient management. 
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2.9.5 Malaria 
The malaria molecular assays used in this study were modified from the original 
papers [265-267] by the malaria molecular laboratory at MORU, Bangkok, Thailand. The 
assays were introduced and optimised at the SMRU laboratory for this study. 
2.9.5.1 18S rRNA (Plasmodium spp.) qPCR assay 
Nucleic acid extraction 
Plasmodium spp. DNA was extracted from 200µl of packed red blood cells (RBC), 
from acute blood specimens, in batches. The QiaAmp DNA blood mini kit (Qiagen) was 
used, following the manufacturer’s instructions. For the final elution step, DNA was eluted 
with 100µl of nuclease-free water (two times) and incubated for five minutes, then 
dehydrated using vacuum concentrator plus (Eppendorf, Hamburg, Germany) and re-
suspended with 10µl of AE buffer. Extracts were processed immediately or stored at 2-8°C 
prior to testing within 24 hours or at -20°C for longer storage. 
qPCR amplification 
The 18S rRNA qPCR assay was used to detect the 18S rRNA gene of the 
Plasmodium genus. Primers and probe were based on Kamau et al. [265] (Table 2.8). The 
assay was performed using the QuantiTect Multiplex PCR No ROX kit (Qiagen) and 
amplification was carried out using the RotorGene 6000 (Corbett Research, Mortlake, 
Australia). Each 10µl of reaction mix contained 2µl of extracted DNA, 5µl of 2X 
QuantiTect Multiplex PCR No ROX master mix (Qiagen), 0.4µl of primer mix (10µM) 
(Sigma-Aldrich), 0.2µl of probe (10µM) (Sigma-Aldrich), and 2.4µl of nuclease-free 
water. Amplification consisted of 95°C for 15 minutes, followed by 50 cycles of 94°C for 
15 seconds and 60°C for 1 minute. A 5-fold serial dilution from 0.128-2,000 parasite/µl 
(seven points) was used for standard controls in duplicates (only one replicate for the 2,000 
parasites/µl). Positive and negative controls were included in each PCR run.  
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Interpretation 
All specimens were considered positive when they had amplification above a fixed 
threshold (0.03) and a Ct value of ≤38. The standard control at 0.64 parasites/µl was 
expected to give a Ct value of 35. The standard control of 0.64-400 parasites/µl had to be 
amplified in duplicate (if not, the run was repeated). An accurate quantification was 
determined using the data points between 0.64-400 parasites/µl (five points). All positive 
specimens by this assay were subjected to P. falciparum and P. vivax speciation by 
microsatellite nested-PCR. 
Table 2.8 Primer and probe sequences for 18S rRNA (Plasmodium spp.) qPCR 
assay. 
Name* Sequences (5’è3’) 
Forward primer GCTCTTTCTTGATTTCTTGGATG 
Reverse primer AGCAGGTTAAGATCTCGTTCG 
Probe FAM-ATGGCCGTTTTTAGTTCGTG-TAMRA 
*Primer and probe sequences from Kamau et al. [265]. 
2.9.5.2 Microsatellite nested-PCR for P. falciparum and P. vivax speciation 
The microsatellite nested-PCR assay was performed on all specimens that were 
positive for the 18S rRNA qPCR assay. The primer sequences were based on Anderson et 
al. and Imwong et al. [266, 267]. The PfPK2 and 3.502 primer sets were used for P. 
falciparum and P. vivax, respectively (Table 2.9). The primers mix PfPK2 F/PfPK2 3R, 
and PfPK2 F/PfPK2 R were used for the first round and second round PCR for P. 
falciparum, respectively and the primers mix PV 3.502 F1/PV 3.502 R1, and PV 3.502 
F2/PV 3.502 R1 were used for the first round and second round PCR for P. vivax, 
respectively. 
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Table 2.9 Primer sequences for P. falciparum and P. vivax microsatellite nested-
PCR speciation. 
Name Sequences (5’è3’) 
PfPK2 F [267] CTTTCATCGATACTACGA 
PfPK2 3R [267] CCTCAGACTGAAATGCAT 
PfPK2 R [267] AAAGAAGGAACAAGCAGA 
PV 3.502 F1 [266] CCATGGACAACGGGTTAG 
PV 3.502 R1 [266] TCCTACTCAGGGGGAATACT 
PV 3.502 F2 [266] GTGGACCGATGGACCTAT 
 
 The assays were performed using MyTaq DNA polymerases (Bioline, London, 
UK) and amplification was carried out using GeneAmp PCR System 9700 (Applied 
Biosystems). The same reaction mixture was used for the first round and second round 
PCR for both P. falciparum and P. vivax. Each 16µl of reaction mixture contained 2µl of 
extracted DNA, 1.5µl of 5X MyTaq reaction buffer (supplied with MyTaq DNA 
polymerase, Bioline), 0.75µl of 50mM MgCl2 (supplied with MyTaq DNA polymerase, 
Bioline), 0.375µl of 5mM dNTPs (Roche), 1.5µl of 2.5µM primers mix (Sigma-Aldrich), 
0.06µl of MyTaq DNA polymerase (5U/µl) (Bioline), and 9.815µl of nuclease-free water. 
The amplification conditions for each PCR were different. For P. falciparum, the 
first round PCR consisted of 30 cycles of 94°C for 1 minute, 52°C for 2 minutes, and 72°C 
for 2 minutes, and final extension at 72°C for 5 minutes. The second round consisted of 
94°C for 2 minutes, followed by 5 cycles of 94°C for 30 seconds, 50°C for 30 seconds, and 
60°C for 30 seconds, and followed by another 25 cycles of 94°C for 30 seconds, 45°C 30 
seconds, and 60°C for 30 seconds, and final extension at 60°C for 2 minutes. For P. vivax, 
the first round consisted of 95°C for 5 minutes, followed by 25 cycles of 94°C for 30 
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seconds, 52°C for 30 seconds, and 72°C for 30 seconds, and final extension at 72°C for 2 
minutes. The second round consisted of 95°C for 5 minutes, followed by 25 cycles of 94°C 
for 30 seconds, 52°C for 30 seconds, and 72°C for 30 seconds, and final extension at 72°C 
for 2 minutes. Positive and negative controls (P. falciparum clone 3D7, P. vivax, 
P.malariae, P. ovale and water) were included in each PCR run.  
Interpretation 
PCR products were analysed using 3% (w/v) agarose gel electrophoresis, run at 120 
volts for 40-70 minutes. A molecular imager Gel Doc XR+ System (BioRad) with the 
Quantity One 1-D analysis software (BioRad) was used for visualisation, imaging and 
analysis of the PCR products. DNA band sizes of 159-192bp indicated P. falciparum and 
128-265bp indicated P. vivax. Assays were valid only if the positive and negative controls 
had appropriate results. 
2.9.6 Infection markers 
2.9.6.1 Complete blood count (CBC) 
Two automated haematology analysers were used at SMRU during the study: A 
Sysmex pocH-100i (Sysmex Corp., Kobe, Japan) was used between March and April 
2011, and a Nihon Kohden celltacF MEK-8222 (Nihon Kohden, Tokyo, Japan) was used 
between April 2011 and February 2013. The former measured 17 clinical parameters 
including a 3-part white blood cell (WBC) differential. The latter measured 22 parameters 
with a 5-part WBC differential. The specimens were processed as part of the routine 
services at SMRU haematology laboratory and the results were sent back to physicians for 
patient management as were the CRP results (section 2.9.6.2). The SMRU haematology 
laboratory also routinely participates in the Thailand NEQAS in Haematology from DMSc: 
unit code HM 1015. 
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2.9.6.2 C-reactive protein (CRP) 
Acute EDTA blood specimens were tested for the level of CRP, using the 
NycoCard CRP test (Axis-Shield, Oslo, Norway) following the manufacturer’s 
instructions. Briefly, 5µl of whole blood was added into the R1 dilution liquid tube 
(containing 400µl of the R1 dilution liquid), and mixed thoroughly for 10 seconds. 50µl of 
diluted specimen was applied to the test device and allowed to soak into the membrane for 
30 seconds. After this, one drop of R2 conjugate was added and allowed to soak for 30 
seconds, then one drop of R3 washing solution was added, and allowed to soak for 20 
seconds. The result was read within five minutes using the NycoCard Reader II and the 
CRP whole blood protocol was selected. A correction for haematocrit (Hct) deviating from 
40% was required by multiplying the CRP result with the respective factor as shown in the 
table below (Table 2.10). A reference range of <5 mg/l was indicated in the product 
description. 
Table 2.10 Haematocrit (Hct) correction factor for CRP 
Hct (%) Factor Hct (%) Factor 
20 – 29 0.8 56 – 58 1.4 
30 – 36 0.9 59 – 61 1.5 
37 – 42 1.0 62 – 63 1.6 
43 – 47 1.1 64 – 65 1.7 
48 – 51 1.2 66 – 67 1.8 
52 – 55 1.3 68 – 69 1.9 
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2.10 Data management and analysis 
Clinical and laboratory data were recorded on study-specific paper forms and 
entered in purpose-designed Microsoft Access 2007 databases (Microsoft, Richmond, WA, 
USA). Clinical data were double-entered into the database and the databases compared to 
identify data entry errors. Laboratory data were single-entered into the database and all 
entries were checked against original forms. Statistical analyses were performed using 
STATA/SE 10.1 (StataCorp LP., College Station, TX, USA) and are described in the 
appropriate result chapters. 
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3 Patient demographics, clinical presentations and general 
laboratory findings 
3.1 Introduction 
SMRU provides clinical support for migrants and refugees living or working on the 
Thailand-Myanmar border, of which Karen and Burman are the majority. This chapter 
describes the characteristics, clinical presentations and laboratory findings of the patients 
recruited in the study and the comparison between non-malaria and malaria patient groups.    
3.2 Materials and Methods 
3.2.1 Patients and methods 
 Febrile patients were recruited into the study from the OPD of two SMRU migrant 
clinics at Wang Pha and Mawker Thai villages, and one clinic at Mae La refugee camp as 
previously described in the Materials and Methods chapter, section 2.2-2.6. All patients 
who presented with fever were screened for malaria by microscopy or RDT. Patients who 
were negative for malaria screen using either method were recruited into PART I of the 
study (non-malaria patients) and patients who had a positive result were recruited into 
PART II (malaria patients). From this chapter onward, the term migrants refers to patients 
from Wang Pha and Mawker Thai clinics while refugees refers to patients from the clinic 
at Mae La camp. Adults refers to patients aged at least 18 years and children refers to 
patients aged between five and 17 years old. 
3.2.2 Statistical analysis 
Data collection was performed as described in the Materials and Methods chapter, 
section 2.6. The data were analysed using STATA/SE 10.1 (StataCorp LP) and graphs 
were drawn using Microsoft Excel 2010 (Microsoft). Numeric data were described by their 
medians and interquartile ranges (IQR) or ranges as appropriate. Non-parametric 
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continuous variables were compared using Wilcoxon rank-sum (Mann Whitney U) test. 
Categorical variables were compared using the Chi-squared (χ2) test, unless otherwise 
stated. 
3.3 Results 
The study was conducted between March 2011 and March 2013, with a total of 
1,029 patients recruited from all three OPD clinics: 908 patients were recruited into PART 
I (non-malaria patients) and 121 patients were recruited into PART II (malaria patients). 
The study did not define which temperature measurement method to use. The method used 
was based on routine practice at each clinic and depended on the discretion of the 
clinicians/medics. The chosen method was recorded in the study CRF. Most patients, 
95.8% (986/1,029), had temperature measured at presentation by the tympanic method, 
2.5% (26/1,029) of patients were measured by the axillary method, 1.5% (15/1,029) were 
measured by the temporal method and 0.2% (2/1,029) by the rectal method. 
Of these, 46.7% (481/1,029) were from the two migrant clinics; 349 patients from 
Wang Pha and 132 patients from Mawker Thai, and 53.3% (548/1,029) were from the 
clinic at Mae La refugee camp. The overall median age of the patients was 19 years (IQR 
12-30, range 5-63), 42.5% (437/1,029) of the patients were children and 63.9% 
(657/1,029) of the patients were male. The overall follow-up rate was high, with 89.2% 
(918/1,029) of the patients returning for a follow-up visit. 
3.3.1 PART I (non-malaria patients) 
3.3.1.1 Patient demographics 
 Of the 908 non-malaria patients recruited, 55.7% (506/908) of the patients were 
from the refugee clinic and 61.8% (561/908) were male (Table 3.1). The number of 
patients recruited from migrant and refugee clinics over the two years of the study period 
by month is shown in Figure 3.1. Patients were recruited throughout the study period 
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peaking for both migrant and refugee populations during the rainy season (May-October). 
The proportion of males was the same for both migrant and refugee populations (Table 
3.1). The median age of the patients was 18 years (IQR 12-30, range 5-63) and 45.2% 
(410/908) of patients were children. The number of patients recruited from migrants and 
refugees by age groups is shown in Figure 3.2. The number of male patients was higher 
than female patients in almost all age groups apart from patients aged between 36-40 years 
(Figure 3.3). The migrant patient group was slightly older than the refugee patient group 
with the median age of 20 years (IQR 12-33) compared to 18 years (IQR 12-27) 
(P=0.022). There were no differences in the proportion of migrant and refugee child 
patients recruited (P=0.051). The follow-up rate was high with 89.4% (812/908) and more 
patients from the refugee clinic were seen at the follow-up visit compared to migrant 
clinics (95.1 vs. 82.3%, P=<0.001). The median interval duration between enrolment and 
follow-up visit was 14 days (IQR 14-14), with a range of 9-29 days. 
Table 3.1 Demographic data of 908 non-malaria patients, comparing migrant and 
refugee populations. 
General characteristics Number of patients (%) P-value 
 All patients Migrants Refugees  
Recruited 908 (100) 402 (44.3) 506 (55.7)  
Sex: male  561 (61.8) 250 (62.2) 311 (61.5) 0.823 
Median (IQR) age, years 18 (12-30) 20 (12-33) 18 (12-27) 0.022 
Children 410 (45.2) 167 (41.5) 243 (48.0) 0.051 
Follow-up rate 812 (89.4) 331 (82.3) 481 (95.1) <0.001 
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Figure 3.1 Number of non-malaria patients recruited from migrants and refugees 
by month. 
 
Figure 3.2 Number of non-malaria patients recruited from migrants and refugees 
by age group. 
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Figure 3.3 Number of non-malaria patients recruited by age and sex. 
3.3.1.2 Clinical presentations and laboratory findings 
 The clinical presentations and laboratory findings of 908 non-malaria patients 
recruited in the study are summarised in Table 3.2. The median duration of fever at 
presentation was two days (IQR 2-3), with a range of 1-7 days. The median temperature 
was 38.5°C (IQR 38.2-39.0), with a range of 38.0-40.9°C. Patients presented early in the 
course of their illness with most patients reporting having symptoms for two days. 
Headache was the most frequent symptom reported (91.1%), followed by joint pain 
(55.8%) and muscle pain (43.2%). Skin rashes, jaundice and abnormal bleeding were 
uncommon. General laboratory findings were also recorded and analysed including CBC 
and CRP as shown in Table 3.2. 
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Table 3.2 Clinical presentations and laboratory findings of 908 non-malaria 
febrile patients. 
Clinical presentations Number of patients (%) Median (range) 
Heart rate (beats/minute) - 96 (60-140) 
Respiratory rate 
(breaths/minute) 
- 26 (18-48) 
Temperature (°C) - 38.5 (38.0-40.9) 
Capillary refill time (second) - 2 (1-2)a 
Blood pressure (mmHg)   
• Systolic 815 (89.8) 100 (70-150) 
• Diastolic 815 (89.8) 70 (40-100) 
Fever 908 (100) - 
Headache 827 (91.1) - 
Joint pain 507 (55.8) - 
Muscle pain 392 (43.2) - 
Cough 366 (40.3) - 
Red eyes 276 (30.4) - 
Lymph nodes palpable 237 (26.1) - 
Abdominal pain 197 (21.7) - 
Constipation 160 (17.6) - 
Pain behind eyes 129 (14.2) - 
Stiff neck 60 (6.6) - 
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Table 3.2 Clinical presentations and laboratory findings of 908 non-malaria 
febrile patients (continued). 
Clinical presentations Number of patients (%) Median (range) 
Skin rash 32 (3.5) - 
• Petechiae 19 (59.4) - 
• Eschar 2 (6.3) - 
• Maculopapular rash 1 (3.1) - 
• Other types of rash 10 (31.3) - 
Jaundice 22 (2.4) - 
Abnormal bleeding 9 (1.0) - 
Laboratory findings   
White blood cells (103/µl) - 7.1 (1.5-30.3)b 
• Neutrophils (103/µl) - 5.2 (0.8-25.8)c 
• Lymphocytes (103/µl) - 0.9 (0-6.6)d 
Haematocrit (%) - 40.2 (18.3-77.2e)b 
Platelets (103/µl) - 214 (30-615)b 
C-reactive protein (mg/l) - 20.7 (4.5-230.4)b 
aData available in 903/908 (99.4%) cases, bData available in 907/908 (99.9%) cases, cData 
available in 904/908 (99.6%) cases, dData available in 905/908 (99.7%) cases, eA 
haematocrit of 77.2% was obtained for a single patient. This is abnormally high and 
therefore likely to be an error. 
3.3.2 PART II (malaria patients) 
3.3.2.1 Patient demographics 
Of the 121 malaria patients recruited, 34.7% (42/121) of the patients were from the 
refugee clinic and 79.3% (96/121) were male (Table 3.3). The number of malaria patients 
recruited from migrants and refugees over the recruitment period by month is shown in 
Figure 3.4. There were more patients recruited from migrants than refugees throughout 
most of the recruitment period. The proportions of male and female were not different 
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between migrants and refugees (Table 3.3). The median age of patients was 23 years (IQR 
18-34, range 5-58), while 22.3% (27/121) of patients were children. The number of 
patients recruited from migrants and refugees by age groups is shown in Figure 3.5. There 
were more patients recruited from migrants than refugees in almost all age groups apart 
from patients aged between 5-15 years. The number of male patients was higher than 
female in almost all age groups apart from patients aged between 5-10 years (Figure 3.6). 
Patients from migrant clinics were older than from the refugee clinic with the median age 
of 25 years (IQR 19-36) compared to 20 years (IQR 15-20) (P=0.006). There were more 
child patients from refugees than from migrants (33.3 vs. 16.5%, P=0.034). The follow-up 
rate was high with 87.6% (106/121) of the patients returning for the follow-up visit. The 
rate was not significantly different between migrants and refugees (83.5 vs. 95.2%, 
P=0.083, Fisher’s exact test). The median interval duration between enrolment and follow-
up visit was 14 days (IQR 14-14), with a range of 11-48 days. 
Table 3.3 Demographic data of 121 malaria patients comparing migrant and 
refugee populations. 
General characteristics Number of patients (%) P-value 
 All patients Migrants Refugees  
Recruited 121 (100) 79 (65.3) 42 (34.7)  
Sex: male  96 (79.3)  66 (83.5)  30 (71.4) 0.117 
Median (IQR) age, years 23 (18-34) 25 (19-36) 20 (15-25) 0.006 
Children 27 (22.3) 13 (16.5) 14 (33.3) 0.034 
Follow-up rate 106 (87.6) 66 (83.5) 40 (95.2) 0.083* 
*Fisher’s exact test 
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Figure 3.4 Number of malaria patients recruited from migrants and refugees by 
month. 
 
Figure 3.5 Number of malaria patients recruited from migrants and refugees by 
age group. 
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Figure 3.6 Number of malaria patients recruited by age and sex. 
3.3.2.2 Clinical presentations and laboratory findings 
 The clinical presentations and laboratory findings of 121 malaria patients recruited 
in the study are summarised in Table 3.4. The median duration of fever at presentation was 
three days (IQR 2-3), with a range of 1-7 days. The median temperature was 39.0°C (IQR 
38.4-39.6), with a range of 38.0-40.6°C. Malaria patients also presented to the clinics early 
in the course of their fever with most patients reporting having symptoms for two or three 
days. Headache was the most common symptom (96.7%), followed by joint pain (66.1%), 
and muscle pain (43.0%). Red eyes and abnormal bleeding were uncommon. None of the 
patients reported skin rashes. 
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Table 3.4 Clinical presentations and laboratory findings of 121 malaria patients. 
Clinical presentations Number of patients (%) Median (range) 
Heart rate (beats/minute) - 95 (60-140) 
Respiratory rate 
(breaths/minute) 
- 24 (20-44) 
Temperature (°C) - 39.0 (38.0-40.6) 
Capillary refill time (second) - 2 (1-2) 
Blood pressure (mmHg)   
• Systolic 116 (95.9) 110 (80-140) 
• Diastolic 116 (95.9) 70 (40-90) 
Fever 121 (100) - 
Headache 117 (96.7) - 
Joint pain 80 (66.1) - 
Muscle pain 52 (43.0) - 
Cough 38 (31.4) - 
Constipation 24 (19.8) - 
Abdominal pain 22 (18.2) - 
Pain behind eyes 19 (15.7) - 
Stiff neck 11 (9.1) - 
Jaundice 10 (8.3) - 
Lymph nodes palpable 8 (6.6) - 
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Table 3.4 Clinical presentations and laboratory findings of 121 malaria patients 
(continued). 
Clinical presentations Number of patients (%) Median (range) 
Red eyes 7 (5.8) - 
Abnormal bleeding 1 (0.8) - 
Skin rash 0 (0) - 
Laboratory findings   
White blood cells (103/µl) - 5.3 (1.4-17.3) 
• Neutrophils (103/µl) - 3.9 (1.0-14.2)a 
• Lymphocytes (103/µl) - 0.6 (0.1-3.0)b 
Haematocrit (%) - 39.1 (21.9-57.4) 
Platelets (103/µl) - 97 (19-485) 
C-reactive protein (mg/l) - 63.0 (7.2-200.1) 
aData available in 118/121 (97.5%) cases, bData available in 120/121 (99.2%) cases 
3.3.3 Comparison of patient demographics, clinical presentations and laboratory 
findings for PART I (non-malaria patients) and PART II (malaria patients) of 
the study 
A comparison of demographics, clinical presentations and laboratory findings 
between the malaria and non-malaria patients are shown in Table 3.5Error! Reference 
source not found.. The median age of patients presenting with malaria was higher than 
those presenting without malaria (23 vs. 18 years, P<0.001) and the proportion of child 
patients was also smaller in the malaria patients (45.2 vs 22.3%, P<0.001). The proportion 
of male patients recruited was higher in the malaria group than the non-malaria group (79.3 
vs. 61.8%, P<0.001), and the proportion of refugee patients was higher in the non-malaria 
group (55.6 vs. 34.7%, P<0.001). The follow-up rate was similar for both malaria and non-
malaria groups.  
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 Malaria patients reported longer duration of fever (three vs. two days, P=0.001) and 
higher presenting temperature (39.0 vs. 38.5°C, P<0.001) than non-malaria patients. The 
non-malaria patients reported significantly higher occurrence of red eyes, skin rash, and 
palpable lymph nodes whereas malaria patients reported higher occurrence of headache, 
jaundice, and joint pain (Table 3.5).  
For the general laboratory findings, the median CRP concentration was much 
higher in patients presenting with malaria compared to non-malaria fever (63.0 vs. 20.7 
mg/l, P<0.001) whereas the platelet count was much lower (97 vs. 214 x103/µl, P<0.001). 
The WBC count and haematocrit were slightly lower in malaria patients compared to the 
non-malaria patients (Table 3.5). 
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Table 3.5 Comparison of patient demographics, clinical presentations and laboratory findings for non-malaria and malaria patients 
(n=1,029). 
 Non-malaria patients (n=908) Malaria patients (n=121) P-value 
Age (years) 18.0 (IQR 12.0-30.0) 23.0 (IQR 18.0-34.0) <0.001 
Children 410/908 (45.2%) 27/121 (22.3%) <0.001 
Sex: male 561/908 (61.8%) 96/121 (79.3%) <0.001 
Location: refugee clinic 506/908 (55.7%) 42/121 (34.7%) <0.001 
Follow-up rate 812/908 (89.4%) 106/121 (87.6%) 0.543 
Days of fever 2 (IQR 2-3) 3 (IQR 2-3) 0.001 
Presenting temperature (°C) 38.5 (IQR 38.2-39.0) 39.0 (IQR 38.4-39.6) <0.001 
Headache 827/908 (91.1%) 117/121 (96.7%) 0.034f 
Stiff neck 60/908 (6.6%) 11/121 (9.1%) 0.311 
Pain behind the eyes 129/908 (14.2%) 19/121 (15.7%) 0.660 
Red eyes 276/908 (30.4%) 7/121 (5.8%) <0.001 
Jaundice 22/908 (2.4%) 10/121 (8.3%) 0.001 
Muscle pain 392/908 (43.2%) 52/121 (43.0%) 0.967 
Joint pain 507/908 (55.8%) 80/121 (66.1%) 0.032 
Cough 366/908 (40.3%) 38/121 (31.4%) 0.060 
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Table 3.5 Comparison of patient demographics, clinical presentations and laboratory findings for non-malaria and malaria patients 
(n=1,029) (continued). 
 Non-malaria patients (n=908) Malaria patients (n=121) P-value 
Constipation 160/908 (17.6%) 24/121 (19.8%) 0.551 
Abdominal pain 197/908 (21.7%) 22/121 (18.2%) 0.375 
Abnormal bleeding 9/908 (1.0%) 1/121 (0.8%) 1.000f 
Skin rash 32/908 (3.5%) 0/121 (0%) 0.026f 
Lymph nodes palpable 237/908 (26.1%) 8/121 (6.6%) <0.001 
White blood cell (103/µl) 7.1 (IQR 5.2-10.0)a 5.3 (IQR 4.1-6.8) <0.001 
• Neutrophils (103/µl) 5.2 (IQR 3.5-7.7)b 3.9 (IQR 3.0-5.0)d <0.001 
• Lymphocytes (103/µl) 0.9 (IQR 0.6-1.4)c 0.6 (IQR 0.5-0.9)e <0.001 
Haematocrit (%) 40.2 (IQR 37.2-43.4)a 39.1 (IQR 35.9-42.6) 0.015 
Platelets (103/µl) 214.0 (IQR 167.0-268.0)a 97.0 (IQR 68.0-129.0) <0.001 
C-reactive protein (mg/l) 20.7 (IQR 8.0-58.5)a 63.0 (IQR 34.0-96.0) <0.001 
aData available in 907/908 (99.9%) cases, bData available in 904/908 (99.6%) cases, cData available in 905/908 (99.7%) cases, dData available in 118/121 
(97.5%) cases, eData available in 120/121 (99.2%) cases, fFisher’s exact test 
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3.4 Discussion 
This study was a two-year exploration of the causes of non-malaria fever and a year 
exploration of co-infection with malaria fever in patients presenting to SMRU clinics on 
the Thailand-Myanmar border. The overall proportion of patient recruitment was similar 
between migrant and refugee populations with a high follow-up rate. Patients presented to 
SMRU clinics early in the course of their illness with the median duration of fever of two 
days (IQR 2-3) for non-malaria patients and three days (IQR 2-3) for malaria patients. The 
difference in the time of presentation to the clinics was not statistically significant between 
refugee and migrant populations for both patient groups. CRP concentration and platelet 
count were clearly different between the malaria and non-malaria patients. The median 
CRP concentration was much higher in malaria patients compared to non-malaria patients. 
This could be due to viral infections in the non-malaria patient group [268]. 
Thrombocytopenia is known to be a common haematological presentation associated with 
acute malaria infection [269, 270]. This study also revealed that the platelet count was 
much lower in the malaria patients compared to non-malaria patients. Several clinical 
presentations and laboratory findings were significantly different between malaria and 
non-malaria patients. Further analyses of those relating to the diagnosis of infections will 
be described in the following chapter. 
 There were some differences in the patient demographics between malaria and 
non-malaria patient groups. The number of patients recruited from the refugee clinic was 
slightly higher than those from migrant clinics for the non-malaria patients (55.7 vs. 
44.3%) whereas the number of patients recruited from migrant clinics was almost two 
times higher than those from the refugee clinic in the malaria patients (65.3 vs. 34.1). This 
reflects the recruitment strategy for malaria patients, which was to recruit, every week, the 
first eligible patient from each site (Mae La, Wang Pha and Mawker Thai) i.e. one refugee 
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and two migrant patients. The slightly higher numbers of refugees recruited with non-
malaria fever compared with migrants is likely to be multi-factorial influenced by distance 
from clinic and higher incidence rates of malaria in locations inhabited by migrants [252]. 
It should also be noted that SMRU is well known for malaria research and treatment, and 
therefore when patients have fever, but they do not think that they have malaria, they are 
more likely to go to other non-SMRU clinics. 
There were more male than female patients in both non-malaria (61.8% male) and 
malaria (79.3% male) groups. The proportion of males was higher for malaria patients 
compared to non-malaria patients (P<0.001), however, the proportion was not significantly 
different between migrants and refugees for both groups. Migrants were significantly older 
than refugees for both malaria and non-malaria patients (P=0.006 and 0.022, respectively). 
The proportion of children was significantly larger in refugees (P=0.034) for malaria 
patients, however, it was not statistically different for non-malaria patients. This may be 
because the older male migrants work more in the field and when they are sick they come 
to the clinics on the way to work. Therefore, they are more likely to seek health care than 
young children, whereas the young child refugees are living in the camp closer to the 
clinic. The follow-up rates were similarly high for both groups, which could be explained 
by the excellent community participation in SMRU research and a reminder system to 
follow-up patients was also in place i.e. a study follow-up card was given at enrolment or 
calls were made prior to appointment. Further analyses of demographic data relating to the 
diagnosis of infections will also be described in the following chapter. 
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4 Causes of acute undifferentiated febrile illness on the 
Thailand-Myanmar border 
4.1 Introduction and aims 
Acute undifferentiated febrile illness (AUFI) is common in SE Asia. Identifying the 
causative agents of AUFI is difficult using either clinical presentations or laboratory 
testing because the common causes of AUFI have non-specific symptoms, and resources 
do not exist to allow comprehensive laboratory interrogation of clinical specimens. With a 
substantial decrease of malaria in SE Asia, the need for understanding the other causes of 
AUFI has increased. The aims of this study were to: 
1. Estimate the occurrence of common non-malaria causes of AUFI, including 
dengue, leptospirosis, rickettsial infections (focusing on scrub typhus and murine typhus), 
and other invasive bacterial infections in the SMRU clinic populations (migrants and 
refugees) and improve understanding of these infections in the population to assist the 
development of the treatment algorithms and patient management of non-malaria fever 
cases.  
2. Assess the impact of dual infection with malaria: 
a. Quantify and detect sub-microscopic malaria infections in febrile patients 
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4.2 Materials and Methods 
4.2.1 Patients and methods 
 All recruited patients from the study: 908 non-malaria febrile patients (PART I) 
and 121 malaria patients (PART II) were included in the analysis. Diagnosis was based on 
the results of gold standard diagnostic tests. These included serological assays for 
diagnosis of dengue/JE, murine typhus, and scrub typhus, and blood culture for other 
bacterial infections. 
 Patients with available paired acute and convalescent serum specimens were tested 
using serological assays. Detection of IgM/IgG antibodies against dengue virus and JE 
virus by ELISAs (AFRIMS) was used to determine dengue and JE virus infection status 
[70, 258]. ELISA and IFA (MORU) were used to detect IgM antibodies against O. 
tsutsugamushi and R. typhi for diagnosis of scrub typhus and murine typhus [207, 263]. 
Blood cultures from all patients at enrolment were used to determine other causes of 
invasive bacterial infections. The qPCR targeting the 16S rRNA gene was used to 
investigate leptospirosis from all acute plasma specimens since the serological gold 
standard test, MAT, was not available at the time of the study [147, 149, 150]. The 
diagnostic tests described above were considered to be reference diagnostic tests for the 
final diagnosis. All diagnoses in this study refer to acute infections. 
 In addition to the malaria microscopy (malaria smear) and RDT (SD BIOLINE 
Malaria Antigen P.f/ Pan POCT, Standard Diagnositcs, Inc.) that were used to screen 
febrile patients in the clinics at the enrolment visit, the highly sensitive qPCR targeting 18S 
rRNA gene specific for Plasmodium species [241, 249] was performed to detect sub-
microscopic malaria infection from all non-malaria febrile patients using acute packed red 
cell specimens. For specimens that were positive by 18S rRNA qPCR assay, the malaria 
parasite species were identified using microsatellite nested-PCR assays specific to P. 
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falciparum (microsatellite marker PFPK2) and P. vivax (microsatellite marker 3.502) [266, 
267]. Specimens were reported as indeterminate species when there was no amplification 
obtained in the nested-PCR assays or insufficient DNA to perform the assays.  
  A CBC and CRP measurement were performed on all acute blood specimens. The 
details of all laboratory methods and their interpretations are described in the Materials and 
Methods chapter, section 2.9. 
4.2.2 Data analysis 
 The data were analysed using STATA/SE 10.1 (StataCorp LP) and the graphs were 
created using STATA/SE 10.1 (StataCorp LP), Microsoft Excel 2010 (Microsoft), and 
GraphPad Prism 7.02 (GraphPad Software Inc., CA, USA). Numeric data were described 
by medians and interquartile ranges (IQR) or means and confidence intervals (CI), as 
appropriate. Demographics, clinical presentations and general laboratory findings were 
described for cases and non-cases of each diagnosis (dengue, leptospirosis, murine typhus 
and scrub typhus). Variables including demographics, clinical presentations, and general 
laboratory findings were assessed (Table 4.1), using univariate logistic regression, to 
determine whether they were associated with the final diagnosis of dengue, leptospirosis, 
murine typhus or scrub typhus. 
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Table 4.1 Variables tested for univariate logistic regression.  
Variables 
Age (year) Days of joint pain 
Sex: male Cough 
Location: refugee clinic Days of cough 
Presenting temperature (°C) Constipation 
Days of fever Days of constipation 
Headache Abdominal pain 
Days of headache Days of abdominal pain 
Stiff neck Abnormal bleeding 
Days of Stiff neck Days of abnormal bleeding 
Pain behind the eyes Skin rash 
Days of pain behind the eyes Days of skin rash 
Red eyes Lymph node palpable 
Days of red eyes White blood cell (103/µl) 
Jaundice Neutrophils (103/µl) 
Days of jaundice Lymphocytes (103/µl) 
Muscle pain Haematocrit (%) 
Days of muscle pain Platelets (103/µl) 
Joint pain C-reactive protein (mg/l) 
 
 Variables that were significant in the univariate logistic regression were selected to 
be considered in the multivariable (multivariate) logistic regression analysis to discover 
demographics, clinical presentations and laboratory findings that were independently 
associated with each disease (i.e. to adjust or control for confounding of the variables). A 
95% CI for the odds ratio (OR) was reported. All tests were performed at 5% significance 
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level. A stepwise regression technique was used to select variables that were independently 
associated with each diagnosis. The probability of entry was set at 0.05 and the probability 
of removal was set at 0.055 [271]. Stepwise multivariate logistic regression was performed 
on all variables that were significant from univariate logistic regression, except WBC 
differentials. If the total WBC count was significant in the multivariate model, then it was 
considered further by expanding the WBC count into differentials to see which were 
having more impact. Non-parametric continuous variables were compared using the 
Wilcoxon rank-sum (Mann Whitney U) test or Kruskal-Wallis equality of population rank 
test, as appropriate. Proportions of malaria qPCR positive specimens were compared 
between groups using two-sample test of proportions (prtest). Geometric means were 
compared using t-test or ANOVA as appropriate. The geometric means of sub-microscopic 
malaria parasitaemia by qPCR were compared between groups using logistic regression of 
log data, followed by ANOVA or pairwise comparison, as appropriate. The tests were 
considered statistically significant with P-value less than 0.05. 
4.3 Results: non-malaria febrile patients (PART I) 
4.3.1 Diagnosis of non-malaria causes of fever 
 A total of 908 non-malaria patients were enrolled into the study between March 
2011 and February 2013. Diagnoses of these febrile patients were based on the results of 
the reference diagnostic tests and are shown in Figure 4.1. The figure demonstrates the 
number of patients and percentage for each diagnosis. Dengue was the most common 
cause of fever in this cohort accounting for 15.9% (144/908) of the patients, followed by 
6.0% (54/908) with leptospirosis, 6.0% (54/908) with murine typhus, 3.2% (29/908) with 
scrub typhus, 1.5% (14/908) co-infection of leptospirosis and scrub typhus, 1.2% (11/908) 
with significant bacterial infections (Table 4.2), 0.7% (6/908) with JE, and 0.1% (1/908) 
co-infection with Streptococcus pneumoniae bacteraemia and scrub typhus. The causes of 
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fever remained unknown in 65.5% (595/908) of the patients. The overall co-infection rate 
in this study was found to be 1.7% (15/908) of the patients.  
 
Figure 4.1 Diagnosis of 908 non-malaria febrile patients based on the results of the 
reference diagnostic tests. 
Patients with invasive bacterial infections were determined according to the blood 
culture results. Blood culture was performed according to the SMRU blood culture SOP 
(MBL-2-B). Staphylococcus sp. (coagulase negative), diphtheroids, or Bacillus sp. were 
regarded as likely contaminants. The significance of all other organisms grown were 
discussed between the clinical microbiologist and the clinician. Of the 908 patients tested, 
only 1.3% (12/908) were positive for significant pathogens, in which Escherichia coli was 
the most common (0.6%, 5/908), followed by Salmonella Typhi (0.2%, 2/908) and one 
patient of each organism (0.1%) including Enterococcus sp., Moraxella catarrhalis, 
Salmonella Paratyphi A, Salmonella sp., and Streptococcus pneumoniae (Table 4.2). Of 
these patients with bacterial infections, one patient had concomitant Streptococcus 
pneumoniae bacteraemia and scrub typhus. 
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Table 4.2 Blood culture results detailing significant organisms. 
Organisms Number of patient (%) 
No growth at five days 828 (91.2) 
Contaminantsa 68 (7.5) 
Escherichia coli 5 (0.6) 
Salmonella Typhi 2 (0.2) 
Enterococcus sp. 1 (0.1) 
Moraxella catarrhalis 1 (0.1) 
Salmonella Paratyphi A 1 (0.1) 
Salmonella sp. 1 (0.1) 
Streptococcus pneumoniaeb 1 (0.1) 
Total 908 (100.0) 
a53 patients with growth of Staphylococcus sp. (coagulase negative), nine patients with 
Bacillus sp., four patients with diphtheroids, one patient with Pseudomonas oryzihabitans, 
and one patient with Streptococcus sp. (alpha haemolytic); bco-infection with scrub typhus 
4.3.2 Occurrence of non-malaria causes of fever in the clinic populations (migrants 
and refugees). 
 The proportions of patients from migrant and refugee clinics by laboratory 
confirmed diagnosis are shown in Figure 4.2. The numbers of diagnoses are low when 
stratified by migrant and refugee clinic populations and were too small to perform useful 
statistical analysis. However, the overall result showed that the proportion of confirmed 
diagnoses was higher in the patients from the refugee clinic than in migrant clinics. The 
proportion of patients with dengue, leptospirosis and murine typhus were much higher in 
refugees than migrants (23.5 vs. 6.2, 7.9 vs. 3.5, and 7.5 vs. 4.0%, respectively). Both 
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refugees and migrants reported similar proportions of scrub typhus (3.4 vs. 3.0%), invasive 
bacterial infections (1.2 vs. 1.2%), JE (0.8 vs. 0.5%), and concomitant leptospirosis and 
scrub typhus (1.4 vs. 1.7%). Only one case of concomitant S. pneumoniae bacteraemia and 
scrub typhus was reported from the migrants. Hence, the proportion of patients with 
unknown diagnosis was higher in the migrants compared to refugees (79.6 vs. 54.3%).  
Only one patient died (0.1%). A 35 year-old man presented to the clinic in Mae La 
refugee camp with fever of 38.0°C after one day onset of fever, headache, red-eyes, muscle 
pain and joint pain. He was diagnosed with unknown fever at the time of presentation. The 
empiric treatment was paracetamol (500mg/tablet) 1¾ tablets, four times daily for five 
days. Four days later, he presented to the SMRU clinic again with septic shock and fever. 
He was hospitalised and was given an intravenous normal saline bolus, ceftriaxone 
intravenous one gram, and oxygen 10 litres/minute by facemask. He was referred urgently 
to the Première Urgence-Aide Médicale Internationale (PU-AMI) clinic in Mae La refugee 
camp. Despite this treatment, he died the next morning. Blood culture for samples 
collected at presentation and the second visit were both negative. No diagnosis of the 
causative agent of fever was made at the time, but subsequently, the acute specimens were 
tested by all reference laboratory tests (see section 4.2.1) and found positive for 
leptospirosis by qPCR tested on acute frozen plasma specimen. 
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Figure 4.2 Proportion of patients from migrant and refugee clinics by laboratory 
confirmed diagnosis.  
4.3.2.1 Age distribution of dengue, leptospirosis, murine typhus and scrub typhus 
patients 
 Age distributions of patients with laboratory confirmed diagnosis of dengue, 
leptospirosis, murine typhus and scrub typhus are shown in Figure 4.3. Patients with 
dengue and leptospirosis diagnosis were younger and mostly reported in patients aged 
between five and 20 years, whereas patients with murine typhus and scrub typhus were 
reported consistently in almost all age groups. 
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Figure 4.3 Age distribution of patients with laboratory confirmed diagnosis of 
dengue, leptospirosis, murine typhus and scrub typhus. 
4.3.3 Seasonality of dengue, leptospirosis, murine typhus and scrub typhus 
 The seasonality of dengue, leptospirosis, murine typhus, and scrub typhus by 
month over the study period of two years (March 2011-March 2013) is shown in Figure 
4.4. A small number of dengue cases were reported during 2011, then there was an 
outbreak of dengue in 2012, peaking between May and July. Leptospirosis cases were 
reported mostly during the rainy season between July and October, whereas murine typhus 
and scrub typhus cases were found throughout the year. There was no clear evidence of 
seasonality for murine typhus and scrub typhus in this study. 
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Figure 4.4 The seasonality of dengue, leptospirosis, murine typhus and scrub 
typhus between March 2011 and March 2013 by month.  
(Rainfall data provided by Mae Sot Meteorology Station, Thai Meteorological 
Department). 
4.3.4 Demographics, clinical presentations and laboratory findings of dengue and 
non-dengue cases 
 Of the 908 non-malaria febrile patients, 812 patients had available paired acute and 
convalescent serum specimens tested and were included in the current analysis. Of these, 
17.7% (144/812) of patients were given a laboratory confirmed diagnosis of acute dengue 
infection by paired serology using the AFRIMS IgM/IgG ELISA assays. Of the 144 
confirmed cases, 8.3% (12/144) had acute primary infection and 91.7% (132/144) had 
acute secondary infection. 
 The distribution of demographics, clinical presentations and laboratory findings for 
dengue and non-dengue cases are shown in Table 4.3. Of the 144 patients with confirmed 
dengue, 45.1% (65/144) were male. The median age of the patients was 15 years (IQR 12-
21). The majority of patients, 82.6% (119/144) were from Mae La refugee camp. The 
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median duration of fever at presentation was two days (IQR 2-3) and the median 
temperature was 38.7°C (IQR 38.3-39.1). Headache was the most frequent symptom 
reported (92.4%), followed by red eyes (56.3%), joint pain (55.6%), palpable lymph nodes 
(47.2%), and muscle pain (43.1 %). Jaundice and abnormal bleeding were uncommon 
(0.7%). 
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Table 4.3 Demographics, clinical presentations and laboratory findings of dengue and non-dengue cases (n=812). 
 Dengue cases (n=144) Non-dengue cases (n=668) 
Demographics Number of 
patients (%) 
Median (IQR) Median days at 
presentation (IQR) 
Number of 
patients (%) 
Median (IQR) Median days at 
presentation (IQR) 
Age (years) - 15.0 (12.0-21.0) - - 19.0 (11.5-31.0) - 
Sex: male 65 (45.1) - - 430 (64.4) - - 
Children 84 (58.3) - - 300 (44.9) - - 
Location: refugee clinic 119 (82.6) - - 362 (54.2) - - 
Clinical presentations       
Heart rate (beats/minute) - 99 (88-105) - - 96 (84-104) - 
Respiratory rate 
(breaths/minute) 
- 26 (24-28) - - 26 (24-28) - 
Presenting temperature (°C) - 38.7 (38.3-39.1) - - 38.5 (38.2-39.0) - 
Capillary refill time (second) - 2 (2-2)a - - 2 (1-2)b - 
Blood pressure (mmHg)       
• Systolic 138 (95.8) 100 (90-110) - 589 (88.2) 100 (100-110) - 
• Diastolic 138 (95.8) 70 (60-70) - 589 (88.2) 70 (60-70) - 
Fever 144 (100) - 2 (2-3) 668 (100) - 2 (2-3) 
Headache 133 (92.4) - 2 (2-3) 605 (90.6) - 2 (2-3) 
Red eyes 81 (56.3) - 2 (1-2) 175 (26.2) - 2 (1-2) 
Joint pain 80 (55.6) - 2 (2-3) 368 (55.1) - 2 (2-3) 
Lymph nodes palpable 68 (47.2) - N/A 155 (23.2) - N/A 
Muscle pain 62 (43.1) - 2 (2-3) 287 (43.0) - 2 (2-3) 
Constipation 30 (20.8) - 2 (2-3) 110 (16.5) - 2 (2-3) 
Pain behind eyes 23 (16.0) - 2 (2-3) 99 (14.8) - 2 (2-3) 
Abdominal pain 22 (15.3) - 2.5 (2-3) 157 (23.5) - 2 (2-3) 
Cough 21 (14.6) - 3 (2-4) 310 (46.4) - 2 (2-3) 
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Table 4.3 Demographics, clinical presentations and laboratory findings of dengue and non-dengue cases (n=812) (continued). 
 Dengue cases (n=144) Non-dengue cases (n=668) 
Clinical presentations Number of 
patients (%) 
Median (IQR) Median days at 
presentation (IQR) 
Number of 
patients (%) 
Median (IQR) Median days at 
presentation (IQR) 
Skin rash 14 (9.7) - 2 (1-3) 17 (2.5) - 3 (1-7) 
• Petechiae 13 (92.9) - 2 (1-3) 6 (35.3) - 1 (1-1) 
• Eschar 1 (7.1) - 3 (3-3) 1 (5.9) - 7 (7-7) 
• Maculopapular rash - - - 1 (5.9) - 4 (4-4) 
• Other types of rash - - - 9 (52.9) - 7 (3-7) 
Stiff neck 12 (8.3) - 2 (2-3) 40 (6.0) - 3 (2-3) 
Jaundice 1 (0.7) - 2 (2-2) 17 (2.5) - 2 (2-4) 
Abnormal bleeding 1 (0.7) - 4 (4-4) 8 (1.2) - 1 (1-2.5) 
Laboratory findings       
White blood cells (103/µl) - 4.7 (3.6-6.1) - - 7.9 (6.0-10.8)c - 
• Neutrophils (103/µl) - 3.1 (2.5-4.7) - - 5.7 (4.1-8.3)d - 
• Lymphocytes (103/µl) - 0.6 (0.4-0.7) - - 1.0 (0.7-1.4)b - 
Haematocrit (%) - 40.1 (37.9-43.2) - - 40.0 (37.1-43.2)c - 
Platelets (103/µl) - 195.5 (155.5-241) - - 222 (170-272)c - 
C-reactive protein (mg/l) - 9.0 (7.9-18.0) - - 25.3 (9.0-72.0)c - 
aData available in 143/144 (99.3%) cases, bData available in 666/668 (99.7%) cases, cData available in 667/668 (99.9%) cases, dData available in 665/668 
(99.6%) cases. Non-dengue cases included 54 murine typhus cases, 44 leptospirosis cases, 29 scrub typhus cases, 14 concomitant leptospirosis and scrub 
typhus cases, 10 invasive bacterial infection cases, 6 JE cases, one concomitant Streptocuccos pneumoniae bacteraemia and scrub typhus case, and 510 
unknown fever cases 
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4.3.5 Clinical characteristics associated with acute dengue infection 
Acute dengue infection was significantly associated with age (negative affect), red 
eyes, cough (negative affect), skin rash, neutrophils (negative affect), lymphocytes 
(negative affect), and CRP concentration (negative affect) when both univariate and 
multivariate logistic regression analysis were performed (Table 4.4 and Table 4.5). Sex, 
location, presenting temperature, days of having red eyes, days of having a cough, 
abdominal pain, palpable lymph node, and platelets were significantly associated with 
acute dengue infection when univariate analysis was performed, but did not remain 
significantly associated when multivariate logistic regression was performed (Table 4.4).  
The risk of being diagnosed with acute dengue infection was increased by 3.1 times 
if a patient had a skin rash and 2.8 times risk if they had red eyes. The risk of being 
diagnosed with acute dengue infection was reduced by 97.5% for every one unit (103/µl) 
increment of lymphocytes, 85.4% if the patient had a cough, 38.9% for every one unit 
(103/µl) increment of neutrophils, 7.4% for every one year of age increment, and 2.6% for 
every one unit (mg/l) increment of CRP concentration.  
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Table 4.4 Univariate logistic regression results for acute dengue infection. 
Variables Odds Ratio (OR) 95% CI P-value 
Age (years) 0.971 0.955-0.987 <0.001 
Sex: male 0.455 0.316-0.656 <0.001 
Location: refugee clinic 4.024 2.547-6.356 <0.001 
Presenting temperature (°C) 1.416 1.032-1.942 0.031 
Days of fever 0.886 0.760-1.034 0.124 
Headache 1.259 0.646-2.454 0.499 
Days of headache 0.973 0.852-1.112 0.691 
Stiff neck 1.427 0.729-2.794 0.299 
Days of stiff neck 1.043 0.831-1.310 0.715 
Pain behind the eyes 1.092 0.666-1.791 0.726 
Days of pain behind the eyes 1.000 0.842-1.187 0.997 
Red eyes 3.622 2.498-5.253 <0.001 
Days of red eyes 1.442 1.251-1.661 <0.001 
Jaundice 0.268 0.035-2.029 0.202 
Days of jaundice 0.572 0.228-1.438 0.235 
Muscle pain 1.004 0.698-1.444 0.984 
Days of muscle pain 0.972 0.864-1.092 0.630 
Joint pain 1.019 0.709-1.464 0.919 
Days of joint pain 0.966 0.862-1.083 0.558 
Cough 0.197 0.121-0.321 <0.001 
Days of cough 0.606 0.503-0.729 <0.001 
Constipation 1.335 0.850-2.096 0.209 
Days of constipation 1.063 0.904-1.249 0.461 
Abdominal pain 0.587 0.360-0.956 0.032 
Days of abdominal pain 0.849 0.713-1.011 0.066 
Abnormal bleeding 0.577 0.072-4.649 0.605 
Days of abnormal bleeding 1.043 0.584-1.864 0.887 
Skin rash 4.124 1.983-8.575 <0.001 
Days of skin rash 1.032 0.920-1.157 0.594 
Lymph nodes palpable 2.961 2.039-4.301 <0.001 
White blood cells (103/µl) 0.632 0.574-0.695 <0.001 
Neutrophils (103/µl) 0.635 0.572-0.704 <0.001 
Lymphocytes (103/µl) 0.029 0.014-0.059 <0.001 
Haematocrit (%) 1.002 0.970-1.036 0.895 
Platelets (103/µl) 0.996 0.994-0.998 0.001 
C-reactive protein (mg/l) 0.969 0.959-0.979 <0.001 
CI= confidence intervals 
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Table 4.5 Multivariate logistic regression results for acute dengue infection. 
Variables Odds Ratio (OR) 95% CI P-value 
Age (years) 0.926 0.901-0.953 <0.001 
Red eyes 2.805 1.649-4.771 <0.001 
Cough 0.146 0.079-0.271 <0.001 
Skin rash 3.139 1.153-8.548 0.025 
Neutrophils (103/µl) 0.611 0.525-0.712 <0.001 
Lymphocytes (103/µl) 0.025 0.010-0.062 <0.001 
C-reactive protein (mg/l) 0.974 0.963-0.985 <0.001 
CI= confidence intervals 
4.3.6 Demographics, clinical presentations and laboratory findings of leptospirosis 
and non-leptospirosis cases 
Acute plasma specimens from all 908 non-malaria febrile patients were tested by 
16S rRNA qPCR assay for the detection of Leptospira DNA. The Leptospira DNA was 
detected in 68 patients. Of these, 14 patients had concomitant leptospirosis and scrub 
typhus infection proven by the16S rRNA qPCR assay for leptospirosis and the reference 
paired serology for scrub typhus. 
Of the 908 patients tested, 894 patients were included in the current analysis (14 
patients with leptospirosis and scrub typhus co-infection were excluded). Of these, 54 
patients were defined as having acute leptospirosis infection and 840 as not having acute 
leptospirosis infection. 
The patient demographics, clinical presentations and laboratory findings for 
leptospirosis and non-leptospirosis cases are shown in Table 4.6. Of the 54 patients with 
confirmed leptospirosis, 79.6% (43/54) were male. The median age of the patients was 15 
years (IQR 11-23), and 74.1% (40/54) of the patients were from Mae La refugee camp. 
The follow-up rate was 81.5% (44/54). The median duration of fever at presentation was 
two days (IQR 2-3) and the median temperature was 38.8°C (IQR 38.3-39.2). Headache 
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was the most frequent symptom reported (94.4%), followed by muscle pain (55.6%), joint 
pain (53.7%), and red eyes (42.6%). Abnormal bleeding was uncommon (1.9%) and no 
patient reported having skin rash. 
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Table 4.6 Demographics, clinical presentations and laboratory findings of leptospirosis and non-leptospirosis cases (n=894, excluded 14 
patients with leptospirosis and scrub typhus co-infection). 
 Leptospirosis cases (n=54) Non-leptospirosis cases (n=840) 
Demographics Number of 
patients (%) 
Median (IQR) Median days at 
presentation (IQR) 
Number of 
patients (%) 
Median (IQR) Median days at 
presentation (IQR) 
Age (years) - 15 (11-23) - - 19 (12-30) - 
Sex: male 43 (79.6) - - 507 (60.4) - - 
Children 30 (55.6) - - 374 (44.5) - - 
Location: refugee clinic 40 (74.1) - - 459 (54.6) - - 
Clinical presentations       
Heart rate (beats/minute) - 99 (90-108) - - 96 (84-104) - 
Respiratory rate 
(breaths/minute) 
- 26 (24-29) - - 26 (24-28) - 
Presenting temperature (°C) - 38.8 (38.3-39.2) - - 38.5 (38.2-39.0) - 
Capillary refill time (second) - 2 (2-2)a - - 2 (1-2)b - 
Blood pressure (mmHg)       
• Systolic 51 (94.4) 100 (90-110) - 750 (89.3) 100 (100-110) - 
• Diastolic 51 (94.4) 70 (60-70) - 750 (89.3) 70 (60-70) - 
Fever 54 (100) - 2 (2-3) 840 (100) - 2 (2-3) 
Headache 51 (94.4) - 2 (2-3) 762 (90.7) - 2 (2-3) 
Muscle pain 30 (55.6) - 2 (2-3) 353 (42.0) - 2 (2-3) 
Joint pain 29 (53.7) - 2 (2-3) 466 (55.5) - 2 (2-3) 
Red eyes 23 (42.6) - 2 (1-2) 248 (29.5) - 2 (1-2) 
Abdominal pain 14 (25.9) - 2 (1-2) 181 (21.5) - 2 (2-3) 
Cough 13 (24.1) - 2 (2-3) 351 (41.8) - 2 (2-3) 
Lymph nodes palpable 13 (24.1) - N/A 221 (26.3) - N/A 
Constipation 8 (14.8) - 2 (2-2.5) 149 (17.7) - 2 (2-3) 
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Table 4.6 Demographics, clinical presentations and laboratory findings of leptospirosis and non-leptospirosis cases (n=894, excluded 14 
patients with leptospirosis and scrub typhus co-infection) (continued). 
 Leptospirosis cases (n=54) Non-leptospirosis cases (n=840) 
Clinical presentations Number of 
patients (%) 
Median (IQR) Median days at 
presentation (IQR) 
Number of 
patients (%) 
Median (IQR) Median days at 
presentation (IQR) 
Pain behind eyes 7 (13.0) - 2 (2-3) 121 (14.4) - 2 (2-3) 
Stiff neck 5 (9.3) - 2 (2-2) 53 (6.3) - 3 (2-3) 
Jaundice 4 (7.4) - 3 (2.5-3.5) 18 (2.1) - 2 (1-4) 
Abnormal bleeding 1 (1.9) - 1 (1-1) 8 (1.0) - 1.5 (1-3.5) 
Skin rash 0 (0) - - 32 (3.8) - 2 (1-4) 
• Petechiae - - - 19 (59.4) - 2 (1-2) 
• Eschar - - - 2 (6.3) - 5 (3-7) 
• Maculopapular rash - - - 1 (3.1) - 4 (4-4) 
• Other types of rash - - - 10 (31.3) - 6 (2-7) 
Laboratory findings       
White blood cells (103/µl) - 9.5 (7.5-13.0) - - 6.9 (5.1-9.7)c - 
• Neutrophils (103/µl) - 8.2 (6.2-10.6)a - - 5.0 (3.4-7.3)b - 
• Lymphocytes (103/µl) - 0.7 (0.5-0.9) a - -  1.0 (0.6-1.4)d - 
Haematocrit (%) - 39.3 (37.1-42.0) - - 40.2 (37.2-43.4)c - 
Platelets (103/µl) - 196 (145-230) - - 216 (168-270)c - 
C-reactive protein (mg/l) - 106.5 (40.8-166.5) - - 18.0 (7.9-50.6)c - 
aData available in 53/54 (98.1%) cases, bData available in 837/840 (99.6%) cases, cData available in 839/840 (99.9%) cases, dData available in 838/840 
(99.8%) cases. Non-leptospirosis cases included 144 dengue cases, 54 murine typhus cases, 29 scrub typhus cases, 11 invasive bacterial infection cases, 6 
JE cases, one concomitant Streptococcus pneumoniae bacteraemia and scrub typhus case, and 595 unknown fever cases  
 
 200 
4.3.7 Clinical characteristics associated with acute leptospirosis infection 
Acute leptospirosis infection was significantly associated with age (negative 
effect), location, days of fever (negative effect), days of cough (negative effect), platelets 
(negative effect), and CRP concentration when both univariate and multivariate logistic 
regression analysis were performed (Table 4.7 and Table 4.8). Sex, presenting temperature, 
red eyes, jaundice and days of jaundice, cough, WBC and its differential counts including 
neutrophils and lymphocytes were significantly associated with acute leptospirosis 
infection when univariate analysis was performed, but did not remain significantly 
associated when multivariate logistic regression was performed (Table 4.7). 
The risk of being diagnosed with acute leptospirosis infection was increased by 2.7 
times if a patient was from the refugee clinic and 2.2% for every one unit (mg/ml) 
increment of CRP concentration. The risk of being diagnosed with acute leptospirosis 
infection was reduced by 40.6% for every one day increment of duration of fever, 33.9% 
for every one day increment of duration of cough, 6.9% for every one year of age 
increment, and 0.8% for every one unit (103/µl) increment of platelets.  
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Table 4.7 Univariate logistic regression results for acute leptospirosis infection. 
Variables Odds Ratio (OR) 95% CI  P-value 
Age (years) 0.972 0.948-0.997 0.030 
Sex: male 2.568 1.305-5.050 0.006 
Location: refugee clinic 2.372 1.271-4.425 0.007 
Presenting temperature (°C) 1.620 1.019-2.575 0.041 
Days of fever 0.734 0.558-0.964 0.026 
Headache 1.740 0.531-5.706 0.361 
Days of headache 0.885 0.716-1.095 0.261 
Stiff neck 1.515 0.579-3.962 0.397 
Days of stiff neck 0.999 0.710-1.406 0.996 
Pain behind the eyes 0.885 0.391-2.004 0.769 
Days of pain behind the eyes 0.960 0.721-1.277 0.778 
Red eyes 1.771 1.012-3.099 0.045 
Days of red eyes 1.152 0.930-1.429 0.196 
Jaundice 3.653 1.192-11.201 0.023 
Days of jaundice 1.422 1.031-1.960 0.032 
Muscle pain 1.725 0.991-3.001 0.054 
Days of muscle pain 1.038 0.876-1.231 0.665 
Joint pain 0.931 0.536-1.617 0.800 
Days of joint pain 0.885 0.733-1.070 0.208 
Cough 0.442 0.233-0.837 0.012 
Days of cough 0.739 0.577-0.946 0.016 
Constipation 0.807 0.373-1.744 0.585 
Days of constipation 0.895 0.674-1.189 0.444 
Abdominal pain 1.274 0.678-2.394 0.451 
Days of abdominal pain 0.911 0.715-1.160 0.449 
Abnormal bleeding 1.962 0.241-15.981 0.529 
Days of abnormal bleeding 0.943 0.311-2.861 0.917 
Lymph nodes 0.888 0.467-1.688 0.717 
White blood cells (103/µl) 1.118 1.062-1.176 <0.001 
Neutrophils (103/µl) 1.171 1.104-1.241 <0.001 
Lymphocytes (103/µl) 0.157 0.071-0.344 <0.001 
Haematocrit (%) 0.967 0.918-1.019 0.208 
Platelets (103/µl) 0.994 0.990-0.998 0.002 
C-reactive protein (mg/l) 1.016 1.012-1.020 <0.001 
CI= confidence intervals 
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Table 4.8 Multivariate logistic regression results for acute leptospirosis infection. 
Variables Odds Ratio (OR) 95% CI P-value 
Age (years) 0.931 0.898-0.964 <0.001 
Location: refugee clinic 2.686 1.312-5.497 0.007 
Days of fever 0.594 0.430-0.819 0.002 
Days of cough 0.661 0.492-0.888 0.006 
Platelets (103/µl) 0.992 0.987-0.997 0.001 
C-reactive protein (mg/l) 1.022 1.017-1.027 <0.001 
CI= confidence intervals 
4.3.8 Demographics, clinical presentations and laboratory findings of murine 
typhus and non-murine typhus cases 
 Acute and convalescent serum specimens were available for 811 patients and were 
included in the current analysis. Of these, 54 patients were given laboratory confirmed 
diagnosis of acute murine typhus infection by paired serology using the MORU in-house 
IgM ELISA and IFA assays. 
 The distribution of patient demographics, clinical presentations and laboratory 
findings for murine typhus and non-murine typhus cases are described in Table 4.9. Of the 
54 patients with confirmed murine typhus, 55.6% (30/54) were male. The median age of 
the patients was 26 years (IQR 18-37), and 70.4% (38/54) of the patients were from Mae 
La refugee camp. The median duration of fever at presentation was three days (IQR 2-4) 
and the median temperature was 38.5°C (IQR 38.2-39.8). Headache was the most frequent 
symptom reported (90.7%), followed by joint pain (64.8%) and muscle pain (55.6%). No 
patients reported having abnormal bleeding and skin rash. 
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Table 4.9 Demographics, clinical presentations and laboratory findings of murine typhus and non-murine typhus cases (n=811). 
 Murine typhus cases (n=54) Non-murine typhus cases (n=757) 
Demographics Number of 
patients (%) 
Median (IQR) Median days at 
presentation (IQR) 
Number of 
patients (%) 
Median (IQR) Median days at 
presentation (IQR) 
Age (years) - 26 (18-37) - - 18.0 (11.0-28.0) - 
Sex: male 30 (55.6) - - 464 (61.3) - - 
Children 10 (18.5) - - 373 (49.3) - - 
Location: refugee clinic 38 (70.4) - - 443 (58.5) - - 
Clinical presentations       
Heart rate (beats/minute) - 89 (80-100) - - 96 (84-104) - 
Respiratory rate 
(breaths/minute) 
- 24 (22-26) - - 26 (24-28) - 
Presenting temperature (°C) - 38.5 (38.2-38.9) - - 38.5 (38.2-39.0) - 
Capillary refill time (second) - 2 (1-2) - - 2 (2-2)a - 
Blood pressure (mmHg)       
• Systolic 53 (98.1) 110 (100-110) - 674 (89.0) 100 (90-110) - 
• Diastolic 53 (98.1) 70 (70-80) - 674 (89.0) 70 (60-70) - 
Fever 54 (100) - 3 (2-4) 757 (100) - 2 (2-3) 
Headache 49 (90.7) - 3 (2-4) 688 (90.9) - 2 (2-3) 
Joint pain 35 (64.8) - 3 (2-5) 413 (54.6) - 2 (2-3) 
Muscle pain 30 (55.6) - 3 (2-4) 319 (42.1) - 2 (2-3) 
Cough 20 (37.0) - 3 (2-4.5) 311 (41.1) - 2 (2-3) 
Lymph nodes palpable 14 (25.9) - N/A 209 (27.6) - N/A 
Pain behind eyes 12 (22.2) - 3 (2-4.5) 110 (14.5) - 2 (2-3) 
Red eyes 12 (22.2) - 2 (1-4) 244 (32.2) - 2 (1-2) 
Abdominal pain 11 (20.4) - 2 (2-4) 168 (22.2) - 2 (2-3) 
Constipation 7 (13.0) - 2 (2-4) 133 (17.6) - 2 (2-3) 
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Table 4.9 Demographics, clinical presentations and laboratory findings of murine typhus and non-murine typhus cases (n=811) (continued). 
 Murine typhus cases (n=54) Non-murine typhus cases (n=757) 
Clinical presentations Number of 
patients (%) 
Median (IQR) Median days at 
presentation (IQR) 
Number of 
patients (%) 
Median (IQR) Median days at 
presentation (IQR) 
Jaundice 3 (5.6) - 2 (1-6) 15 (2.0) - 2 (2-4) 
Stiff neck 2 (3.7) - 5 (3-7) 50 (6.6) - 2 (2-3) 
Abnormal bleeding 0 (0) - - 9 (1.2) - 1 (1-3) 
Skin rash 0 (0) - - 31 (4.1) - 2 (1-4) 
• Petechiae - - - 19 (61.3) - 2 (1-2) 
• Eschar - - - 2 (6.5) - 5 (3-7) 
• Maculopapular rash - - - 1 (3.2) - 4 (4-4) 
• Other types of rash - - - 9 (29.0) - 7 (3-7) 
Laboratory findings       
White blood cells (103/µl) - 5.6 (3.9-7.5) - - 7.4 (5.3-10.3)b - 
• Neutrophils (103/µl) - 3.8 (2.6-5.2) - - 5.5 (3.7-7.8)a - 
• Lymphocytes (103/µl) - 1.0 (0.7-1.6) - - 0.9 (0.6-1.3)c - 
Haematocrit (%) - 39.3 (36.9-43.0) - - 40.1 (37.3-43.2)b - 
Platelets (103/µl) - 196.5 (150-238) - - 217 (170-269)b - 
C-reactive protein (mg/l) - 24.7 (15.0-48.6) - - 19.0 (7.9-61.0)b - 
aData available in 754/757 (99.6%) cases, bData available in 756/757 (99.9%) cases, cData available in 755/757 (99.7%) cases 
Non-murine typhus cases included 144 dengue cases, 44 leptospirosis cases, 29 scrub typhus cases, 14 concomitant leptospirosis and scrub typhus cases, 
10 invasive bacterial infection cases, 6 JE cases, one concomitant S. pneumoniae bacteraemia and scrub typhus case, and 509 unknown fever cases 
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4.3.9 Clinical characteristics associated with acute murine typhus infection 
Acute murine typhus infection was significantly associated with age, days of fever 
and neutrophils (negative effect) when both univariate and multivariate logistic regression 
analysis were performed (Table 4.10 and Table 4.11). Days of headache, days of pain 
behind the eyes, days of muscle pain, and days of joint pain were significantly associated 
with acute murine typhus infection when univariate analysis was performed, but did not 
remain significantly associated when multivariate logistic regression was performed (Table 
4.10). The risk of being diagnosed with acute murine typhus was increased by 1.5 times for 
every one day increment of duration of fever and 3.4% for every one year of age 
increment. The risk of being diagnosed with acute murine typhus infection was reduced by 
17.8% for every one unit (103/µl) increment of neutrophils. 
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Table 4.10 Univariate logistic regression results for acute murine typhus infection. 
Variables Odds Ratio (OR) 95% CI P-value 
Age (years) 1.035 1.015-1.056 <0.001 
Sex: male 0.789 0.453-1.377 0.405 
Location: refugee clinic 1.683 0.922-3.073 0.090 
Presenting temperature (°C) 0.837 0.493-1.420 0.509 
Days of fever 1.550 1.304-1.844 <0.001 
Headache 0.983 0.379-2.549 0.972 
Days of headache 1.388 1.168-1.649 <0.001 
Stiff neck 0.544 0.129-2.298 0.407 
Days of stiff neck 1.021 0.716-1.455 0.909 
Pain behind the eyes 1.681 0.858-3.293 0.130 
Days of pain behind the eyes 1.275 1.051-1.548 0.014 
Red eyes 0.601 0.311-1.162 0.130 
Days of red eyes 0.969 0.751-1.249 0.805 
Jaundice 2.910 0.816-10.378 0.100 
Days of jaundice 1.329 0.928-1.905 0.121 
Muscle pain 1.716 0.984-2.992 0.057 
Days of muscle pain 1.302 1.124-1.507 <0.001 
Joint pain 1.534 0.862-2.731 0.146 
Days of joint pain 1.302 1.122-1.512 0.001 
Cough 0.844 0.477-1.493 0.559 
Days of cough 1.078 0.915-1.270 0.369 
Constipation 0.699 0.309-1.580 0.389 
Days of constipation 0.929 0.698-1.235 0.610 
Abdominal pain 0.897 0.453-1.778 0.755 
Days of abdominal pain 1.027 0.835-1.265 0.799 
Lymph nodes 0.918 0.489-1.722 0.789 
White blood cells (103/µl) 0.847 0.768-0.933 0.001 
Neutrophils (103/µl) 0.792 0.700-0.895 <0.001 
Lymphocytes (103/µl) 1.226 0.851-1.765 0.274 
Haematocrit (%) 0.978 0.928-1.030 0.402 
Platelets (103/µl) 0.997 0.993-1.000 0.076 
C-reactive protein (mg/l) 0.997 0.992-1.003 0.367 
CI= confidence intervals 
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Table 4.11 Multivariate logistic regression results for acute murine typhus 
infection. 
Variables Odds Ratio (OR) 95% CI P-value 
Age (years) 1.034 1.012-1.056 0.002 
Days of fever 1.552 1.291-1.866 <0.001 
Neutrophils (103/µl) 0.822 0.730-0.926 0.001 
CI= confidence intervals 
4.3.10 Demographics, clinical presentations and laboratory findings of scrub typhus 
and non-scrub typhus cases 
 Acute and convalescent serum specimens were available for 811 patients and were 
tested by paired serology using the MORU in-house IgM ELISA and IFA assays for scrub 
typhus. Of these, 44 patients were given a laboratory confirmed diagnosis of acute scrub 
typhus infection. Of the 44 patients, 14 patients had concomitant leptospirosis and scrub 
typhus infection proven by the 16S rRNA qPCR assay (leptospirosis) and the reference 
paired serology (scrub typhus). One patient had concomitant S. pneumoniae bacteraemia 
and scrub typhus proven by blood culture (S. pneumoniae) and the reference paired 
serology (scrub typhus).  
Of the 811 patients, 796 patients were included in the current analysis (excluding 
15 patients with co-infections). Of these, 29 patients were defined as having acute scrub 
typhus infection and 767 patients as not having acute scrub typhus infection. 
 The distribution of patient demographics, clinical presentations and laboratory 
findings for scrub typhus and non-scrub typhus cases are shown in Table 4.12. Of the 29 
patients with confirmed scrub typhus, 69.0% (20/29) were male. The median aged of the 
patients was 18 years (IQR 12-33), and 58.6% (17/29) were from the refugee clinic. The 
median duration of fever at presentation was three days (IQR 2-4) and the median 
temperature was 38.5°C (IQR 38.3-39.0). Headache was the most frequent symptom 
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reported (89.7%), followed by joint pain (51.7%). No patients reported having abnormal 
bleeding and skin rash. 
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Table 4.12 Demographics, clinical presentations and laboratory findings of scrub typhus and non-scrub typhus cases (n=796, excluded 15 
patients with co-infections). 
 Scrub typhus cases (n=29) Non-scrub typhus cases (n=767) 
Demographics Number of 
patients (%) 
Median (IQR) Median days at 
presentation (IQR) 
Number of 
patients (%) 
Median (IQR) Median days at 
presentation (IQR) 
Age (years) - 18 (12-33) - - 18 (12-29) - 
Sex: male 20 (69.0) - - 463 (60.4) - - 
Children 14 (48.3) - - 362 (47.2) - - 
Location: refugee clinic 17 (58.6) - - 457 (59.6) - - 
Clinical presentations       
Heart rate (beats/minute) - 90 (84-104) - - 96 (84-104) - 
Respiratory rate 
(breaths/minute) 
- 28 (24-32) - - 26 (24-28) - 
Presenting temperature (°C) - 38.5 (38.3-39.0) - - 38.5 (38.2-39.0) - 
Capillary refill time (second) - 2 (2-2) - - 2 (1-2)a - 
Blood pressure (mmHg)       
• Systolic 27 (93.1) 100 (90-120) - 686 (89.4) 100 (100-110) - 
• Diastolic 27 (93.1) 70 (60-70) - 686 (89.4) 70 (60-70) - 
Fever 29 (100) - 3 (2-4) 767 (100) -  2 (2-3) 
Headache 26 (89.7) - 2 (2-3) 697 (90.9) - 2 (2-3) 
Joint pain 15 (51.7) - 3 (2-5) 420 (54.8) - 2 (2-3) 
Cough 11 (37.9) - 3 (2-3) 317 (41.3) - 2 (2-3) 
Abdominal pain 11 (37.9) - 2 (2-3) 165 (21.5) - 2 (2-3) 
Muscle pain 10 (34.5) - 3 (3-6) 330 (43.0) - 2 (2-3) 
Red eyes 8 (27.6) - 2 (2-3) 243 (31.7) - 2 (1-2) 
Pain behind eyes 7 (24.1) - 3 (2-5) 114 (14.9) - 2 (2-3) 
Constipation 6 (20.7) - 3 (3-3) 130 (16.9) - 2 (2-3) 
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Table 4.12 Demographics, clinical presentations and laboratory findings of scrub typhus and non-scrub typhus cases (n=796, excluded 15 
patients with co-infections) (continued). 
 Scrub typhus cases (n=29) Non-scrub typhus cases (n=767) 
Demographics Number of 
patients (%) 
Median (IQR) Median days at 
presentation (IQR) 
Number of 
patients (%) 
Median (IQR) Median days at 
presentation (IQR) 
Lymph nodes palpable 6 (20.7) - N/A 214 (27.9) - N/A 
Stiff neck 4 (13.8) - 2.5 (1.5-3.0) 46 (6.0) - 3 (2-3) 
Jaundice 2 (6.9) - 4.5 (2-7) 16 (2.1) - 2 (2-3.5) 
Abnormal bleeding 0 (0) - - 9 (1.2) - 1 (1-3) 
Skin rash 0 (0) - - 31 (4.0) - 2 (1-4) 
• Petechiae - - - 19 (61.3) - 2 (1-2) 
• Eschar - - - 2 (6.5) - 5 (3-7) 
• Maculopapular rash - - - 1 (3.2) - 4 (4-4) 
• Other types of rash - - - 9 (29.0) - 7 (3-7) 
Laboratory findings       
White blood cell (103/µl) - 7.5 (5.7-8.8) - - 7.1 (5.2-9.9)b - 
• Neutrophils (103/µl) - 5.6 (3.9-7.0) - - 5.2 (3.5-7.6)c - 
• Lymphocytes (103/µl) - 0.8 (0.7-1.0) - - 0.9 (0.6-1.4)a - 
Haematocrit (%) - 39.1(37.2-43.6) - - 40.1 (37.3-43.1)b - 
Platelet (103/µl) - 18 (130-254) - - 216 (170-266)b - 
C-reactive protein (mg/l) - 55.2 (40.7-114.0) - - 18.0 (7.9-55.0)b - 
aData available in 765/767 (99.7%) cases, bData available in 766/767 (99.9%) cases, cData available in 741/767 (96.6%) cases 
Non-scrub typhus cases included 144 dengue cases, 54 murine typhus cases, 44 leptospirosis cases, 10 invasive bacterial infection cases, 6 JE cases, and 
509 unknown fever cases  
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4.3.11 Clinical characteristics associated with acute scrub typhus infection 
Acute scrub typhus infection was significantly associated with days of fever and 
CRP concentration when both univariate and multivariate logistic regression analysis were 
performed (Table 4.13 and Table 4.14). Days of pain behind the eyes, days of jaundice, 
and abdominal pain were significantly associated with acute scrub typhus infection when 
univariate analysis was performed, but did not remain significantly associated when 
multivariate logistic regression was performed (Table 4.13). The risk of being diagnosed 
with acute scrub typhus infection was increased by 1.3 times for every one day increment 
of duration of fever and 0.8% for every one unit (mg/l) increment of CRP concentration. 
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Table 4.13 Univariate logistic regression results for acute scrub typhus infection. 
Variables Odds Ratio (OR) 95% CI P-value 
Age (years) 1.005 0.977-1.034 0.723 
Sex: male 1.459 0.656-3.247 0.355 
Location: refugee clinic 0.961 0.453-2.040 0.917 
Presenting temperature (°C) 1.471 0.780-2.774 0.233 
Days of fever 1.395 1.107-1.758 0.005 
Headache 0.870 0.257-2.948 0.824 
Days of headache 1.201 0.944-1.528 0.136 
Stiff neck 2.508 0.838-7.509 0.100 
Days of stiff neck 1.194 0.836-1.705 0.330 
Pain behind the eyes 1.823 0.761-4.365 0.178 
Days of pain behind the eyes 1.305 1.026-1.659 0.030 
Red eyes 0.821 0.359-1.881 0.642 
Days of red eyes 1.116 0.829-1.501 0.470 
Jaundice 3.477 0.761-15.885 0.108 
Days of jaundice 1.541 1.072-2.214 0.019 
Muscle pain 0.697 0.320-1.519 0.364 
Days of muscle pain 1.097 0.884-1.361 0.402 
Joint pain 0.885 0.421-1.859 0.747 
Days of joint pain 1.079 0.868-1.341 0.493 
Cough 0.868 0.404-1.862 0.715 
Days of cough 1.063 0.852-1.326 0.590 
Constipation 1.278 0.510-3.201 0.600 
Days of constipation 1.128 0.833-1.526 0.436 
Abdominal pain 2.230 1.033-4.814 0.041 
Days of abdominal pain 1.125 0.886-1.428 0.335 
Lymph nodes 0.674 0.271-1.678 0.397 
White blood cells (103/µl) 0.968 0.877-1.068 0.517 
Neutrophils (103/µl) 0.988 0.888-1.100 0.831 
Lymphocytes (103/µl) 0.640 0.318-1.289 0.211 
Haematocrit (%) 0.991 0.925-1.062 0.806 
Platelets (103/µl) 0.996 0.991-1.001 0.089 
C-reactive protein (mg/l) 1.010 1.004-1.015 0.001 
CI= confidence intervals 
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Table 4.14 Multivariate logistic regression results for acute scrub typhus infection. 
Variables Odds Ratio (OR) 95% CI P-value 
Days of fever 1.284 1.006-1.638 0.044 
C-reactive protein (mg/l) 1.008 1.003-1.014 0.004 
CI= confidence intervals 
4.3.12 The usefulness of non-specific infection markers in the laboratory confirmed 
cases of dengue, leptospirosis, murine typhus and scrub typhus 
 The CBC and CRP tests were performed on acute specimens from all patients as 
part of the routine laboratory testing at SMRU, haematology laboratory. A total of 281 
patients with laboratory confirmed diagnosis of dengue (n=144), leptospirosis (n=54), 
murine typhus (n=54) and scrub typhus (n=29) were included in the current analysis. The 
results of CRP test and CBC test including WBC count, haematocrit, and platelet count 
were compared between the four disease groups. The distribution of WBC count, 
haematocrit, platelet counts, and CRP concentration by diagnosis groups are shown in 
Figure 4.5.  
 The distribution of WBC count was significantly different between the disease 
groups (P=0.0001). Patients with dengue diagnosis had significantly lower WBC counts 
(4.7 x103/µl [IQR 3.6-6.1]) compared to patients with the other bacterial diagnoses 
(leptospirosis, P<0.0001; murine typhus, P=0.0178; and scrub typhus, P<0.0001). 
Amongst those patients with bacterial diagnoses, patients with leptospirosis had 
significantly higher WBC counts (9.5 x103/µl [IQR 7.5-13.0]) compared to patients with 
scrub typhus (7.5 x103/µl [IQR 5.7-8.8]) and murine typhus (5.6 x103/µl [IQR 3.9-7.5]) 
(P=0.0010, and P<0.0001, respectively). Patients with murine typhus had significantly 
lower WBC counts compared to patients with scrub typhus (P=0.0216), however, most of 
these patients had WBC counts within the normal range (Figure 4.5). For WBC 
differentials, neutrophils and lymphocytes were significantly different between the disease 
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groups, however, most patients had neutrophils within the normal ranges. Patients with 
confirmed dengue, leptospirosis and scrub typhus had lymphocytes lower than the normal 
range (Figure 4.5). 
  CRP concentrations above 5.0 mg/l were reported in all patients. The differences 
in CRP concentrations between the four diagnosis groups were statistically significant 
(P=0.0001). Patients with dengue had significantly lower concentration of CRP (9.0 mg/l 
[IQR 7.9-18.0]) compared to the other bacterial diagnoses (P<0.0001 for all). Amongst 
patients with bacterial diagnoses, patients with leptospirosis had higher concentration of 
CRP (106.5 mg/l [IQR 40.8-166.5]), followed by scrub typhus (55.2 mg/l [IQR 40.7-
114.0]) and murine typhus (24.7 mg/l [IQR 15.0-48.6]) (Figure 4.5). Patients with murine 
typhus had significantly lower CRP concentration than those of patients with leptospirosis 
(P<0.0001) and scrub typhus (P=0.0004). There was no difference in the CRP 
concentration between patients with leptospirosis and scrub typhus (P=0.0915). 
 The differences in the distributions of haematocrit, and platelet count were not 
statistically significant between the four diagnosis groups and most of them were within 
the normal ranges (Figure 4.5). 
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Figure 4.5 Distributions of white blood cells, neutrophils, lymphocytes, haematocrit, platelets and C-reactive protein concentration by 
diagnosis. 
Dashed lines show normal ranges (source: Haematology laboratory, SMRU [272-274] and SMRU CBC data). 
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4.3.13 Sub-microscopic malaria 
 Acute packed RBC specimens were available from all 908 patients who were 
reported malaria negative by microscopy or RDT (Standard Diagnostics) at the clinics. Of 
these, malaria DNA was detected in 17.5% (159/908) of the patients by the 18S rRNA 
qPCR assay specific for Plasmodium sp. The number of patients with the qPCR positive by 
reference diagnosis is shown in Table 4.15. 
Table 4.15 Number of patients with malaria qPCR positive by diagnosis. 
Diagnosis Number of patients (%) 
No diagnosis 115 (72.3) 
Dengue 18 (11.3) 
Leptospirosis 11 (6.9) 
Scrub typhus 7 (4.4) 
Invasive bacterial infection 3 (1.9) 
Leptospirosis/ Scrub typhus 2 (1.3) 
Murine typhus  2 (1.3) 
S. pneumoniae bacteraemia/ Scrub typhus 1 (0.6) 
Total 159 (100) 
 
 The proportion of malaria qPCR positive in patients that were malaria smear/RDT 
negative by each diagnosis group is shown in Figure 4.6. Overall, the malaria DNA was 
detected in almost all diagnosis groups. The proportion of malaria qPCR positive 
specimens in patients with unknown diagnosis was 19.3% (115/595; 95% CI 16.2-22.7) 
compared to 14.1% (44/313; CI 10.4-18.4) of patients with a diagnosis (P=0.047). 
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Amongst the patients with known diagnosis, a positive malaria qPCR was reported in 
12.5% (18/144; 95% CI 7.6-19.0) of patients with dengue, 20.4% (11/54; 95% CI 10.6-
33.5) of patients with leptospirosis, 24.1% (7/29; 95% CI 10.3-43.5) of patients with scrub 
typhus, 27.3.0% (3/11; 95% CI 6.0-61.0) of patients with invasive bacterial infection, 3.7% 
(2/54; 95% CI 0.5-12.7) of patients with murine typhus, 14.3% (2/14; 95% CI 1.8-42.8) of 
patients with concomitant leptospirosis and scrub typhus, and 100% (1/1) of the 
concomitant S. pneumoniae bacteraemia and scrub typhus. No positive qPCR was reported 
in patients with JE. Based on these findings it is possible that some of the undiagnosed 
patients had malaria infections. To investigate this further, sub-microscopic malaria in 
these groups is analysed in relation to parasitaemia. 
  
Figure 4.6  Proportion of malaria qPCR positive in patients with smear/RDT 
negative by diagnosis. 
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 The lower limit of detection (LoD) of this qPCR assay was 12.8 parasites/ml of 
blood (equivalent to 0.64 parasite/µl of DNA extract). The geometric mean of parasitaemia 
for 159 positive patients was 281.1 parasites/ml of blood (95% CI 172.5-458.2). 
 The distribution of malaria parasite density from the 159 qPCR positive patients 
was analysed by diagnosis groups (Figure 4.7). Overall, the malaria parasitaemia was very 
low in all diagnosis groups. The geometric mean of malaria parasitaemia in patients with 
no diagnosis was 312.5 parasites/ml of blood (95% CI 172.0-567.8), a geometric mean of 
253.6 parasites/ml (95% CI 75.9-847.5) was reported from patients with dengue, 161.7 
parasites/ml (95% CI 15.6-1,670.0) was reported from patients with leptospirosis and 83.4 
parasites/ml (95% CI 2.3-3,027.4) was reported from patients with scrub typhus. There 
were three patients with reported high parasitaemia (>106 parasites/ml of blood) in the no 
diagnosis group. The numbers of qPCR positive patients were small in the other diagnosis 
groups (Figure 4.7). The malaria parasite densities were not statistically different between 
groups (P=0.9013) and were also not significantly different comparing between patients 
with diagnosis and the no diagnosis group (P=0.4905) (Figure 4.8).  
 It is generally accepted that a parasitaemia of more than 5,000-10,000 parasites/ml 
of blood or 100,000 parasites/ml of blood should be detected by microscopy or RDT, 
respectively. However, the methods used to calculate parasitaemia by microscopy, RDT, 
and qPCR are different and therefore it is difficult to compare.  For example, the qPCR 
detects 18S rRNA gene of parasite genome where there are 5-8 copies/parasite genome. 
The detection and calculation are accounted for all stages of malaria parasite including 
merozoite where it is not accounted in the microscopic examination. 
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Figure 4.7 Malaria parasitaemia by qPCR assay in patients with smear/RDT 
negative by diagnosis groups. 
 
Figure 4.8 Malaria parasitaemia by qPCR assay in patients with smear/RDT 
negative comparing diagnosis and no diagnosis groups. 
P=0.9013 
P=0.4905 
  220 
 DNA extracts from all positive malaria qPCR were tested further for the P. 
falciparum and P. vivax speciation by microsatellite nested-PCR assays. The analytical 
LoD of the assays were five parasites/µl and one parasite/µl for P. falciparum and P. vivax, 
respectively. The distribution of malaria qPCR positive patients by species and diagnosis is 
shown in Table 4.16. Of the 159 patients, 97 patients were found to have P. vivax, 22 
patients had P. falciparum, and 16 patients were detected with mixed P. falciparum and P. 
vivax. It was not possible to specify species in the other 24 patients (negative for both P. 
falciparum and P. vivax). The geometric mean parasitaemia for P. vivax, P. falciparum, 
and mixed P. falciparum and P. vivax by qPCR were 383.8 parasites/ml of blood (95% CI 
223.7-658.3), 344.2 parasites/ml (95% CI 85.8-1,380.7), and 2,514.9 parasites/ml (95% CI 
205.8-30,728.9), respectively. The geometric mean for indeterminate species was 15.4 
parasites/ml (95% CI 10.1-23.4).   
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Table 4.16 Distribution of malaria qPCR positive patients by species and diagnosis. 
Number of patients Diagnosis 
P. falciparum P. vivax P. falciparum and P. vivax Indeterminate species Total 
No diagnosis 13 74 12 16 115 
Dengue 4 10 1 3 18 
Leptospirosis 2 5 2 2 11 
Scrub typhus 0 4 1 2 7 
Invasive bacterial infection 2 1 0 0 3 
Murine typhus 1 1 0 0 2 
Leptospirosis/ Scrub typhus 0 2 0 0 2 
S. pneumoniae bacteraemia/ Scrub typhus 0 0 0 1 1 
Total 22 97 16 24 159 
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4.4 Results: Malaria patients (PART II) 
4.4.1 Malaria and co-infections 
 In the malaria part of the study (PART II), 121 malaria patients were recruited. All 
patients were tested and found positive either by malaria smear and/or RDT (SD BIOLINE 
Malaria Antigen P.f/ Pan POCT, Standard Diagnostics, Inc.) at the enrolment visit (see 
section 2.5). Of specimens tested by smear only, smear and RDT and RDT only 81, 21 and 
19 patients were positive respectively. The distribution of malaria species by smear/RDT at 
enrolment is shown in Table 4.17. Of the 121 malaria patients, 61 patients were positive 
for P. falciparum, 48 patients were positive for P. vivax, and 12 patients were positive for 
Plasmodium other species. The RDT had three lines: “C” (control), “Pan” (Plasmodium 
species; P. vivax, P. malariae and P. ovale), and “P.f” (P. falciparum) lines. According to 
the SMRU SOP (RT5), a positive “Pan” line was recorded as positive for P. vivax. 
Therefore, in this part of the study, 61 patients were reported having P. falciparum and 60 
patients were reported having P. vivax.  
Table 4.17 Distribution of malaria species by smear/RDT at enrolment. 
 P. falciparum P. vivax Plasmodium other species Total 
Smear 54 48 NA 102 
RDT* 7 NA 12 19 
Total 61 48 12 121 
*RDT had three lines: control, P. falciparum, and Plasmodium other species (P. vivax, P. 
malariae and P. ovale) 
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 Malaria parasite density was reported from 102 patients who tested positive by 
smear. The parasite counts were calculated to parasitaemia per ml of blood [(number of 
parasites counted against 500 WBC x number of WBC/µl of blood x 1,000)/500, or 
(number of parasites counted against 1,000 RBC x number of RBC/µl of blood x 
1,000)/1,000]. The geometric mean parasitaemia was 7.2 x106 parasites/ml of blood (95% 
CI 4.9 x106-1.1 x107). The malaria qPCR was also performed in this patient group. The 
geometric mean of 2.2 x106 parasites/ml of blood (95% CI 1.3 x106-3.6 x106) was reported 
by qPCR. 
 In addition, the qPCR assay was able to quantify the parasitaemia from 18/19 
patients who were positive by the RDT. The geometric mean parasitaemia of the 18 
patients was 3.0 x106 parasites/ml of blood (95% CI 1.7 x106-5.2 x106). 
 From a total of 121 malaria patients, 120 patients were positive by qPCR. The 
overall parasite density quantified by qPCR was reported with the geometric mean of 2.3 
x106 parasites/ml of blood (95% CI 1.5 x106-3.5 x106). This parasite density of the malaria 
patients (smear/RDT positive) was significantly higher than those of the sub-microscopic 
malaria patients (2.3 x106 vs. 281.1 parasites/ml of blood, P<0.0001). The qPCR negative 
patient tested positive by RDT only at the enrolment visit in the clinic. 
 The malaria species were also identified by the microsatellite nested-PCR assay 
from all 121 malaria patients (120 patients were qPCR positive). Of these, 55 (45.5%) 
patients were found to have P. vivax, 43 (35.5%) patients had P. falciparum, 20 (16.5%) 
patients were found to have mixed P. falciparum and P. vivax, and the species was 
undetermined for three (2.5%) patients (Table 4.18).  
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Table 4.18 Distribution of malaria species by microsatellite nested-PCR and 
smear/RDT. 
 Species by smear/RDT 
Species by microsatellite nested-PCR P. falciparum P. vivax Total (%) 
P. falciparum 43 0 43 (35.5) 
P. falciparum and P. vivax 16 4 20 (16.5) 
P. vivax 0 55 55 (45.5) 
Indeterminate species 2 1 3 (2.5) 
Total 61 60 121 (100) 
 
 All reference laboratory diagnostic tests for the diagnosis of the other non-malaria 
causes of fever were performed in the malaria patients as well as in the non-malaria 
patients to assess the impact of dual infections with malaria. Co-infection was found in 
8.3% (10/121) of the malaria patients, of which nine (7.4%) patients had laboratory 
confirmed diagnosis of acute scrub typhus infection and one (0.8%) patient had acute 
dengue infection (Figure 4.9). 
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Figure 4.9 Dual infections with 121 malaria febrile patients based on the results of 
the reference diagnostic tests. 
4.5 Discussion 
 This study aimed to determine the optimal testing strategies and evaluate several 
diagnostic methodologies for acute diagnosis of the common non-malaria causes of AUFI, 
including dengue, leptospirosis and rickettsial infections, in a rural and limited resources 
setting of SE Asia. Although it was not designed as an epidemiological study, the outcome 
diagnosis from the enrolled patients allowed the study to determine the causes of non-
malaria AUFI and estimate the occurrence of these infections in the SMRU clinic 
populations where the definitive diagnosis of non-malaria AUFI is generally not given and 
the data are scarce. The causes of non-malaria AUFI were determined for patients 
presenting to the SMRU clinics over two years of the study period between 2011 and 2013. 
Dengue, leptospirosis, murine typhus and scrub typhus were found to be common causes 
of AUFI in this study. This finding has confirmed the results from previously published 
papers that these infections were common in this region [6, 7, 11, 12, 19, 21]. Using the 
reference laboratory diagnostic tests, 34.6% of the patients had a confirmed diagnosis in 
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this study. Previous studies reported rates of laboratory confirmation of diagnoses of 
between 33.2% and 73.3% (Table 1.1). However, it is difficult to directly compare such 
studies because of differences in study design and laboratory tests used. There were 
differences in time of the study, enrolment criteria (history of fever, temperature cut-off 
points and measurement methods), populations (age, gender, pregnancy status, 
geographical areas) and very importantly, the laboratory methods and diagnostic 
algorithms. 
Dengue was the most common diagnosis found in the present study, accounting for 
15.9% of patients. This was similar to the result of a previous fever study conducted in the 
same area in 2008, in which dengue was the major cause of AUFI. However, the 
proportion of dengue cases in that study was almost three times higher than the present 
study (44.4%) [16]. A study of the causes of febrile illness conducted on the Thailand-
Myanmar border between 1999-2002 found that malaria was the most common cause of 
fever. However, once malaria was excluded, leptospirosis (17.5%) became the most 
common cause of fever rather than dengue [11]. Leptospirosis and murine typhus were the 
second most common diagnoses in the present study, accounting for 6.0% of the patients. 
This was followed by scrub typhus, the third most common, accounting for 3.2%. These 
studies contrast with the report from an epidemiological study conducted in 10 
community-based hospitals in Thailand during 1991-1993 [6]. This study found that scrub 
typhus was the most common cause of AUFI, accounting for 7.5% and leptospirosis was 
reported in only 1.1% of cases. Conversely, another study of AUFI conducted between 
2001 and 2002 in five hospitals in Thailand reported that leptospirosis was the major cause 
of adult AUFI accounting for 36.9% of cases, and scrub typhus was the second most 
common cause found (16.0%) [7]. The number of scrub typhus cases being lower than that 
of murine typhus in the present study is not consistent with the evidence that scrub typhus 
is a more rural disease than murine typhus [12, 170], but it is consistent with the previously 
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published data from SMRU clinics (2004-2006) where a higher number of murine typhus 
cases was reported [10]. Although, there is no data available for murine typhus in the Thai 
national reporting system, there is enough evidence from studies and reports that murine 
typhus is circulating and is common. Scrub typhus and murine typhus coexist in endemic 
regions [6, 7, 170, 188]. This finding emphasised the need to focus more on murine typhus 
in the rural areas. 
The differences between the present study and previous reports may be explained 
by several factors. First, there was variation in the study designs, such as inclusion criteria, 
time of study, geographical areas, age group of patients, pathogens investigated, laboratory 
diagnostic tests and algorithms used to determine the causes of fever. These differences 
need to be taken into account when considering different results. For example, in the study 
of 10 hospitals during 1991-1993 [6], leptospirosis was diagnosed using MAT test that 
included only Leptospira bataviae as an antigen whereas the later study (five hospitals 
during 2001-2002) used a panel of reference strains from 24 representative serogroups as 
the antigen in the MAT test and culture for leptospires was also performed [7]. Only qPCR 
was used to diagnose leptospirosis in the present study. In addition, patients with malaria 
or clinically obvious dengue virus infection were also excluded from the latter study [7]. 
Second, the current study was considerably influenced by an outbreak of dengue in 2012. 
The outbreak also contributed to a very much higher number of patients recruited in the 
second year compared to the first year of recruitment (Figure 3.1 and Figure 4.4). The data 
from national disease surveillance, Thailand, showed that there were peaks in the number 
of dengue cases in 2008, 2010, and 2013 [113]. Although, dengue was the major cause of 
AUFI in the present study, the proportion of cases was much lower than the study in 2008 
[16]. Lastly, there was an outbreak of leptospirosis in Thailand between 1997 and 2002. 
The number of leptospirosis cases reported in Thailand was less than 200 per year prior to 
1996 and was remarkably changed to over 2,000 cases in 1997 with a sudden increase up 
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to 14,285 cases in 2000. The extended outbreak occurred during 1997-2002 with a gradual 
decline to below 6,000 cases per year since [113]. 
Overall co-infections occurred in 1.7% of the non-malaria AUFI patients. 
Concomitant leptospirosis and scrub typhus infections accounted for almost all cases, 
occurring in 1.5% of patients. This co-infection has been reported previously in Thailand 
[7, 11, 275]. Co-infection may be common in areas that are exposed to multiple pathogens 
and share common risk factors. It is possible that the diagnostic tests play an important role 
in diagnosis of co-infection. Despite the development of molecular methods, serology 
assays remain the gold standard diagnostic test and have been widely used. The 
interpretation of serology assays is known to be problematic as antibodies from previous 
infections may persist and cross reactivity is common. Diagnosis of acute infection should 
be based on the rising antibody titres between paired acute and convalescent specimens 
[191]. Diagnostic accuracy of the assays depends on the timing of specimen collection and 
cut-off titres in which the optimal cut-off varies by prevalence of diseases in different 
geographical areas [207]. However, in the present study, molecular method (PCR) was 
used for diagnosis of acute leptospirosis infection from acute plasma specimen and IgM 
antibody detection was used for diagnosis of acute scrub typhus infection from paired 
acute and convalescent serum specimens. False positive scrub typhus results due to cross 
reactivity is a possibility, however, avoided for leptospirosis.  
Despite the reference diagnostic tests used in the present study, the diagnoses for 
65.4% of non-malaria AUFI patients remained unknown highlighting the importance of 
other pathogens in this population. Among these patients, 14.3% had only single acute 
specimen. The convalescent specimen could not be obtained because patients did not 
return for the follow-up visit or the patient died, although, the follow-up rate was very high 
in the current study (89.4%). The lack of convalescent specimens remains a major problem 
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in the serological diagnosis of infectious diseases, since the development of detectable 
antibody levels may take several days to weeks and antibodies are often undetectable in 
acute specimens, particularly when patients seek medical care early in the course of their 
illness. Molecular diagnostic tools such as PCR to detect nucleic acids of pathogens or 
rapid antigen detection on acute specimens are useful in this circumstance. Evaluations of 
such assays have been performed in this study and are described in the next chapters of this 
thesis.  
The patients from the refugee clinic reported a higher proportion of confirmed 
diagnosis cases. Dengue and leptospirosis revealed seasonal variation in this study (Figure 
4.4.). Dengue peaked between May and July, a similar time frame but narrower than the 
epidemiological trend in Thailand that showed a seasonal peak between May and 
September [276]. Leptospirosis peaked in the rainy season between July and October, 
which was also described elsewhere [115]. Cases of murine typhus and scrub typhus 
occurred throughout the study period with no distinguishing seasonal peak. Our results for 
scrub typhus contrasted with other reports where both scrub typhus and leptospirosis 
peaked in rice-growing seasons between July and November [7, 170]. On the other hand, 
murine typhus revealed a consistent result with a study of epidemiology of rickettsioses in 
Thailand, in which murine typhus was evenly diagnosed in all seasons [170]. The 
epidemiology and seasonality data of murine typhus in Thailand are scarce and are not 
well described. It is also not included in the Thai national reporting system [48].  
Dengue, leptospirosis, murine typhus and scrub typhus share non-specific clinical 
presentations. Few clinical features and laboratory findings predict the cause of these 
infections. In the present study, younger age, red eyes, skin rash, cough (negative effect), 
lower neutrophil and lymphocyte counts and lower CRP concentration were independently 
associated with dengue. Leptospirosis was associated with younger age, location: refugee 
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clinic, shorter duration of fever and cough, lower platelet and higher CRP concentration. 
Murine typhus was associated with older age, longer duration of fever, and lower 
neutrophil counts, and scrub typhus was associated with longer duration of fever and 
higher CRP concentration. The results were different to a study of causes of non-malaria 
fever in Laos, which reported only platelet count (≤100,000/µl) was associated with 
dengue. An age of 15 years or younger, vomiting, cough, CRP level (>5 mg/l) were 
associated with leptospirosis. Female sex and hepatomegaly were associated with scrub 
typhus, and the association with murine typhus was not mentioned [12]. Studies in 
Thailand reported that dengue was associated with low platelet and WBC counts [16, 55]. 
The present study did not show that low platelet and WBC counts were associated with 
dengue to the same degree as the previous study in Thailand. That study described low 
platelet (<140,000/mm3) and WBC counts (<5,000/mm3) were strongly associated with 
dengue infection (odds ratio = 26.3 and 8.3, respectively) [55]. There are several 
explanations for this observation. Firstly, in the present study, patients presented early in 
the course of their fever when the reduction of platelets and WBC may not be observed 
[33]. Secondly, the previous study was focused on only dengue and scrub typhus so that 
could narrow down the variation factors in the analysis, whereas dengue cases in the 
present study were compared to non-dengue cases (including all other diagnoses and 
unknown diagnosis). In the current study, platelets were significantly lower in dengue 
compared to non-dengue cases in the univariate analysis but lost significance in the 
multivariate analysis. Eschar is the most important clinical sign that discriminates scrub 
typhus from other infectious diseases, but its presence is not consistent [170, 186, 188]. In 
the present study, an eschar was reported in only two patients. One patient had laboratory 
confirmed diagnosis of acute secondary dengue infection by paired serology (IgM/IgG 
ELISA, and PCR was also positive for DENV-1) and another patient had no diagnosis 
(negative for all available diagnostic tests). No patients with laboratory confirmed scrub 
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typhus had an eschar. This was likely to be due to clinicians not having the time or 
opportunity to examine patients thoroughly. Clinical diagnosis of murine typhus is more 
challenging since no specific clinical finding was reported. This emphasises the need for 
clinically useful rapid bedside diagnostic tests for these diseases.  
The usefulness of non-specific infection markers (i.e. CBC and CRP) were assessed 
in the present study for differential diagnosis of dengue, leptospirosis, murine typhus and 
scrub typhus. Only the CRP concentration and WBC count were significantly different 
between these diseases. Although the WBC, neutrophil and lymphocyte counts showed 
significant differences between diagnosis groups, these differences were mostly within the 
normal ranges (WBC and neutrophil counts) and lower ranges (lymphocyte count). 
Therefore, they were not very useful for the differential diagnosis in this population. 
The CRP result is useful to distinguish between acute viral and bacterial infections 
as confirmed in the present study (Figure 4.5). CRP is an established biomarker of 
bacterial infection and most of our patients presented early in the course of their fever (the 
median of two days), which is in the time of peak secretion of CRP (36-50 hours) [277]. 
Patients with diagnoses of dengue, leptospirosis, murine typhus and scrub typhus had CRP 
levels above 5.0 mg/l, which correlated to the expected normal values (<5.0 mg/l) 
according to the manufacturer’s instructions. Results from the present study are in line 
with a recent large study that measured and compared CRP and procalcitonin levels to 
distinguish viral from bacterial and malarial causes of fever in patients from rural SE Asia. 
A subset of specimens from the present study was included in this publication and the 
results were comparable to specimens from Cambodia and Laos. This study revealed that 
CRP level was elevated in bacterial and malarial infections when compared with viral 
infections [268]. While the CRP level is able to discriminate viral from bacterial infection, 
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the cut-off value of CRP to differentiate between different diseases is uncertain and the 
optimal cut-off has not been established [268, 277]. 
In a malaria low transmission area like SE Asia, the proportion of sub-microscopic 
infections is high compared to the areas of high transmission intensity [238]. In the present 
study, sub-microscopic malaria infection was examined in non-malaria AUFI patients. 
Malaria smear and RDT were applied to rule out malaria patients at enrolment. Using 
sensitive qPCR to detect and quantify sub-microscopic infection, malaria DNA was 
detected in 17.5% of the patients and the parasite density was low with a geometric mean 
of 281.1 parasites/ml of blood. The sub-microscopic malaria infection might not be the 
cause of fever in the present study as the malaria parasitaemia was very low. A previous 
malaria epidemiological study from SMRU in a Karen population reported that the 
estimated pyrogenic parasite density was 1,460 parasites/µl for P. falciparum and 181 
parasites/µl for P. vivax, although, the parasitaemia was determined by microscopy [237]. 
In addition, malaria DNA was detected in patients who already had confirmed diagnoses of 
the other causes of their illness (27.7% [44/159]). Although the majority of the sub-
microscopic malaria infection was found in patients with unknown diagnosis, the overall 
parasite density was low in all diagnosis groups including the unknown diagnosis group. 
There were no differences in the parasite density between these groups (Figure 4.7) nor 
were there when comparing patients with known diagnosis and the no diagnosis group 
(Figure 4.8). There were three patients with unknown diagnosis who had high parasitaemia 
(>106 parasites/ml of blood), in which malaria could be the cause of their fever, however 
the number of patients with high parasitaemia was small and a definitive conclusion could 
not be made. There is no consensus threshold of parasite density for individuals to develop 
fever, although the symptomatic threshold for P. falciparum is known to be higher than for 
P. vivax. The threshold for P. falciparum has been established in malaria-naive host, which 
ranged between 1,900-10,700 parasites/µl, but this threshold is highly variable between 
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individuals. It is also different between different strains of P. falciparum. In endemic areas, 
individuals may not develop fever until the parasite density reaches 5,000-10,000 
parasites/µl [278, 279]. Therefore, the significance of detecting sub-microscopic levels of 
malaria in the present study is unknown and warrants further investigation.  
In the malaria part of the present study (PART II), co-infection with malaria was 
found in 8.3% (10/121) of the patients. Malaria and scrub typhus was the main co-infection 
accounting for 7.4% (9/121) and only one patient had malaria and dengue co-infection 
(0.8%). This is consistent with the previously published data on causes of fever in 
pregnancy on the Thailand-Myanmar border (SMRU clinics) where malaria and rickettsial 
co-infection was the most common, but with slightly more cases of murine typhus than 
scrub typhus (3 vs. 2 cases, respectively). Co-infection with dengue was also reported in 
one case [10]. Conversely, this differs from the data of another fever study in non-pregnant 
adults on the Thailand-Myanmar border where dual infections were common, and co-
infections of malaria and leptospirosis were the most common [11]. These studies had 
different criteria for patient recruitment, duration of study, diagnostic tests and diagnosis 
algorithms that could impact on the detection of co-infections. The malaria part of the 
current study provided preliminary data for the rate of dual infections. A study that 
includes a larger number of malaria patients is required to confirm this finding. The 
proportions of patients with P. vivax and P. falciparum infections were equal (50% each), 
no mixed infection of different species was found by smear/RDT. Using the PCR method, 
the proportion of patients infected with P. vivax (45.5%) was higher than that of P. 
falciparum (35.5%), and mixed infections of P. falciparum and P. vivax was found in 
16.5% (80% of the mixed infections were diagnosed with P. falciparum by 
microscope/RDT). This is in line with the previous reports in Thailand where P. 
falciparum was the predominant species in Thailand until 1998 when the proportion of P. 
falciparum and P. vivax became equal: P. vivax cases have been more frequent at some 
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points since then [14, 280, 281]. The mixed species infection of malaria is known to be 
common in endemic areas and the detection rate is higher when using PCR rather than 
microscopy. The most common mixed species infection is P. falciparum and P. vivax. The 
other mixed species such as mixed P. falciparum and P. malariae, and mixed P. vivax and 
P. ovale have been reported but rarely [280, 282, 283]. The levels of mixed P. falciparum 
and P. vivax infections recorded in Thailand were 0.3-0.7% of the patients with positive 
smears [281]. Higher levels of this mixed infection have been reported in the West border. 
In fact, malaria in Thailand has been limited to a few border areas, mainly Myanmar and 
Cambodia since 1950s [283]. The high level of mixed infection in the current study was 
confirmed by PCR and is consistent with that recorded from previously published data 
from SMRU [237, 283].  
The PCR was not able to determine the species in three patients (two were P. 
falciparum, and one were P. vivax by microscopy or RDT). The first patient was positive 
only by RDT for P. falciparum. The 18S rRNA qPCR specific for Plasmodium sp. and the 
microsatellite nested-PCR for speciation were negative. Given the higher sensitivity of the 
qPCR compared to the RDT, this patient could have had a false positive RDT result due to 
persistence of HRP-II antigen that can remain detectable for weeks after acute infection. 
Alternatively, it could have been a false negative qPCR result resulting from extraction 
failure or presence of PCR inhibitors [239]. The second patient was positive for P. 
falciparum by microscopy and RDT, and the 18S rRNA qPCR was also positive with the 
parasitemia of 1.3 x106 parasites/ml of blood. The microsatellite nested-PCR was negative 
and there was insufficient specimen to repeat the test. The last patient had smear positive 
for P. vivax and the 18S rRNA qPCR was also positive with the parasitemia of 1.3 x105 
parasites/ml of blood, however the microsatellite nested-PCR was unable to determine the 
species. 
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5 Clinical evaluation of diagnostic tests for early diagnosis of 
acute dengue infection from a single specimen 
5.1 Introduction and aims                             
 Dengue is an important and widespread mosquito-borne viral disease in humans, 
with a recent estimate of 390 million dengue infections globally each year, of which 96 
million present as symptomatic infections [38]. It causes a wide range of clinical 
manifestations from mild to severe and life threatening. Clinical management of patients is 
based on supportive treatment since specific anti-viral treatment for dengue infection is not 
yet available [34]. Diagnosis of acute dengue infection using clinical symptoms and signs 
is difficult, since it is hard to distinguish from other common antibiotic treatable causes of 
acute febrile illness such as leptospirosis [284] and scrub typhus [55]. Confirmation of 
diagnosis usually relies on laboratory testing. Hence, a rapid and reliable laboratory 
diagnostic test is required during the acute phase of infection for early diagnosis of dengue 
virus infection to assist patient management. 
 Laboratory confirmation of dengue virus infection may involve a combination of 
multiple diagnostic tests to achieve accurate diagnosis. Diagnostic accuracy of the tests 
depends largely on timing of infection and timing of specimen collection. Currently, timely 
and clinically useful laboratory diagnosis of dengue virus infection relies on nucleic acid 
detection (rRT-PCR or RT-PCR) or NS1 antigen detection (ELISA or ICT) from a single 
specimen during the acute phase of infection [16, 33]. After the acute phase of infection, 
serology becomes more useful. Serological assays such as IgM and IgG antibody detection 
by ELISAs are widely used to confirm dengue infection and discriminate between primary 
and secondary infections [70]. These serological assays usually require paired acute and 
convalescent serum specimens to determine differences between IgM and IgG antibody 
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levels, causing a delay in diagnosis and therefore, is useful for confirmation of infection 
rather than early diagnosis that facilitates clinical management of patients. 
 In this chapter, the performance characteristics of two diagnostic tests (NS1 antigen 
and IgM antibody ICT, and one-step SYBR Green based rRT-PCR) were evaluated 
prospectively for the detection of dengue virus infection during the acute phase of infection 
from patients presenting with acute undifferentiated febrile illness in a rural SE Asian 
clinical setting. The aims were to:  
1. Determine the diagnostic accuracy and clinical value of using a new generation rapid 
diagnostic test (IgM/IgG antibody plus NS1 antigen detection, a combined single ICT) 
to diagnose acute dengue virus infection. 
2. Assess inter-operator variation for the interpretation of the ICT results. 
3. Determine the diagnostic accuracy and clinical value of using a molecular diagnostic 
method (rRT-PCR) to diagnose acute dengue virus infection. 
4. Evaluate the molecular diagnostic assay (rRT-PCR) as an alternative to the ICT, and as 
a possible replacement for the current serological methods as gold standard test for the 
confirmation of acute dengue virus infection. 
5. Assess the impact of malaria infection (sub-microscopic) on the performance 
characteristics of the diagnostic tests under evaluation. 
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5.2 Materials and Methods 
5.2.1 Patients and methods 
The study was conducted between March 2011 and March 2013 in three SMRU 
outpatient clinics (OPD) on the Thailand-Myanmar border, as described previously in 
chapter 2. Briefly, any patients aged at least five years presenting to the clinics with a fever 
of at least 38°C of up to seven days’ duration and with a negative result for malaria smear 
or RDT were recruited into the study. Patients who had a clear alternative clinical 
diagnosis such as pneumonia, urinary tract infection, chickenpox, measles or skin/soft 
tissue infection were excluded.  
Blood specimens were collected for laboratory diagnosis as described in section 
2.6. Acute plasma specimens were used for detection of dengue viral nucleic acid by one-
step SYBR Green based rRT-PCR assay [16, 259] and for detection of dengue NS1 antigen 
and IgM antibody by ICT (SD BIOLINE Dengue Duo, Standard diagnostics, Inc.). This 
ICT contains NS1 antigen detection and IgM/IgG antibody detection in a single cassette. 
Only the results of NS1 antigen and IgM antibody detection were included in the current 
analysis as markers of the early diagnosis of acute dengue infection. The tests were read by 
three independent readers who did not confer and the results were blinded. Inter-operator 
variability in the reading of the test results between the three readers was analysed. The 
consensus results were then used for final interpretation. Paired acute and convalescent 
serum specimens were tested using the AFRIMS dengue virus and JE virus IgM and IgG 
antibody ELISAs as the reference tests [70, 258]. In addition to the diagnosis of acute 
dengue infection, the serotype of dengue virus (DENV-1 to 4) was identified using a 
nested-RT PCR assay [74, 80]. This assay was performed using the same RNA extracts of 
acute plasma specimens from all patients positive by the rRT-PCR assay.  
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The impact of malaria infection (sub-microscopic) on the performance 
characteristics of the dengue diagnostic tests under evaluation was assessed. The term 
“malaria infection” in this chapter refers to sub-microscopic malaria infection, in which the 
malarial DNA was detected using 18S rRNA qPCR assay [241]. The details of laboratory 
testing procedures and their interpretations were described in section 2.9. 
The lower limit of detection (LoD) of the one-step SYBR Green based rRT-PCR 
assay was assessed to determine the laboratory sensitivity of the assay for the detection of 
dengue virus group. The dengue virus control strains were obtained from AFRIMS, 
consisting of DENV-1 (Hawaii strain), DENV-2 (New Guinea strain), DENV-3 (H87 
strain), and DENV-4 (814669 strain). Ten-fold dilution series of DENV-1, DENV-2, and 
DENV-3, starting from 10,000 to 0.1 PFU/ml and 100,000 to 1.0 PFU/ml for DENV-4 
were constructed and tested in duplicate. A DENV 1-4 mixture was used as positive 
control of the assay and its LoD was also determined using a 10-fold serial dilution of the 
DENV 1-4 mixture tested in duplicate. The dilution mixture was prepared starting from the 
mix of 1,000 PFU/ml of DENV-1 to 3 and 10,000 PFU/ml of DENV-4, then diluted 10-
fold until the dilution mixture of 0.01 PFU/ml of DENV-1 to 3 and 0.1 PFU/ml of DENV-
4. R2 value (coefficient of correlation) obtained for the standard curve and efficiency of the 
PCR assay were reported. The laboratory specificity of the assay was not performed, 
because of the limitation of resources for the other positive control viruses. However, the 
original protocol stated that this primer set was highly specific and did not amplify West 
Nile virus (Eg 101 strain), yellow fever virus (17D vaccine strain) and JE virus (JaGAr 
strain) [259]. 
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5.2.2 Data analysis 
 Statistical analyses were performed using STATA/SE 10.1 (StataCorp LP) and 
graphs were drawn using Microsoft Excel 2010 (Microsoft). Diagnostic accuracy of the 
tests under evaluation (NS1 antigen and IgM antibody ICT, and rRT-PCR on acute plasma 
specimen) was calculated by comparing the results of individual tests and combinations of 
multiple tests (combined using an “OR” operator) with the reference results (IgM and IgG 
antibody ELISAs on paired serum specimens). A 2 x 2 table was constructed, in which the 
reference results were cross-tabulated with the results of the tests under evaluation to 
determine the rate of true positive, true negative, false positive and false negative results. 
The sensitivity, specificity, positive predictive value (PPV), negative predictive value 
(NPV) with 95% CI and area under ROC curve (AUC) were calculated using the “diagt” 
routine and roctab command in STATA [285]. The McNemar test was used to compare 
sensitivities of the tests. Kappa values were generated to determine the level of inter-
operator variation in the reading of the NS1 antigen and IgM antibody ICT test results, and 
the agreement between clinical diagnosis and laboratory confirmed diagnosis of acute 
dengue virus infection [286]. To assess the impact of malaria infection on the performance 
characteristics of the dengue diagnostic tests, the sensitivity, specificity, PPV and NPV 
with 95% CI and the AUC were stratified for patients who were positive and negative for 
malaria qPCR separately using the “diagt” routine and roctab command in STATA [285].  
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5.3 Results 
5.3.1 Patients  
Patients who presented to the OPD clinics with acute undifferentiated febrile illness 
were investigated, and 908 patients were recruited into the study. Convalescent serum 
specimens were obtained from 89.4% (812/908) of the patients. Only patients with 
available paired acute and convalescent serum specimens were included in the further 
analysis. 
Of the 812 patients included in the analysis, 61.0% (495/812) were male. The 
median age was 18 years (IQR 12-29, range 5-63) and the median temperature at 
presentation was 38.5°C (IQR 38.2-39.0). The median duration of fever at the time of first 
presentation was two days (IQR 2-3) and the median interval between obtaining initial 
acute-phase serum specimens and convalescent serum specimens was 14 days (IQR 14-14, 
range 9-29). A laboratory confirmed diagnosis of acute dengue virus infection was given to 
17.7% (144/812) of patients using the results of the reference tests. Acute primary dengue 
infection was confirmed in 12 patients and 132 patients had acute secondary dengue 
infections (Table 5.1). 
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Table 5.1 Laboratory confirmed diagnosis of 812 febrile patients using reference 
tests. 
Reference resultsa Number of patients (%) 
Acute primary dengue infection 12 (1.5) 
Acute secondary dengue infection 132 (16.3) 
Acute JE infection 6 (0.7) 
Acute secondary flavivirus infectionb 1 (0.1) 
Recent dengue infection 1 (0.1) 
Recent secondary dengue infection 2 (0.25) 
No evidence of flavivirus infection 658 (81.0) 
Total 812 (100) 
aAFRIMS dengue virus and JE virus IgM and IgG antibody ELISAs on paired acute and 
convalescent serum specimens 
bOther flaviviruses: anti-dengue IgM of <40 EIA units in acute specimen with an increase 
in anti-dengue or anti-JE IgG between acute and convalescent specimens to an absolute 
value of >100 units, but the anti-dengue IgM units were less than the anti-JE IgM unit in 
the convalescent specimen (Appendix 2). 
Presumptive diagnoses were given at the clinics based on clinical presentations. Of 
the 812 patients, 24.0% (195/812) were clinically diagnosed with dengue virus infection. 
The agreement between clinical diagnosis and the laboratory confirmed diagnosis of acute 
dengue infection was poor (Kappa=0.4602) (Table 5.2). The clinical diagnosis for the 
patients with the laboratory confirmed diagnosis of acute dengue virus infection is shown 
in Table 5.3. Of the 144 laboratory confirmed acute dengue infections, 67.4% (97/144) of 
patients were clinically diagnosed with dengue at presentation. For the other 47 patients, 
22 patients (15.3%) were diagnosed with unknown fever, 16 patients (11.1%) with 
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leptospirosis, five patients (3.5%) with typhoid, three patients (2.1%) with viral illness and 
one patient (0.7%) with scrub typhus. 
Table 5.2 Clinical diagnosis and laboratory confirmed diagnosis of acute dengue 
virus infection. 
Laboratory confirmed diagnosis 
Clinical diagnosis 
Dengue Not dengue 
Total 
Dengue (%) 97 (67.4) 98 (14.7) 195 (24.0) 
Not dengue (%) 47 (32.6) 570 (85.3) 617 (76.0) 
Total (%) 144 (100) 668 (100) 812 (100) 
 
Table 5.3 Clinical diagnosis for patients with a laboratory confirmed diagnosis of 
acute dengue virus infection. 
Clinical diagnosis Laboratory confirmed acute dengue cases (%) 
Dengue 97 (67.4) 
Unknown fever 22 (15.3) 
Leptospirosis  16 (11.1) 
Typhoid 5 (3.5) 
Viral illness 3 (2.1) 
Scrub typhus 1 (0.7) 
Total 144 (100) 
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5.3.2 Lower limit of detection (LoD) of the one-step SYBR Green based rRT-PCR 
assay for universal detection of dengue viruses 
 The assay was able to detect all four serotypes of dengue virus, as it was designed 
for universal detection of dengue viruses. However, it was not designed for specific 
serotype detection and therefore was unable to distinguish between different serotypes. 
The laboratory sensitivity of the assay for the detection of dengue viruses using 
amplification curve and melting curve analysis are shown in Figure 5.1 and Figure 5.2. The 
assay validation was performed for 24 replicates i.e. each 10-fold serial dilution was tested 
in duplicate for 12 qPCR runs (3 runs for each of DENV-1 to -4). All replicates were 
positive for each dilution point (100% repeatability and reproducibility). The assay LoD 
was determined to be 0.03 PFU/reaction (or equivalent to 1 PFU/ml of plasma specimen) 
for the detection of DENV-1, DENV-2 and DENV-3; and 0.33 PFU/reaction (or equivalent 
to 10 PFU/ml) for DENV-4. The LoD of the DENV 1-4 mixture was similar to the LoD of 
the individual serotypes, in which it was between 0.03-0.33 PFU/reaction (or equivalent to 
1-10 PFU/ml) (Figure 5.4). Following validation of the assay, an optimal fluorescence 
threshold was set at 14,000 for all PCR runs. Specific melting temperatures were between 
80.0°C and 83.3°C.  
Standard curves were generated from the amplification plots of each serotype 
representing DENV-1, DENV-2, DENV-3, DENV-4, and DENV 1-4 mixture. The average 
R2 value of the standard curve for each serotype (DENV-1 to 4) and the DENV 1-4 
mixture were 0.96, 0.97, 0.96, 0.94, and 0.93 respectively. The efficiency of the assay in 
detection of DENV-1, DENV-2, DENV-3, DENV-4 and DENV 1-4 mixture was 90.0, 
91.7, 97.4, 106.8 and 127.3, respectively. Figure 5.3 and Figure 5.4 show examples of 
standard curves for a PCR run of each dengue serotype and the DENV 1-4 mixture. 
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Figure 5.1 Amplification curves of the rRT-PCR assay for the detection of DENV-
1, DENV-2, DENV-3, and DENV-4. 
Legend: blue=333.33 PFU/reaction, red=33.33 PFU/reaction, green=3.33 PFU/reaction, 
pink=0.33 PFU/reaction, light blue=0.03 PFU/reaction, Orange=0.003 PFU/reaction, 
grey=negative control for DENV-1, DENV-2, and DENV-3 
Legend: blue=3,333.33 PFU/reaction, red=333.33 PFU/reaction, green=33.33 
PFU/reaction, pink=3.33 PFU/reaction, light blue=0.33 PFU/reaction, orange=0.03 
PFU/reaction, grey=negative control for DENV-4 
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Figure 5.2 Melting curves of the rRT-PCR assay for the detection of DENV-1, 
DENV-2, DENV-3, and DENV-4. 
Legend: blue=333.33 PFU/reaction, red=33.33 PFU/reaction, green=3.33 PFU/reaction, 
pink=0.33 PFU/reaction, light blue=0.03 PFU/reaction, Orange=0.003 PFU/reaction, 
grey=negative control for DENV-1, DENV-2, and DENV-3 
Legend: blue=3,333.33 PFU/reaction, red=333.33 PFU/reaction, green=33.33 
PFU/reaction, pink=3.33 PFU/reaction, light blue=0.33 PFU/reaction, orange=0.03 
PFU/reaction, grey=negative control for DENV-4 
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Figure 5.3 Standard curves of the rRT-PCR assay for the detection of DENV-1, 
DENV-2, DENV-3, and DENV-4. 
Legend: blue=333.33 PFU/reaction, red=33.33 PFU/reaction, green=3.33 PFU/reaction, 
pink=0.33 PFU/reaction, light blue=0.03 PFU/reaction, Orange=0.003 PFU/reaction, 
grey=negative control for DENV-1, DENV-2, and DENV-3 
Legend: blue=3,333.33 PFU/reaction, red=333.33 PFU/reaction, green=33.33 
PFU/reaction, pink=3.33 PFU/reaction, light blue=0.33 PFU/reaction, orange=0.03 
PFU/reaction, grey=negative control for DENV-4 
 
R2=0.99 R2=0.97 
R2=0.99 R2=0.97 
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Figure 5.4 Amplification curve, standard curve and melting curve analysis of the 
rRT-PCR assay for the detection of DENV 1-4 mixture. 
Legend: blue=33.33-333.33 PFU/reaction, red=3.33-33.33 PFU/reaction, green=0.33-3.33 
PFU/reaction, pink=0.03-0.33 PFU/reaction, light blue=0.003-0.03 PFU/reaction, 
orange=0.0003-0.003 PFU/reaction, grey=negative control (the former number is for 
DENV-1 to 3 and the latter is for DENV-4) 
 
 
R2=0.93 
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5.3.3 Detection of dengue virus by rRT-PCR assay 
  Acute plasma specimens from 812 patients were tested using the rRT-PCR assay 
for the detection of dengue virus RNA. Of these, 18.0% (146/812) of the patients were 
given a positive result in which a specific melting temperature between 80.0-83.3°C was 
obtained. The median Ct value for these positive specimens was 19.7 (IQR 17.7-22.5, 
range 12.7-31.7). There was always some non-specific amplification in negative 
specimens, however no specific melting temperatures were obtained and the Ct values of 
the negative specimens (666/812) were late with the median of 30.0 (IQR 29.6-30.4, range 
28.2-34.2). 
In addition, the serotype of dengue virus (DENV-1 to 4) was identified by nested-
RT PCR assay using the RNA extracts from the 146 patients that were positive by the rRT-
PCR assay. All specimens from 146 patients were also positive by the nested-RT PCR and 
the serotypes were identified. Of these, 134 patients (91.8%) had DENV-1, eight patients 
(5.5%) had DENV-3 and four patients (2.7%) had DENV-4. No patients with DENV-2 
infection were identified during the study period. 
5.3.4 Detection of dengue virus by the Dengue Duo ICT 
The SD BIOLINE Dengue Duo ICT (Standard diagnostics, Inc.) was performed on 
all 812 acute plasma specimens. The overall results of the tests, both NS1 antigen and IgM 
antibody detections, read by the three independent readers were similar as shown in Table 
5.4. 
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Table 5.4 NS1 antigen and IgM antibody Dengue Duo ICT results (n=812) read 
by three independent readers. 
Tests Reader 1 Reader 2 Reader 3 Final results 
 Positive Negative Positive Negative Positive Negative Positive Negative 
NS1 130 682 130 682 130 682 130 682 
IgM 40 772 40 772 40 772 40 772 
 
5.3.5 Inter-operator variation for interpretation of the Dengue Duo ICT results 
 The inter-operator variation for interpretation of the ICT results was assessed using 
Kappa statistics. The results of both NS1 antigen detection and IgM antibody detection 
were easy to read and reliable for different readers. There was excellent inter-operator 
agreement amongst three readers for both assays (Kappa=1.00, and 0.96 for NS1 antigen 
detection and IgM antibody detection, respectively). The consensus results (i.e. 2/3 readers 
with the same interpretation) were then used for the final results (Table 5.4) and further 
analysis. 
5.3.6 Diagnostic accuracy of the individual tests 
 The performance characteristics of rRT-PCR, NS1 antigen detection and IgM 
antibody detection on the acute plasma specimen compared to the reference tests are 
shown in Table 5.5. rRT-PCR or NS1 antigen detection alone had high sensitivity, 97.2% 
and 86.1% respectively. The sensitivity of rRT-PCR was significantly higher than that of 
the NS1 antigen detection (P=0.0003). The sensitivity of IgM antibody detection alone was 
low (7.6%), which was significantly lower than both rRT-PCR (P<0.0001) and NS1 
antigen detection (P<0.0001). 
 Specificities of rRT-PCR, NS1 antigen detection and IgM antibody detection were 
99.1%, 99.1%, and 95.7% respectively. The diagnostic accuracy of the tests was also 
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measured by the area under ROC curve (AUC). The AUC of rRT-PCR and NS1 antigen 
detection were excellent (0.98 and 0.93, respectively), but poor for IgM antibody detection 
(0.52) (Table 5.5). 
5.3.7 Diagnostic accuracy of the combinations of the tests 
 The performance characteristics of the combinations of the tests on acute plasma 
specimens are shown in Table 5.5. These included the combination of NS1 antigen 
detection and IgM antibody detection from the ICT (NS1+IgM), and the combination of 
rRT-PCR and the ICT (rRT-PCR+NS1+IgM). The overall sensitivity of the combination of 
rRT-PCR+NS1+IgM was 98.6%, which was significantly higher than the sensitivity of the 
NS1+IgM combination (86.1%) or NS1 antigen detection or IgM antibody detection alone 
(all P<0.0001), but not significantly higher than the rRT-PCR alone (P=0.5000). The 
combination of NS1+IgM was significantly more sensitive than IgM antibody detection 
alone (P<0.0001), but not significantly different from the NS1 antigen detection alone 
(P=1.0000). The sensitivity of the NS1+IgM combination was significantly lower than that 
of rRT-PCR alone (P=0.0004). 
 The overall specificity of the combinations of the tests was slightly lower compared 
to the individual tests. The specificity of the combinations of rRT-PCR+NS1+IgM, and 
NS1+IgM tests was 94.5%, and 94.9%, respectively. The AUC for both combinations was 
excellent with 0.97 and 0.91 for the combination of rRT-PCR+NS1+IgM, and NS1+IgM, 
respectively (Table 5.5). 
5.3.8 Effect of fever duration at presentation on diagnostic test sensitivity for early 
diagnosis of acute dengue infection 
 The effect of fever duration at the time of presentation on test sensitivity is shown 
in Figure 5.5. The sensitivity of rRT-PCR alone (83.3-100%) and the combination of rRT-
PCR+NS1+IgM was high throughout the early stage of infection (92.9-100%). The 
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sensitivity of NS1 antigen detection was also high throughout, but was lower than rRT-
PCR for the detection in patients presenting with one to four days of fever (78.6-87.8%). 
The sensitivity of IgM antibody detection alone was low and increased later, peaking in 
patients presenting with five days of fever (33.3%). There was no positive IgM antibody 
detection in patients presenting with six days of fever. The sensitivity of NS1 antigen 
detection combined with IgM antibody detection was covered by the NS1 antigen 
detection, in which the sensitivity was similar to the NS1 antigen detection alone. The 
numbers of patients presenting with six and seven days of fever were small, and therefore 
the 95% confidence intervals around the sensitivities were wide. 
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Table 5.5 Performance characteristics of rRT-PCR, NS1 antigen detection, and IgM antibody detection on acute plasma specimens 
compared to reference tests for early diagnosis of acute dengue infection (n=812). 
Tests  Reference results* %Sensitivity (95% CI) %Specificity (95% CI) %PPV (95% CI) %NPV (95% CI) AUC 
  Dengue 
Not 
dengue 
     
rRT-PCR + 140 6 97.2 (93.0-99.2) 99.1 (98.1-99.7) 95.9 (91.3-98.5) 99.4 (98.5-99.8) 0.9816 
 - 4 662      
NS1 + 124 6 86.1 (79.4-91.3) 99.1 (98.1-99.7) 95.4 (90.2-98.3) 97.1 (95.5-98.2) 0.9261 
 - 20 662      
IgM + 11 29 7.6 (3.9-13.3) 95.7 (93.8-97.1) 27.5 (14.6-43.9) 82.8 (79.9-85.4) 0.5165 
 - 133 639      
rRT-PCR+NS1+IgM + 142 37 98.6 (95.1-99.8) 94.5 (92.4-96.1) 79.3 (72.7-85.0) 99.7 (98.9-100) 0.9654 
 - 2 631      
NS1+IgM + 124 34 86.1 (79.4-91.3) 94.9 (93.0-96.4) 78.5 (71.2-84.6) 96.9 (95.3-98.1) 0.9051 
 - 20 634      
AUC= area under ROC curve, CI= confidence interval, NPV= negative predictive value, PPV= positive predictive value, rRT-PCR= real-time reverse 
transcriptase PCR  
*AFRIMS dengue virus and JE virus IgM and IgG antibody ELISAs on paired acute and convalescent serum specimens 
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Figure 5.5 Effect of fever duration at presentation on sensitivity of the tests for 
early diagnosis of acute dengue infection (n=812). 
(A) rRT-PCR, (B) NS1 antigen, (C) IgM antibody, (D) combination of rRT-PCR, NS1 
antigen and IgM antibody, (E) combination of NS1 antigen and IgM antibody 
*No positive IgM antibody detection in patients presenting with six days of fever 
(A) (B) 
(C)* 
(E) 
(D) 
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5.3.9 Impact of malaria infection on the diagnostic accuracy of the tests for early 
diagnosis of acute dengue infection 
 From a total of 812 non-malaria febrile patients in the current analysis, malarial 
DNA was detected in 139 patients by 18S rRNA qPCR assay (sub-microscopic malaria 
infection). Malarial DNA was detected in 12.5% (18/144) of patients with laboratory 
confirmed diagnosis of acute dengue infection and was detected in 18.1% (121/668) of 
patients in whom the reference tests did not confirm acute dengue infection. The impact of 
malaria infection on the performance characteristics of the tests under evaluation for early 
diagnosis of acute dengue infection was assessed by stratified diagnostic accuracies of the 
tests in malaria qPCR positive patients (Table 5.6) and malaria qPCR negative patients 
(Table 5.7). The overall diagnostic accuracy of all individual and combination tests was 
similar between malaria qPCR positive and negative patients. The sensitivity of all tests 
was slightly higher in malaria qPCR negative patients compared to malaria qPCR positive 
patients, however the differences were not statistically significant. Similarly, the specificity 
of all tests was slightly better in patients with malaria qPCR positive, although they were 
not statistically different. There was insufficient evidence to determine if malaria infection 
had a significant impact on the accuracy of the diagnostic tests evaluated in this study. 
Therefore, the malaria infection had no impact or might have only a minimal impact that 
was not clinically important on the performance characteristics of the dengue diagnostic 
tests. 
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Table 5.6 Impact of malaria infection on the performance characteristics of the tests for early diagnosis of acute dengue infection in malaria 
qPCR positive patients (n=139). 
Tests  Reference results* %Sensitivity (95% CI) %Specificity (95% CI) %PPV (95% CI) %NPV (95% CI) AUC 
  Dengue 
Not 
dengue 
     
rRT-PCR + 17 0 94.4 (72.7-99.9) 100 (97.0-100) 100 (80.5-100) 99.2 (95.5-100) 0.9722 
 - 1 121      
NS1 + 15 1 83.3 (58.6-96.4) 99.2 (95.5-100) 93.8 (69.8-99.8) 97.6 (93.0-99.5) 0.9125 
 - 3 120      
IgM + 0 8 0 (0-18.5) 93.4 (87.4-97.1) 0 (0-36.9) 86.3 (79.2-91.6) 0.4669 
 - 18 113      
rRT-PCR+NS1+IgM + 17 8 94.4 (72.7-99.9) 93.4 (87.4-97.1) 68.0 (46.5-85.1) 99.1 (95.2-100) 0.9392 
 - 1 113      
NS1+IgM + 15 8 83.3 (58.6-96.4) 93.4 (87.4-97.1) 65.2 (42.7-83.6) 97.4 (92.6-99.5) 0.8836 
 - 3 113      
AUC= area under ROC curve, CI= confidence interval, NPV= negative predictive value, PPV= positive predictive value, rRT-PCR= real-time reverse 
transcriptase PCR 
*AFRIMS dengue virus and JE virus IgM and IgG antibody ELISAs on paired acute and convalescent serum specimens 
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Table 5.7 Impact of malaria infection on the performance characteristics of the tests for early diagnosis of acute dengue infection in malaria 
qPCR negative patients (n=673). 
Tests  Reference results* %Sensitivity (95% CI) %Specificity (95% CI) %PPV (95% CI) %NPV (95% CI) AUC 
  Dengue 
Not 
dengue 
     
rRT-PCR + 123 6 97.6 (93.2-99.5) 98.9 (97.6-99.6) 95.3 (90.2-98.3) 99.4 (98.4-99.9) 0.9826 
 - 3 541      
NS1 + 109 5 86.5 (79.3-91.9) 99.1 (97.9-99.7) 95.6 (90.1-98.6) 97.0 (95.2-98.2) 0.9280 
 - 17 542      
IgM + 11 21 8.7 (4.4-15.1) 96.2 (94.2-97.6) 34.4 (18.6-53.2) 82.1 (78.9-85.0) 0.5245 
 - 115 526      
rRT-PCR+NS1+IgM + 125 29 99.2 (95.7-100) 94.7 (92.5-96.4) 81.2 (74.1-87.0) 99.8 (98.9-100) 0.9695 
 - 1 518      
NS1+IgM + 109 26 86.5 (79.3-91.9) 95.2 (93.1-96.9) 80.7 (73.1-87.0) 96.8 (95.0-98.1) 0.9088 
 - 17 521      
AUC= area under ROC curve, CI= confidence interval, NPV= negative predictive value, PPV= positive predictive value, rRT-PCR= real-time reverse 
transcriptase PCR 
*AFRIMS dengue virus and JE virus IgM and IgG antibody ELISAs on paired acute and convalescent serum specimens 
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5.4 Discussion 
Accurate early diagnosis of acute dengue virus infection remains challenging in SE 
Asia where dengue is endemic. Clinical presentations are often confused with other causes 
of acute undifferentiated fever and diagnosis based on clinical features is non-specific [16, 
33], as shown in the current study where only 49.7% (97/195) of patients who were 
clinically diagnosed with dengue had laboratory confirmed diagnosis of acute dengue virus 
infection.  
In the current study, the diagnostic accuracy and clinical usefulness of the rRT-PCR 
assay, and NS1 antigen and IgM antibody detection ICT were evaluated for the timely 
diagnosis of acute dengue infection from a single plasma specimen. The overall 
performance characteristics of the IgM antibody detection were poor with a sensitivity of 
7.6%, although the specificity was high (95.7%). The positive predictive value (PPV) was 
27.5% and the negative predictive (NPV) value was 82.8%, resulting in many 
misdiagnosed cases if the test were to be used in absence of the NS1 positive line in the 
ICT cassette. There are several explanations for this observation. Firstly, most of the 
patients presented early in the course of their illness with a median of two days (IQR 2-3) 
of fever, when the IgM antibody level was undetectable. Secondly, the majority of the 
dengue confirmed cases were secondary infections in which the IgM antibody levels are 
variable and might be undetectable [24]. The NS1 antigen and IgM antibody detection ICT 
had excellent inter-operator agreement between readers. This means that the results are 
easy to interpret and reliable for different readers. The feasibility assessment of using this 
ICT in the field has been described elsewhere. This ICT appeared to be stable in the 
tropical field where the ambient temperature is high. [287].  
Following the validation of the rRT-PCR assay, the analytical sensitivity was 
between 0.03 and 0.33 PFU/reaction (or equivalent to 1-10 PFU/ml of plasma specimen) 
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which was better than that stated in the original protocol (between 4.1 and 43.5 PFU/ml) 
[259]. Both the rRT-PCR and NS1 antigen detection had excellent diagnostic accuracy 
(Table 5.5) and either could potentially be used as a single test for early confirmation of 
acute dengue infection. The rRT-PCR was the most accurate test (97.2% sensitivity and 
99.1% specificity) and had slightly better performance than the NS1 antigen detection 
(86.1% sensitivity and 99.1% specificity, and the AUC was 0.98 vs. 0.92, respectively). In 
practice, the NS1 antigen detection and the IgM/IgG antibody detection were on the same 
ICT cassette, although different strips (one for NS1 antigen and another one for IgM/IgG 
antibody detection). The ICT used ~120µl of acute plasma specimen and the results were 
available in 15 minutes. The cost of this ICT was 450 THB per test (13.2 USD). The rRT-
PCR used 200µl of the acute plasma specimen and the result was available in around 7 
hours from receipt in the laboratory (1.5 hours for nucleic acid extraction, 4.5 hours for 
rRT-PCR and one hour for setting up, interpretation and reporting). The cost of rRT-PCR 
plus nucleic acid extraction was 700 THB per specimen (20.5 USD). For the combinations 
of the tests, the combination of rRT-PCR+NS1+IgM had very high sensitivity, although 
the specificity decreased compared to individual tests. Combining the IgM antibody with 
the NS1 antigen detection, the sensitivity was not better than the NS1 antigen detection 
alone and resulted in an inevitable drop in the specificity. 
The clinical diagnostic accuracy of the rRT-PCR assay and NS1 antigen detection 
rapid test have been evaluated and reported in many studies for the acute diagnosis of 
dengue from a single specimen [16, 71, 259, 288, 289]. In the current study, the sensitivity 
of rRT-PCR (97.2%) was slightly better than the original protocol, which found that the 
assay could only detect dengue in 83.0% of acute serum specimens from confirmed dengue 
cases [259]. This is also true for the previous fever diagnostic study at SMRU where the 
sensitivity of the rRT-PCR alone was 88.9% for the acute diagnosis of dengue infection 
from acute plasma specimens [16]. Interestingly, given that most of the patients had acute 
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secondary dengue infection in the current study, NS1 antigen detection ICT had high 
sensitivity (86.1%). Teoh and colleagues reported the sensitivity of NS1 antigen detection 
(NS1 Ag Strip) was 95.9% for the primary dengue infection and 43.7% for the secondary 
dengue infection. This may be explained because patients in the current study presented to 
the clinics very early in the course of their fever with a median of two days illness (IQR 2-
3, range 1-7) while the median duration of fever from the study of Teoh et al was six days 
(range 1 to ≥11) [288]. 
The impact of malaria infection on the diagnostic accuracy of the tests was assessed. 
Importantly, rRT-PCR and NS1 antigen detection were highly sensitive and specific 
independent of malaria infection status. This is also true for the combination of NS1+IgM 
ICT and rRT-PCR+NS1+IgM, which were covered by the NS1 antigen detection or rRT-
PCR. The IgM antibody detection alone had high specificity but low sensitivity also 
independent of the malaria infection status. Indeed, the cross reactivity between dengue 
and malaria on the dengue IgM antibody detection rapid tests has been described elsewhere 
[73, 290], however, malaria infection status did not have an impact on the IgM antibody 
detection in this evaluation. This could be due to the low malaria parasite density of sub-
microscopic infection as described in chapter 4. 
The current study has several limitations. Analysis of the performance characteristics 
of the diagnostic tests comparing primary (n=12) and secondary (n=132) dengue infection 
was not performed, since the number of patients with confirmed diagnosis of acute primary 
dengue infection was small. However, this reflects the situation in most resource-limited 
clinical settings as well as the situation in most dengue endemic areas like SE Asia, 
specifically Thailand where almost 90% of dengue cases are secondary infection [41]. The 
evaluation of the diagnostic tests comparing all four serotypes of dengue virus could not be 
performed because all serotypes were not represented in the study. Over 90% of cases were 
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DENV-1 and none were DENV-2. The performance of diagnostic tests depends on the 
timing of infection and timing of specimen collection. Since patients in this study 
presented to the clinics very early in the course of their illness, the analysis was limited to 
the small number of patients who presented after five days duration of fever. This may 
affect the performance characteristics of the tests, particularly IgM antibody detection, in 
which its detectable levels appear during this time and peak slightly later for primary 
infection and the lower levels for secondary infection [24]. The nucleic acid detection (RT-
PCR) assay could detect dengue viral RNA from first day of fever until seven days [259]. 
NS1 antigen could be detected from blood on the first day after onset of fever up to day 
nine of fever [61]. 
The present study has demonstrated that the rRT-PCR or new generation rapid ICT 
test that combines NS1 antigen and IgM/IgG antibody detection can reliably be used as a 
single test in a clinical setting for the early diagnosis of acute dengue infection from a 
single specimen. The rRT-PCR was the most accurate test in this evaluation, however it 
was more expensive and took longer to get the result than using a rapid test. In addition, it 
requires a considerable investment for setting up a laboratory, especially where the system 
is not already in place. This study has confirmed the findings of the previous pilot study at 
SMRU as well as provided more useful information with a larger sample size and a better 
reflection of the general situation of AUFI in a rural SE Asian clinical setting. This study 
was specifically looking at the performance characteristics of a clinic bedside diagnostic 
test rather than a laboratory based diagnostic test as in the previous study [16]. In the 
previous study, evaluations of NS1 antigen detection and IgM antibody detection were 
performed in an ELISA format. Although it is standardised and inexpensive, the 
turnaround time is longer than the ICT format and this new generation ICT was 
unavailable at the time. The overall performance of NS1 antigen detection ICT in this 
evaluation (86.1% sensitivity and 99.1% specificity) was better than the ELISA used in the 
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previous study (54.2% sensitivity and 100% specificity). For the IgM antibody detection, 
the ICT had lower sensitivity (7.6%), but higher specificity (95.7%) compared to the 
previously evaluated ELISA (16.7% sensitivity and 87.8% specificity). However, the 
sensitivity was poor for both evaluations. Indeed, the rRT-PCR and NS1 antigen detection 
have proven useful with high diagnostic accuracy and ability to be used as a single test for 
early diagnosis. The design of the previous study did not provide information on the 
impact of malaria infection on the diagnostic accuracy of the test. Therefore, the data from 
the current study suggests that in a clinical setting in rural areas where resources are 
limited, this new generation ICT is useful to facilitate the management of patients. The 
rRT-PCR could replace the gold standard serology for early diagnosis during the acute 
phase of dengue infection. 
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6 Clinical evaluation of diagnostic tests for early diagnosis of 
acute scrub typhus and murine typhus infections from a 
single specimen 
6.1 Introduction and aims 
Scrub typhus and murine typhus are important acute febrile illnesses in the Asia 
Pacific region and are endemic in Thailand [7, 10]. Clinical diagnosis of rickettsial 
infections is difficult because early symptoms are similar to other regionally endemic 
infections such as dengue, leptospirosis, and malaria [11]. Scrub typhus, caused by 
Orientia tsutsugamushi, and murine typhus, caused by Rickettsia typhi, are obligate 
intracellular Gram-negative bacteria which are transmitted to humans by the bite of 
trombiculid mites (chigger) and rat fleas (mainly Xenopsylla cheopis), respectively [167]. 
The organisms are difficult to isolate in-vitro from clinical specimens, requiring prolonged 
culture and biosafety level-3 (BSL-3) precautions [194]. Thus, isolation is not appropriate 
for routine clinical laboratory diagnosis. Serological testing, using the IFA for the 
detection of rising antibody titres on paired acute and convalescent specimens, is the 
current serological gold standard for confirmation of rickettsial infection [196]. However, 
serology is not useful for early diagnosis since antibodies are rarely detectable during the 
acute phase of illness, a convalescent specimen is required for accurate diagnosis 
especially in an endemic setting and there is no consensus on how to interpret the results 
based on a single acute specimen [191]. Many rapid bedside diagnostic tests based on the 
detection of antibodies were developed and evaluated for the clinical usefulness of early 
diagnosis for scrub typhus and murine typhus infection [208, 209, 291, 292], but their 
availability or diagnostic accuracy is inadequate. Given the limitations of serology, many 
molecular based methods have been developed for rapid detection of rickettsial species 
[210, 220] from different blood fractions, as well as skin or tissue [212, 213, 216, 219], to 
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enable detection of bacterial DNA prior to the development of antibodies and give a result 
in time to assist patient management during the acute phase of illness. 
 In this chapter, the performance characteristics of three diagnostic tests: SD 
BIOLINE Scrub typhus IgM ICT (Standard diagnostics, Inc.) and 47kDa qPCR assay for 
scrub typhus, and 17kDa qPCR assay for murine typhus were evaluated prospectively. The 
tests were evaluated using a single specimen during the acute phase of infection from 
patients presenting with AUFI in a rural SE Asian clinical setting. The aims were to: 
1. Determine the diagnostic accuracy and clinical value of using the SD BIOLINE Scrub 
typhus IgM antibody detection ICT (Standard diagnostics, Inc.) to diagnose acute scrub 
typhus infection. 
2. Assess inter-operator variation for the interpretation of the ICT results. 
3. Determine the diagnostic accuracy and clinical value of using molecular diagnostic 
assays to diagnose acute scrub typhus (47kDa qPCR assay) and acute murine typhus 
(17kDa qPCR assay) infections. 
4. Evaluate the 47kDa qPCR assay as an alternative to the ICT, and as a possible 
replacement for the current serological methods as gold standard tests for the 
confirmation of acute scrub typhus infection. 
5. Evaluate the 17kDa qPCR assay as a possible method to replace the current serological 
methods as gold standard tests for the confirmation of acute Rickettsia spp. (mainly 
murine typhus) infection. 
6. Assess the impact of malaria infection (sub-microscopic) on the performance 
characteristics of the diagnostic tests under evaluation. 
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6.2 Materials and Methods 
6.2.1  Patient specimens and methods 
 All available paired acute and convalescent serum specimens from non-malaria 
febrile patients were included in this evaluation. Blood specimens were collected for 
laboratory confirmed diagnosis and diagnostic test evaluation as described in section 2.6. 
Acute plasma specimens were tested using SD BIOLINE Scrub typhus IgM ICT (Standard 
diagnostics, Inc.) for detection of IgM antibody against O. tsutsugamushi. The tests were 
read by three independent readers who did not confer and the results were blinded. Inter-
operator variability in the reading of the test results between three readers was analysed. 
After that, the consensus results were used for the final interpretation of the test results. 
Acute buffy coat specimens were tested using 47kDa and 17kDa qPCR assays for 
detection of O. tsutsugamushi and Rickettsia spp. DNA, respectively [210, 217]. All 
positive specimens for 17kDa qPCR assay were tested further by ompB qPCR assay for 
detection of R. typhi DNA [218]. Specimens positive for 17kDa and ompB qPCR assays 
were defined as positive for murine typhus infection. Any specimens positive for 17kDa 
qPCR assay but negative for ompB qPCR assay were sent for sequencing (Macrogen, 
Seoul, Republic of Korea) for confirmation of rickettsial species. Paired serum specimens 
were tested using the in-house ELISA/IFA assays (MORU) for detection of IgM antibody 
against O. tsutsugamushi and R. typhi as the reference tests [207, 208, 261-263].  
 The LoD of the 47kDa, 17kDa, and ompB qPCR assays was assessed to determine 
the laboratory sensitivity of the assays for the detection of O. tsutsugamushi, Rickettsia 
spp., and R. typhi, respectively. Plasmid controls were obtained from O. tsutsugamushi 
strain UT76 (47kDa gene), and R. typhi strain Wilmington (17kDa and ompB genes). For 
each assay, a 10-fold serial dilution of linearised plasmid DNA positive control starting 
from 100,000 to 1.0 copies/µl was constructed and tested in duplicate. R2 value (coefficient 
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of correlation) obtained for the standard curve and efficiency of the qPCR assays were 
reported. The laboratory specificity of the three assays was determined by testing with 1.0 
ng/µl of the following organisms: Enterococcus faecalis, E. coli, P. falciparum, P. vivax, 
Pseudomonas aeruginosa, S. aureus, Streptococcus Group B and S. pneumoniae and 3.3-
33.3 PFU/µl of DENV1-4 mix. 
 Bacterial loads were calculated with the following formula: number of the target 
DNA copies/ml of blood = [(number of copies/µl of DNA template)/2] x 100. Numbers of 
copies/µl of DNA template were calculated using 10-fold serial dilution of linearised 
plasmid DNA (100,000-10 copies/µl), resulting in numbers of copies/µl of DNA extract. 
The factor 2 adjusted for the 1:2 ratio of DNA extract to buffy coat, resulting in numbers 
of copies/µl of buffy coat. The factor 100 corrected for the buffy coat fraction, which made 
up approximately 10% of the whole blood [293].  
 In addition, the impact of malaria infection on the performance characteristics of 
the scrub typhus and murine typhus diagnostic tests for early diagnosis of acute phase of 
infection was assessed. In this chapter, the term “malaria infection” refers to sub-
microscopic malaria infection, in which the malarial DNA was detected using 18S rRNA 
qPCR assay [241]. The details of laboratory testing and their interpretations were described 
in section 2.9. 
6.2.2 Data analysis 
 Data were analysed using STATA/SE 10.1 (StataCorp LP) and graphs were created 
using Microsoft Excel 2010 (Microsoft). Diagnostic accuracy of the tests under evaluation 
(SD BIOLINE Scrub typhus IgM ICT (Standard diagnostics, Inc.), 47kDa qPCR, and 
17kDa PCR assays) was calculated by comparing the results of individual tests and a 
combination of the tests (combined using an “OR” operator) with the reference results 
(IgM antibody ELISA/IFA on paired serum specimens). The reference results were cross-
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tabulated with the results of the diagnostic tests under evaluation to determine the rate of 
true positive, true negative, false positive and false negative results. The sensitivity, 
specificity, PPV, NPV with 95% CI and AUC were calculated using the “diagt” routine 
and roctab command in the STATA [285]. The McNemar test was used to compare 
sensitivity of the tests. Kappa values were generated to determine the level of inter-
operator variation in the reading of the SD BIOLOINE Scrub typhus IgM ICT results 
(Standard diagnostics, Inc.) and the agreement between clinical diagnosis and laboratory 
confirmed diagnosis of acute scrub typhus and murine typhus infections [286]. The impact 
of malaria infection on the performance characteristics of the scrub typhus and murine 
typhus diagnostic tests were assessed by stratifying the sensitivity, specificity, PPV, NPV 
with 95% CI and AUC for patients with malaria qPCR positive and negative groups using 
the “diagt” routine and roctab command in STATA [285]. 
6.3 Results 
6.3.1 Patient specimens 
 Paired acute and convalescent serum specimens were available from 89.3% 
(811/908) of the non-malaria febrile patients and were included in the analysis. A 
laboratory confirmed diagnosis of acute scrub typhus was given to 5.4% (44/811) of 
patients and acute murine typhus was confirmed in 6.7% (54/811) of the patients by the 
results of the reference tests. 
 Presumptive diagnoses were given at the clinics based on the clinical presentations. 
Of the 811 patients, 1.6% (13/811) were clinically diagnosed with scrub typhus infection. 
The agreement between clinical diagnosis and the laboratory confirmed diagnosis of acute 
scrub typhus infection was poor (Kappa = 0.0106) (Table 6.1). None of the patients were 
given a clinical diagnosis of murine typhus.  
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 The clinical diagnoses for patients with the laboratory confirmed diagnosis of acute 
scrub typhus and acute murine typhus infections are shown in Table 6.2. Of the 44 patients 
with laboratory confirmed acute scrub typhus infection, only one patient was clinically 
diagnosed with scrub typhus at presentation.  
Table 6.1 Clinical diagnosis and laboratory confirmed diagnosis of acute scrub 
typhus infection. 
Laboratory confirmed diagnosis 
Clinical diagnosis 
Scrub typhus Not scrub typhus 
Total  
Scrub typhus (%) 1 (2.3) 12 (1.6) 13 (1.6) 
Not scrub typhus (%) 43 (97.7) 755 (98.4) 798 (98.4) 
Total (%) 44 (100) 767 (100) 811 (100) 
 
Table 6.2 Clinical diagnoses for patients with the laboratory confirmed diagnosis 
of acute scrub typhus and acute murine typhus infections. 
Laboratory confirmed diagnosis 
Clinical diagnosis 
Acute scrub typhus (%) Acute murine typhus (%) 
Dengue 5 (11.4) 4 (7.4) 
Leptospirosis 9 (20.5) 17 (31.5) 
Scrub typhus 1 (2.3) 1 (1.9) 
Typhoid 9 (20.5) 5 (9.3) 
Unknown fever 20 (45.5) 27 (50.0) 
Total 44 (100) 54 (100) 
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6.3.2 Laboratory sensitivity and specificity of 47kDa, 17kDa and ompB qPCR assays 
 The laboratory sensitivity of the 47kDa, 17kDa and ompB qPCR assays for the 
detection of the O. tsutsugamushi, Rickettsia spp., and R. typhi, respectively, was 
determined using 10-fold dilution series of linearised plasmid DNA. Amplification curves 
were plotted as shown in Figure 6.1. The accurate quantification could be calculated using 
the data points between 10-100,000 copies/µl (five points). The assay validation was 
performed for eight replicates for 47kDa assay (each 10-fold serial dilution was tested in 
duplicate for four qPCR runs), eight replicates for 17kDa assay (each 10-fold serial 
dilution was tested in duplicate for four qPCR runs) and six replicates for ompB assay 
(each 10-fold serial dilution was tested in duplicate for three qPCR runs). All replicates 
were positive for each dilution point for the three assays (100% repeatability and 
reproducibility). The LoD of the three assays was similar, which was determined to be 
between 1-10 copies/µl of DNA template (or equivalent to 50-500 copies/ml of blood). 
Following validation of the assays, an optimal fluorescence threshold was set at 25,000 for 
47kDa qPCR assay, and 30,000 for 17kDa and ompB qPCR assays for all qPCR runs. A 
standard curve was generated from the amplification plots of each assay. The average R2 
values of the standard curves were 1.00 for all three assays. The efficiency of the 47kDa, 
17kDa and ompB assays was 89.4, 87.8 and 98.8%, respectively. Figure 6.2 shows 
examples of standard curves for a qPCR run of each assay. For the laboratory specificity, 
the three qPCR assays were specific. There were no amplifications for all other organisms 
tested.  
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Figure 6.1 Amplification curves of the 47kDa, 17kDa and ompB qPCR assays for 
the detection of O. tsutsugamushi, Rickettsia spp., and R. typhi, respectively, using 10-
fold serial dilution of linearised plasmid DNA. 
Legend: blue=100,000 copies/µl, red=10,000 copies/µl, green=1,000 copies/µl, pink=100 
copies/µl, light blue= 10 copies/µl, orange=1 copy/µl, and grey=negative control 
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Figure 6.2 Standard curves of the 47kDa, 17kDa and ompB qPCR assays for the 
detection of O. tsutsugamushi, Rickettsia spp., and R. typhi, respectively, using 10-fold 
serial dilution of linearised plasmid DNA. 
Legend: blue=100,000 copies/µl, red=10,000 copies/µl, green=1,000 copies/µl, pink=100 
copies/µl, light blue=10 copies/µl, orange=1 copy/µl, and grey=negative control 
 
 
 
R2=1.0
0 
R2=1.0
0 
R2=1.0
0 
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6.3.3 Detection of O. tsutsugamushi DNA by 47kDa qPCR assay  
 Acute buffy coat specimens from 811 patients were tested using the 47kDa qPCR 
assay for the detection of O tsutsugamushi DNA. Of these, 1.6% (13/811) of the patients 
were given a positive result. 
 Quantification of the O. tsutsugamushi DNA in positive acute buffy coat specimens 
was obtained from 4/13 specimens using the 47kDa qPCR assay. The copy number ranged 
from 12.0 to 25.6 copies/µl of DNA extract (600 to 1,280 copies/ml of blood) with a 
median of 18.1 copies/µl of DNA extract (905 copies/ml of blood). The quantification of 
the other 9/13 positive specimens was lower than the accurate quantification threshold 
(<10 copies/µl of DNA extract). Thus, the actual quantification was not reported (Table 
6.3). Of all 13 patients with acute buffy coat specimens positive in the 47kDa qPCR assay, 
10 patients were confirmed as having acute scrub typhus infection by the results of the 
reference tests, and the other three positives were from non-acute scrub typhus cases (no 
diagnosis). Of 10 confirmed scrub typhus cases, the quantification of the O. tsutsugamushi 
DNA was obtained from 3/10 specimens. The copy number ranged from 12.0 to 22.4 
copies/µl of DNA extract (600 to 1,120 copies/ml of blood) with a median of 13.8 
copies/µl of DNA extract (690 copies/ml of blood). The quantification of the other 7/10 
positive specimens was not reported, since they were lower than the accurate quantification 
threshold (<10 copies/µl of DNA extract). For the three positive specimens from non-acute 
scrub typhus cases, the quantification was obtained from only one specimen which was 
25.6 copies/µl of DNA extract (1,280 copies/ml of blood). 
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Table 6.3 Quantification of O. tsutsugamushi DNA in positive acute buffy coat 
specimens using 47kDa qPCR assay. 
 
Number of 47kDa qPCR 
positive (%) 
Median copies/µl of DNA 
extract (range) 
4 (30.8) 18.1 (12.0-25.6) 
9 (69.2) <10 All positive 47kDa qPCR 
13 (100)  
3 (30.0) 13.8 (12.0-22.4) 
7 (70.0) <10 Acute scrub typhus* 
10 (100)  
1 (33.3) 25.6 (25.6-25.6) 
2 (66.7) <10 Not acute scrub typhus 
3 (100)  
47kDa qPCR= quantitative real-time PCR targeting 47kDa 
*Confirmed diagnosis of acute scrub typhus infection by IgM ELISA/IFA using paired 
acute and convalescent specimens 
6.3.4 Detection of scrub typhus IgM antibody by the Scrub typhus IgM ICT 
 The SD BIOLINE Scrub typhus IgM ICT (Standard diagnostics, Inc.) was available 
for 810 tests and these results were included in the current analysis. The overall results of 
the test read by three independent readers were slightly different as shown in Table 6.4. 
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Table 6.4 Scrub typhus IgM antibody ICT results (n=810) read by three 
independent readers. 
Tests Reader 1 Reader 2 Reader 3 Final results 
 Positive Negative Positive Negative Positive Negative Positive Negative 
IgM 62 748 63 747 71 739 62 748 
 
6.3.5 Inter-operator variation for interpretation of the Scrub typhus IgM ICT 
results 
 The inter-operator variation in reading the results of the ICT was assessed using 
Kappa statistics. The result of the test was easy to read. There was excellent inter-operator 
agreement amongst three readers (Kappa=0.9445). The consensus results (i.e. 2/3 readers 
with the same interpretation) were then used for the final results (Table 6.4) and further 
analysis. 
6.3.6 Diagnostic accuracy of scrub typhus diagnostic tests  
 The performance characteristics of 47kDa qPCR assay and scrub typhus IgM 
antibody detection ICT (IgM ICT) for early diagnosis of the scrub typhus infection on the 
acute specimens compared to the reference tests are shown in Table 6.5. Both tests had 
high specificity (99.6 and 93.5% for 47kDa qPCR and IgM ICT, respectively), but poor 
sensitivity (22.7 and 27.3% for 47kDa qPCR and IgM ICT, respectively). The sensitivity 
improved when combining the 47kDa qPCR and the IgM ICT (36.4%), although, the 
specificity fell slightly compared to the 47kDa qPCR alone, but it remained high (93.2%). 
There was no difference between the sensitivity of the 47kDa qPCR and the IgM ICT 
(P=0.5217). The sensitivity of the combination of 47kDa qPCR and IgM ICT (47kDa 
qPCR+IgM ICT) was significantly higher than the 47kDa qPCR or the IgM ICT alone 
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(P=0.0143 and P=0.0455). The AUC of 47kDa qPCR, IgM ICT, and combination of 
47kDa qPCR+IgM ICT were poor (0.61, 0.60, and 0.65, respectively).  
 Correlation between the IgM ICT results and IgM IFA titres on acute specimens 
from patients with confirmed acute scrub typhus infection is shown in Table 6.6. Most 
patients with confirmed acute scrub typhus infection had low IgM IFA titres of ≤1:400 in 
the acute specimens (42/44 patients) and this correlated with the positivity rate of the IgM 
ICT, which was low in these specimens. The positivity rate of the IgM ICT was higher in 
acute specimens with high IgM IFA titres, however the number of patients with high IgM 
IFA titres on acute specimens was small. 
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Table 6.5 Performance characteristics of the scrub typhus IgM ICT and 47kDa qPCR on acute specimens compared to reference tests for 
early diagnosis of acute scrub typhus infection (n=810). 
Tests  Reference results* 
%Sensitivity 
(95% CI) 
%Specificity 
(95% CI) 
%PPV  
(95% CI) 
%NPV  
(95% CI) 
AUC 
  Scrub typhus Not scrub typhus      
47kDa qPCR + 10 3 22.7 (11.5-37.8) 99.6 (98.9-99.9) 76.9 (46.2-95.0) 95.7 (94.1-97.0) 0.6117 
 - 34 763      
IgM ICT + 12 50 27.3 (15.0-42.8) 93.5 (91.5-95.1) 19.4 (10.4-31.4) 95.7 (94.0-97.1) 0.6037 
 - 32 716      
47kDa qPCR+IgM ICT + 16 52 36.4 (22.4-52.2) 93.2 (91.2-94.9) 23.5 (14.1-35.4) 96.2 (94.6-97.5) 0.6479 
 - 28 714      
47kDa qPCR= quantitative real-time PCR targeting 47kDa, AUC= area under ROC curve, CI= confidence interval, IgM ICT= IgM antibody detection 
immunochromatographic test, NPV= negative predictive value, PPV= positive predictive value 
*IgM ELISA/IFA using paired acute and convalescent specimens 
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Table 6.6 Correlation between scrub typhus IgM antibody detection ICT results 
and IgM IFA titres on acute specimens from patients with confirmed acute scrub 
typhus infection* (n=44). 
Scrub typhus IgM ICT results 
IgM IFA titres 
Negative (%) Positive (%) 
Total 
<1:100 17 (89.5) 2 (10.5) 19 
1:100 7 (70.0) 3 (30.0) 10 
1:200 7 (87.5) 1 (12.5) 8 
1:400 1 (20.0) 4 (80.0) 5 
1:800 0 (0) 1 (100) 1 
1:25600 0 (0) 1 (100) 1 
Total 32 (72.7) 12 (27.3) 44 
IgM ICT= IgM antibody detection immunochromatographic test, IgM IFA= IgM antibody 
detection indirect immunofluorescent assay 
*Confirmed diagnosis of acute scrub typhus infection by IgM ELISA/IFA using paired 
acute and convalescent specimens 
6.3.7 Detection of Rickettsia spp. and R. typhi by 17kDa and ompB qPCR 
assays/sequencing confirmed R. typhi 
 Acute buffy coat specimens from 811 patients were tested using the 17kDa qPCR 
assay for the detection of Rickettsia spp. DNA. Of these, 2.8% (23/811) of the patients 
were given a positive result. 
 All DNA extracts from 23 acute buffy coat specimens that were positive by the 
17kDa qPCR assay were then tested using ompB qPCR assay for the detection of R. typhi 
DNA. Of these, 78.3% (18/23) of the patients were given a positive result. For the other 
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five ompB negative specimens, one was identified as R. typhi, one was R. felis, and three 
were unable to be identified by sequencing, since good quality DNA could not be obtained 
(very low positive). 
Therefore, there were a total of 19 patients with acute buffy coat specimens 
positive for 17kDa qPCR assay and confirmed to have R. typhi by ompB qPCR/sequencing 
assay. Of these, 17 patients were confirmed to have acute murine typhus infection by the 
reference tests and two patients were not confirmed to have acute murine typhus infection. 
All 17kDa qPCR positive specimens were determined to have less than 10 copies/µl of 
DNA extract, below the accurate quantification threshold.  
6.3.8 Diagnostic accuracy of murine typhus diagnostic test 
 For murine typhus, the performance characteristics of the 17kDa qPCR assay were 
evaluated. This assay was performed as a screening test for the detection of Ricksttsia spp. 
and the ompB qPCR assay was performed on all specimens that were positive by the 
17kDa qPCR assay to identify the detection of R. typhi. Therefore, only specimens that 
were positive for both 17kDa qPCR and ompB qPCR/sequencing confirmed R. typhi were 
included in the current analysis. The performance characteristics of the 17kDa qPCR assay 
for the early diagnosis of the acute murine typhus infection on the acute specimens 
compared to the reference tests are shown in Table 6.7. The 17kDa qPCR had excellent 
specificity (99.7%), but the sensitivity was poor (31.5%). The AUC of the assay was also 
poor (0.66).  
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Table 6.7 Performance characteristics of the 17kDa qPCR on acute specimens compared to reference tests for early diagnosis of acute 
murine typhus infection (n=811). 
 Reference resultsb Test 
 Murine typhus Not Murine typhus 
%Sensitivity 
(95% CI) 
%Specificity 
(95% CI) 
%PPV (95% CI) %NPV (95% CI) AUC 
17kDa qPCRa + 17 2 31.5 (19.5-45.6) 99.7 (99.0-100) 89.5 (66.9-98.7) 95.3 (93.6-96.7) 0.6561 
 - 37 755      
17kDa qPCR= quantitative real-time PCR targeting 17kDa, AUC= area under ROC curve, CI= confidence interval, NPV= negative predictive value, 
PPV= positive predictive value 
aSpecimens positive for 17kDa and ompB qPCR assays/sequencing confirmed R. typhi 
bIgM ELISA/IFA using paired acute and convalescent specimens 
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6.3.9 Effect of fever duration at presentation on diagnostic test sensitivity for early 
diagnosis of acute scrub typhus and acute murine typhus infections 
 For scrub typhus infection, the effect of fever duration at the time of presentation 
on the sensitivity of the diagnostic tests is shown in Figure 6.3. For the 47kDa qPCR assay 
alone, there were no positive specimens in patients presenting with one and five days of 
fever. The sensitivity of the 47kDa qPCR in patients presenting between two and four days 
and at six days of fever was around 20-30%. The sensitivity peaked in patients presenting 
with seven days of fever, although the numbers of patients presenting with six and seven 
days of fever were small. For the IgM ICT alone, the sensitivity was low at the beginning 
and increased later, peaking in patients presenting with four days of fever (66.7%). 
 The sensitivity of the 47kDa qPCR+IgM ICT combination was improved in 
patients presenting with two days of fever (38.9%) and covered the gap for patients 
presenting with one and five days of fever when the 47kDa qPCR alone was unable to 
detect scrub typhus infection. The overall numbers of patients presenting after three days 
of fever were small and the confidence intervals around the sensitivity were very wide 
(Figure 6.3). 
 For murine typhus infection, the sensitivity of the 17kDa qPCR assay varied 
between 25.0 and 55.6% by duration of fever. The sensitivity was 50.0% in patients 
presenting with one day of fever. The sensitivity decreased to below 30.0% in patients 
presenting with two and three days of fever, and increased again in patients with four and 
five days of fever (55.6%). The sensitivity slightly decreased again in patients presenting 
with six days of fever (33.3%). There were no positive specimens for 17kDa qPCR in 
patients presenting with seven days of fever (Figure 6.4). 
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Figure 6.3 Effect of fever duration at presentation on tests sensitivity for early 
diagnosis of acute scrub typhus infection (n=810). 
(A) 47kDa qPCR, (B) IgM ICT, and (C) combination of 47kDa qPCR and IgM ICT 
*No positive 47kDa qPCR in patients presenting with one and five days of fever 
(A)* (B) 
(C) 
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Figure 6.4 Effect of fever duration at presentation on the sensitivity of the 17kDa 
qPCR assay for early diagnosis of acute murine typhus infection (n=811). 
Note: there were no positive 17kDa qPCR in patients presenting with seven days of fever 
6.3.10 Impact of malaria infection on the diagnostic accuracy of the tests for early 
diagnosis of acute scrub typhus infection 
For the scrub typhus diagnostic tests, 810 non-malaria febrile patients were 
included in the current analysis. Malarial DNA was detected in 139 patients by 18S rRNA 
qPCR assay (sub-microscopic malaria infection). The malarial DNA was detected in 
22.7% (10/44) of patients with laboratory confirmed diagnosis of acute scrub typhus 
infection and was detected in 16.8% (129/766) of patients with laboratory confirmed non-
acute scrub typhus infection by the reference tests.  
The impact of malaria infection on the performance characteristics of the diagnostic 
tests under evaluation for early diagnosis of acute scrub typhus infection was assessed by 
stratified diagnostic accuracies of the tests in malaria qPCR positive patients (Table 6.8) 
and malaria qPCR negative patients (Table 6.9). The sensitivity of 47kDa qPCR assay was 
higher in malaria positive patients (30.0%) compared to the negative patients (20.6%), 
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however the number of true positive and false negative in malaria positive patients were 
small and the 95% CI around the sensitivity were wide. These differences were not 
statistically significant. The sensitivity of the IgM ICT and the combination of 47kDa 
qPCR+IgM ICT was lower in malaria positive patients (20.0 and 30.0% for IgM ICT and 
47kDa qPCR+IgM ICT, respectively) compared to the negative patients (29.4 and 38.2% 
for IgM ICT and 47kDa qPCR+IgM ICT, respectively). They were also not significantly 
different. 
Similarly, the specificity of 47kDa qPCR was higher in malaria positive patients 
(100 vs. 99.5%) and the specificity of the IgM ICT and the combination of 47kDa 
qPCR+IgM ICT was lower in malaria positive patients (88.4 vs. 94.5% and 88.4 vs. 94.2% 
for IgM ICT and 47kDa qPCR+IgM ICT, respectively). These differences were not 
statistically significant. There was not enough evidence to prove that malaria infection had 
a significant impact on the diagnostic accuracies of the tests under this evaluation. In 
addition, the overall clinical sensitivity of the 47kDa qPCR (22.7%), IgM ICT (27.3%) and 
the combination of 47kDa qPCR+IgM ICT (36.4%) was generally poor (Table 6.5) and 
they were not much different to the sensitivity of both malaria positive and negative 
patients when stratified.  
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Table 6.8 Impact of malaria infection on the performance characteristics of the diagnostic tests for early diagnosis of acute scrub typhus 
infection in malaria qPCR positive patients (n=139). 
 Reference results* Tests 
 Scrub typhus Not Scrub typhus 
%Sensitivity 
(95% CI) 
%Specificity 
(95% CI) 
%PPV  
(95% CI) 
%NPV  
(95% CI) 
AUC 
47kDa qPCR + 3 0 30.0 (6.7-65.2) 100 (97.2-100) 100 (29.2-100) 94.9 (89.7-97.9) 0.6500 
 - 7 129           
IgM ICT + 2 15 20.0 (2.5-55.6) 88.4 (81.5-93.3) 11.8 (1.5-36.4) 93.4 (87.5-97.1) 0.5419 
 - 8 114           
47kDa qPCR+IgM ICT + 3 15 30.0 (6.67-65.2) 88.4 (81.5-93.3) 16.7 (3.6-41.4) 94.2 (88.4-97.6) 0.5919 
 - 7 114           
47kDa qPCR= quantitative real-time PCR targeting 47kDa, AUC= area under ROC curve, CI= confidence interval, IgM ICT= IgM antibody detection 
immunochromatographic test, NPV= negative predictive value, PPV= positive predictive value 
*IgM ELISA/IFA using paired acute and convalescent specimens 
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Table 6.9 Impact of malaria infection on the performance characteristics of the diagnostic tests for early diagnosis of acute scrub typhus 
infection in malaria qPCR negative patients (n=671). 
 Reference results* Tests 
 Scrub typhus Not Scrub typhus 
%Sensitivity 
(95% CI) 
%Specificity 
(95% CI) 
%PPV  
(95% CI) 
%NPV  
(95% CI) 
AUC 
47kDa qPCR + 7 3 20.6 (8.7-37.9) 99.5 (98.6-99.9) 70.0 (34.8-93.3) 95.9 (94.1-97.3) 0.6006 
 - 27 634           
IgM ICT + 10 35 29.4 (15.1-47.5) 94.5 (92.4-96.1) 22.2 (11.2-37.1) 96.2 (94.3-97.5) 0.6196 
 - 24 602           
47kDa qPCR+IgM ICT + 13 37 38.2 (22.2-56.4) 94.2 (92.1-95.9) 26.0 (14.6-40.3) 96.6 (94.9-97.9) 0.6621 
 - 21 600           
47kDa qPCR= quantitative real-time PCR targeting 47kDa, AUC= area under ROC curve, CI= confidence interval, IgM ICT= IgM antibody detection 
immunochromatographic test, NPV= negative predictive value, PPV= positive predictive value 
*IgM ELISA/IFA using paired acute and convalescent specimens 
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6.3.11 Impact of malaria infection on the diagnostic accuracy of the 17kDa qPCR 
assay for early diagnosis of acute murine typhus infection 
For the murine typhus diagnostic test, 811 non-malaria febrile patients were 
included in the current analysis. Of the 139 patients with sub-microscopic malaria 
infection, malarial DNA was detected in 3.7% (2/54) of patients with laboratory confirmed 
diagnosis of acute murine typhus infection and was detected in 18.1% (137/757) of 
patients with laboratory confirmed non-acute murine typhus infection by the reference 
tests. The impact of malaria infection on the performance characteristics of the 17kDa 
qPCR assay for early diagnosis of acute murine typhus infection was assessed by stratified 
diagnostic accuracies of the test in malaria qPCR positive patients (Table 6.10) and malaria 
qPCR negative patients (Table 6.11). The sensitivity of 17kDa qPCR assay was higher in 
the malaria positive patients (50.0%) compared to the negative patients (30.8%), however 
the number of patients with positive test in malaria positive group was small and the 95% 
confidence interval around the sensitivity was very wide. The specificity was similar 
between the malaria positive (99.3%) and negative (99.8%) patients which was very high. 
Similar to the performance of the scrub typhus diagnostic tests, the sensitivity of the 17kDa 
qPCR assay was generally poor (31.5%, Table 6.7) and not clinically useful. 
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Table 6.10 Impact of malaria infection on the performance characteristics of the 17kDa qPCR assay for early diagnosis of acute murine 
typhus infection in malaria qPCR positive patients (n=139). 
 Reference resultsb Test 
 Murine typhus Not Murine typhus 
%Sensitivity 
(95% CI) 
%Specificity 
(95% CI) 
%PPV  
(95% CI) 
%NPV  
(95% CI) 
AUC 
17kDa qPCRa + 1 1 50.0 (1.3-98.7) 99.3 (96.0-100) 50.0 (1.3-98.7) 99.3 (96.0-100) 0.7464 
 - 1 136           
17kDa qPCR= quantitative real-time PCR targeting 17kDa, AUC= area under ROC curve, CI= confidence interval, NPV= negative predictive value, 
PPV= positive predictive value 
aSpecimens positive for 17kDa and ompB qPCR assays/sequencing confirmed R. typhi 
bIgM ELISA/IFA using paired acute and convalescent specimens 
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Table 6.11 Impact of malaria infection on the performance characteristics of the 17kDa qPCR assay for early diagnosis of acute murine 
typhus infection in malaria qPCR negative patients (n=672). 
 Reference resultsb Test 
 Murine typhus Not Murine typhus 
%Sensitivity 
(95% CI) 
%Specificity 
(95% CI) 
%PPV  
(95% CI) 
%NPV  
(95% CI) 
AUC 
17kDa qPCRa + 16 1 30.8 (18.7-45.1) 99.8 (99.1-100) 94.1 (71.3-99.9) 94.5 (92.5-96.1) 0.6530 
 - 36 619           
17kDa qPCR= quantitative real-time PCR targeting 17kDa, AUC= area under ROC curve, CI= confidence interval, NPV= negative predictive value, 
PPV= positive predictive value 
aSpecimens positive for 17kDa and ompB qPCR assays/sequencing confirmed R. typhi 
bIgM ELISA/IFA using paired acute and convalescent specimens 
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6.4 Discussion 
  Rapid and accurate diagnostic tests are urgently needed for the diagnosis of 
rickettsial infections, especially in endemic areas where the infections are potentially 
serious and require specific treatment but cannot be reliably distinguished from other 
causes of fever, potentially resulting in incorrect treatment and under-reporting [172, 294]. 
Without laboratory diagnostic tests, it is almost impossible to differentiate scrub typhus 
and murine typhus infections from the other causes of fever based on the clinical 
presentation alone as shown in the current study where none of the febrile patients were 
clinically diagnosed with murine typhus infection and only one patient was clinically 
diagnosed with scrub typhus infection. 
 In the current study, the performance characteristics and clinical usefulness of an 
IgM ICT and two real-time qPCR assays were evaluated for the early diagnosis of scrub 
typhus (IgM ICT and 47kDa qPCR) and murine typhus (17kDa qPCR) infections during 
acute phase of febrile illness. For the scrub typhus IgM ICT, the overall performance was 
poor with a clinical sensitivity of 27.3%. Although the specificity was high (93.5%), the 
PPV and NPV were 19.4 and 95.7%, respectively. This would result in many misdiagnosed 
cases if the test was to be used alone. The low sensitivity of the IgM ICT could be due to 
the different antigens of O. tsutsugamushi used in the test compared to the reference tests 
(IgM ELISA/IFA) [229]. The Karp and Gilliam strains are predominant in Thailand [295] 
and the Karp, Gilliam and Kato strains were used as antigens for the reference tests in this 
study whereas the Boryong strain was used for the IgM ICT. 
 Duration of fever at presentation had an impact on the IgM ICT in this evaluation, 
since most patients presented very early in the course of their fever (median of two days 
[IQR 2-3]) when the IgM antibody had not reached the detectable level [189]. This was 
also true when looking at the IgM antibody titres in acute specimens tested by the IgM IFA 
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assay. Most of the patients with confirmed acute scrub typhus infection had low IgM IFA 
titres (84.1%) which were <1:400 [206] and had ≥4-fold increased titres in convalescent 
specimens which were collected two weeks later. 
 Both real-time qPCR assays were previously shown to have excellent laboratory 
specificity and sensitivity (three copies/µl for both assays) [210, 217, 223]. Following the 
validation of the assays with the ABI 7500 FAST real-time PCR system (Applied 
Biosystems), the assays also retained excellent laboratory sensitivity and specificity. They 
were capable of detecting as little as 1-10 copies of target template per reaction (1-10 
copies/µl of DNA extract). The diagnostic accuracy and clinical utility of using these 
qPCR assays were then evaluated using acute specimens. Despite the great laboratory 
sensitivity and specificity of the assays during validation that could potentially be used for 
diagnosis, the clinical sensitivity was disappointing, with 22.7 and 31.5% for 47kDa and 
17kDa assays, respectively. However, excellent clinical specificities were obtained from 
both assays (99.6 and 99.7% for 47kDa and 17kDa qPCRs, respectively). There are several 
explanations for this. Firstly, the low clinical diagnostic sensitivity was attributed to low 
bacterial loads. The median O. tsutsugamushi bacterial loads from 30.8% (4/13) 
quantifiable positive specimens were 905 copies/ml of blood (range 600-1,280). This 
corresponded to 18 copies/reaction (range 12.0-25.6). The quantitative data suggested that 
the bacterial loads in blood during rickettsial illness were too low to be reliably detectable 
using molecular methods. In particular, the number of positive results below the accurate 
quantification level obtained from both assays is indicative of analyte levels below the 
threshold of the assay accurate detection (<10 copies/reaction). At such quantities, they are 
not always reliably detectable as defined by the MIQE guideline [296]. The molecular 
diagnostic challenges for scrub typhus and murine typhus infections with low bacterial 
loads have been described elsewhere and the data suggested that O. tsutsugamushi 
bacterial loads were approximately 10-fold higher than R. typhi bacterial loads in patients 
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from Thailand and Laos [230]. This is in line with the results in the present study where the 
O. tsutsugamushi bacterial loads seem to be higher as 30.8% (4/13) of them were 
quantifiable, although the number was small. To improve the assay detection limit, 
increasing the specimen volume can be performed, however it requires an optimisation as 
it also increases the human genomic DNA that could have a negative impact on the 
performance of the test and it might not be feasible in some clinical settings. Molecular 
methods generally have an advantage over serological methods as they are able to detect 
bacterial DNA during early rickettsial illness when the antibody is rarely detectable [189]. 
However, they did not show much advantage in the present study, since the overall 
sensitivity of the qPCR assays was low and there were insufficient data when stratified by 
duration of fever at presentation. 
 Secondly, laboratory confirmation in this evaluation was based on the results of 
gold standard paired serology using IgM ELISA/IFA assays, of which IFA is known to be 
an imperfect gold standard. Interpretation of IFA results is inherently subjective and it is 
difficult to standardise due to various, or lack of, local cut-offs [191, 202]. This may be 
affecting the diagnostic accuracy of the tests under evaluation, however, the conservative 
four-fold rising titres between paired acute and convalescent specimens were used in the 
current evaluation. The recent robust Scrub Typhus Infection Criteria (STIC; a 
combination of culture, IgM IFA, and PCR assays) was reported, which provided a high 
confidence in confirmed diagnosis and was proposed to be used as a reference for 
evaluating alternative diagnostic tests [228, 229]. However, it was not possible to fully 
implement in the current evaluation, since BSL-3 facilities were not available at SMRU for 
performing culture of the organisms and only one PCR assay was available which was 
under evaluation. Moreover, the low specificity of the STIC due to the low specificity of 
the IgM IFA was reported with Bayesian LCMs, the most recent analysis method to 
estimate the true accuracy of diagnostic tests where the gold standard is imperfect [195].  
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 The impact of malaria infection on the performance characteristics of the diagnostic 
tests was assessed. Both qPCR assays and the IgM ICT remained highly specific and 
poorly sensitive independent of malaria infection status.  
 In summary, despite the excellent specificity of the IgM ICT, 47kDa and 17kDa 
qPCR assays, all of them had poor sensitivity and were not appropriate to use as an early 
diagnostic tool for scrub typhus and murine typhus infections. This study highlights the 
need for rapid and accurate early diagnostic tools for scrub typhus and murine typhus 
infections. 
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7 Implementation of a leptospirosis qPCR assay 
7.1 Introduction and aim 
Laboratory diagnosis is important to confirm leptospirosis because clinical 
diagnosis is difficult and inaccurate due to its broad range and non-specific clinical 
presentations. The diagnosis of leptospirosis by the gold standard serology, MAT, or 
culture requires an experienced laboratory. These assays are time consuming, laborious 
and available at the reference laboratories, resulting in diagnosis delays. RDTs are easy to 
use as rapid bedside tests, but lack accuracy for early diagnosis of acute infection [146]. 
Detection of nucleic acid, for example by PCR, is useful during the acute phase of 
infection. This chapter describes the validation and implementation of the leptospirosis 
qPCR assay. Since there were no leptospirosis diagnostic tests available at SMRU at the 
time of the study, the aims were to introduce, validate and implement the 16S rRNA qPCR 
assay for detection of Leptospira spp. DNA in acute phase specimens for early diagnosis of 
leptospirosis. 
7.2 Materials and Methods 
7.2.1 Patient specimens and methods 
Acute plasma specimens from 908 non-malaria febrile patients were tested using 
the 16S rRNA qPCR assay to detect the Leptospira DNA for early diagnosis of acute 
leptospirosis infection. 
The 16S rRNA qPCR assay was validated at SMRU laboratory using ABI 7500 
FAST real-time PCR system (Applied Biosystems). The LoD of the assay was assessed to 
determine the laboratory sensitivity of the assay for the detection of Leptospira DNA. A 
10-fold serial dilution of the linearised plasmid DNA standard control from L. interrogans 
starting from 10,000 to 1 copies/µl was constructed and tested in duplicate. The assay 
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validation was performed for 20 replicates (each 10-fold serial dilution was tested in 
duplicate for 10 qPCR runs). An average R2 value (coefficient of correlation) obtained for 
the standard curve and efficiency of the qPCR assay were reported. Specificity of the assay 
was determined by testing with 1.0 ng/µl of the following organisms: E. faecalis, E. coli, 
P. falciparum, P. vivax, Ps. aeruginosa, S. aureus, Streptococcus Group B and S. 
pneumoniae, and 3.3-33.3 PFU/µl of DENV1-4 mix. 
 Bacterial loads were calculated with the following formula: number of the target 
DNA copies/ml of plasma = [(number of copies/µl of DNA template)/2] x 1,000. Number 
of copies/µl of DNA template were calculated using 10-fold serial dilution of the linearised 
plasmid DNA (10,000-1 copies/µl), resulting in numbers of copies/µl of DNA extract. The 
factor 2 adjusted for the 1:2 ratio of DNA extract to plasma, resulting in number of 
copies/µl of plasma. The factor 1,000 corrected for the copies/µl of plasma to copies/ml of 
plasma. The Leptospira spp. have two copies of the 16S rRNA gene [150], therefore the 
number of copies/ml of plasma is divided by 2 resulting in the number of genomic 
equivalent (GE)/ml of plasma. 
7.2.2 Data analysis 
Data were analysed using STATA/SE 10.1 (StataCorp LP). The agreement between 
clinical diagnosis and laboratory diagnosis of acute leptospirosis infection was calculated 
using Kappa statistics [286]. 
7.3 Results 
7.3.1 Laboratory sensitivity and specificity of 16S rRNA qPCR assay 
The laboratory sensitivity of the 16S rRNA qPCR assay was determined to be 1 
copy/µl or 0.5 GE/µl of DNA template (equivalent to 500 copies/ml or 250 GE/ml of 
plasma). All 20 replicates were positive for each dilution point (100% repeatability and 
reproducibility). Following the validation of the assay, an optimal fluorescence threshold 
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was set at 10,000 for all qPCR runs. Standard curves were generated from the 
amplification plots. The average R2 value of the standard curves was 1.00 and the assay 
efficiency was 95.7%. Figure 7.1 shows examples of amplification curve and standard 
curve for a qPCR run of the assay. For the laboratory specificity, this assay was specific as 
there were no amplifications for all other organisms tested using this cut-off threshold. 
  
Figure 7.1 Amplification curve and standard curve analysis of the 16S rRNA 
qPCR for the detection of Leptospira DNA. 
Legend: blue=10,000 copies/µl, red=1,000 copies/µl, green=100 copies/µl, pink=10 
copies/µl, light blue=1 copy/µl, and grey=negative control.  
7.3.2 Detection of Leptospira DNA by 16S rRNA qPCR assay 
 Acute plasma specimens from 908 febrile patients were tested using the 16S rRNA 
qPCR assay for the detection of Leptospira DNA. Of these, 7.5% (68/908) of the patients 
were given a positive result. Quantification of the Leptospira DNA was obtained from 68 
positive plasma specimens. The copy number ranged from 1.0 to 297.4 copies/µl of DNA 
extract with a median of 6.9 copies/µl of DNA extract (IQR 3.4-18.6), equivalent to 250 to 
74,350 GE/ml of plasma with a median of 1,725 GE/ml of plasma (IQR 850-4,650). 
R2=0.99 
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 Presumptive diagnoses were given at the clinics based on clinical presentations. Of 
the 908 patients, 20.2% (183/908) were clinically diagnosed with leptospirosis infection. 
The agreement between clinical diagnosis and the laboratory diagnosis for acute 
leptospirosis infection was poor (Kappa = 0.0602) (Table 7.1). The clinical diagnoses for 
patients with the laboratory diagnosis of acute leptospirosis are shown in Table 7.2. Of the 
68 patients with the laboratory diagnosis of acute leptospirosis infection, 41.2% (28/68) of 
the patients were clinically diagnosed with leptospirosis at presentation. 
Table 7.1 Clinical diagnosis and laboratory diagnosis of acute leptospirosis 
infection. 
Laboratory diagnosis 
 Clinical diagnosis 
Leptospirosis Not leptospirosis 
Total 
Leptospirosis (%) 28 (41.2) 155 (18.5) 183 (20.2) 
Not leptospirosis (%) 40 (58.8) 685 (81.5) 725 (79.8) 
Total (%) 68 (100) 840 (100) 908 (100) 
 
Table 7.2 Clinical diagnosis for patients with the laboratory diagnosis of acute 
leptospirosis infection. 
Clinical diagnosis Laboratory diagnosis of acute leptospirosis cases (%) 
Leptospirosis 28 (41.2) 
Unknown fever 27 (39.7) 
Dengue 6 (8.8) 
Scrub typhus 4 (5.9) 
Typhoid 2 (2.9) 
Sepsis 1 (1.5) 
Total 68 (100) 
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7.4 Discussion 
Clinical presentations of leptospirosis are often confused with other causes of fever, 
as shown in the present study where only 15.3% (28/183) of patients who were clinically 
diagnosed with leptospirosis had laboratory diagnosis of acute leptospirosis infection. It is 
therefore important to confirm diagnosis of this infection by the laboratory. 
This chapter describes the validation and implementation of the 16S rRNA qPCR 
assay for leptospirosis diagnosis. The 16S rRNA qPCR assay for the detection of 
Leptospira spp. DNA was evaluated and used instead of the gold standard serology, MAT, 
as it was not available at SMRU at the time of the study. From this evaluation, the assay 
was found to be both sensitive and specific when using control nucleic acids. The 
analytical sensitivity of the assay was 1 copy/µl or 0.5 GE/µl of DNA template. The 
sensitivity was similar to the previously published paper from MORU where the analytical 
sensitivity was 10 GE/reaction or equivalent to 2 GE/µl of DNA template [149]. The 
specimen type, specimen volume and extraction method used in this study were different 
from the study published by MORU. In the present study, 200µl of plasma specimen was 
extracted using the MagCore HF16 automated magnetic platform (RBC Bioscience), and 
elution volume was 100µl, whereas at MORU 5ml of whole blood specimen was extracted 
using the Nucleon BACC Genomic DNA extraction kit (GE Healthcare Bioscience, 
Marlborough, MA, USA), and elution volume was 1ml. As these factors could have 
affected the clinical diagnostic accuracy of the test, further study to evaluate their impact is 
warranted. Although, the concentration factor between the method of MORU (1:5) and this 
study (1:2) was not so different. 
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8 Practical implications in the absence of the gold standard 
diagnostic tests 
8.1 Introduction and aims 
Differential diagnosis for non-malaria causes of AUFI is challenging in clinical 
settings where laboratory diagnostic tests are inadequate. Current gold standard diagnostic 
tests, usually based on culture of organisms or paired serology, are unsuitable for clinical 
use as they may take days to weeks for results. Thus, they are unable to provide results 
quickly enough to aid patient management [120, 191]. There is an urgent requirement for 
accurate and rapid diagnostic tests to identify the causes of non-malaria AUFI during the 
acute phase of infection. This chapter describes the practical implications of using non-
gold standard diagnostic tests (referred to here as alternative tests) that are available in the 
SMRU setting to determine the causes of non-malaria AUFI in the absence of the gold 
standard diagnostic tests. The aim was to determine the causes of non-malaria AUFI in 
patients presenting with fever where a definitive diagnosis cannot be made in the field with 
a clinical useful turnaround time. 
8.2 Materials and Methods 
8.2.1 Patient specimens and methods 
Acute blood specimens from 908 non-malaria febrile patients were tested using 
alternative diagnostic tests as shown in Table 8.1Error! Reference source not found.. 
Plasma specimen was used to perform rRT-PCR and ICT assays for diagnosis of acute 
dengue virus infection, 16S rRNA qPCR assay for acute leptospirosis infection and ICT for 
acute scrub typhus infection. Buffy coat specimen was used to perform 47kDa, 17kDa, 
ompB qPCRs and sequencing for acute rickettsial infections. Whole blood was used to 
perform blood culture for invasive bacterial infection.  
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In addition to the diagnosis of acute dengue virus infection by the alternative 
diagnostic tests as described above, the serotype of dengue virus was identified using a 
nested-RT PCR assay [74, 80]. This assay was performed using RNA extracts from all 
positive specimens by the dengue rRT-PCR assay. The details of all laboratory methods 
and their interpretations are described in the Materials and Methods chapter, section 2.9. 
Table 8.1 Alternative diagnostic tests used for testing acute blood specimens. 
Diseases  Diagnostic tests 
Dengue Dengue group specific one-step SYBR Green based 
rRT-PCR [16, 259], and SD BIOLINE Dengue Duo 
NS1, IgM/IgG ICT (Standard diagnostic, Inc.)a 
Leptospirosis  16S rRNA (Leptospira spp.) qPCR [147, 149, 150] 
Scrub typhus 47kDa qPCR [210], and SD BIOLINE Scrub typhus 
IgM ICT (Standard diagnostic, Inc.) b 
Murine typhus and other 
Rickettsia spp.c 
17kDa qPCR, ompB qPCR [217, 218], and Sequencing 
(Macrogen) 
Invasive bacterial infections BacT/ALERT blood culture (BioMérieux) 
aAnalysed using the results of NS1 and IgM for the SD BIOLINE Dengue Duo, bSD 
BIOLINE Scrub typhus IgM ICT was available for 898 tests, cSequencing was performed 
on 17kDa positive/ompB negative qPCR specimens to confirm Rickettsia spp. 
8.2.2 Data analysis 
 Data were analysed using STATA/SE 10.1 (StataCorp LP) and graphs were created 
using Microsoft Excel 2010 (Microsoft). Positive results of each alternative diagnostic test 
were combined using “OR” operator to determine the proportion of patients for each 
diagnosis. 
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8.3 Results 
8.3.1 Diagnosis by alternative tests 
 All available alternative diagnostic tests in the SMRU setting were used and 
included in the current analysis for early diagnosis of acute infection on acute phase of 
specimens (Table 8.1). Regardless of the results of gold standard diagnostic tests for 
dengue, leptospirosis and rickettsial infections, of the 908 non-malaria febrile patients, 
20.2% (183/908) of the patients were diagnosed with dengue, followed by 6.8% (62/908) 
for scrub typhus, 6.5% (59/908) for leptospirosis, and 1.9% (17/908) for murine typhus. 
The proportions of other diagnoses and co-infections were small (4.0%, 36/908), leaving 
60.7% (551/908) of the patients with no diagnosis for their fever (Figure 8.1). The details 
of the other diagnoses and co-infections are shown in Table 8.2.  
 
Figure 8.1 Diagnosis of 908 non-malaria febrile patients based on the results of 
alternative diagnostic tests. 
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Table 8.2 Other diagnoses and co-infections based on the results of alternative 
diagnostic tests. 
Diagnoses Number of patients (%) 
Invasive bacterial infection* 11 (1.2) 
Dengue/ Scrub typhus 10 (1.1) 
Leptospirosis/ Scrub typhus 6 (0.7) 
Dengue/ Murine typhus 3 (0.3) 
Leptospirosis/ Dengue 3 (0.3) 
Escherichia coli/ Scrub typhus 1 (0.1) 
Rickettsia felis 1 (0.1) 
Scrub typhus/ Murine typhus 1 (0.1) 
Total 36 (4.0) 
*As described in the chapter 4 
 
The number of patients that were positive for each alternative diagnostic test is 
shown in Table 8.3. From a total of 199 dengue positive patients by rRT-PCR and/or RDT, 
166 patients were positive by the rRT-PCR assay. These patients were investigated further 
for the infecting serotype of dengue virus. The serotype of dengue virus was identified 
from all 166 patients: 150 patients had DENV-1, 11 patients had DENV-3 and 5 patients 
had DENV-4. None of the patients were found to have DENV-2. 
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Table 8.3 Number of patients positive by each alternative diagnostic tests. 
Diagnostic tests Number of patients (%), n=908 
Dengue  
• rRT-PCR 166 (18.3) 
• NS1 ICT 144 (15.9) 
• IgM ICT 43 (4.7) 
• rRT-PCR+NS1+IgM 199 (21.9) 
Leptospirosis  
• 16S rRNA qPCR 68 (7.5) 
Scrub typhus  
• 47kDa qPCR 18 (2.0) 
• IgM ICTa 73 (8.1) 
• 47kDa qPCR+ IgM ICT 80 (8.8) 
Murine typhus  
• 17kDa qPCRb 21(2.3) 
Rickettsia felis  
• Sequencing 1 (N/A)c 
Invasive bacterial infectiond  
• Blood culture 12 (1.3) 
aData available for 898/908 patients, bSpecimens positive for 17kDa and ompB qPCR 
assays/sequencing confirmed Rickettsia typhi, cOnly performed to confirm this case by 
sequencing, dAs described in chapter 4. 
  
302 
8.4 Discussion 
There is a pressing need for rapid and accurate diagnostic tests to improve the 
diagnosis of non-malaria AUFI. The gold standard tests, either culture of the organisms or 
paired serology, for confirmation of dengue, leptospirosis and rickettsial infections which 
are the most common causes of AUFI, are not clinically useful [33, 110, 120, 196]. The 
results turnaround time, particularly of paired serology, is retrospective rather than 
prospective by definition.  
This chapter describes the practical implications of using alternative diagnostic tests 
that are available in the SMRU setting and that have quick turnaround times to determine 
the causes of AUFI in a single acute phase specimen. In the absence of the gold standard 
diagnostic tests, diagnoses were made in 39.3% of the non-malaria febrile patients in 
which the proportion was slightly higher than those diagnosed by the gold standard tests 
(34.6%) (see chapter 4). In addition to more patients being given diagnoses based on the 
results of the alternative tests, the proportion of co-infections also increased compared with 
gold standard methods. This may be due to differences in detection windows and/or the 
diagnostic accuracy of the tests.  
SMRU clinics provide healthcare to marginalised populations in a rural setting. The 
detection and treatment of malaria was one of SMRU’s main goals, however, due to 
successful management the number of malaria cases seen has decreased drastically in 
recent years (Figure 1.22). Accessible diagnostic tools, such as microscopy and RDT, and 
expertise have been key for successful management of malaria patients. Despite the drop in 
the number of malaria cases, patients were still presenting at SMRU clinics with fever, 
however, prior to the work presented in this thesis there were no diagnostic tools to guide 
the management of these patients. Although it was not possible to implement gold standard 
serology tests at the SMRU laboratories for any of the non-malaria febrile illnesses, rapid 
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diagnostic tests (ICT) for dengue and scrub typhus were introduced and evaluated as well 
as PCR assays for dengue, leptospirosis and rickettsial infections. The performance of 
these diagnostic tests was evaluated and described in previous chapters of this thesis. 
Although not routinely available at SMRU, paired acute and convalescent serum 
specimens were also sent out to undergo the reference serology tests for dengue (at 
AFRIMS), and scrub typhus and murine typhus (at MORU) for confirmation of infections. 
Even though the follow-up rate was high in the present study, the convalescent serum 
specimen was not available in 10.6% (96/908) of the patients that were lost follow-up. The 
lack of a convalescent specimen is the main obstacle in diagnosis of acute infection based 
on the gold standard paired serology [191]. The accuracy of the serology tests varies based 
on the disease prevalence, clinical variability, and availability and timing of the 
convalescent specimen [297]. Although, the evaluation of the optimal cut-off point and 
accuracy of the serology tests have been described, further studies to evaluate these in 
different settings are still required [192, 195, 207]. In the present study, patients with only 
a single specimen were not analysed by the reference serology but all acute blood 
specimens were tested and analysed using alternative diagnostic tests. Of these single 
specimens, 10/96 patients had diagnosis of leptospirosis by the 16S rRNA qPCR assay.   
There are several points that need to be addressed in the practical selection of 
alternative diagnostic tests used for early diagnosis of acute infection in the SMRU setting. 
The clinical diagnostic accuracy needs to be evaluated in the setting where the tests are 
being implemented. The clinical diagnostic accuracy of a test may differ from the 
analytical accuracy in the controlled laboratory environment (chapter 5-6) or in different 
clinical settings. This is in relation to the detection window of the tests and the timing of 
specimen collection. For example, for molecular diagnostic tools for detection of nucleic 
acid of the causative agent during viraemia or bacteraemia, the specimen should be 
collected during the acute phase of infection or soon after the symptom onset. On the other 
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hand, antibody based detection might not be useful during this time since the detectable 
antibody may take several days to weeks to develop. Specific antibody is rarely detectable 
in acute specimens, especially when patients present early in the course of their illness as 
was the case for this study (a median of two days (IQR 2-3) duration of fever). The result 
turnaround time, cost, and availability of the tests all need to be considered. The diagnostic 
tests should ideally have rapid result turnaround times so that useful to assist patient 
management. The cost of the tests should be affordable, especially in resource poor 
settings where AUFI is common. There should be a reliable and affordable supply chain to 
the site where they are needed. The estimated costs and turnaround times for the alternative 
diagnostic tests used in this study are shown in Appendix 3. In addition, other 
considerations include storage conditions, shelf life of the product, skills required to 
perform the test and requirement for additional equipment.  
In resource limited settings, the diagnostic test of choice should be considered 
according to the WHO ASSURED criteria (Affordable, Sensitive, Specific, User friendly, 
Robust and rapid, Equipment free, Deliverable to those who need them) [298]. Only few 
accessible rapid diagnostic tests for non-malaria AFUI met these criteria, albeit with 
limited sensitivity and specificity [15]. The present study has shown that the new 
generation rapid test that included NS1 antigen detection for early diagnosis of acute 
dengue infection is clinically useful for the management of patients and fit with the 
ASSURED model (chapter 5). For scrub typhus, the IgM ICT had high specificity but the 
sensitivity was poor. It was not found to be appropriate to use as an early diagnostic test in 
the field. The test is also not yet commercially available (chapter 6). The molecular 
methods have high sensitivity and specificity and could be able to detect non-cultivable or 
slow growing pathogens to get quicker results than the culture of these pathogens, but 
generally failed to meet the ASSURED criteria in terms of affordable, equipment free, 
rapid and not easy to deliver to use in the field [299]. As shown in the present study, the 
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dengue rRT-PCR assay had excellent performance for early diagnosis using a single 
specimen but did not fulfil the ASSURED criteria (chapter 5). For scrub typhus and murine 
typhus, the performance of the qPCR assays was not good enough to use as a single 
diagnostic test since the sensitivity of the tests were poor, although the specificity was high 
(chapter 6). For leptospirosis, the analytical sensitivity and specificity of the 16S rRNA 
qPCR were excellent. An evaluation of clinical diagnostic accuracy is required in the 
current setting, although the evaluation has been done elsewhere [149]. 
There is no single diagnostic test that is perfect and clinically useful in the resource 
limited setting that meet the ASSURED criteria. Different diagnostic tests each have their 
own limitations. The clinical diagnostic accuracy of the tests, optimal detection window, 
timing of specimen collection, result turnaround time, cost, and availability of the tests 
need to be considered to determine the optimal testing strategy for early diagnosis of acute 
infection to assist the management of the non-malaria AUFI patients. It is difficult to find 
an ASSURED based diagnostic test that is comparable to the optimal laboratory based 
assays. However, a slightly less sensitive rapid bedside test might be more useful to 
patients as it could provide the result in time to guide the correct treatment. If budget is 
available, the rRT-PCR for dengue could be used as the reference test in the absence of 
gold standard serology. This would be appropriate to the current setting of the SMRU 
where the molecular laboratory is already in place, although this might not be feasible in 
other settings.  
This study suggests the SD BIOLINE Dengue Duo NS1, IgM/IgG ICT (Standard 
diagnostic, Inc.) is suitable to implement in the resource limited clinical setting. The other 
alternative diagnostic tests under evaluation for leptospirosis and rickettsial infections are 
not recommended. 
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9 Concluding remarks 
The work described in this thesis has determined the diagnostic accuracy and 
clinical value of using rapid tests to diagnose causes of non-malaria fever focussing on 
dengue, leptospirosis, and rickettsial infections (mainly scrub typhus and murine typhus) in 
a rural SE Asian clinical setting. 
9.1 Key findings 
1. Using the reference laboratory diagnostic tests to confirm the causes of non-malaria 
AUFI in this study, a diagnosis was confirmed in 34.6% of the patients. Dengue 
was the most common diagnosis (15.9%), followed by leptospirosis (6%), murine 
typhus (6%), and scrub typhus (3.2%). Co-infection was not uncommon, occurring 
in 1.7% of the patients with concomitant leptospirosis and scrub typhus accounting 
for almost all of these cases (1.5%). 
2. The new generation ICT for dengue diagnosis that included NS1 antigen detection 
(SD BIOLINE Dengue Duo NS1, IgM/IgG ICT, Standard diagnostic, Inc.) was 
useful for patient management and appropriate to implement in the field for early 
diagnosis of acute infection. 
3. The molecular diagnostic tool, rRT-PCR, could replace the gold standard serology 
for early diagnosis of acute dengue infection using a single specimen. 
4. Neither rapid diagnostic test (SD BIOLINE Scrub typhus IgM ICT, Standard 
diagnostic, Inc.) nor molecular diagnostic assays (47kDa and 17kDa qPCRs) under 
this evaluation were clinically useful for diagnosis of scrub typhus or murine typhus 
infection. 
5. CRP was clinically useful to distinguish between acute viral and bacterial infections 
as the CRP level was more elevated in bacterial infection.  
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6. Malarial DNA was detected in 17.5% of non-malaria febrile patients with very low 
parasitaemia, which was unlikely to be the cause of their fever.  
7. In malaria patients, co-infection with scrub typhus was common in this area. 
9.2 General discussion 
While malaria has significantly decreased globally, non-malaria causes of fever have 
become apparent and remains a major cause of AUFI in SE Asia. In rural and resource 
limited settings, diagnostic tests for non-malaria causes of AUFI are inadequate for clinical 
use. When patients present with non-malaria fever, it is impossible to give a definitive 
diagnosis based on the clinical presentation alone, and therefore without access to reliable 
diagnostic tests certain infections are mis- or under-diagnosed. This work was conducted to 
determine the optimal testing strategies for diagnosis of the common non-malaria causes of 
fever and improve understanding of these infections to assist management of patients in a 
rural SE Asia clinical setting.  
When implementing new testing strategies, it is important to look at all available data 
relevant to the setting. Prior to this study there were only a few publications looking at the 
causes of fever on the Thailand-Myanmar border and in Thailand. This work is the first 
laboratory-based investigation in the SMRU to confirm diagnosis and describe non-malaria 
causes of fever in non-pregnant migrant and refugee populations. With a large cohort 
recruited over two years it was possible to determine the clinical diagnostic accuracy of 
tests with a clinically useful turnaround time. With limited resources, the work was 
focussed on diagnosis of dengue, leptospirosis and rickettsial infections (mainly scrub 
typhus and murine typhus). These infections have previously been found to be common 
causes of AUFI in SE Asia and existing data from SMRU also indicated that these 
infections were common in the SMRU target population (data obtained from SMRU 
pregnancy study conducted between 2004-2006 and a pilot non-pregnancy fever study 
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conducted in 2008). Hence, the inclusion of these diseases in the evaluation of diagnostic 
tests is directly useful to the local population and will be useful to the wider SE Asia 
population. 
The diagnosis of non-malaria AUFI remains challenging. The causes include a wide 
variety of infections with non-specific clinical presentations. Whilst gold standard 
diagnostic tests for the common causes of AUFI are not available in the SMRU 
laboratories, even if they were the results would not be given to the clinician in time to 
guide patient management. In practice, diagnostic tools for dengue, leptospirosis, scrub 
typhus and murine typhus have not been available in SMRU. This study has validated the 
use of ICT and rRT-PCR for early diagnosis of acute dengue infection. This ICT is now 
implemented at SMRU for routine diagnosis of dengue and the rRT-PCR is available for 
confirmatory testing. The 16S rRNA qPCR for leptospirosis had high analytical 
performance and could potentially be useful for the early diagnosis of leptospirosis, 
however, further evaluation of its clinical diagnostic accuracy in this setting is required. 
For scrub typhus and murine typhus, diagnostic tests under this evaluation were inadequate 
for clinical use in routine diagnosis. Although highly specific, they were found to lack 
sensitivity and should therefore only be used with the knowledge that a negative result 
does not rule out the possibility of rickettsial disease. Development and assessment of 
improved diagnostic tests for these infections warrant further investigation. While 
composite gold standard diagnostic tests, for example a combination of culture, 
antigen/antibody based detection and nucleic acid detection, have been proposed and 
widely used to robustly confirm diagnosis for research purposes, this approach is not 
feasible in most routine clinical diagnostic settings due to the delay in getting results and 
cost effectiveness. 
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Many other causes of AUFI, that have not been investigated in this study, remain to 
be investigated and more than half of the patients remain undiagnosed. The study has built 
a bio-bank of well-characterised clinical specimens that could be useful for future 
diagnostic test evaluations, to investigate the presence of known and emerging pathogens 
including Zika virus and Chikunganya virus and to enable novel genomic approaches for 
pathogen discovery to be applied. This should enable a more complete picture of the 
causes of AUFI in this setting to be ascertained.   
9.3 Limitations 
The number of patients with confirmed diagnosis of acute primary dengue infection 
in this study was small. This limited the evaluation of the dengue ICT and the rRT-PCR 
assay in patients with acute primary dengue infection compared to the patients with acute 
secondary dengue infection. However, this did not compromise the clinical usefulness of 
the tests for this region or other dengue endemic areas including Thailand where 87% of 
dengue cases are secondary infections [41]. In addition, the tests tended to perform better 
for primary dengue infection [288, 290, 300]. 
The gold standard serology for confirmation of leptospirosis infection, MAT, was 
not available at the time of the study nor were there any other diagnostic tools available for 
diagnosis of leptospirosis infection at SMRU. Although MAT testing could have been 
performed externally, there was insufficient funding at the time of the study to cover a test 
that was not regarded to be accurate. Therefore, the qPCR assay that had previously been 
validated for human leptospirosis cases in Thailand was introduced and used [149]. The 
evaluation of the clinical diagnostic accuracy of this test could therefore not be determined 
in this study, however, archived specimens are available for future testing if and when 
possible. 
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Diagnosis of rickettsial infections is notoriously difficult. IFA, an imperfect gold 
standard serology test that has been used for confirmation of the scrub typhus and murine 
typhus infections for decades was used in the present study. There are a number of ways to 
interpret the results, and for this study a ≥4-fold rising titres between paired acute and 
convalescent specimens was applied to identify cases. The STIC interpretation criteria 
were not followed, as it was not feasible to implement them retrospectively [228, 229]. 
Bayesian LCMs, the most recent analysis method to estimate true accuracy of diagnostic 
tests where the gold standard is imperfect could be useful to improve the analysis in the 
study [195]. 
 Although patients with a clear clinical diagnosis of a respiratory tract infection 
were excluded, 50% of undiagnosed cases did have a cough. Therefore, it is possible that 
some of the patients had a respiratory tract infection and detection of respiratory pathogens 
may have improved the diagnostic yield in this study. Unfortunately, appropriate 
specimens for respiratory tract pathogens were not collected during the study and therefore 
retrospective testing is not possible. 
Early diagnosis of non-malaria AUFI remains challenging. The need for a rapid and 
accurate diagnostic test remains notably urgent. There is considerably more to be done to 
develop clinically useful diagnostic tests for AUFI in low- and middle-income countries. 
In spite of the limitations described above, all objectives and aims that are stated in 
section 1.7 were addressed. 
9.4 On-going and future research 
Since the first large outbreak of Zika virus infection on Yap Island in the Federated 
States of Micronesia in 2007, Zika virus infection has become a global concern. Thailand 
reported cases in 2012-2014, indicating that the virus is endemic in Thailand [301]. 
Thailand has also recently reported the first two locally acquired cases of Zika-linked 
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microcephaly in SE Asia [302]. The specimens from the current study are being tested by 
PCR and serology assays to look for evidence of acute Zika virus infection in the 
population. So far, the preliminary result shows that 4/908 acute specimens are positive for 
Zika virus by three different PCR assays (two published assays by Lanciotti et al., 2008 
and one in-house assay developed by Agency for Science, Technology and Research (A* 
STAR, Connexis North Tower, Singapore) [303]. This is the first report of Zika virus on 
the Thailand-Myanmar border, with positive cases for years 2011-2012. Although, the 
number of positive cases detected by PCR is low, this work confirms that Zika virus is a 
cause of AUFI in this region. On-going work is now focusing on completing the serology 
analysis and current work investigating the occurrence of Zika virus in pregnancy. Further 
investigation for the occurrence of Chikungunya virus in the area is also underway as it 
shares the same vector with dengue virus and Zika virus. 
Next generation sequencing technology is becoming more widely available and can 
be used to identify novel microbes present in clinical specimens. This genomic approach 
for pathogen discovery has been successfully used to discover and characterise novel viral 
pathogens [304]. In the present study, the causes of AUFI remain unknown in more than 
half of the non-malaria febrile patients and it is planned to use a sequencing based 
approach to investigate them further.  
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11 Appendix 1 Case report form (CRF) of fever diagnostic 
study (FDS) 
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12 Appendix 2 Interpretation algorithm of dengue virus and 
Japanese encephalitis virus infection using in-house AFRIMS 
ELISA (AFRIMS SOP VIR-SR-007).  
Permission from Ananda Nisalak, AFRIMS, Bangkok, Thailand 
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13 Appendix 3 Estimated cost and result turnaround time for 
alternative diagnostic tests used in the study 
Diagnostic tests Cost per test 
THB (USD)a 
Result turnaround 
time 
Dengue    
1.  rRT-PCR 200 (5.9) 5 hours 
Plus nucleic acid extraction 300 (8.8) 2 hours 
Plus internal control assay 200 (5.9) -b 
2. SD BIOLINE Dengue Duo NS1, 
IgM/IgG ICT (Standard diagnostic, 
Inc.) 
450 (13.2) 15 minutes 
Leptospirosis   
3. 16S rRNA qPCR 200 (5.9) 3 hours 
Plus nucleic acid extraction 300 (8.8) 2 hours 
Plus internal control assay 200 (5.9) -b 
Scrub typhus   
4. 47kDa qPCRc 200 (5.9) 3 hours 
Plus nucleic acid extraction 300 (8.8) 4 hours 
Plus internal control assay 200 (5.9) -b 
5. SD BIOLINE Scrub typhus IgM 
ICT (Standard diagnostic, Inc.) 
N/Ad 15 minutes 
Murine typhus and other Rickettsia spp.   
6. 17kDa qPCRc 200 (5.9) 3 hours 
7. ompB qPCRc 200 (5.9) 3 hours 
8. Sequencing (Macrogen)e 170.50 (5.0) 3-5 days 
Plus nested PCR, gel 
electrophoresis and PCR 
product purification  
200 (5.9) 2 days 
Plus shipping 852.25 (25) -f 
Invasive bacterial infection   
9. Blood culture 200-400 (5.9-11.7) 1-7 days 
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a1 USD = 34.09 THB, bInternal control assay was performed together with the target 
assays, cNucleic acid extraction and internal control assay were performed only once for 
scrub typhus, murine typhus and other Rickettsia spp. qPCRs, dNot commercially 
available-supported by the Standards diagnostics, Inc (free of charge), esent to Macrogen, 
Republic of Korea, f3-5 days including testing. 
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Short Report: A Prospective Evaluation of Real-Time PCR Assays for the Detection
of Orientia tsutsugamushi and Rickettsia spp. for Early Diagnosis of Rickettsial
Infections during the Acute Phase of Undifferentiated Febrile Illness
Wanitda Watthanaworawit,* Paul Turner, Claudia Turner, Ampai Tanganuchitcharnchai, Allen L. Richards,
Kevin M. Bourzac, Stuart D. Blacksell, and Franc¸ois Nosten
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Abstract. One hundred and eighty febrile patients were analyzed in a prospective evaluation ofOrientia tsutsugamushi
and Rickettsia spp. real-time polymerase chain reaction (PCR) assays for early diagnosis of rickettsial infections. By paired
serology, 3.9% (7 of 180) and 6.1% (11 of 180) of patients were confirmed to have acute scrub or murine typhus,
respectively. The PCR assays for the detection of O. tsutsugamushi and Rickettsia spp. had high specificity (99.4% [95%
confidence interval (CI): 96.8–100] and 100% [95% CI: 97.8–100], respectively). The PCR results were also compared with
immunoglobulin M (IgM) immunofluorescence assay (IFA) on acute sera. ForO. tsutsugamushi, PCR sensitivity was twice
that of acute specimen IgM IFA (28.6% versus 14.3%; McNemar’s P = 0.3). For Rickettsia spp., PCR was four times as
sensitive as acute specimen IgM IFA (36.4% versus 9.1%; P = 0.08), although this was not statistically significant. Whole
blood and buffy coat, but not serum, were acceptable specimens for these PCRs. Further evaluation of these assays in a
larger prospective study is warranted.
INTRODUCTION
Scrub and murine typhus, caused by Orientia tsutsugamushi
and Rickettsia typhi, respectively, are important acute febrile
illnesses in Thailand.1,2 Clinical diagnosis is difficult because
early symptoms are similar to other common infections such
as dengue, leptospirosis, and malaria.3 Laboratory confirma-
tion is also difficult, conventionally requiring either culture
of the infectious agent in cell monolayers at biosafety level-3,4
or paired serology (indirect immunofluorescence assay [IFA])
for the detection of rising antibody titers.5
MATERIALS ANDMETHODS
We prospectively evaluated two real-time polymerase
chain reaction (PCR) assays for the rapid diagnosis of rickett-
sial infections using several blood fractions. These assays were
designed for use on the JBAIDS instrument (Joint Biological
Agent Identification and Diagnostic System; BioFire Diag-
nostics, Inc. (formerly Idaho Technology), Salt Lake City,
UT): a ruggedized, field-portable real-time PCR system.
Specimens from 180 patients recruited into a study of fever
of unknown origin on the Thailand-Myanmar border were
included in the evaluation. Consenting patients’ ³ 5 years
of age, with a febrile illness (³ 38°C) of £ 7 days duration and
a negative malaria test, were eligible for inclusion. Venous
blood (EDTA tube) was collected for PCR at enrollment
and serum was collected at enrollment and Day 14 for IFA
analyses. Blood specimens were aliquoted and stored at
−80°C before testing. This study was approved by the Ethics
Committee of the Faculty of Tropical Medicine, Mahidol
University, Thailand (MUTM 2011-008-01) and Oxford Trop-
ical Research Ethics Committee (OXTREC 42-10).
To compare the impact of use of different blood fractions
in these PCRs, DNA was extracted from whole blood (adult
patients only), buffy coat (all patients), and selected acute
serum specimens (described below). Eight hundred micro-
liters of whole blood and serum were extracted using the IT
1-2-3 Platinum Path purification kit (BioFire Diagnostics,
Inc.) and 200 mL of buffy coat was extracted using the
QIAamp DNA blood mini kit (Qiagen, Hilden, Germany),
following the manufacturer’s instructions. Elution volumes
were 200 mL (whole blood/buffy coat) and 100 mL (serum).
Two JBAIDS-based TaqMan probe-based real-time PCR
assaysweredesigned for the specificdetectionofO. tsutsugamushi
(47-kDa outer membrane protein gene) or Rickettsia spp.
(17-kDa antigen gene). Primer and probe sequences for 17-kDa
gene were modified slightly from previously published assays
(see Reference 6) and optimized for use on the JBAIDS
platform (R17KF_4: 5¢-AAA CAA GGK CAN GGH ACA
CTT CTT G-3¢, R17KR: 5¢-AAG TAA TGC RCC TAC ACC
TAC TC-3¢, and RProbeV2: 5¢-6FAM-CCG AAT TGA GAA
CCA AGT AAT GC-TAMRA-3¢). The limit of detection was
determined by testing the lowest level of spiked template that
could be detected in at least 95% of specimens (i.e., 19 out of
20 replicates) and found to be 25 copies of target template per
reaction. Both target assays were multiplexed with an internal
inhibition control. The DNA extracts (20 mL/assay) were added
to the freeze-dried reagent tubes along with 20 mL of reconsti-
tution buffer and immediately tested in duplicate (individual
reaction volume 20 mL; DNA template volume 10 mL/reaction)
on the JBAIDS instrument. Positive and negative controls were
included in each PCR run. The JBAIDS instrument software
automatically determined the specific operation of the instru-
ment, i.e. times, temperatures, and number of PCR cycles, and
determined a result for the duplicate reactions. Whole blood
and buffy coat specimens were tested for all adult patients. For
children, only buffy coat fractions were tested because there
was insufficient whole blood/serum to be tested. If an adult
patient tested positive for the O. tsutsugamushi or Rickettsia
assay in whole blood or buffy coat, the corresponding serum
*Address correspondence to Wanitda Watthanaworawit, Shoklo
Malaria Research Unit, 68/30 Ban Toong Road, Mae Sot, Tak 63110,
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specimen was then also tested. The PCR was repeated for speci-
mens yielding uncertain results (discordant results between
duplicate reactions) on first testing.
For comparison, three alternate rickettsial real-time PCR
assays were run on buffy coat specimens, using the same DNA
extracts as for the JBAIDS-based PCRs. These PCRs targeted
47-kDa outer membrane protein gene of O. tsutsugamushi,6
17-kDa antigen gene of Rickettsia spp.,7 and R. typhi ompB,8
as previously described. A human RNaseP gene PCR was
used as an internal control to confirm the absence of PCR
inhibition and to monitor extraction efficiency.9 One micro-
liter of DNA template was added into each 25 mL PCR reac-
tion. The PCR was done on an ABI 7500 Fast instrument
(Life Technologies, Grand Island, NY).
All statistical data analyses were perform using STATA/SE
10.1 (StataCorp, College Station, TX). Diagnostic accuracy
of the PCRs was calculated by comparing PCR results to the
paired sera IFA results in 2 +2 cross tabulation using the
“diagt” routine.10 The McNemar test was used to compare
test sensitivities. Binomial exact confidence intervals were
calculated throughout.
RESULTS
Using a ³ 4-fold rise in IFA immunoglobulin M (IgM)
antibody titers between the paired acute and convalescent
serum specimens to define acute infection,11 6.1% (11 of 180)
of the patients were diagnosed with acute murine typhus and
3.9% (7 of 180) were with acute scrub typhus. Using a cut-off
titer of 400 as evidence of acute infection as previously
described,12 the sensitivity and specificity of acute specimen
IgM IFA were 14.3% (95% confidence interval [CI]: 0.4–
57.9) and 97.7% (95% CI: 94.2–99.4) for scrub typhus, 9.1%
(95% CI: 0.2–41.3) and 99.4% (95% CI: 96.7–100) for murine
typhus (raw data not shown), respectively.
One hundred and four whole blood fractions and 180 buffy
coat fractions were tested by JBAIDS PCR. Three and
six corresponding serum fractions were tested for the
O. tsutsugamushi and Rickettsia assay, respectively. The overall
positivity of the O. tsutsugamushi and Rickettsia assays was
1.7% (3 of 180) and 2.2% (4 of 180), respectively, when any
of the blood fractions gave a positive result.
The specificity of O. tsutsugamushi assay was 99.0% (95%
CI: 94.6–100) using whole blood, 99.4% (95% CI: 96.8–100)
using buffy coat, and 99.4% (95% CI: 96.8–100) when the
results of all blood fractions were combined. The sensitivity
of the assay using whole blood, buffy coat, and combined
blood fractions was 50.0% (95% CI: 6.8–93.2), 28.6% (95%
CI: 3.7–71.0), and 28.6% (95% CI: 3.7–71.0), respectively.
Serum fractions did not correctly identify either of the patients
with positive whole blood or buffy coat fractions. A total
of seven patients had serologically confirmed acute scrub
typhus infection by paired IgM IFA. Of these, three patients
were children and only the buffy coat fraction was tested
by PCR, none of which gave positive results. Of the four adult
patients, two were positive by PCR in both whole blood
and buffy coat fractions, but were negative in the serum
fraction. There was perfect correlation between results
obtained from whole blood and buffy coat fractions. One
additional adult patient who had no evidence of acute scrub
typhus infection by paired IgM IFA was positive for PCR
in all blood fractions.
For Rickettsia assay, the specificity was 100% in all blood
fractions, although as a consequence of the small number of
serum specimens tested (N = 6), the 95% CI for the serum
fraction result was wide (2.5–100). The sensitivity of the assay
using whole blood, buffy coat, serum, and combined blood
fractions was 30.0% (95% CI: 6.7–65.2), 27.3% (95% CI:
6.0–61.0), 40.0% (95% CI: 5.3–85.3), and 36.4% (95% CI:
10.9–69.2), respectively. A total of 11 patients had serologi-
cally confirmed positive acute murine typhus infection by
paired IgM IFA. One patient was a child and only buffy coat
fraction was tested by PCR, which had a negative result.
Of the 10 adult patients, four patients were positive by PCR
in whole blood and/or buffy coat fractions. There was poor
correlation between the results obtained from whole blood
and buffy coat fractions and the corresponding serum fraction.
For O. tsutsugamushi, PCR sensitivity was twice that of
acute specimen IgM IFA (28.6% [95% CI: 3.7–71.0] versus
14.3% [95% CI: 0.4–57.9]; McNemar’s P = 0.3). For Rickettsia
spp., PCR was four times as sensitive as acute specimen IgM
IFA (36.4% [95% CI: 10.9–69.2] versus 9.1% [95% CI: 0.2–
41.3]; P = 0.08).
The comparison of five PCR assays for detection of
O. tsutsugamushi andRickettsia spp. DNA from blood are shown
in Tables 1 and 2. Both O. tsutsugamushi PCR and 47-kDa
PCR showed perfect concordant results; 1.67% (3 of 180)
were positive for both PCRs (Table 1). For Rickettsia spp.
PCR, 1.67% (3 of 180) was positive. One uncertain result was
considered negative because there was no evidence for acute
murine typhus by reference test (Table 2). However this result
could represent a true infection by another spotted-fever group
Rickettsia sp. 1.11% (2 of 180) were positive for 17-kDa PCR
and the same specimens (1.11% [2 of 180]) were confirmedly
positive by ompB PCR.
CONCLUSION
We found that both of the O. tsutsugamushi and Rickettsia
assays had high specificity and there was good correlation with
the alternate PCR assays. The clinical sensitivity was low but
Table 1
Comparison of two PCR assays for detection of Orientia
tsutsugamushi DNA from blood*
Paired serology result (IgM IFA)
O. tsutsugamushi PCR
(JBAIDS instrument)
47 kDa PCR
(ABI instrument)
Negative Positive Negative Positive
Not scrub typhus 172 1 172 1
Acute scrub typhus 5 2 5 2
*PCR = polymerase chain reaction; IFA = immunofluorescence assay; IgM = immuno-
globulin M.
Table 2
Comparison of three PCR assays for detection of Rickettsia spp.
DNA from blood*
Paired serology
result (IgM IFA)
Rickettsia spp. PCR
(JBAIDS instrument)
17 kDa PCR
(ABI instrument)
ompB PCR
(ABI instrument)
Negative Positive Uncertain Negative Positive Negative Positive
Not murine
typhus
168 0 1 169 0 169 0
Acute murine
typhus
8 3 0 9 2 9 2
*PCR = polymerase chain reaction; IgM = immunoglobulin M; IFA = immunofluores-
cence assay.
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PCR was more sensitive than acute specimen IgM IFA. It is
probable that a combination of both molecular and antibody-
based detection assays would be the ideal panel to adequately
cover all diagnostic window periods and might allow confirma-
tion of infection quickly enough to be useful for patient man-
agement.13,14 A further evaluation of these real-time PCR
assays in a larger prospective study is warranted.
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Abstract. We assessed the diagnostic accuracy of two immunochromatographic tests (ICTs), the Access Bio
CareStart Scrub Typhus test (Somerset, NJ) (IgM), and the SD BIOLINE Tsutsugamushi test (Kyonggi-do, Republic of
Korea) (IgG, IgM, or IgA) compared with indirect immunofluorescence assay (IFA) and real-time PCR results as ref-
erence tests using 86 paired acute and convalescent specimens from febrile patients. The sensitivity and specificity of
the CareStart test were 23.3% (95% confidence interval [CI]: 11.8–38.6) and 81.4% (95% CI: 66.6–91.6), respectively,
for acute specimens and 32.6% (95% CI: 19.1–48.5) and 79.1% (95% CI: 64.0–90.0), respectively, for convalescent
specimens. For the SD BIOLINE test, sensitivity and specificity were 20.9% (95% CI: 10.0–36.0) and 74.4% (95% CI:
58.8–86.5), respectively, for acute specimens and 76.7% (95% CI: 61.4–88.2) and 76.7% (95% CI: 61.4–88.2), respec-
tively, for convalescent specimens. The poor sensitivity obtained for both ICTs during this study when performed on
acute specimens highlights the difficulties in prompt diagnosis of scrub typhus.
INTRODUCTION
Scrub typhus, caused by Orientia tsutsugamushi, is an
important cause of acute undifferentiated febrile illness in
Thailand1,2 and a common cause of fever on the Thailand–
Myanmar border.3,4 Clinical manifestations are similar to
other causes of fever such as dengue, leptospirosis, and
malaria, making clinical diagnosis difficult.4 Laboratory con-
firmation relies on isolation of the organism at biosafety
level 3 or paired serology (indirect immunofluorescence
assay [IFA]) or on a combination of tests, that is, in vitro iso-
lation, IFA, and polymerase chain reaction (PCR),5–7 which
are expensive, time consuming, and do not provide results in
time to inform patient management. Several groups have
developed and assessed the clinical utility of rapid bedside
diagnostic tests for early diagnosis of this infection to assist
patient management.8–11 However, either diagnostic accuracy
or commercial availability is limited. We evaluated the per-
formance characteristics of two immunochromatographic
tests (ICTs), the SD BIOLINE Tsutsugamushi (Standard
Diagnostics, Inc., Kyonggi-do, Republic of Korea) test and
the CareStart Scrub Typhus test (Access Bio, Inc., Somerset,
NJ) using paired acute and convalescent serum specimens
from patients with undifferentiated febrile illness.
MATERIALS AND METHODS
From a recent fever study in northwest Thailand, 86 par-
ticipants were retrospectively selected for the current evalua-
tion: 43 were confirmed to have acute scrub typhus infection
and 43 patients were confirmed as not having acute scrub
typhus infection by the detection of specific IgM antibody by
IFA and real-time PCR assay targeting the O. tsutsugamushi
47-kDa outer membrane protein gene.12 Acute scrub typhus
was defined as 1) ≥ 4-fold increase in IFA IgM titer, 2) sero-
conversion, 3) a high static titer of ≥ 1:25,600 between acute and
convalescent specimens, and/or 4) PCR positive in the acute
specimen. All specimens were stored at −80°C before testing.
The study was approved by the Ethics Committee of the Fac-
ulty of Tropical Medicine, Mahidol University, Thailand
(MUTM 2011-008-01) and Oxford Tropical Research Ethics
Committee (OXTREC 42-10).
Two ICTs were assessed: the CareStart Scrub Typhus test
for the detection of IgM antibody against O. tsutsugamushi
(not currently commercially available) and the SD BIOLINE
Tsutsugamushi test for the detection of IgG, IgM, or IgA
antibodies to O. tsutsugamushi, which uses a recombinant
O. tsutsugamushi (strains Kato, Karp, and Gilliam) surface anti-
gen (available for purchase in Thailand for approximately
150 THB/US$ 4.6 /test and has the Conformité Européénne
[CE] marking). Both ICTs were performed on both acute and
convalescent specimens following the manufacturer’s instruc-
tions. In brief, for the CareStart test, 10 μL serum was added to
the test devices followed by one drop of assay buffer (40 μL).
The results were read at 10 minutes. For the SD BIOLINE test,
10 μL serum was added to the test devices followed by three
drops of assay diluent. The results of the tests were read at
15 minutes. Both tests had two lines, a test line “T” and a con-
trol line “C.”An absence of “C” line indicated an invalid result.
The results of the tests were read by three independent readers,
and the majority result was used for the final interpretation.
All statistical analyses were calculated using STATA/SE 10.1
(StataCorp., College Station, TX). Diagnostic accuracy of the
tests was calculated by comparing the ICT results with the ref-
erence (composite IFA and PCR) results. A 2 × 2 table was
constructed, in which the reference results were cross-tabulated
with the ICT results to define the rate of true-positive, true-
negative, false-positive, and false-negative results. The sensitiv-
ity, specificity, positive predictive value, and negative predictive
value with 95% confidence intervals (CIs) were calculated
*Address correspondence to Wanitda Watthanaworawit, Shoklo
Malaria Research Unit, Mahidol Oxford Tropical Medicine Research
Unit, Faculty of Tropical Medicine, Mahidol University, 68/30 Ban
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tropmedres.ac
1168
using the “diagt” routine.13 Kappa values were generated to
determine the level of interoperator variation in the reading
of the ICT test results.14
RESULTS AND DISCUSSION
Of the 86 patients tested, 68.6% (59/86) were male. The
median age was 20 years (interquartile range [IQR]: 14–35
years), median temperature at presentation was 38.6°C
(IQR: 38.2–39.1°C), median duration of fever at the time of
presentation was 2 days (IQR: 2–3 days), and the median
interval between obtaining initial acute-phase specimens and
convalescent specimens was 14 days (range: 11–30 days). The
performance characteristics of the CareStart Scrub Typhus test
and the SD BIOLINE Tsutsugamushi test compared with the
results of the reference tests are shown in Table 1. The sensi-
tivity of the CareStart test was low for both acute and conva-
lescent specimens (23.3% [95% CI: 11.8–38.6] and 32.6%
[95% CI: 19.1–48.5], respectively). The specificities of the
CareStart test using both acute and convalescent specimens
were 81.4% (95% CI: 66.6–91.6) and 79.1% (95% CI: 64.0–
90.0), respectively. Both the sensitivity and specificity of the
CareStart test were much lower in this study than in the study
previously reported by Blacksell and others,9 which found the
sensitivity to be 96.8% and the specificity to be 93.3% for
acute-phase specimens. This may reflect the fact that our
patients presented earlier in the course of their illness, when
there is an absence of antibodies, with a median of 2 days
(IQR: 2–3 days) of fever, compared with 8 days (range: 7–
10 days) in the study of Blacksell and others. This result is
consistent with the temporal antibody response for scrub
typhus infectious.15
For the SD BIOLINE test, the sensitivity was higher for
convalescent specimens (76.7% [95% CI: 61.4–88.2]) com-
pared with acute specimens (20.9% [95% CI: 10.0–36.0]).
The specificity of the test was similar when performed on
acute and convalescent specimens (74.4% [95% CI: 58.8–
86.5] and 76.7% [95% CI: 61.4–88.2], respectively). The sen-
sitivity and specificity of the test obtained in this study were
lower than those that the company claimed in the product
insert (99% and 96%, respectively), although, the timing of
blood collection was not mentioned. It is difficult to con-
clude, because of the limitations of the test, whether IgG,
IgM, or IgA play a role in the positive result and whether
the specificity of the test is compromised due to the detec-
tion of past infections.
Both ICTs tested in this study demonstrated very good
interoperator agreement among three readers (Table 1). The
SD BIOLINE test demonstrated better kappa values (0.98
and 0.98 for acute and convalescent specimens, respectively)
compared with those of the CareStart test (0.84 and 0.85 for
acute and convalescent specimens, respectively).
Given the small sample size of this evaluation, the 95% CI
around the calculated sensitivities and specificities are wide.
However, from these preliminary findings, both tests had poor
sensitivity when performed on acute specimens taken early in
the course of infection; however, this was improved for conva-
lescent specimens. Consequently, both tests when performed
at the acute phase of infection are not likely to be useful for
patient management. Individual IgM or IgG antibody-based
tests taken at appropriate time points post-onset of fever
could be performed, which may give a clearer answer and
aid the differentiation of past and current infections. In addi-
tion, there were four scrub typhus patients who had low IFA
IgM titers on acute specimens (two were less than 100, one
at 100, and one at 200, rising to 6,400, 12,800, 12,800, and
25,600 in convalescent specimens, respectively) but were pos-
itive by 47-kDa real-time PCR assay, none of whom were
positive by either ICTs tested using acute specimens. This
emphasizes the usefulness of nucleic acid detection during
acute phase of scrub typhus infection. The eschar PCR could
be useful for early diagnosis of scrub typhus. It is more likely
to give a positive result than blood, especially, when patient
has already been treated with antibiotics.16 In our study,
blood specimens were collected before antibiotics were
started, and none of the patients in this sample set presented
with eschar at the enrollment. It should be noted that the
use of IFA alone as the gold standard test has limitations,
and it is far from a perfect gold standard as standard IFA
slides are not available, there is no consensus on cutoff titers,
and difficulties with cross-reactivity and subjective endpoint
TABLE 1
The performance characteristics of CareStart Scrub Typhus assay for detection of IgM antibody and SD BIOLINE Tsutsugamushi assay for
detection of IgG, IgM, or IgA antibodies using acute and convalescent specimens compared with the results of reference tests*
Specimen timing and diagnosis Positive Negative % Sensitivity (95% CI) % Specificity (95% CI) % PPV (95% CI) % NPV (95% CI) Kappa value
CareStart Scrub Typhus IgM (N = 86)
Acute
Acute scrub typhus 10 33 23.3 (11.8–38.6) 81.4 (66.6–91.6) 55.6 (30.8–78.5) 51.5 (39.0–63.8) 0.84
Not acute scrub typhus† 8 35
Convalescent
Acute scrub typhus 14 29 32.6 (19.1–48.5) 79.1 (64.0–90.0) 60.9 (38.5–80.3) 54.0 (40.9–66.6) 0.85
Not acute scrub typhus 9 34
SD BIOLINE Tsutsugamushi IgG, IgM, or IgA (N = 86)
Acute
Acute scrub typhus 9 34 20.9 (10.0–36.0) 74.4 (58.8–86.5) 45.0 (23.1–68.5) 48.5 (36.0–61.1) 0.98
Not acute scrub typhus 11 32
Convalescent
Acute scrub typhus 33 10 76.7 (61.4–88.2) 76.7 (61.4–88.2) 76.7 (61.4–88.2) 76.7 (61.4–88.2) 0.98
Not acute scrub typhus 10 33
CI = confidence interval; IgM = immunoglobulin M; PPV = positive predictive value; NPV = negative predictive value.
*Immunofluorescence assay (IFA) IgM antibody and 47-kDa real-time polymerase chain reaction (PCR).
†Five cases of dengue, one Japanese encephalitis, 10 leptospirosis, 11 malaria, and 16 undiagnosed.
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(reader variability). Therefore using it as the reference test
could have affected negatively on the performance results of
the novel tests.6,17 However, the appropriate gold standard
for scrub typhus remains elusive.
This study illustrates the limitations of two ICTs for the
timely diagnosis of scrub typhus, highlighting the need to fur-
ther investigate the utility of other diagnostic methodologies,
for example, antigen- or nucleic acid-based detection (which
may be more useful for diagnosing scrub typhus, especially
for patients presenting to the clinic early in the course of
their illness, when antibody responses have not yet developed)
and/or combination of antigen/nucleic acid with antibody-
based rapid detection that may improve the diagnostic accu-
racy for early diagnosis.5,18
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